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Childhood absence epilepsy (CAE) is one of the most prevalent paediatric epilepsies, accounting 
for between 10-17% of all diagnosed cases of epilepsies seen in school-aged children. Absence 
seizures are characterized by behavioural arrest/loss of awareness and electrographic signature of 
spike-wave discharges (SWDs) measuring 2.5-4 Hz on an electroencephalogram (EEG). These 
brief episodes of impaired consciousness can occur hundreds of times a day and might increase 
the chance of physical injury when undertaking activities like swimming and cycling. Current 
treatment options are not sufficient and up to 30% of patients are pharmaco-resistant. ~60% of 
children with CAE have severe neuropsychiatric comorbid conditions including attention deficits, 
mood disorders, impairments in memory and cognition. Ethosuximide (ETX), an anti-absence 
epileptic drug which was first introduced almost six decades ago remains the first choice for initial 
monotherapy for the treatment of CAE. Large-scale clinical trials suggested that efficacy of 
ethosuximide is considerably lower than previous findings. Thus, safe, effective and patient 
specific treatment approach is imperative. For this, it is crucial first to understand the precise 
cellular and molecular mechanisms of absence seizures which may enable the development of 
novel therapeutic targets and discovery of new anti-epileptic drugs (AEDs). 
EEG and functional imaging evidence suggest that absence seizures are likely due to aberrant 
activity within the cortico-thalamocortical (CTC) network. Studies involving the genetic rodent 
models have shown that the cortex is the driving source for the origin of SWDs but is not capable 
of maintaining discharges on its own, nor is the thalamus. General consensus is that, within the 
CTC network, a cortical focus initiates rhythmic epileptic discharges, however, once the rhythmic 
oscillations are established, both the cortex and thalamus form an integrated network. Rhythmic 
absence-SWDs are sustained via the cortex and thalamus driving each other. Within the CTC 
network, feed-forward inhibition (FFI) is essential to prevent runaway excitation. FFI is mediated 
by fast spiking parvalbumin expressing (PV+) inhibitory interneurons in the somatosensory cortex 
(SScortex) and the reticular thalamic nucleus (RTN). Studies conducted in well-established 
stargazer mouse model of absence epilepsy with a genetic deficit in stargazin i.e. TARP [a 
transmembrane α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor 
regulatory protein] have shown reduced expression of GluA4-AMPARs at excitatory synapses in 
feed-forward inhibitory (PV+) interneurons in the SScortex and RTN thalamus of the CTC 
 iii 
network. However, the extent of this deficit in AMPARs expression impacting FFI and possibly 
contributing towards generation of absence-SWDs is not established via functional studies.  
 
Hence, this thesis was aimed at investigating the impact of dysfunctional feed-forward inhibitory 
PV+ interneurons within CTC network on absence seizure generation and behaviour. For this 
purpose, inhibitory and excitatory Designer Receptors Exclusively Activated by Designer Drug 
(DREADD) approach was utilized to silence/excite feed-forward inhibitory PV+ interneurons 
within the CTC network. DREADD mediated regional silencing of PV+ interneurons within the 
CTC network generated ETX-sensitive absence-like SWDs. Activating PV+ interneurons either 
prevented or suppressed pentylenetetrazole (PTZ)-induced absence-SWDs. Finally, impact of 
impaired FFI in γ-aminobutyric acid (GABA) levels by affecting its synthesizing enzymes (GADs) 
and transporter proteins (GATs) in stargazer animal model of absence epilepsy and CNO treated 
inhibitory Gi-DREADD animals was determined. Results indicate that upregulation of GAD65 in 
the SScortex of epileptic stargazers may be a consequence of absence seizures or this may have 
contribution in absence seizure generation.  
 
The work presented in this thesis provide an electrophysiological insight into the possible 
mechanism underlying the absence seizure generation. This work provides convincing evidence 
that dysfunctional feed-forward inhibitory PV+ interneurons within the CTC network is likely to 
be involved in altered excitation/inhibition balance resulting SWDs as activating these 
interneurons dramatically protected animals from PTZ induced absence seizures. The clinical 
relevance of this study is that it potentially uncovers the possibility of focally targeting PV+ 
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Chapter 1. Introduction 
 
1.1 Epilepsy 
The term ‘epilepsy’ is derived from the Greek word επιλαμβανέιν which means ‘to take hold 
of’ or ‘to seize’ (Engel and Pedley, 1997). The oldest detailed account of epilepsy to be found 
is the Babylonian textbook of medicine available in the British Museum which dates back to 
2000 BC. This book accurately details information of many of the seizures we recognize today. 
It highlights a supernatural nature of this disorder, with each seizure type linked with the name 
of a spirit or god - usually evil. Therefore, epilepsy was often thought as a spiritual disorder.  
Hippocrates was the first to believe that epilepsy is a disorder of the brain and not a spiritual 
illness. In ‘The Scared Disease’ (400 BC) Hippocrates wrote:  I am about to discuss the disease 
called “sacred”. It is not, in my opinion, any more divine or more sacred than any other 
diseases, but has a natural cause … Its origin, like that of other diseases, lies in heredity … the 
fact is that the cause of this affection … is the brain …, (Jones and Withington, 1952). These 
statements were considered a revolutionary hypothesis at that time. During the 1750s, in 
Sweden, people with epilepsy were forbidden to marry by law and in the USA 17 states had 
similar legislation until 1956 (Brodie, 2003). Such supernatural views about epilepsy continued 
during 19th century and are still an issue in non-first world societies. 
In 1849, physician Robert Bentley Todd gave a talk titled “On the Pathology and Treatment of 
Convulsive Diseases” in the Lumleian annual lectures series organized by Royal College of 
Physicians of London. He stated that … “epilepsy denotes a state of abnormal nutrition of the 
brain…the periodic evolution of the nervous force which gives rise to the epileptic paroxysm 
may be compared to the electric phenomenon described by Faraday under the name of 
disruptive discharge” ... (Reynolds, 2005). In the 1890 edition of Lumleian lectures, a 
neurologist, John Hughlings Jackson, hypothesized that epileptic discharges are due to sudden 
brief electro-chemical discharges of energy in the brain (York and Steinberg, 2011). In 1912, 
Pavlev Yurevich Kaufman, a student in Russian physiologist Ivan Pavlov’s lab, first described 
experimentally induced seizures in dogs (Kaufman, 1912). Two years later, Polish scientists, 
Napoleon Cybulsky and Jelenska-Macieszyna officially published abnormal cortical 
discharges in the form of photographs (Cybulski and Jelenska-Macieszyna; 1914). German 
psychiatrist Hans Berger developed the first human electroencephalograph in 1929. The first 
effective antiepileptic drug, Bromide was introduced in 1857. Phenobarbitone and phenytoin 
were later introduced in 1912 and 1938, respectively. EEG helped to locate the origin of 
epileptic discharges and neurosurgical treatment was available during 1950s in Montreal, Paris 
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and London. In the last few decades, development of neuroimaging techniques, neurosurgical 
therapies and research facilities have allowed us to understand more about seizures. 
Additionally, the use of human EEG recordings and animal models have helped investigate the 
disease mechanisms and treatment options. Despite the development of cutting-edge 
experimental techniques and identification of various therapeutic targets, drug efficacy on 
human patients is disappointing and their development is very slow. Currently available anti- 
AEDs are ineffective or induce intolerable side effects in about a third of all patients. Similarly, 
although a considerable amount of effort has been put into enhancing the quality of life of 
epileptic patients, they still experience discrimination in society and are subjected to social 
stigma. Thus, identification of novel therapeutic targets for better understanding the 
mechanisms of seizures are needed for patient specific treatment.   
 
1.1.1 Definition of epilepsy 
Epilepsy is a neurological disorder characterized by recurring seizures. A seizure is a transient 
episode of abnormal electrical activity in the brain. Such episodes interrupt normal neuronal 
function and can be diagnosed by characterizing electrophysiological features in the EEG and 
expression of clinical behaviour (World Health Organization Fact Sheet, 2019). The 
International League Against Epilepsy (ILAE) is a major official scientific organization 
involved in epilepsy research, education and training since 1909. In 2005, ILAE defined 
epilepsy “as a disorder of the brain characterized by an enduring predisposition to generate 
epileptic seizures and by the neurobiologic, cognitive, psychological, and social consequences 
of this condition. The definition of epilepsy requires the occurrence of at least one epileptic 
seizure. And, an epileptic seizure is a transient occurrence of signs and/or symptoms due to 
abnormal excessive or synchronous neuronal activity in the brain” (Fisher et al., 2005). In 
2014, ILAE released a more practical definition, which defines epilepsy as “a disease of the 
brain defined by any of the following conditions 1. At least two unprovoked (or reflex) seizures 
occurring >24 h apart 2. One unprovoked (or reflex) seizure and a probability of further 
seizures similar to the general recurrence risk (at least 60%) after two unprovoked seizures, 
occurring over the next 10 years 3. Diagnosis of an epilepsy syndrome” (Fisher et al., 2014).  
 
1.1.2 Prevalence, incidence and mortality of epilepsy 
Epilepsy has many possible causes, but for the majority of cases a cause is unknown or 
presumed to be genetic factors. Other causes of epilepsy include brain tumours, stroke, 
traumatic brain injury, infection, developmental brain abnormalities etc. Epilepsy is a disorder 
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with a high prevalence rate. The prevalence of epilepsy is defined as the total number of alive 
cases over a period of time. Recent studies have shown that prevalence of epilepsy ranges from 
2.2-22.2/1000 in low income countries and 2.7-7.1/1000 in high income or developed 
economies. Lifetime prevalence of this disease ranges from 3.6-15.4/1000 in low income 
countries and 2.3-15.9/1000 in high income economies (Banerjee et al., 2009).  
Incidence of epilepsy is defined as the total number of newly diagnosed cases of epilepsy over 
a period of time. It is generally calculated as cases per 100,000 populations/year. The 
worldwide annual incidence of epilepsy is 67.7 per 100,000. This figure varies with geography, 
age, ethnicity and socioeconomic difference (Sander et al., 2003; Fiest et al., 2017). Age-
specific studies have shown that incidence of epilepsy to be higher between the first year of 
life to early childhood, lowest in the adult stage and subsequently increases in the elderly age 
group (Banerjee et al., 2009). WHO states that five million people are diagnosed with epilepsy 
each year (World Health Organization Fact Sheet, 2019). 
 
Epilepsy is a very common disease in the elderly compared to other age groups, but studies 
have shown that the cumulative mortality rate at the age of 45 includes 25% of patients who 
develop epilepsy in childhood (Banerjee et al., 2009; Bell et al., 2014; Beghi and Giussani et 
al., 2018).  Studies have also revealed that people with epilepsy are always at higher risk (3-4 
times) of premature death compared to the normal population. The highest rate of premature 
mortality was found in countries with low and middle-income economies (Ding et al., 2006; 
Hitiris et al., 2007; Trinka et al., 2013; Keezer et al., 2016). Figure 1.1 shows worldwide deaths 
attributed to epilepsy per million. A report based on disability-adjusted life year (DALYs), 
which measures overall disease burden and life expectancy, showed that 3% of global DALYs 
were from neurological disorders of which epilepsy accounted for a quarter (Murray et al., 
2013). Studies have also reported that up to 2% of paediatric population aged 0-17 have at least 
one active form of epilepsy (Forsgren, 2004; Russ et al., 2012; Zack and Kobau; 2017). Up to 
10% of people worldwide experience seizure at least once in their lifetime.  
Currently, 50 million people worldwide is believed to have epilepsy and 80% of them are from 
low-and middle-income countries (World Health Organization Fact Sheet, 2019). One in fifty 





























Fig. 1.1 Worldwide estimated deaths due to epilepsy per million persons in 2012. (Data from WHO, grouped by deciles) 
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1.1.3 Classification of epilepsy 
Classification of epilepsy began in the 1960s (Marsan, 1965; Gastaut, 1970). The first official 
classification released by ILAE in 1981 was named the International Classification of Epileptic 
Seizures (ICES) (Angeles, 1981). According to this scheme, epileptic seizures were 
dichotomized into partial and generalized groups. Advancements in the scientific techniques 
and achieved research outcomes improved the understanding of epilepsy and various revisions 
of classification were made over the time. In 1985, the classification was revised again, and a 
dual dichotomy scheme was proposed. This classification was based on semiology (focus vs 
generalized seizures) and etiology (idiopathic vs symptomatic) (Dreifuss et al., 1985). In 2010, 
ILAE issued a report on revised terminologies and concepts for the organization of seizures 
and epilepsies (Berg et al., 2010). This scheme also introduced the concept of a ‘neuronal 
network’. Seizures were classified on the basis of their point of origin. For example: focal 
seizure was defined as a seizure originating within a neuronal network affecting one 
hemisphere only. A generalized seizure was defined as a seizure which involves multiple points 
within neuronal networks distributed in both hemispheres. This scheme provoked controversy 
and scientists criticized the scheme for being too complicated for daily practice and lacking 
accurate scientific understanding (Ferrie, 2010; Guerrini, 2010; Wolf, 2010; Beghi, 2011; 
Duncan, 2011). In 2017, ILAE released a new classification for both seizures and epilepsies 
which reflect current scientific knowledge (Fisher et al., 2017a; 2017b, Scheffer et al., 2017) 
(Fig. 1.2 and 1.3). According to this proposal, epilepsy was classified on three levels i.e. seizure 
type, epilepsy type and epileptic syndrome (Fig. 1.2). The epilepsy classification divided 
epilepsies into four subtypes i.e. focal, generalized, combined generalized and focal, and 
unknown (Fig. 1.2). Diagnosis of epileptic syndromes was the third level of classification. This 
is important because diagnosis plays a crucial role in prognosis and treatment of epilepsy. In 
addition, etiological classification has been added which was previously advocated in the 2010 
scheme. Structural, genetic, infectious, metabolic, immune, and unknown were the six 
etiological subgroups (Fig. 1.2). This scheme advised clinicians to categorize an epileptic 
disorder into one of the above etiological subgroups during every stage of diagnosis. According 
to this scheme, seizures were classified on clinical terms rather than pathogenic mechanisms 
i.e. focal, generalized, and unknown onset (Fig. 1.3). 
Focal onset was subdivided on the basis of awareness or level of consciousness of the patient. 





























Fig. 1.2 Framework for multilevel classification of the epilepsies as per 2017 ILAE scheme. The asterisk (*) 


















Fig. 1.3 Framework for operational classification of seizure types as per 2017 ILAE scheme. 2Degree of 
awareness usually is not specified. 3Due to inadequate information or inability to place in other categories. (Taken 
from Fisher et al., 2017a)  
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on the first signs or symptoms seen during the seizure. ‘Focal to bilateral tonic-clonic’ seizures 
were categorized as those focal seizures which later became generalized. Both subtypes of focal 
and generalized onset seizures were distinguished on the basis of clinical and video-EEG 
profiles. Unknown onset seizures were those seizures which did not conform to the requirement 
of focal or generalized onset or have not been sufficiently described to meet the criteria. This 
current ILAE classification system has more practical, descriptive and realistic approach to 
seizures from infant to adult patients compared to older versions. This version has provided a 
common language and updated view of seizures and epilepsies for clinical practice, research 
sector and teaching. However, recently, experts have outlined the shortcomings of this new 
scheme. Lüders and colleagues criticized this new classification for relying heavily on 
semiological parameters to classify seizures and mixing the semiological terms with 
epileptogenic zone terminologies. They also criticized the replacement of simple and widely 
accepted terminologies with complicated and less informative terms in this new version. They 
suggested that evolution of symptomatology is an important characteristic of epileptic seizures 
and the new version has limited this aspect by including very few repertoires for seizure 
evolutions. These experts also criticized the four-diagnostic level of ILAE 2017 classification 
by saying ‘redundant, overlapping and confusing’. They purposed a four-dimensional system 
of the classification of epilepsy i.e. seizure type, location of epileptogenic zone, etiology, and 
comorbidities (Lüders et al., 2019). 
 
1.2 Childhood absence epilepsy: the focus of this thesis 
ILAE 2017 basically classified seizures by onset: 1. focal onset seizures- which originate 
within one neuronal network and are restricted to one hemisphere of the brain, 2. generalized 
onset seizures- which originate at some point within the brain and involve neuronal networks 
of both hemispheres of the brain, 3. seizures with unclear onset or known onset but if clinician 
is less than 80% confident, they were recognized as the seizure of unknown onset. Focal 
seizures were again classified on the basis of the level of awareness and first motor or non-
motor traits/features seen in the patient. As awareness is impaired, generalized onset seizures 
were not categorized on the basis of level of awareness. Generalized seizures were categorized 
on the basis of motor or non-motor manifestations where motor seizures are basically classified 
into two categories i.e. tonic-clonic and other motor seizures. Non-motor generalized seizures 
mainly refer to absence seizures (Fisher, 2017; Falco-Walter et al., 2018; Pack, 2019). 
Behavioral features of various types of generalized onset seizures as per ILAE classification 
are listed in Table 1.1. 
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Table 1.1 Behavioral features of various types of generalized onset seizures based on ILAE 
classification. (Adapted from Fisher, 2017; Falco-Walter et al., 2018; Pack, 2019) 
Types of generalized onset 
seizures 
Behavioral features 
 Tonic-clonic Loss of awareness, rhythmic stiffening (tonic phase) and 
jerking (clonic phase) of limbs and face 
Clonic  Rhythmical jerking of limbs and/or face without stiffening 
phase 
Tonic Stiffening of limbs without clonic jerking phase 
Myoclonic Unsustained irregular bilateral jerking of eyes, face and limbs 
Myoclonic-tonic-clonic Similar to tonic-clonic seizure but few myoclonic jerks on 
both sides of body 
Myoclonic-atonic Few myoclonic jerks with a limp drop (especially children 
with Doose syndrome) 
Atonic Sudden loss of muscle tone and strength (very brief) 
Epileptic spasms Flexion of trunk and flexion/extension of limbs 
 Typical Sudden loss of ongoing activity with sometimes eyes fluttering 
and head nodding (spike and wave discharges in EEG) 
Atypical Similar to typical absence seizure but slow onset and recovery, 
and change in tone is seen  
Myoclonic First few jerks and then an absence seizure 
Eyelid myoclonia Jerk of the eyelids and deviation of the eyes 
(sometimes associated with absence seizures) 
 
Non-motor or absence seizures are common in various forms of adult and pediatric epilepsies. 
However, CAE and juvenile absence epilepsy (JAE) are two epilepsy syndromes where 
absence seizures are the basic features. These two epilepsies have closely matching 
characteristics and they overlap in the age of onset. Children with CAE have more severe 
impairment of consciousness and more frequent absence seizures compared to JAE (Tenney 
and Glauser, 2013). CAE is the most common form (10-17%) of all pediatric epilepsies, which 



















1.2.1 Absence epilepsy: an overview  
Absence epilepsy is a genetic, generalized and non-convulsive form of epilepsy. This form of 
epilepsy is common in children 2-12 years of age and peaks between 5 and 7 years. This 
disorder is more prevalent in girls than in boys (Camfield et al., 1996; Matricardi et al., 2014). 
Absence seizures (previously termed as petit mal seizures) are characterized by a sudden and 
brief loss of consciousness that interrupt ongoing activity (Crunelli and Leresche, 2002a). The 
episode of ‘absence’ happens so fast that it is easy to miss or confuse with daydreaming or not 
paying attention. During these episodes, the child suddenly loses their sense of awareness 
followed by staring blankly into space and not responding to the surroundings. Absence 
seizures are also associated with eyelid flickering and purposeless movement of the fingers, 
hands and/or mouth. As soon as the seizure stops, the patient resumes their normal activities. 
Although the seizure of this kind only lasts for few seconds, it can occur hundreds of times a 
day (Panayiotopoulos, 1999) and may be associated with difficulties in learning, problems in 
visual attention, behavioural disorder, poor academic achievement and cognitive dysfunction 
(Vanasse et al., 2005; Caplan et al., 2008; Killory et al., 2011; Vega et al., 2011; Tenney and 
Glauser, 2013 ). This disorder is also believed to cause disruptions in the structural network of 
the developing brain and these alterations may cause the impairments to grow worse over time 
(Qiu et al., 2017). Similar to other forms of epilepsy, children with absence epilepsy may also 
undergo some form of social isolation and discrimination. 
 
1.2.2 EEG features of absence seizures 
The primary diagnostic test for absence seizures is EEG. The EEG signature of absence 
seizures is a bilateral synchronous SWDs measuring 2.5-4 Hz. SWDs consists of a high 
amplitude spike, positive transient and a slow wave as shown in figure 1.4A. These SWDs 
appear in clusters and can last for about 4-20 seconds (Panayiotopoulos, 2001). Studies 
conducted on human patients and animal model of absence epilepsy have shown that absence 
seizures are initiated from certain cortical regions (Meeren et al., 2002; Holmes et al., 2004; 
Gotman et al., 2005; Polack et al., 2007; Bai et al., 2010; Berman et al., 2010). During absence 
seizure, SWDs are also present in the thalamus (Williams, 1953; Velasco et al., 1989; Iannetti 
et al., 2001). This has led to a widespread consensus that SWDs seen in absence seizures are 
generated due to the dysfunctional behavior in the brain network involving cortex and thalamus 
(Kostopoulos, 2001; Blumenfeld; 2002; Crunelli and Leresche, 2002b). EEG traces from 
rodent genetic models of absence epilepsy showing the characteristic spike and wave pattern 














































Fig. 1.4 EEG recordings of absence seizure in a child with CAE and rodent genetic models of absence 
epilepsy.  (A) EEG recordings from a child with frequent absence seizures showing 3-Hz SWDs (Crunelli and 
Leresche, 2002a) and from rodent genetic models of absence epilepsy (B) stargazer mouse (Meyer et al., 2018) 
(C) Wistar Albino Glaxo from Rijswijk (WAG/Rij) rat (D’Amore et al., 2016) (D) Genetic Absence Epilepsy Rat 




1.2.3 Aetiology of absence epilepsy 
Aetiology of absence epilepsy is considered to be genetic with complex and multiple gene 
defects (Steinlein, 2004). Studies have shown that if any individual’s first-degree relative (a 
family member who shares about 50 percent of their genes) have positive history of this 
disorder, there is 16-45% chance that the individual will acquire absence epilepsy. Genetically 
identical monozygotic twins carry this risk from 70 to 85% (Fig. 1.5) (Bianchi, 1995; Loiseau 
et al., 1995; Berkovic, 1997; 1998; Scheffer and Berkovic, 2003). Even though the mode of 
inheritance is not yet completely understood, absence epilepsy is considered as a familial 
disease with complex genotype compared to other inherited epilepsies. In few cases, familial 
genetic defects have been linked with abnormal changes in membrane receptors and channels 




























Fig 1.5 Photograph and EEG profile of Constance and Kathryn, monozygous twins who suffered from 
childhood absence epilepsy. This case was reported by American neurologist William Gordon Lennox in 1949. 
(Adapted from Vadlamudi et al., 2004) 
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Genes associated with absence epilepsy are mostly found to be involved either with 
GABAergic neurotransmission or T-type calcium channel. Mutation in a1 subunit of GABAA 
receptor was reported in patients with absence epilepsy (Feucht et al., 1999; Maljevic et al., 
2006). Studies conducted in a Mexican population with history of absence epilepsy were 
reported to have multiple mutations in GABRB3 gene (which encodes for the b3 subunit of 
GABAA receptor) (Tanaka et al., 2008). Some possible association of this mutation and 
absence epilepsy were seen in studies conducted in Austria (Feucht et al., 1999; Urak et al., 
2006) but such link was not observed in a study in Germany (Hempelmann et al., 2007). 
Mutation in GABRG2 gene which codes for the g2 subunit of this receptor was found to be 
associated with absence epilepsy (Wallace et al., 2001; Kananura et al., 2002; Kang and 
Macdonald, 2016). However, this mutation was not evident as a major genetic cause of absence 
epilepsy in two separate studies conducted on Chinese and Japanese subjects (Lu et al., 2002; 
Ito et al., 2005). A few cases of absence epilepsy were also linked to mutation in SLC2A1 gene 
[deficiency of Glucose transporter type 1 (GLUT1)] (Suls et al., 2009; Arsov et al., 2012; 
Muhle et al., 2013) and LGI4 gene (leucine-rich, glioma inactivated 4) (Gu et al., 2004).  
 
CACNA1G, CACNA1H and CACNA1I are three different genes which encode three variants 
of the a1subunits of T-type Ca2+ channel [i.e. α1G (Cav3.1, chromosome 17q22), α1H (Cav3.2, 
chromosome 16p13.3), and α1I (Cav3.3, chromosome 22q13.1)]. Studies have revealed that 
CACNA1G and CACNA1H genes are not directly linked but have close association and may 
play a crucial role in the development of epileptic phenotype (Heron et al., 2004; Singh et al., 
2007). CACNA1H was found to be a susceptible gene causing absence epilepsy in the Chinese 
Han population (Chen et al., 2003; Liang et al., 2006; 2007) and one rat model of absence 
epilepsy (GAERS) (Proft et al., 2017) but not in Caucasians (Heron et al., 2007). The 
CACNA1I gene has been reported to have no significant relationship with absence epilepsy in 
the Chinese Han population (Wang et al., 2006). Mutations of CACNG3 (which encodes g3 
subunit of Ca2+ channel) (Everett et al., 2007a) and CLCN2 (which encodes chloride channel 
protein 2) (Everett et al., 2007b; Saint-Martin et al., 2009) genes have been linked to absence 
epilepsy. Mutations in CACNA1A gene which encodes for the a1A subunit of P/Q-type high 
voltage gated Ca2+ channels have been reported in patients with absence seizure and episodic 
ataxia (Jouvenceau et al., 2001; Imbrici et al., 2004). This mutation was also found in a few 
mouse models of absence epilepsy and ataxia (Fletcher et al., 1996; Doyle et al., 1997; Fletcher 
and Frankel, 1999; Wakamori et al., 1998). In summary, population-wide association analysis 
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and investigation of genetic variants in specific probands showed that no single gene is 
ubiquitously linked to absence epilepsy. It thus appears that this disorder is associated with 
multiple genetic defects. The search for a therapeutic target by utilizing animal models may 
provide useful information.  
 
1.2.4 Age of onset, prevalence and mortality of absence epilepsy 
Childhood absence epilepsy mostly occurs in children and may continue into adulthood. The 
age of onset of this disorder is 2-12 years with peak manifestations at 5-7 years of age. In terms 
of gender, boys and girls are equally affected but girls are believed to be more susceptible to 
develop absence epilepsy (Crunelli and Leresche, 2002a). One study has shown that 59-73% 
of cases of absence epilepsy occur in females (Durá and Yoldi, 2006). Prevalence of this 
disorder has been estimated from 0.4 to 0.7 per 1000 individuals (Jallon and Latour, 2005); 
and, the incidence of this disorder is 36 per 100,000 individuals (Aaberg et al., 2017). Absence 
epilepsy does not cause deaths directly but there is always a risk of physical injury to the 
children when individuals face episodes of absence seizures while swimming, cycling, etc. 
These injuries may lead to death.  
 
1.2.5 Prognosis and treatment of absence epilepsy 
Several epidemiologic cohort studies have reported wide range of remission rates of CAE. It 
should be noted that these remission rates depend on the different selection criteria adopted in 
those studies, diverse follow-up periods, age at last assessment, therapy, inclusion of absence 
epilepsies other than CAE etc. It has been reported that remission rate of absence epilepsy is 
up to 74% (Tenney and Glaucer, 2013). Five-year remission rate ranges from 56-65% (Wirrell 
et al., 1996; Trinka et al., 2004). In one third of patients, seizures remain either as absence 
seizures (10-15%) or absences with either myoclonic or generalized tonic–clonic seizures (5–
15%) or develop into juvenile myoclonic epilepsy (5-15%) (Camfield et al., 2014). One study 
showed that absences persisted beyond the age of 20 years in only 10% of patients (Loiseau et 
al., 1995). One recent study reported that if absence epilepsy persists beyond adolescence, 
long-term seizure and psychosocial outcome do not differ between childhood and juvenile 
onset of absence epilepsy (Holtkamp et al., 2017). JAE presents in late childhood or 
adolescence, where 80% of subjects suffer from generalized tonic-clonic seizures, infrequent 
typical absences and myoclonic jerks and often achieve seizure control. Patients with JAE 
usually require lifelong treatment (Wirrell et al., 2003). Studies have also shown that the 
tendency to develop generalized tonic-clonic seizure is high when absence epilepsy develops 
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later in childhood (past 8 years of age). Such risk is as high as 50% (Bouma et al., 1996). It is 
important to note that even after complete remission, individuals require special educational 
help. They face linguistic difficulties and are less likely to graduate from high school or attend 
college/university as their academic performance is below average. They also experience long 
term psychosocial impairment (Wirrell et al., 1997; Pavone et al., 2001; Camfield et al., 2014). 
Altogether, it seems that higher the patient’s age, chance of terminal seizure remission 
increases and it's still unclear if CAE needs to be treated beyond adolescence.   
AEDs are used for the treatment of CAE to reduce the frequency of seizures. ETX and valproic 
acid are the first choice AEDs used for the treatment of absence epilepsy which act on T-type 
calcium channel and sodium-channels. ETX reduces the amplitude of the low-threshold (T-
type) calcium current in the neurons of the ventrobasal complex and the reticular nucleus of 
the thalamus; however, valproic acid is believed to increase the level of γ-aminobutyric acid 
(GABA) in the brain and affect sodium and calcium channels (Matricardi et al., 2014). Success 
rate of ETX and valproic acid lies between 70-80% (Richens, 1995; Schachter, 1997; Hwang 
et al., 2012), but a systemic review of clinical studies published in 2010 concluded that there 
is insufficient evidence to recommend any drugs for clinical practice against absence epilepsy. 
This review criticized the poor methodological quality and insufficient number of participants 
used in clinical trials (Posner et al., 2005). Large-scale clinical trials conducted after this 
publication suggest that efficacy of ETX and valproate were considerably lower i.e. 45-53% 
(ETX) and 44-58% (valproate) (Glauser et al., 2010; 2013) than previous findings.  Patients 
unresponsive to monotherapy of either ETX or valproic acid and lamotrigine were found to 
have responded to a combination of two of the three drugs (Schachter, 1997; Glauser et al., 
2010). Various other drugs such as clonazepam, benzodiazepine, and acetazolamide are also 
prescribed in small doses for the treatment of this disorder (Hughes, 2009; Panayiotopoulos, 
1999). Medications that are used to treat convulsive seizures (such as phenytoin, 
carbamazepine, vigabatrin, tiagabine) have been found to worsen absence seizures (Schachter 
et al., 1997; Parker et al., 1998; Perucca et al., 1998) and to induce seizure in some cases 
(Schapel and Chadwick, 1996; Ettinger et al., 1999). Several studies have reported that AEDs 
can have adverse side effects in patients which include ataxia, sedation, dizziness and cognitive 
dysfunction. Seizure aggravation, poor efficiency, unpredictability of effect, loss of effect 
during prolonged treatment and drug resistance are other major problems associated with AEDs 
(Bauer, 1996; Abou-Khalil, 2012; van Luijtelaar and Sitnikova, 2006). The tolerability profile 
of each drug is different and drug interaction is another major issue in the clinical use of AEDs 
(Patsalos and Perucca, 2003a; 2003b; French and Pedley, 2008).  
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Hence, more targeted approaches are required for the treatment of absence epilepsy which are 
safe, effective, and patient specific. This requires a deep understanding of cellular and 
molecular mechanisms of absence seizures to develop novel therapeutic targets and discovery 
of new AEDs. 
 
1.2.6 Pathogenesis of absence epilepsy in human patients and animal models 
CAE is considered as a disorder with a multifactorial genetic etiology. No significant and 
conclusive findings were obtained from genetic analysis. Remission rates and effectiveness of 
treatment and are encouraging but not promising. Pathophysiological mechanisms are still 
unclear and mostly unknown. The use of animal models, however, has allowed us to conduct 
various types of experiments and interrogate the mechanisms underlying this disorder which 
are impossible to perform on human patients. Findings gathered from animal and human 
studies regarding the pathogenesis of this disease are described below.  
 
1.2.6.1 Animal models 
Animal models are powerful tools to examine and understand the basic principles and 
mechanisms of diseases and disorders. To date, various animal models of epilepsy or epileptic 
seizures are established and characterized. They mirror the genetic make-up and/or the 
phenotype of human epileptic patients. Some models of epilepsy or epileptic seizures are 














Fig. 1.6 An overview of models of epilepsy or epileptic seizures (Taken from D’Amore, 2016) 
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The focus of this thesis is absence epilepsy. So, the existing absence epilepsy models or 
absence seizure models will be briefly described.  
 
Animal models related to absence epilepsy  
The utility of any model depends on a number of parameters such as similarity to human 
condition and symptoms, predictive validity and tractability to investigation. The animal 
models related to absence epilepsy that has been developed and characterized can be broadly 
classified into two groups i.e. pharmacological models in which seizures are induced by the 
administration of drugs or chemical substances and genetic models which involve strains that 
are genetically predisposed to absence seizures. Pharmacological models are widely popular 
where chemicals such as PTZ, γ-Hydroxy-butyrate, penicillin, bicuculline, picrotoxin etc. are 
acutely or chronically administrated to induce absence seizures. These models are normally 
used to elucidate the mechanisms of ictogenesis but not epileptogenesis (Avanzini, 1995; 
Kostopoulos, 2017). These chemicals are efficiently used to screen antiepileptic drugs in 
epileptic studies (Krall et al., 1978; Snead, 1992; Löscher, 2011; Velíšková et al., 2017). On 
the other hand, genetic rodent models of absence epilepsy show spontaneous seizures and 
closely reflect the pathophysiology of human absence seizures. Genetic models are widely used 
to interrogate and understand the pathogenesis of absence epilepsy. Stargazer mouse, GAERS 
and WAG/Rij are currently the most widely used animal models of absence epilepsy which are 
briefly described below.  
Stargazer mice 
The stargazer mouse model is one of over 20 monogenic mouse mutants showing the same 
phenotype i.e. frequent SWDs associated with behavioral arrest that are sensitive towards anti-
absence epileptic drug ethosuximide (Maheshwari and Noebels, 2014). In the 1980s, abnormal 
behavioural features such as unsteady gait and repeated head elevations were seen in A/J mouse 
inbred strain at The Jackson Laboratory (JAX#001756) (Noebels et al., 1990). Later, breeding 
studies revealed the genetic cause. Electro-clinical feature (6-7Hz SWDs with behavioural 
arrest) of this animal model was also characterized and was found to be similar to absence 
seizure in humans (Noebels et al., 1990). It was also revealed that SWDs first appear around 
postnatal days 17-18 in stargazers (Qiao and Noebels, 1993).  
 
Stargazers are the result of defect in the calcium channel g2-subunit gene CACNG2 which 
reduces the expression of stargazin protein (Noebels et al., 1990; Letts et al., 1997; 1998). 
Stargazin is a transmembrane AMPAR regulatory protein (TARP) critical for synaptic 
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targeting and membrane trafficking of AMPARs at excitatory glutamatergic synapses (Chen et 
al., 2000). AMPA receptors are glutamate-gated ion channels, which primarily mediates the 
fast-excitatory synaptic transmission in CNS. Release of glutamate at the excitatory synapse 
leads to the rapid opening of AMPA receptors and membrane depolarization. Defects of the 
stargazin protein causes the loss of AMPARs which impairs excitation at glutamatergic 
synapses. This might lead to the loss of function of inhibitory neuron synapse and alter CTC 
network oscillations. Studies have shown that there is significant reduction of GluA4 
containing subunits of AMPARs in cortical PV+ inhibitory neurons in stargazer mice. These 
studies concluded that loss of excitatory drive onto inhibitory PV+ interneurons may be 
involved in the generation of seizures (Adotevi and Leitch, 2016; 2017; 2019). Other studies 
have also shown that impaired AMPA receptor regulation in the SScortex (Maheshwari et al., 
2013) and thalamus (Menuz and Nicoll, 2008; Barad et al., 2012) may contribute in generation 
of absence seizures. In addition, GABA level (Hassan et al., 2018) and GABAR expression 
(Seo and Leitch, 2014; 2015) were found to be upregulated in the CTC network of stargazers. 
This is also believed to contribute to absence seizures in stargazer mice.  
 
Rat absence epilepsy models 
GAERS and WAG/Rij are the two most frequently used rat polygenic models of absence 
epilepsy (Marescaux and Vergnes, 1995; Coenen et al., 1992). GAERS were developed by 
selective breeding of the 30% of Wistar rats displaying short and irregular spontaneous SWDs. 
WAG/Rij strain is an inbred strain of albino rats. These rat models feature 7–11 Hz SWDs 
which starts in the cortex and spread bilaterally to both cortical and thalamic regions (Meeren 
et al., 2002; Polack et al., 2007; Rudolf et al., 2004). SWDs first appear at around 2 months 
and postnatal day 30 in WAG/Rij and GAERS, respectively (Coenen and Van Luijtelaar, 2003; 
Marescaux and Vergnes, 1995). In both models, number, duration and frequency of SWDs 
increases with age. Even though, the frequency of the oscillations seen in these rat models are 
higher than in human patients, the waveform of the SWDs in EEG is remarkably similar to the 
ictal waveforms seen in human patients with absence epilepsy (Sitnikova and van Luijtelaar, 
2007).  
In human absence seizure, SWDs typically recur at a slow frequency of about 3 Hz (2.5-4 Hz), 
whereas in rodent models they occur faster i.e. epileptic stargazers (6-7 Hz) and GAERS and 
WAG/Rij rats (7–11 Hz). Features of SWDs exhibit the same general trend and belong to the  
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Stargazer PN17-18 6 6-7 CACNG2 Absence, ataxia, headtossing 
Tottering ~4 weeks 0.3-10 6-7 CACNA1A Absence, ataxia, focal motor 
seizure 
Lethargic After PN15 0.6-5 5-7 CACNB4 Absence, ataxia, focal motor 
seizure, lethargic, dyskinesia 
Ducky - 0.6-5 5-7 CACNA2D2 Absence, ataxia, dyskinesia 
C3H/Hej ~PN26 3.4 7-8 Natural IAP retrotran-
sposon insertion in Gria4 
Absence 
Rocker - 1-1.7 6-7 CACNA1A (chemical 
mutagenesis) 






Oscillations: PN15-25 2-3 5-6 CACNA1H Absence 
Mixed SWDs: PN26-40 5-9 5-6 
SWD: >PN60 12-22 7-9 
WAG/Rij ~2 months 1-45 7-11 - Absence 
GRY 6-8 weeks 8-10 7-8 CACNA1A Absence, ataxia 
SER 7-8 weeks 1-17 5-7 tm and zi Absence, tonic, tonic-clonic 
 
Table 1.2 Epileptic features of genetic models of absence epilepsy in mice and rats. The main characteristics is the presence of SWDs which 
varies in terms of duration and rhythmicity. The age of onset of SWDs also varies with strain and species. Reported mutations mainly concern 
calcium channels. PN: postnatal day (Adapted from Jarre et al., 2017). 
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same electrophysiological phenomena in all rodent models, some parameters of SWDs show slight 
to significant differences between rodent models (Onat et al., 2007, Akman et al., 2008, 
Chahboune et al., 2009). Akman and colleagues have reported that the number, cumulative total 
duration and mean duration of SWDs are significantly higher in GAERS compared to another rat 
model (WAG/Rij), while the discharge frequency is higher in the WAG/Rij.  
 
In relation to the nature of the SWDs waveforms, spike (upward defections) and late positive 
transient (downward defections) are larger in the GAERS group implying a single cycle of the 
SWD contains more energy in faster components (spike and late positive transient) in the GAERS 
(Fig. 1.4). On the other hand, mean SWD frequency for WAG/Rij is significantly higher in the 
beginning of each SWD and decreased strongly than that in GAERS (Akman et al., 2010). Such 
differences in the SWD phenotype may be due to the changes in specific components of the basic 
mechanism that is probably common for both strains (Akman et al., 2010). Genetic studies on 
GAERS (Rudolf et al., 2004) and WAG/Rij (Gauguier et al., 2004) rats showed polygenic control 
of SWDs and also the differential effect of gene variants (at the loci) on the average duration and 
number of SWDs. One example of such difference was reported by Powel and colleagues in 2009. 
They found a T-type Ca2+ channel mutation plays significant role in the absence epilepsy 
phenotype in GAERS in terms of number and cumulative duration of seizures. Interestingly, 
WAG/Rij rats did not carry any copy of this mutation (Powell et al., 2009). Thus, differences in 
features of SWDs might be important variables in defining phenotypes of the absence epilepsy and 
distinctly different spike-wave cycle seen in GAERS compared to other models might be an 
additional phenotypic feature of absence epilepsy. The epileptic features of animals described 
above and other few other rodent models of absence epilepsy (such as tottering, ducky, rocker and 
C3H/Hej, GRY, SER etc.) are shown in the Table (Table 1.2).  
 
1.2.6.2 Human patients 
New imaging techniques have been particularly successful in detecting changes in the epileptic 
brain of human patients. These methods include magnetic resonance imaging (MRI), proton 
magnetic resonance spectroscopy (PMRS), low-resolution electromagnetic tomography 
(LORETA), positron emission tomography (PET), diffusion tensor imaging (DTI), functional MRI 
(fMRI), single photon emission spectroscopy (SPECT), intrinsic optical signal (IOS) imaging, and 
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near-infrared spectroscopy (NIRS) (Lenkov et al., 2013). Outcomes from the use of these 
techniques in patients with other forms of epilepsy have been very promising (Chahboune et al., 
2009; Mishra et al., 2011), but these techniques are not heavily used and researched in patients 
with absence epilepsy. Most of the imaging techniques described below are based on the same 
basic principle that increased neuronal activity increases the metabolism which changes the 
cerebral blood flow and the amount of oxygen consumed. 
Studies have shown that PET was the first imaging technique utilized in patients with absence 
epilepsy. Result from these studies indicated that there is an increase of neocortical and thalamic 
glucose metabolism in children with absence epilepsy (Engel et al., 1985;1996; Ochs et al., 1987; 
Iannetti et al., 2001). Similarly, 4-8% of the increase in thalamic blood flow was seen in patients 
during absence seizures (Prevett et al., 1995) and few contrasting results were observed. A SPECT 
study found an increased blood flow, but another technique, Doppler ultrasound, revealed 
reduction of blood flow in the middle cerebral artery during episodes of absence seizures (Bode, 
1992; Yeni et al., 2000; Nehlig et al., 2004). NIRS reported increased cerebral blood volume in 
patients with convulsive seizures but in patients with absence epilepsy there was a mild reduction 
in cerebral blood volume (Haginoya et al., 2002). 
A combination of LORETA and 256 channel EEG scalp recording with equivalent dipole (BESA) 
have shown that SWDs are distributed onto distal cortical areas during absence seizures (Holmes 
et al., 2004; Tucker et al., 2007; Clemens et al., 2011). The use of fMRI also demonstrated the 
participation of thalamic and cortical networks during absence seizures (Salek-Haddadi et al., 
2003). Recently, combination EEG-fMRI has revealed changes in blood-oxygenation-level 
dependent (BOLD) effect in the basal ganglia–thalamocortical network during interictal and ictal 
events of absence seizures (Li et al., 2009). In agreement with the results from Li and colleagues, 
other studies have reported the involvement of cortical-subcortical network during absence 
seizures (Salek-Haddadi et al., 2003; Berman et al., 2010; Moeller et al., 2010). In addition to the 
methods explained above, other techniques such as optical imaging of intrinsic signal (IOS), 
voltage-sensitive dye imaging (VSD), photoacoustic imaging (PA) and optical coherence 
tomography (OCT) are also emerging as techniques offering maximum potential but have not been 
used extensively in absence seizure research (Lenkov et al., 2013).  
Imaging studies on human patients have also indicated the involvement of cortical and thalamic 
regions of the brain during the episodes of absence seizures. These studies suggest that the 
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dysfunctional CTC network is one of the reasons underlying absence seizure generation. However, 
precise cellular and molecular mechanisms underlying absence seizure generation are not fully 
understood. Therefore, a deep understanding of anatomical framework and neuronal elements of 
CTC network, and their normal functioning is required which is described in the next section.  
 
1.3 The Cortico-thalamocortical Network 
The CTC network is the complex network of reciprocal connections between two crucial brain 
structures i.e. cortex and thalamus. Communication between these two regions are mediated by 
thalamocortical (TC) and corticothalamic (CT) pathways (Jones, 2002; Pinault and O’Brien, 
2005). Anatomical function and structure of the CTC network can be divided into cortical and 
thalamic components.  
 
1.3.1 The cerebral cortex  
The cortical part is entirely composed of neocortex which makes up around 76% of the entire brain 
and 90% of the cerebral cortex. Cellular organization of the neocortex is a vertical six-layered 
arrangement into functional units called cortical layers (Noback et al., 2005). The cortex is made 
up of both excitatory and inhibitory neurons. 80% of all cortical neurons are excitatory pyramidal 
neurons while the remaining 20% are inhibitory interneurons (Markram et al., 2004). The most 
superficial layer I which is also known as the molecular or plexiform layer, contains very few 
neurons and mostly axons, dendrites and axon terminals of neurons whose cell bodies are located 
in deeper cortical layers. Layers II and IV contain densely packed granule cells and are known as 
the external granular layer and internal granular layer, respectively. Layers III and V contain 
mainly pyramidal cells which are referred to as the external pyramidal layer and internal pyramidal 
layer respectively. Layer VI is known as the multiform layer and contains several different 
neuronal types including some fusiform cells, granule cells and pyramidal cells. Cortical layers I-
III primarily form intracortical connections whereas V-VI layers serve as the output layers 
connecting the cortex to other subcortical regions (Akgül and McBain, 2016). The internal granular 
layer (layer IV) and multiform layer (layer VI) are the integral part of the CTC network as layer 
IV receives TC projections from thalamic nuclei and layer VI sends reciprocal excitatory CT 
projections back to the thalamus (Markram et al., 2004). The cortex generally relies on potent 
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GABAergic inhibition to regulate neural cortical excitability and excitatory TC input (Jones, 
2009). 
1.3.2 The thalamus 
The thalamus is situated between the cerebral cortex and midbrain, superior to the brain stem. It 
provides the largest source of afferent fibers to the cerebral cortex. It is functionally composed of 
different nuclei that are involved in the relay of motor and sensory signals to the cerebral cortex 
(Sherman and Guillery, 1996; 2002). Thalamic nuclei are reciprocally connected with the cortex 
which controls the flow of information to a specific cortical region (Siegel and Sapru, 2011).  
 
Reticular thalamic nucleus (RTN) 
During development, RTN migrates dorsally and ends up as a thin capsule of GABAergic neurons 
wrapping around the dorsal thalamus laterally, anteriorly, and partially posteriorly and ventrally. 


























Fig. 1.7 A simplified illustration of the CTC network showing reciprocal connections between cortex and 




the corticothalamic (CT) projection forming the CT-RTN connection. It also receives excitatory 
input from the thalamocortical (TC) relay neurons (Liu and Jones, 1999). TC and CT projections 
to the RTN are reciprocally connected which allows the RTN to evaluate information transmitted 
to-and-from the cortex (Steriade et al., 1987; Fuentealba et al., 2005a; 2005b) as shown in figure 
1.7. CT inputs to the RTN are more numerous than TC inputs which forms about 70% of synapses 
onto the RTN neurons. 
 
Ventral Posterior (VP) nucleus 
The ventral posterior (VP) nucleus is composed of two nuclei i.e. ventral posterolateral nucleus 
(VPL) and ventral posteromedial nucleus (VPM). The relay neurons of the VP are excitatory, and 
these neurons receive excitatory input from the peripheral afferent fibers and cortical CT 
projections (Sherman and Guillery, 1996). The main source of inhibition in VP comes from the 
RTN (Fuentealba and Steriade, 2005a; 2005b). VP relay neurons also send excitatory TC 
projections to the cortical principal cells and collateral fibers to the RTN. 
The fundamental anatomy of the various projections of the CTC network are listed below 
(McCafferty, 2014):  
1) Thalamocortical (TC): thalamic nuclei to layer IV (primarily) of associated cortical region. 
2) Intracortical connections: inter-layer (IV to II/III, IV to V/VI) and inter-region (II/III to II/III, 
II/III to V/VI). 
3) Corticothalamic (CT): layers V and VI to specific and non-specific thalamic nuclei, the majority 
being precise reciprocals of TC projections. 
4) Intrathalamic connections: extent unknown. 
5) Thalamoreticular and corticoreticular: collaterals from TC and CT projections innervating RTN 
en route to associated cortical & thalamic region respectively. 
6) Reticulothalamic: sole projections of RTN, inhibiting TC cells in the thalamic nucleus. 
7) Intrareticular: inhibitory communications between neurons of the RTN. 
 
Thalamic relay neurons of the VP region and the cortical pyramidal neurons form mutual 
excitatory connections that are regulated through the activation of inhibitory interneurons within 
the thalamus and the cortex (McCormick and Contreras, 2001). The organization of the CTC 
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circuitry allows the inhibitory neurons of the RTN to be excited by collateral inputs coming from 
both the cortex and the TC relay cells, thus shifting between oscillatory and burst firing modes in 
order to regulate external stimuli. These modes are dependent on the state of voltage-dependent T-
type Ca2+ channels (Williams and Stuart, 2000), which are highly expressed in the cortex and 
thalamus and are positioned to regulate synchronized oscillations within the CTC circuitry. As 
illustrated in the figure 1.7, the thalamic relay neurons receive sensory afferents from the periphery 
and project excitatory glutamatergic TC fibers to the excitatory pyramidal neurons and fast spiking 
interneurons within layer IV of the cortex. In turn the cortical neurons project reciprocal CT fibers 
from layer VI to the thalamic relay neurons. TC and CT projections also send excitatory collaterals 
to RTN. RTN neurons via FFI generate GABA mediated inhibitory postsynaptic potentials (IPSPs) 
to VP relay neurons which hyperpolarizes thalamic relay neurons. The IPSP deinactivate T-type 
calcium currents and produces action potential bursts of the relay neurons. This post inhibitory 
burst firing of the TC relay neurons then excites both cortex and RTN to begin a cycle of rhythmic 
oscillatory activity.   
Neuronal firing in the CTC network is dependent on the physiological state of the animal. Sleep 
spindles are characterized by low amplitude/high frequency activity whereas wakefulness is 
characterized by high amplitude/low frequency activity. Normal activity of the components of 
CTC network results in rhythmic spindle-like oscillation (also known as synchronized neuronal 
firing) which are required for normal brain functioning.  
Rhythmic spindle-like oscillations changes into pathological SWDs due to the dysfunctional 
behavior within the CTC network (Kostopoulos, 2001; Blumenfeld; 2002; Crunelli and Leresche, 
2002a). However, there is a long-standing debate about the role of CTC components on the 
pathophysiology of absence seizures. The existing theories in the pathophysiology of absence 
seizures, various concepts postulated in the past regarding the involvement of cortex and thalamus 
in absence seizure generation and recent developments are briefly described below and illustrated 
in the figure 1.8.  
Centrencephalic theory 
This theory was based on the findings from the studies conducted in human patients and cats 
(Jasper and Kershman, 1941; Morison and Dempsey, 1942; Jasper et al., 1947). According to this 
theory, epileptic discharges originate from the ‘centrencephalic integrating system’ which is 





Studies conducted by Gibbs and Gibbs in 1952 and Bennett in 1953 raised concerns over the 
validity of the centrencephalic theory (Gibbs and Gibbs, 1952; Bennett, 1953). The cortical theory 
purposed the leading role of the cortex in the generation of generalized absence seizures which 
was later supported by the work from other research groups (Bancaud, 1969; Niedermeyer, 1972; 
Lüders, 1984). Altogether, these studies postulated that generalized absence seizures are primarily 
due to cortical abnormalities and thalamus only has a secondary role in carrying out the 
thalamocortical interactions.  
 
Corticoreticular theory 
In 1968, Gloor purposed the essential roles of both the cortex and reticular system (thalamus and 
brain stem) in the generation of absence seizures (Gloor, 1968). This proposal was later refined by 
a study in the cat model of feline penicillin generalized epilepsy (Prince and Farrell,1969). This 
theory is still widely accepted although the specific roles of cortex and thalamus and the exact 
mechanisms are still debated.  
 
Thalamic clock theory 
In 1991, Buzsàki proposed the thalamic clock theory. In his experiments, thalamic lesions 
(specifically RTN cells) stopped cortical high voltage spindles but ablation of cortex didn’t abolish 
thalamic high voltage spindles in Fischer 344 rats. Buzsàki hypothesized that RTN contain the 
pacemaker cells for thalamus and phasic bursting in RTN induces bursting in TC relay cells which 
in turn excite more RTN cells. He further stated that these episodes recruit more cells until the 
entire thalamic network is involved in rhythmic discharges. These events finally force the rhythm 
onto the cortex (Buzsàki, 1991). This hypothesis was also supported by studies conducted in two 
other rat strains (GAERS and WAG/Rij) (Avanzini et al., 1992; Inoue et al., 1993; Seidenbecher 
et al., 1998). Altogether, these studies concluded that RTN serve as the pacemaker and TC relay 






Cortical focus theory and recent developments 
The cortical focus theory was purposed by Meeren and colleagues after performing nonlinear 
association analysis of the multi-site local field potentials measurements in the cortico-thalamic 
regions in WAG/Rij rats. They found that absence seizures initiate from the peri-oral region of 
primary SScortex. SWDs recorded in the other regions lagged behind this focal site. In their 
experiments, they consistently found cortical focus always leading the thalamic counterpart during 
the first few seconds (~500ms) of seizures. Afterwards, cortex and thalamus regions lag and lead 
the discharges in an unpredictable way (Meeren et al., 2002).  
 
Results from other studies also supported the ‘cortical focus theory’. In GAERS, SWDs were 
found to be originated from SScortex (barrel field region) (Polack et al., 2007; Studer et al., 2019) 
and in pharmacological animal model (gamma-hydroxybutyric acid) absence seizures originated 
from prefrontal cortex (Snead et al., 1992; Venzi et al., 2015). This was confirmed when regional  
blocking of the firing of the neurons by infusing sodium channel blocker tetrodotoxin in SScortex 
(but not in motor cortex) of GAERS prevented absence seizures (Polack et al., 2009). These animal 
models were more sensitive to ethosuximide applied in the primary SScortex than ventrobasal 
thalamus or motor cortex (Marescaux et al., 1984; Richards et al., 2003; Manning et al., 2004). 
Notably, a recent study found that spontaneous SWDs seen in PLCβ4 knock-out mice originates 
from SScortex (Lee et al., 2019).  
 
In relation to the initiation of absence seizure in human patients, EEG, MEG and fMRI studies 
conducted in young to adult populations, have shown neuronal activity changes in different regions 
of the cortex such as posterior cingulate cortex, precuneus, lateral parietal cortex and/or frontal 
cortex before the involvement of other regions of the brain (Holmes et al., 2004; Westmijse et al., 
2009; Carney et al., 2010; Bai et al., 2011; Gupta et al., 2011; Benuzzi et al., 2012; Tenney et al., 
2013; Wu et al., 2017). The first study on a cohort of patients with CAE have shown pre-ictal 
increase in blood oxygenation level-dependent signal amplitude in cortical area(s) (Bai et al., 2010, 
2011; Moeller et al., 2010). Recently, a study investigated the dynamic behavior of large-scale 
brain networks by utilizing the phase synchrony data of the BOLD signal between different brain 
regions in people with generalized SWD and concluded that at least a minute before absence 























Fig. 1.8 Schematic representation of the 5 theories on the origin of generalized absence epilepsy. Thalamic theories are shown in the left side: the 
centrencephalic theory of Penfield and Jasper, and the thalamic clock theory of Buzsáki. Cortical theories are shown in the right side: the cortical theory of Bancaud, 
Lüders and Niedermeyer, and the cortical focus theory of Meeren and colleagues. Corticoreticular theory of Gloor is shown in the middle. (Taken from Lüders et 
al, 1984 and Meeren et al., 2005)
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various cortical regions show linear and significant increase in synchrony. Such high level of 
synchrony was evident in the cortical regions even 20 seconds after the end of electrographic  
activity (Tangwiriyasakul et al., 2018). Rodent models of absence seizures, however, do not 
show widespread cortical changes in cerebral blood flow/volume and fMRI as seen in human 
patients. These variabilities might be due to the differences in cortical functions between 
human and animal models or mechanistic limitations of rodent models or anesthetics procedure 
used during animal imaging (reviewed in Crunelli et al., 2020). In summary, these data from 
animal and human studies indicate that altered cortical network is the originator of absence 
seizures.  
However, experimental evidence suggests that thalamic regions are also responsible in 
generating absence-SWDs in animals (Avoli, 2012; Taylor and Crunelli, 2014; Luttjohann and 
Van Luijtelaar, 2015; Sorokin et al., 2017). Pharmacological manipulations such as infusion of 
GABA agonists into thalamus of GAERS promoted SWDs but infusion of GABA or glutamate 
antagonists prevented SWDs (Marescaux et al., 1992; Danober et al., 1998; Paz et al., 2007, 
Cope et al., 2009). Studies have shown that unilateral lesioning of the rostral region of RTN 
caused the complete suppression of SWDs but lesion on the caudal RTN (keeping rostral RTN 
intact) increased bilateral SWDs (Avanzini et al., 1993; van Luijtelaar & Weltink, 2001; 
Berdiev et al., 2007; Meeren et al., 2009). And, blocking GABAA receptors of RTN (using 
antagonists) increased the duration and number of SWDs (Aker et al., 2002; 2006). 
Counterintuitively, cortical infusion of ethosuximide, lidocaine or tetrodotoxin significantly 
suppressed SWDs in epileptic animals (Polack et al., 2009, Manning et al., 2004, Sitnikova and 
van Luijtelaar, 2004) whereas thalamic delivery was not sufficient to cease SWDs (Richards 
et al., 2003, Polack et al., 2009). Altogether, these studies indicate that even though absence 
seizures are initiated in the cortex, thalamic components themselves can recruit cortical 
network for absence seizure generation.  
The CTC oscillations are primarily dependent on GABAergic and glutamatergic 
neurotransmissions and normal CTC functioning is due to the reciprocity of the excitatory and 
inhibitory mechanisms which are described in terms of ‘microcircuits’ (Paz and Huguenard, 
2015). Disruption or disturbance of any of these microcircuits may lead to the generation of 
seizure.   
1.4 Microcircuit motifs of the CTC network 
Feed-forward excitation (FFE), FFI, feed-back/recurrent excitation (FBE), feed-back/recurrent 
inhibition (FBI), convergence/divergence and counter inhibition are the common microcircuit 
motifs of brain. However, FFI, FBI, FBE and counter inhibition are the motifs of the CTC 
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networks whose dysfunctions have been identified in epilepsy (Fig. 1.9) (Paz and Huguenard, 












Fig. 1.9 Different microcircuit motifs involved in epilepsy. (A) Feedback/recurrent excitation (FBE): 
Presynaptic neuron excites a postsynaptic neuron and that postsynaptic neuron excites the presynaptic neuron. (B) 
Counter inhibition: Inhibitory interneurons form a network for inhibitory output. (C) Feed-back Inhibition (FBI): 
Activation of inhibitory neurons controls the local excitatory activity (D) Feed-forward Inhibition (FFI): An 
inhibitory interneuron is excited by a presynaptic cell which then inhibits the next follower cell. Purple and red 
represent excitatory glutamatergic and inhibitory GABAergic neurons, respectively. (Taken from Paz and 
Huguenard, 2015)  
 
A. Feedback/recurrent excitation (FBE) 
This is the major form of connectivity in the cortex and the hippocampus. Cortex mostly 
receives excitatory input from the cortical excitatory neurons (Braitenberg and Schutz, 1991) 
and few from the thalamic relay nuclei (Gil and Amitai, 1996; Porter et al., 2001). Recurrent 
excitation activates both excitatory pyramidal neurons and local inhibitory interneurons. The 
latter is believed to control the amplitude and spread of the recurrent excitation resulting in 
proportionality or balance (Douglas et al., 1999).  
 
B. Counter inhibition  
Counter inhibition occurs due to the suppression of the firing of inhibitory interneuron by 
another inhibitory interneuron. In a similar manner the suppressive effect on target excitatory 
cells via FFI and FBI, the counter inhibition forms a network for inhibitory output in some 
interneurons. Counter inhibition promotes excitatory activity by disinhibiting downstream 
excitatory cells. Such disinhibition between inhibitory interneurons (PV+ cells) promoting 
oscillatory output have been implicated in ictogenesis in limbic epilepsy (Grasse et al., 2013). 
The concept of intra-RTN inhibition (inside RTN) is thought to be an example of counter 
inhibition but this remains controversial because it is unclear that inhibition in RTN is either 
intra-RTN inhibition (via counter inhibition) or via external GABAergic inputs. An in vivo 
study conducted by deleting RTN specific GABAA receptor β3 subunits caused the specific 
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loss of intra RTN inhibition and enhanced the generation of epileptic seizures (Huntsman et 
al., 1999). In support of this, it has been revealed that clonazepam reduces the output of RTN 
neurons to TC cells by uplifting (enhancing) intra RTN counter inhibition (Huguenard and 
Prince, 1994). Recently, using optogenetics, researchers have found that intra-RTN inhibition 
only occurs in mice up to two-weeks post birth (not in adult mice) and that the majority of 
GABAergic inputs come from other brain regions (Hou et al., 2016). This was also supported 
by another recent study which found that GABAergic neurons of the lateral hypothalamus 
innervate the RTN and induce excitation (Herrera et al., 2016). This is controversial since 
1990s when some researchers found axonal collaterals between RTN neurons (Cox et al., 
1996), whereas others did not find such projections (Pinault et al., 1997;1998).   
 
C. Feedback inhibition (FBI) 
Feedback inhibition mostly occurs within the local networks. It can be classified into recurrent 
and lateral feedback inhibition. In recurrent feedback inhibition, neurons are activated by local 
excitatory neurons and in turn inhibit the neurons that excited them. However, in lateral 
feedback inhibition neurons not only inhibit specific excitatory cells from which it received 
excitatory input but also targets others within the network (Tremblay et al., 2016). 
 
D. Feed-forward inhibition (FFI)    
FFI is the major inhibitory mechanism which regulates the excitation of excitatory neurons and 
synapses. In FFI, a presynaptic cell excites inhibitory neuron and inhibitory neuron then inhibit 
the next following cell. Changes in FFI in different circuits can cause abnormal circuit 
dynamics and can start epileptic seizures. FFI is primarily mediated by fast spiking 
parvalbumin-containing (PV+) inhibitory interneurons (Cammarota et al., 2013; Paz and 
Huguenard, 2015; Jiang et al., 2016). PV+ interneurons upon receiving the excitatory input 
from the adjacent excitatory pyramidal neuron, fire and release GABA onto the other excitatory 
pyramidal neurons. PV+ interneurons make a synaptic contact with pyramidal cells in the cell 
bodies, axonal initial segment and proximal dendrites which enables powerful inhibition, and 
this limits excitation.   
 
1.5 Parvalbumin-expressing (PV+) inhibitory interneurons 
PV+ interneurons are the major class of GABAergic interneurons and are named after the 
characteristic protein they carry i.e. parvalbumin (a regulatory calcium-binding protein). They 
are found in cortical layer II-VI, RTN thalamus, cerebellum, hippocampal regions, and pars 
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reticulata of the substantia nigra (Celio, 1986; Cowan et al., 1990; Schwaller et al., 2002; 
Klausberger et al., 2005).  
PV+ interneurons, typically have fast-spiking, low input resistance, and high-amplitude rapid 
after-hyperpolarization characteristics (Kawaguchi et al., 1987; Kawaguchi and Kubota, 1997), 
which enables them to fire a rapid train of action potentials unlike any other neuron in the 
cortex. They are therefore likely to have a profound impact on the spiking output of their targets 
(for review see Ferguson and Gao, 2018). In the SScortex, PV+ interneurons synapse on to 
soma/proximal dendrites/axon initial segment of excitatory pyramidal cells (Inan and 
Anderson, 2014; Tremblay et al., 2016). PV+ interneurons are densely connected to pyramidal 
cells across cortical layers and areas influencing their excitability (Packer and Yuste, 2011; Hu 
et al., 2014). A single PV interneuron contacts nearly every local pyramidal neuron (Ferguson 
and Gao, 2018). Packer and Yutse (2011) estimated that a typical PV+ interneuron in the cortex 
makes contact with hundreds to thousands of post-synaptic targets (both pyramidal cells and 
other PV+ interneurons) and each excitatory pyramidal cell is contacted by ~50-200 inhibitory 
PV+ interneurons. Studies have shown that these interneurons have a major contribution in 
mediating FFI within the CTC network (Paz and Huguenard, 2015) and other brain networks 
involving the cortex and the thalamus (Delevich et al., 2015; Nassar at al., 2018). These 
interneurons mediate neuronal inhibition via feed-forward and/or feed-back mechanisms in 
other brain regions such as hippocampus (Kullman, 2011; Hu et al., 2014), striatum 
(Szydlowski et al., 2013) and amygdala (Lucas et al., 2016). These features and properties of 
PV+ interneurons enable them to prevent runaway excitation within the CTC network. 
 
1.5.1 PV+ interneurons in CTC network  
Inhibitory interneurons of the CTC network are classified on the basis of their morphological, 
anatomical, biophysical and synaptic properties. PV+ interneurons, somatostatin-expressing 
(SOM+) inhibitory interneurons and vasoactive intestinal polypeptide-expressing (VIP+) 
interneurons are the most common inhibitory interneurons in the CTC network (Tremblay et 
al., 2016). Based on the morphological features, PV+ interneurons are classified into basket 
and chandelier cells. Basket cells have curved axon terminals and target the soma and proximal 
dendrites of pyramidal neurons. Chandelier cells target axon initial segment of pyramidal cells 
and are named ‘chandelier’ because they resemble a ‘candelabrum’ (Inan and Anderson, 2014; 
Tremblay et al., 2016). Basket cells are the most common type of PV+ interneurons of the CTC 
network. PV+ interneurons (both basket and chandelier cells) represent 40% of total cortical 
GABAergic inhibitory interneurons. These interneurons occupy all cortical layers except for 
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layer 1 (Tremblay et al., 2016). Distribution and relative expression of different types of 
inhibitory interneurons within the CTC network cortical layers and RTN in mouse brain is 

























Fig. 1.10 Distribution and relative expression of different types of inhibitory interneurons in cortical layers 
and RTN thalamus. (A) Distribution of PV, SST, and VIP expressing interneurons in cortical layer 1-6 (Adapted 
from Tremblay et al., 2016) (B) Relative proportion of PV and SST expressing interneurons in the anterior-
posterior, medial-lateral, and dorsal-ventral axes of RTN (Taken from Clemente-Pere et al., 2017).  
 
1.6 Functional roles of PV+ interneurons in the CTC network 
1.6.1 Feed-forward inhibition (FFI) in cortex 
Sensory signals from relay neurons of VP region travel to layer IV of cortex. Intracortical 
circuits are connected and composed of a large number of excitatory neurons. These neurons 
boost the excitatory signals to deeper cortical layers. The incoming-excitatory sensory signals 
excite PV+ interneurons in the cortex, which causes the release of inhibitory neurotransmitter 
33 
 
GABA onto the excitatory neurons of the cortex. This causes a powerful inhibition which 
prevents runaway excitation in the neocortex.  
 
1.6.2 Feed-forward inhibition (FFI) in thalamus 
The thalamus is regarded as a sensory relay station which shapes sensory information by means 
of two inhibitory pathways i.e. feed-forward inhibition and feed-back inhibition. It receives 
excitatory input from afferent fibers in the periphery and CT projection from the cortex 
(Sherman and Guillery, 1996). CT neurons from cortical layer VI send reciprocal excitatory 
projections to the VP relay neurons and a collateral branch onto the PV+ inhibitory neurons of 
the RTN, which then provide FFI to VP relay neurons. Intra-RTN inhibition also occur at the 
same time which is believed to participate in an individual burst. The VP relay neurons also 
have excitatory collaterals to the RTN that generate feed-back inhibition on to VP relay 
neurons. It is believed that most of the inhibition in VP regions comes from the RTN via FFI 
which is regulated by PV+ interneurons (Fuentealba et al., 2005a; 2005b).  
 
1.7 PV+ interneurons and neurological disorders 
PV+ interneurons maintain a balance between excitation and inhibition within the CTC 
network. These interneurons are also involved in maintaining different brain functions and 
behaviours. It is thus possible that epilepsy and various neurological disorders arise as a result 
of disruption in the excitation/inhibition balance, dysfunction and impairment of PV+ 
interneurons (Marin et al., 2012; Hu et al., 2014). Dysfunction of these interneurons is regarded 
as one of the reasons for abnormal oscillatory rhythm and memory loss in amyloid precursor 
protein transgenic mice which mimic crucial aspects of Alzheimer’s disease (AD) (Verret et 
al., 2012). Similar abnormalities of PV functioning were seen in other animal models of AD 
(Caccavano et al., 2020; Lu et al., 2020). Studies have shown a strong link between reduced 
expression of PV+ interneurons and GABA hypofunction in adult patients with schizophrenia 
(Akbarian et al., 1995; Hashimoto et al., 2003). Similar abnormalities were also seen in various 
animal models of schizophrenia (Lewis et al., 2012). Reduction in GABAergic transmission 
due to dysfunctional PV interneurons is believed to impair gamma oscillations leading to 
cognitive impairment in schizophrenia (Sohal et al., 2009; Cohen et al., 2015; Parker et al., 
2020). Significant reduction in the number of these interneurons was observed in human 
patients suffering from Huntington disease (Kim et al., 2014). Studies conducted in animal 
models and human patients suffering from autism spectrum disorder have altered functioning 
of PV+ interneurons caused by either decrease in the number of PV+ cells or downregulation 
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of parvalbumin (Filice et al., 2016; Lauber et al., 2016; 2018; Hashemi et al., 2017). Studies 
have also outlined the important role of these interneurons in Parkinson’s disorder (Salin et al., 
2009; Gritton et al., 2019), neuropathic pain (Petitjean et al., 2015) and Tourette syndrome 
(Kalanithi et al., 2005; Kataoka et al., 2010).   
 
1.8 PV+ interneurons and epilepsy 
PV+ interneurons were first characterized and labelled as ‘fast firing neurons’ in the early 1980 
(Celio et al., 1981; Celio, 1984; 1986) and the possibility of a relationship between these 
interneurons and epilepsy was reported a few years later (Sloviter, 1989; 1991a; 1991b). In 
1996, abnormal patterns of immunostaining and altered cytoarchitecture of PV and GAD were 
reported in multiple regions of the neocortex in human patients with temporal lobe epilepsy 
(Marco et al., 1996). One year later, Scotti and colleagues reported the loss of hippocampal PV 
in seizing gebrils. They found a significant reduction in the density of PV stained neurons in 
repeatedly seizing gerbils compared to non-seizing controls (Scotti et al., 1997). PV deficient 
(PV−/−) mice were more susceptible to PTZ-induced seizures (Schwaller et al., 2004) but such 
phenomena was not observed in kainate-induced seizures in PV−/− mice (Bouilleret et al., 
2000a). However, conflicting results have been obtained since then, which showed either 
substantial loss (Bouilleret et al., 2000b; Marx et al., 2013), transient (Sloviter, 1991b; Scotti 
et al., 1997; Wittner et al., 2001) or marginal (Wyeth et al., 2010) reduction of hippocampal 
PV expression in animal models and human subjects of epilepsy. Roles of dysfunctional 
hippocampal PV+ interneurons in epilepsy has also been extensively studied (see review Liu 
et al., 2014). It is widely established that PV+ interneurons regulate the network excitability 
and gamma oscillations in the cortex. Studies have shown that various subunits of voltage-
gated sodium and potassium channels support the functioning of PV+ interneurons and 
impairment of parvalbumin functioning is also linked to defects or mutation of the genes 
encoding those ion channels which regulate the membrane excitability of cortex.   
 
Mutations in the SCN1A gene which encodes for the voltage-gated sodium channel Nav1.1 
represents a common genetic cause of generalized epilepsies and Dravet syndrome. Recent 
studies have shown that the inactivation of one SCN1A allele in PV interneurons results in 
spontaneous seizures in animals (Ogiwara et al., 2007; Dutton et al., 2013). Specific deletion 
of SCN1A in GABAergic inhibitory interneurons in the forebrain resulted in generalized 
seizures and premature death (Cheah et al., 2012).  
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Epilepsy phenotype seen in KCNA1–/– mice lacking the voltage-gated potassium channel 
Kv1.1 is attributed to the impaired excitability of cortical PV+ interneurons (Goldberg et al., 
2008; Gautier et al., 2015). KV3.1, KV3.2 and KV3.3, subunits of the KV3 voltage-gated 
potassium ion channels are strongly expressed in cortical PV+ interneurons. A de novo 
mutation in KCNC1 gene (which encodes for KV3.1) have been linked to progressive 
myoclonic childhood epilepsy (Muona et al., 2015). Studies have shown that knocking out 
KV3.1 and KV3.2 subunits in animals results in the impairment of thalamocortical oscillations 
(Espinosa et al., 2008), decreased cortical inhibition and increased susceptibility towards 
seizures (Lau et al., 2000). Mutations in the gene KCNA2, KCNB1, KCND3, KCNQ2, 
KCNQ3 which encodes for Kv1.2, Kv2.1, Kv4.3, Kv7.2 and Kv7.3 potassium channels 
respectively, have been linked with epilepsy in human patients (Soh et al., 2014; Saitsu et al., 
2015; Smets et al., 2015; Syrbe et al., 2015) but the impact of the mutation on PV+ interneurons 
has not yet been established. 
 CaV2.1 (P/Q‐type) calcium channels help to sustain GABA release from PV+ interneurons 
(Zaitsev et al., 2007). A recent study has shown that removal of the CACNA1A gene [which 
encodes the α1 subunit of CaV2.1 (P/Q‐type) voltage‐gated Ca2+ channel] from cortical PV+ 
interneurons generates generalized seizures in mice (Rossignol et al., 2013). The stargazer 
mouse model of absence epilepsy is another example. The stargazer mutation underlying the 
epileptic phenotype is a defect in the calcium channel γ2-sununit gene CACNG2, which 
reduces the expression of stargazin protein. This protein is a transmembrane AMPAR 
regulatory protein (TARP) which is crucial for synaptic targeting of AMPARs. Studies have 
shown that there is a significant loss of GluA4-containing AMPARs at excitatory synapses in 
PV+ interneurons of the cortex and RTN thalamus (Adotevi and Leitch, 2016; 2017; 2019; 
Barad et al., 2012; 2017) which is believed to impair FFI and might contribute to absence 
seizure generation. Other studies have also shown impaired expression and regulation of 
AMPA receptors in the PV+ interneurons in the SScortex (Maheshwari et al., 2013) and the 
thalamus (Menuz and Nicoll, 2008) of stargazers.  
Thus, multiple evidence has shown the functional importance of PV+ interneurons in 
regulating excitability of the neuronal network. Impaired function of these interneurons has 
also been associated with various neurological disorders including epilepsy. Some examples 
were described above. However, there is always a limitation of employing genetic models for 
the characterization of a specific neuronal subtype; for example, functional characterization of 
PV+ interneurons to pinpoint their specific roles by selective (neuron-specific) manipulation 
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in a given neuronal network would be more beneficial. Neuron-specific manipulation will 
allow us to test various hypothesis which are not possible in genetic model.  
    
1.9 Manipulation of neuronal subpopulation  
Selective control of a defined neuronal population is always a challenge. But for the better 
understanding of the neurons that may contribute to the functioning of the brain, behavior or 
phenotype, manipulation of selective neuronal population is crucial. Various strategies and 
techniques have been implemented in the past to selectively modulate neurons in vivo i.e. the 
use of electrical manipulation (such as microstimulation, electrolytic lesions), physical 
manipulation (such as ablation, thermal cooling), pharmacological manipulation (such as the 
use of agonists, antagonists, drug delivery) and genetic manipulation (such as overexpressing 
or knocking out of genes) (Carter and Shieh, 2015). However, these techniques were not 
precise and lacked temporal resolution. They also generated an off-target effect to surrounding 
cells. To overcome these problems and challenges, new tools have been developed and 
continuously optimized over the past few years.   
Pharmacogenetics or chemogenetics is one of the emerging tools of modern neuroscience 
which is used to modulate, examine, and understand the targeted neuronal population of 
different regions of the brain. In simple terms, this technique refers to genetically encoded 
membrane receptors that are designed to be activated by specific chemical compounds. To 
date, the most technically successful chemogenetic tools are DREADDs. This novel 
technology involves insertion of engineered receptors (designer receptors) into specific 
neurons that are only activated by synthetic ligands (designer drugs) As explained above, FFI 
is essential to prevent runaway excitation within the CTC network which is regulated by PV+ 
interneurons. Thus, it is possible to alter/restore the actions of inhibitory feed-forward PV+ 
interneurons with DREADD technology. The use of DREADD technology to manipulate PV+ 
interneurons may be beneficial for understanding the mechanisms of absence seizures. As 
DREADDs are engineered G-protein coupled receptors (GPCRs), the next few sections will 
briefly explain about GPCRs and DREADD technology.  
 
1.10 G Protein Coupled Receptors (GPCRs)  
GPCRs are the largest known class of membrane receptors in eukaryotes. They are also known 
as seven-transmembrane domain receptors or serpentine receptors because of their seven 
transmembrane spanning alpha-helices (Bear et al., 2007). Humans have nearly 1000 known 
different types of GPCRs. These receptors are the targets of 30-50% of all modern medicinal 
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drugs (Overington et al., 2006). They can recognise a variety of ligands including peptides, 
hormones, lipids, neurotransmitters, photons and odorants. All GPCRs share a similar core 
structure consisting of an extracellular N-terminus, an intracellular C-terminus, three 
extracellular and three intracellular interhelical loops. The extracellular loops serve as binding 
sites for structurally distinct ligands whereas the intracellular loops provide multiple interaction 
sites for different subtypes of G-proteins (Thiel et al., 2013) (Fig. 1.11). G-proteins associated 
with GPCRs are heterotrimeric in structure i.e. they have a, b, and g subunits. In the inactive 
state, GPCR remains as a heterotrimeric G protein complex (Bear et al., 2007) (Fig. 1.10). 
When any signalling molecule binds with GPCR, then it undergoes a conformational change. 
The exact mechanism of conformational change is not exactly understood, but it is believed 
that a receptor molecule always exists in conformational equilibrium between active and 
inactive biophysical states, with the binding of any signalling molecule shiftng the equilibrium 
to the active state (Rubenstein and Lanzara, 1998). Because of this conformational change, a-
subunit of G-protein exchanges guanosine diphosphate (GDP) for guanosine triphosphate 
(GTP). This causes the a-subunit to dissociate and move away from b-g dimer. Ga and Gbg 
subunits are now available to activate effector protein. Effector protein may be different, based 
on the type of G protein-mediated signalling pathway. As long as the ligand or signalling 
molecule binds to GPCRs, this whole chain of event will happen repeatedly. G subunit is itself 
an enzyme which can hydrolyse GTP back to GDP and all subunits again can combine to form 
an inactive heterotrimer. This is the overall basic mechanism of the GPCR signalling pathway.  
G protein exerts its effect by activating certain enzymes. Stimulation of those enzymes triggers 
a series of biochemical reactions and lead to the activation of downstream enzymes which are 
called the second messenger cascade. The a-subunit of G protein mediates signal transduction 
in a variety of signalling pathways. There are four families of a-subunits (Gi/o, Gq, Gs, and 
G12/13) (Digby et al., 2006; Wettschureck and Offermanns, 2005). There are two main signal 

























Fig. 1.11 General core structure and functioning of GPCRs. (Adapted from Thiel et al., 2013)   
 
Phosphatidylinositol signalling pathway  
The effector of this pathway is phospholipase C (PLC). The a-subunit of activated G protein 
binds and stimulates PLC. As PLC is a lipase enzyme, it catalyses the cleavage of 
phosphatidylinositol 4,5-biphosphate (PIP2) into two-second messengers, diacylglycerol 
(DAG) and inositol 1,4,5-triphosphate (IP3) (Fig. 1.11). Due to insoluble lipid properties of 
DAG, it remains within the plasma membrane and stimulates the downstream enzyme protein 
kinase C (PKC). PKC then regulates transcription, immune response, cell growth, and various 
biological processes through PKC-mediated phosphorylation of other proteins. IP3 diffuses 
away in the cytosol and binds with IP3 gated calcium channels found in the membrane of 
endoplasmic reticulum which elicit the release of calcium ions from the endoplasmic reticulum 
to the cytosol. Elevation of cytosolic Ca++ changes the membrane potential which triggers 
widespread long-lasting effects and stimulates various downstream enzymes.  
Cyclic-Adenosine Monophosphate (cAMP) signalling pathway  
This pathway is based on the two types of G-proteins, i.e. stimulatory G protein (Gs) and 
inhibitory G protein (Gi). However, the effector of both pathways is adenylyl cyclase (AC). In 
the Gs mediated pathway, after the α-subunit of Gs dissociates from b-g dimer, it activates the 
effector protein adenylyl cyclase (AC). AC catalyses the conversion of adenosine triphosphate 
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(ATP) to cAMP which is the second messenger of this pathway. cAMP activates the 
downstream enzyme protein kinase A (PKA). In doing so, cAMP binds to the regulatory 
subunit of PKA and deactivate it by changing its structure which allows the catalytic subunit 
of PKA to become free. The kinase enzyme present in the catalytic subunit of PKA then 
phosphorylates its substrates and activates various transcription factors. However, Gi proteins 
inhibits the cAMP pathway by inhibiting AC, decreasing the production of cAMP from ATP 
which in turn results the reduced activity of cAMP-dependent kinase.  
 
1.10.1 Complexity of GPCR signaling 
Studies have shown that up to 50% of modern medicinal drugs target GPCRs and other 
membrane proteins (Hermans, 2003). Drugs targeting GPCRs are often nonspecific affecting 
the activity of more than one GPCR. The same GPCR is present in multiple tissues and a ligand 
can activate various GPCRs having different affinities towards the G protein. This might lead 
to the activation of various effector enzymes producing off-target effects. This might also 
confound in vivo studies. Various pharmacological approaches in the past have been developed 
to reduce the complexity of GPCR signalling by utilizing particular agonists and antagonists 
for specific GPCRs (Gurwitz et al., 1994; Wisler et al., 2007; Thomas et al., 2008; Digby et 
al., 2012). Most of these approaches were unsuccessful because they caused serious side 
effects, off-target effects and lacked selectivity (Conn et al., 2009; Agulhon et al., 2010). 
However, the idea of designing appropriate ligands with high specificity and selectivity to 
avoid undesirable GPCR-mediated adverse effects was never ruled out. 
 
1.10.2 Engineered GPCRs 
Over the last few decades various techniques have been developed and optimized for selective 
control of a defined cell population. Each approach has their own advantages and 
disadvantages. Sub-sections below will briefly describe the most recent and widely recognized 
chemogenetic tools based on G protein signalling, i.e. G-protein receptor-ligand system.  
 
1.10.2.1 Receptors Activated Solely by Synthetic Ligands (RASSLs) 
The first breakthrough in the development of designer GPCRs were called as Receptors 
Activated Solely by Synthetic Ligands (RASSLs). This technique was based on the use of 




Strader and colleagues substituted a single amino acid residue to mutate the β‐adrenergic 
receptors which were fully activated by catechol‐containing esters and ketones, compounds 
which did not activate wild-type β‐adrenergic receptors (Strader et al., 1987; 1991). Coward 
and colleagues applied the same rational approach to design GPCRs (Coward et al., 1998). 
After this study, there were series of investigations to develop designer GPCRs (Kristiansen et 
al., 2000; Pauwels and Colpaert, 2000; Srinivasan et al., 2003; 2007; Bruysters et al., 2005). 
The development of these modified receptors was very inspiring, and these novel tools were 
highly beneficial in various in vivo studies. However, several disadvantages were also noticed, 
since these designer receptors showed a significant degree of constitutive activity and resulted 
in serious side effects upon in vivo use. Few cases of off-target activity were also reported 
(Coward et al., 1998; Sweger et al., 2007; Rogan and Roth, 2011) 
 
1.10.2.2 Designer Receptors Exclusively Activated by Designer Drugs (DREADDs) 
To date, the most technically successful and widely used engineered GPCR is DREADD. 
DREADDs are mutationally modified muscarinic acetylcholine receptors. These receptors are 
only activated by clozapine-N-oxide (CNO) and do not respond to the muscarinic receptor 
agonist/endogenous ligand acetylcholine. Based upon the DREADDs we choose, different kind 
of signalling pathways (Gi, Gq, Gs) in the cell can be activated (Rogan and Roth, 2011). 
Muscarinic acetylcholine receptors consist of five subtypes (M1-M5). The coupling preference 
for M1, M3 and M5 receptors are towards Gq/11 proteins which leads to depolarization and 
neuronal firing whereas M2 and M4 receptors prefer Gi/o proteins that results neuronal 
silencing via hyperpolarization (Kruse et al., 2014).  
 
The first set of experiments to modify and develop muscarinic acetylcholine receptor 
DREADD was performed by Armbruster et al., (2007). Initially, they used modified rat 
muscarinic (M3) receptor which had a deletion in its third intracellular loop (rM3∆i3). This 
type of engineered receptor was previously used for ligand activation studies in mammals. 
They created ten independent clones of mutant rM3∆i3, eight of these ten independent clones 
contained the Y148X3.33 mutation. They found that a majority of mutant receptors were unable 
to respond, however one clone was found to be mildly responsive to CNO. A subset of clones 
was selected and remutated to produce a second-generation library and to identify the mutants 
that exhibit high affinity for clozapine and CNO but not for acetylcholine. Those second 
generation rM3∆i3 receptor mutants were finally screened with ~5nM CNO. Screening was 
based on the comparison of the pharmacological profile and responsiveness for CNO, 
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clozapine and acetylcholine. The two best clones were chosen and tested on a human cell line 
which resulted a new class of RASSLs and termed as DREADDs. The finally selected receptors 
had tyrosine in the 149th position of the third transmembrane replaced with cysteine and alanine 
present in the 239th position of the fifth transmembrane replaced with glycine which generated 
the hM3Dq DREADD. Similarly, two-point mutations (Y113C in the third transmembrane and 
A203G in the fifth transmembrane) resulted hM4Di DREADD. hM3Dq and hM4Di DREADD 
are the most common DREADD in use today (Armbruster et al., 2007). Brief description of 
commonly available DREADDs are stated below and respective signalling pathways are 
illustrated in the figure 1.12.  
 
Gi-DREADDs (hM4Di and KORD) 
Gi-DREADDs are designed to be used for neuronal silencing. Binding of CNO activates α-
subunit which inhibits AC. This reduces the level of cAMP and the activity of PKA. The other 
subunit, i.e. βγ interacts with G protein-coupled inwardly rectifying potassium channel 
(GIRKs) which causes the potassium ion to move outside. This causes the hyperpolarization 
and decreases the firing of presynaptic neurons (Armbruster et al., 2007; Rogan and Roth, 
2011). Beside hM4Di, a k-opoid receptor-DREADD (KORD) has been recently developed. 
KORD is activated by a designer drug named Salvinorin B (Vardy et al., 2015). 
 
Gq-DREADDs (hM3Dq) 
Gq-DREADDs are used to induce neuronal firing and increase overall excitability. CNO 
binding activates PLC and that hydrolyses PIP2 to DAG and IP3. The hydrolysis of PIP2 closes 
voltage-gated potassium channels causing depolarization and this induces neuronal firing 
(Guettier et al., 2009). 
 
Gs-DREADD (rM3Ds) 
This type of DREADD is based on the rat M3 muscarinic receptor. Upon CNO binding, Gs α-
subunit activates AC, which helps the conversion of ATP to cAMP. This starts the PKA 




















Fig 1.12 Signalling pathways of common available DREADDs. Red stars within the transmembrane signifies the location of point mutations performed in 
endogenous receptors to obtain various DREADDs. KCNQ, voltage-gated potassium channel; K+, potassium ion; PIP2: phosphatidylinositol 4,5-bisphosphate, 
PLC, phospholipase C; DAG, diacyl glycerol; PKC, protein kinase C; IP3, inositol-1,4,5-trisphosphate; ß-Arr, ß-arrestin; cAMP, cyclic adenosine monophosphate; 
PKA, protein kinase A; ERK1/2, extracellular signal-regulated kinases ½; GIRK, G protein-coupled inwardly rectifying potassium channel.  
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β-arrestin DREADD (rM3Darr) 
This β-arrestin-specific DREADD contains one point mutation in  M3 muscarinic DREADDs 
which only can activate M3D-arr DREADD (Nakajima and Wess, 2012).  
 
1.10.2.3 Designer drug CNO and recent developments  
CNO is the designer drug for DREADD receptors. CNO was chosen as a designer drug mainly 
because of its inert nature towards endogenous targets and structural similarity to the antipsychotic 
drug Clozapine (parent compound of CNO). Structurally, CNO contains an N-oxide group whereas 
clozapine lacks this moiety. Negatively charged oxygen present in CNO creates electrostatic 
repulsion between the positively charged nitrogen molecule and the negatively charged side chain 
of the receptors. Thus, binding affinity of CNO with muscarinic receptors is lower compared to 
that of clozapine-receptor binding (Wess et al., 2013), and few mutations to muscarinic receptor 
family generated DREADD receptors that are sensitive towards CNO (Alexander et al., 2007). 
CNO is a highly potent, bioavailable, and pharmacologically inert drug. It has rapid biodistribution 
and CNS penetration. CNO mediated DREADD activation is also robust and prolonged (Rogan 
and Roth 2011; Roth et al., 2016). Reports have shown that systemic administration of CNO peaks 
in plasma between 15-30 min is effective up to 1 hour (Manvich et al., 2018; Jendryka et al., 2019), 
and almost undetectable after 2 h (Guettier et al., 2009); but behavioural and electrophysiological 
effects remain up to 9 h (Alexander et al., 2009). 
However, recently the use of CNO as a designer drug for DREADDs was called into question. 
Studies showed that CNO is back-metabolizes to clozapine and N-desmethylclozapine (NDMC) 
after systemic administration into rodents (Manvich et al., 2018; Jendryka et al., 2019). Gomez 
and colleagues stated that back-metabolized clozapine may have contribution to DREADD 
activation but not CNO. They also concluded that accumulated clozapine may occupy other 
endogenous receptor targets in the brain (eg. dopamine, histamine, 5-HT), and produce unwanted 
off-target effects which may confound behavioural studies (Gomez et al., 2017). Whereas, another 
recent study demonstrated that the concentration of reverse-metabolized clozapine in plasma, 
cerebrospinal fluid and brain tissue is very low compared to CNO. The availability of both 
compounds in the brain varies with species (Jendryka et al., 2019). Thus, it’s unlikely that 
DREADD activation is solely from back metabolized clozapine after CNO application. Similarly, 
numerous reports did not find any DREADD-independent behavioural effect of CNO (up to 
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10mg/kg) (Mahler et al., 2018). On the other hand, as suggested by Gomez et al., (2019) the use 
of low doses of clozapine as designer drug is also not an ideal approach (Goutaudier et al., 2019). 
It’s not a surprise that CNO reverse-metabolizes to its parent compound upon peripheral injection, 
as it was previously demonstrated in mammalian species (Jann et al., 1994) and was recommended 
for use at lower doses (Roth et al., 2016). High affinity of clozapine for DREADDs was stated 
since its first development in 2007 (Alexander et al., 2009). Also, previous studies have also shown 
that clozapine increases anxiety in animals (Manzaneque et al., 2002) and is also linked to 
agranulocytosis and pro-epileptic effects (Ruffman et al., 2006).  Other chemical approaches such 
as the use of olanzapine (Weston et al., 2019), compound 21, perlapine (Thompson et al., 2018; 
Jendryka et al., 2019), JHU37152 and JHU37160 (Bonaventura et al., 2019) to activate DREADD 
have been reported but these compounds are not yet fully characterized.  
Altogether, these studies questioning the use of CNO as a designer drug, however, have 
highlighted important aspects of DREADD related experiments. It’s now clear and widely 
established that depending upon the experimental approach, optimization of appropriate dose of 
CNO and the use of standard controls (non-DREADD expressing and saline treated DREADD 
animals) are highly recommended in DREADD based experiments. The use two different ligands 
to confirm DREADD mediated behavioural results are also recommended (Goutaudier et al., 
2019).    
 
1.11 DREADD and Optogenetics 
In order to understand the scope and significance of DREADD technology, it is necessary to 
understand how this technique differs from other similar techniques such as optogenetics.  
 
Optogenetics is another cutting-edge technique which uses the combination of optics and genetics 
to control, monitor, and modulate neuronal activity. It involves the use of light to control neurons 
which are genetically modified to express light sensitive channel (Deisseroth et al., 2006; Fenno 
et al., 2011). This technique allows the investigation of the neuronal manipulation in real time. In 
simple terms, light responsive proteins (opsins) are genetically introduced into the neuronal cell 
membrane and based on the intensity and wavelength of light, change of membrane potential is 
recorded. This provides direct control over neuronal activity as neurons communicate via changes 
of the cross-membrane voltage (Deisseroth, 2015; Zhang et al., 2007). Both chemogenetics and 
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optogenetics enable the pathway-specific silencing or activation of neurons and are targeted for 
cell-specific manipulation. Enhanced and selective control of neuronal population is the most 
common key advantage of chemogenetics and optogenetics (Tønnesen and Kokaia, 2017). While 
they serve similar purposes, both techniques offer different advantages and limitations. The few 
parameters in which chemogenetics (DREADD) and optogenetics differ are briefly described 
below.  
 
Route of neuronal activation 
DREADDs are easier to implement and more easily adapted for behavioural applications where 
CNO can be administered via various routes (systemic injections, focal injections, food, water) 
(Urban and Roth, 2015). But, optogenetics require the administration of light via expensive 
specialized instruments (Zhang et al., 2010). In DREADDs, administration of CNO via food or 
water seems very convenient and this approach is relatively less invasive. Repeated injection or 




One of the basic differences between both techniques is the onset of the effect. Optogenetics can 
reversibly manipulate neuronal activity in the range of milliseconds, the response is immediate. 
But in case of DREADDs, onset of receptor activation takes min. However, for lengthy 
behavioural experiments where prolonged neuronal modulation is required, DREADDs are ideal.  
 
Frequency and concentration 
One of the potential limitations of DREADD is that the amount and concentration of CNO required 
to control a given neuronal population is not fixed. DREADD would be more successful if this 
technique had the ability to determine the amount of CNO required for a neuronal response (Urban 
and Roth, 2015). With optogenetics, the experimenter has direct control over the light stimulation, 
so it’s possible to maintain the frequency of neuronal activity. Optogenetics also allows the 
experimenter to record how the neurons respond to stimulation. This allows us to investigate 
various type of behaviour and activity based on the level of stimulation. However, one of the major 
 46 
disadvantage associated with optogenetics is the difficulty in penetrating tissue by light (Pavlov 
and Schorge, 2014).  
 
Possibility of multiplexing 
Bidirectional control of neuronal activity is possible in both techniques. Currently, DREADD 
offers three options for neuronal silencing, i.e. hM4Di (CNO-mediated), KORD (Salvinorin B 
mediated), and GluCl (ivermectin mediated) (Armbruster et al., 2007; Frazier et al., 2013; 
Marchant et al., 2016; Vardy et al., 2015). Designer compounds for all three approaches are 
different and have a different pharmacology, thus multiplexing is possible. Multiplexing is also 
possible in optogenetics as actuators designed for this technique respond to blue, orange, yellow, 
green and red light. This selectivity gives us a theoretical possibility of multiplexing. However, 
various factors should be considered before multiplexing within the same experimental animal. 
Employment of DREADD and optogenetics in the same experimental animal provides another 
possibility for multiplexing (Forcelli, 2017).  
 
Issues regarding CNO 
CNO is the only agonist which is well characterized and widely used to activate DREADDs. So, 
the DREADD activity is fully dependent on the pharmacokinetic property of injected CNO 
(Forcelli, 2017). Studies have found that repeated CNO dosing in the same animal may create 
decreased responses due to the desensitization of DREADD receptors (Roth, 2016). Previously, it 
was established that back transformation of CNO to clozapine was only limited in human and 
guinea-pig but not in rats and mouse (Wess et al., 2013). Current reports suggest that back 
transformation of CNO to clozapine and N-desmethylclozapine in mouse, rat and macaque 
subjects (MacLaren et al., 2016; Gomez et al., 2017; Raper et al., 2017; Jendryka et al., 2019). To 
resolve this issue, alternative chemical approaches for DREADD activation have been proposed 
but they are not yet fully characterized (Thompson et al., 2018; Weston et al., 2019; Bonaventura 
et al., 2019). On the other hand, optogenetics does not require any designer drug for neuronal 
silencing or activation but it requires surgical implantation of a device which might cause 
permanent damage to the brain affecting neuronal activity (Whissell et al., 2016). Optogenetics 
also requires expensive equipment such as optic fibres, light, waveform generators, and other 
specialized instruments to carry out the experiments. Recently, a new step-function opsin with 
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ultra-high light sensitivity (SOUL) has been engineered to minimize the invasive nature of 
optogenetics (Gong et al., 2020).  
 
Scale and clinical aspect 
One of the biggest advantages of DREADDs over optogenetics is scale. The human brain is around 
1000-times larger than the rodent brain. The difference in the size of the brain and circuits make 
optogenetics more difficult to control neuronal activity using light. DREADD technology does not 
require implantation of hardware for long periods as in optogenetics. Even in the rodent brain, 
light distribution can be an issue. This difference in scale and size of distribution make the 
translation of findings from rodents to human challenging for optogenetics. The only advantage of 
specific distribution of light is that specific regions of brains can be targeted (Forcelli, 2017; 
Tønnesen and Kokaia, 2017). On the other hand, DREADD expression can be achieved by using 
double transgenic mice or by delivering virus into specific regions of brain and then systemic or 
focal administration of designer drug can activate DREADDs. Because of these advantages, 
research and studies are already started in non-human primates (Eldridge et al., 2016; Grayson et 
al., 2016; 2020; Upright et al., 2018; Bonaventura et al., 2019; Nagai et al., 2016; Deffains et al., 
2020).As explained above, optogenetics is ahead of chemogenetics in real-time neuromodulation 
and temporal resolution. The popularity of optogenetics is trying to outstrip chemogenetics but, 
chemogenetics also offers several diverse features which cover various aspects of experiments.  
 
1.12 Use of DREADD technology to study various CNS disorders and animal behaviours 
DREADD technology has been extensively used in biomedical research particularly in 
neuroscience due to its ability to selectively activate or silence neuronal firing. This technology 
has been effectively used to understand the pathogenesis of various neurological disorders. Some 
recent findings are summarized below.  
 
Alzheimer’s disease (AD):  
AD is a form of progressive dementia caused by depletion of neuronal cells. This disease is 
believed to be associated with the presence of intracellular neurofibrillary tangles and extracellular 
amyloid plaques [neurotoxic peptide amyloid beta (Aβ)]. These are considered as the 
neuropathologic hallmarks of AD. DREADD mediated inhibition in the cortex of AD-like mouse 
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markedly reduced the number of amyloid plaques and the levels of peptide amyloid beta in a dose 
dependent manner. This study targeted the cortical region as the cortex is prone to amyloid 
deposition (Yuan and Grutzendler, 2016). In another study, DREADD mediated activation of 
pyramidal neurons in the dorsal subiculum was able to reduce synaptic deficits with improved 
glutamatergic transmission between subiculum and nucleus accumbens. This enhanced 
hippocampal neuronal excitability in the Tg2576 mouse model of AD. The network involving the 
subiculum and nucleus accumbens is critical in formation of hippocampal-related spatial memory 
(Cordella et. al., 2018). Other studies also used an excitatory DREADD approach to understand 
tau pathology in AD (Wu et al., 2016; Schultz et al., 2018).    
 
Parkinson disease (PD): 
PD is second most common neurodegenerative disorder after AD. Clinical signs of PD include 
bradykinesia, gait impairment, rigidity of muscles and tremor. Systemically, PD refers to the 
progressive loss of dopaminergic neurons in the substantia nigra leading to the reduced dopamine 
levels in the dorsal striatum that is believed to cause the abovementioned abnormalities. CNO 
mediated activation of DREADD expressing transplanted dopaminergic neurons in 6-
hydroxydopamine (6-OHDA) lesioned mice had improved behavioural features (Dell’Anno et al., 
2014; Aldrin-Kirk et al., 2016; Chen et al., 2016). Similar behavioural improvements were also 
seen in lactacystin rat model of PD after chemogenetic activation of cholinergic pedunculopontine 
neurons (Pienaar et al., 2015). 
 
Down syndrome: 
Down’s syndrome is a common chromosomal disorder in which patients suffer from intellectual 
disability with clinical signs such as flat face and nasal bridge. This disorder affects most body 
systems and commonly leads to Alzheimer’s dementia at a much earlier age. Fortress and 
colleagues found restored memory function and improved intellectual activity in an animal model 
of Down’s syndrome using excitatory-DREADD approach (Fortress et al., 2015). Recently, using 
the inhibitory-DREADD approach it was revealed that loss of the pontine nucleus locus coeruleus-
noradrenergic projections might be the underlying cause of dementia in individuals with this 
disorder (Hamlett et al., 2020).  
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Schizophrenia and autism spectrum disorders (ASD): 
Cognitive inflexibility and attention deficits are common symptoms associated with schizophrenia. 
Selective inhibition of PV+ interneurons and GAD65 neurons of the ventral hippocampus using 
inhibitory DREADD approach induced behavioural features similar to schizophrenia. This linked 
the pathophysiology of schizophrenia to GABA dysfunction (Nguyen et al., 2014). Few other 
studies also utilized a DREADD approach to understand the pathophysiological mechanisms of 
cognitive impairment and other abnormalities seen in schizophrenia (Parnaudeau et al., 2013; 
Koike et al., 2016). Autism spectrum disorder (ASD) is another mental disorder which is 
characterized by impaired verbal, non-verbal communication and social behaviour. One study 
employed an excitatory-DREADD approach and revealed improved social behaviour in 
CNTNAP2 (gene identified as responsible for ASD) knockout mice by activating oxytocin 
expressing neurons in the hypothalamus (Peñagarikano et al., 2015).  
Apart from neurological disorders, a DREADD based approach has been successfully employed 
to study animal behaviour such as learning (Maharjan et al., 2018), addiction (Ferguson and 
Neumaier, 2015; Dobrzanski and Kossut, 2017), memory (Tuscher et al., 2018), sleep (Varin and 
Bonnavion, 2018), feeding (Koch et al., 2015; Vardy et al., 2015; Luo et al., 2018), breathing 
(Brust et al., 2014; Sheikhbahaei et al., 2018) , anxiety (Zhang et al., 2017; Mazzone et al., 2018; 
Salvi et al., 2019), stress (Wei et al., 2018; Nawreen et al., 2019), decision making (Ferguson et 
al., 2013), fear (Arico et al., 2017; Gilman et al., 2018) etc.  
 
1.13 DREADD technology in epileptic-seizure related studies 
In 2015, Bryan Roth, the principal investigator of the research group which invented DREADD, 
mentioned seizures and Parkinson disease as the exceptional candidates for a DREADD based 
approach (English and Roth, 2015). Kätzel and colleagues were the first to report in vivo use of 
DREADDs in relation to epileptic seizures. In that work, CNO was able to stop chemically induced 
(pilocarpine or picrotoxin) focal seizures in rats (Kätzel et al., 2014). The first in vitro use of 
DREADD approach was reported in hippocampal slice cultures where Avaliani and colleagues 
expressed inhibitory DREADDs in hippocampal principal cells and administration of CNO was 
able to suppress epileptic activity (Avaliani et al., 2016). In another study, activation of PV 
interneurons via excitatory DREADD approach significantly reduced 4-aminopyridine (4-AP) 
induced seizure activity (Cǎlin et al., 2018). Various studies have been published since then in 
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different rodent models where DREADDs have been used to understand more about seizures i.e. 
temporal lobe seizures (Fishell and Dimidschstein, 2018; Wang et al., 2018; Desloovere et al., 
2019; Goossens et al., 2019), pilocarpine induced status epilepticus (Zhou et al., 2019) and 
amygdala kindled seizures (Wicker and Forcelli, 2016). However, to date, there are no published 
reports utilizing DREADD technology to investigate the functional roles of PV+ interneurons on 
absence seizure generation.  
 
1.14 Manipulating PV+ interneurons with DREADDs in vivo  
There are two main ways of manipulating neuronal population with DREADD technology in vivo 
i.e. viral approach and transgenic mouse approach. Both approaches can be further divided into 
two categories: Cre-dependent and Cre-independent. Schematic diagrams of manipulating 
neuronal subpopulation with DREADD technology are illustrated in figure 1.13 and 1.14.  
The work included in this thesis is based on the Cre-dependent transgenic mouse approach (Zhu 
et al., 2016) where PV-Cre mice were crossed with DREADD (hM4Di or hM3Dq)-floxed mice so 
that the inhibitory or excitatory DREADD receptors are expressed into PV+ interneurons (Fig. 
1.13). In the Tet-dependent transgenic mice approach, mice expressing tetracycline-sensitive 
DREADD are generated using Tet-off system (Fig. 1.13). Briefly, littermates from TRE 
(Tetracycline-responsive promoter element)-DREADD are crossed with mice having the 
tetracycline-controlled transactivator protein (tTA) driven by the promoter (such as CaMKIIα, c-
fos etc.). Normally, in the absence of tetracycline or its analog doxycycline, tTA binds to the TRE 
and activates transcription of the DREADD in the targeted brain regions. This is a reversible 
approach as administration of tetracycline or doxycycline eliminates DREADD expression. This 
approach is relatively less popular (Alexander et al., 2009; Garner et al., 2012; Zhu et al., 2014). 
Cre-dependent viral approach is popular and mostly used DREADD mediated approach. To 
establish the expression of DREADD receptors into specific neuronal population, virus particles 
containing DREADD construct are delivered into the appropriate regions of the brain (Fig.1.14). 
As mentioned previously, in this study, a Cre-dependent transgenic mouse approach was used to 
manipulate PV+ interneurons with DREADDs. PV-Cre mice were bred with either inhibitory 
DREADD (hM4Di-flox) mice or excitatory DREADD (hM3Dq-flox) mice to generate double 
transgenic mice expressing inhibitory or excitatory DREADD receptors in PV+ interneurons. 
hM4Di/hM3Dq-floxed mice have loxP-flanked STOP cassette designed to prevent transcription  
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Fig. 1.13 Schematic diagram of in vivo manipulation of neuronal population with DREADD technology using transgenic mice approach. According to this 
approach, DREADD can be expressed genetically by crossing DREADD mice with Cre or Tet-off driver mouse lines and designer receptors are expressed only in 






























Fig. 1.14 Schematic diagram of in vivo manipulation of neuronal population with DREADD technology using viral approach. In viral approach, Cre-
dependent and Cre-independent options are available. In the Cre-dependent approach, viral double-floxed inverted DREADD construct are microinfused in brain 





































Fig. 1.15 Manipulating PV+ neurons with inhibitory or excitatory DREADD using Cre-dependent 








of the downstream HA-hM4Di/hM3Dq-pta-mCitrine coding region (Fig. 1.15). Mating these 
strains removes the loxP-flanked STOP cassette only in the cell type specified by the Cre-
recombinase system. This allows the strong expression of DREADD receptors only in PV+ 
interneurons. 
 
1.15 Rationale and aims of the thesis 
Although it is well established that absence seizures arise due to the disturbances within the 
CTC circuitry, the precise cellular and molecular mechanisms are still unclear. FFI is essential 
to prevent runaway excitation within the CTC network and is mediated by fast spiking PV+ 
inhibitory interneurons. Previously using stargazer mouse model of absence epilepsy, it has 
been demonstrated that loss of loss of excitatory drive (impaired AMPARs trafficking) to PV+ 
interneurons might be one of the reasons of  impaired FFI within the CTC network and possibly 
contributing to absence seizure generation (Menuz and Nicoll, 2008; Barad et al., 2012; 2017; 
Maheshwari et al., 2013; Adotevi and Leitch, 2016; 2017; 2019). However, the extent to which 
the deficits in excitatory drive leads to dysfunctional FFI has not been established via functional 
studies. Hence, the aim of this project was to investigate the impact of dysfunctional FFI within 
the CTC network on absence seizure generation and behaviour. PV+ interneurons of the CTC 
network were functionally targeted by using DREADD technology. To target these 
interneurons, mice expressing Cre recombinase in PV+ interneurons (PV-Cre) were bred with 
inhibitory (hM4Di-flox) or excitatory (hM3Dq-flox) DREADD mice. Firstly, simultaneous 
video/EEG recordings and behavioural tests were used to investigate the impact of functionally 
silencing feed-forward inhibitory PV+ interneurons within the CTC network in terms of 
absence seizure generation and behavioural parameters. Secondly, the effect of functionally 
exciting these interneurons during chemically induced absence seizures was tested. Thirdly, 
the impact of dysfunctional FFI on the expression level of GABA synthesizing enzymes 
(GADs) and transport proteins (GATs) were examined in epileptic stargazers, as studies have 
shown that GABAergic system is heavily implicated in rodent absence seizure models (Cope 
et al., 2009; Seo and Leitch, 2014; 2015; Hassan et al., 2018). The findings from this project 
could provide an electrophysiological insight and advance our understanding of some 
mechanisms underlying absence seizures. This may help in developing future treatment 






The main objectives of this PhD project were to:  
1) Assess the selective expression of inhibitory DREADD receptors in PV+ interneurons in 
PVCre/Gi-DREADD mice using immunohistochemistry. 
2) Examine EEG signals before and after global and focal silencing of PV+ interneurons via 
CNO administration in PVCre/Gi-DREADD mice.  
3) Investigate the behavioural changes in PVCre/Gi-DREADD mice after global and focal 
silencing of PV+ interneurons using open-field and rotarod tests.  
4) Assess the selective expression of excitatory DREADD receptors in PV+ interneurons in 
PVCre/Gq-DREADD mice using immunohistochemistry. 
5) Examine EEG signals during chemically induced absence seizures in PVCre/Gq-DREADD 
mice pre-treated with CNO to activate PV+ interneurons.  
6) Investigate the expression pattern of GABA synthesizing enzymes (GADs – 65&67) and 
transport proteins (GATs –1&3) in the SScortex and the thalamus of epileptic stargazers 
and non-epileptic controls via immunohistochemistry.  
7) Demonstrate the relative expression of GADs and GATs in whole-tissue lysate of the 
SScortex and the VP thalamus of epileptic stargazers and non-epileptic controls via western 
blotting. 
8) Demonstrate the relative expression of GADs and GATs in whole-tissue lysate of the 
SScortex of CNO treated PVCre/Gi-DREADD animals via western blotting.  
1.16 Outline of thesis chapters 
This thesis consists of 6 chapters. These include an introductory chapter, a methodology 
chapter, three experimental chapters and a general discussion chapter. Introductory chapter 1 
provides in-depth, current and critical review of literatures and overall background to this PhD 
project. Chapter 2 provides a detailed account of materials and experimental methods 
employed to accomplish the research objectives. Chapter 3 represents the results of silencing 
feed-forward inhibitory PV+ interneurons in the CTC network on absence seizure generation 
and behavioural parameters outlined under objectives 1-3. The results from chapter 3 have been 
published (Panthi and Leitch, 2019). Chapter 4, based on objectives 4 and 5, discusses the 
impact of activating feed-forward inhibitory PV+ interneurons in the CTC network during 
chemically induced absence seizures. Chapter 5 demonstrates the expression profiles of GADs 
and GATs in epileptic stargazers and CNO treated inhibitory DREADD animals as outlined 
under objectives 6-8. Chapter 6 describes in-depth analysis of results obtained in this study 
including critiques of methodology employed and future directions. 
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Chapter 2. Materials and Methods 
2.1 Animals  
The animals used in this project were PV-Cre x hM4Di-flox mice, PV-Cre x hM3Dq-flox mice 
and stargazer mice. Mice were bred and housed at the University of Otago animal facility at 
controlled room temperature (22–24°C) with ad libitum access to food and water. All animal 
experiments were performed in accordance with the University of Otago Animal Ethics 
Committee under the AEC no. D94/16, AUP-19-98 and DET 32/17. DREADD related 
experiments were performed in both male and female mice whereas for stargazers based 
experiments only male mice used. All experiments were performed in adult animals (3 months 
of age). The weight of mice was between 23-43 g.  
 
2.1.1 Breeding paradigm for PV-Cre x hM4Di-flox and PV-Cre x hM3Dq-flox mice 
PV-Cre knockin, hM4Di-flox and hM3Dq-flox mice were obtained from Jackson Laboratories, 
USA. PV-Cre knockin mice express Cre recombinase in PV+ interneurons without disrupting 
endogenous parvalbumin expression. hM4Di-flox and hM3Dq-flox mice have a loxP-flanked 
STOP cassette designed to prevent transcription of the downstream HA-hM4Di-pta-mCitrine 
or HA-hM3Dq-pta-mCitrine coding region, respectively (Fig. 2.1). Mating these strains (PV-
Cre and hM4Di-flox or hM3Dq-flox) removes the loxP-flanked STOP cassette only in the cell 
type specified by the Cre-recombinase system (Fig. 2.1). This allows the strong expression of 
hemagglutinin (HA)-tag only in PV+ interneurons. In this study, PV-Cre mice were crossed 
with either hM4Di-flox mice or hM3Dq-flox mice to generate double transgenic mice 
expressing inhibitory (Gi) or excitatory (Gq) DREADD receptors in PV+ interneurons, 
respectively. To establish and maintain PV-Cre x hM4Di-flox mice colony, homozygous 
female PV-Cre mice were crossed with either homozygous hM4Di-flox males to generate 
litters of homozygous PV-Cre x hM4Di-flox mice, or crossed with heterozygous hM4Di-flox 
males to generate litters with heterozygous PV-Cre x hM4Di-flox and non-DREADD 
expressing wild-type (WT) control littermates, as illustrated in Fig. 2.1. Similarly, in case of 
PV-Cre x hM3Dq-flox mice colony, homozygous female PV-Cre mice were crossed with 
heterozygous hM3Dq-flox males to generate litters with heterozygous PV-Cre x hM3Dq-flox 
and non-DREADD expressing wild-type (WT) control littermates, as illustrated in Fig. 2.1. 
Only female PV-Cre mice were crossed with either male hM4D or hM3Dq mice to avoid 


































Fig. 2.1 Breeding paradigm for DREADD animals. Schematic showing breeding to generate PV-Cre x hM4Di-
flox or PV-Cre x hM3Dq-flox offspring and non-DREADD wild type controls by crossing a female PV-Cre mouse 
with either a male hM3Dq-flox or male hM4Di-flox mouse.  
 
 
2.1.2 Breeding paradigm for stargazer mice 
Stargazer mice were obtained from Jackson Laboratories, USA. These mice have monogenic 
mutation of the stargazin allele on mouse chromosome 15. In case of stargazer animals, two 
colonies were kept and continuously maintained. Heterozygous males were mated with either 
heterozygous females or homozygous females as shown in figure 2.2. The offspring of Het x 
Het colony were wild type (+/+), heterozygous (+/stg), and homozygous mutant stargazer 
(stg/stg) mice, whereas offspring of the Het x Homo colony were +/stg and stg/stg mice (Fig. 
2.2). Female homozygous stargazer mutant mice are fertile but male homozygous stargazer 
mutant mice are infertile. Mice used in this study were adult males aged 2-3 months. For 
comparative analysis in different experiments, homozygous stargazers (stg/stg) and non-





Fig. 2.2 Breeding paradigm for stargazer mice. Schematic showing breeding to generate stargazer mutant mice 
by crossing heterozygous males with either heterozygous females (Het x Het colony) or homozygous females 
(Het x Homo colony).  
 
Animals used in this study are hereafter donated as shown in the Table below: 
Colony Genotype Hereafter denoted as 
PV-Cre x hM4Di-flox 
(Inhibitory DREADD) 
Homozygous or heterozygous PVCre/Gi-DREADD 
Wild type Non-DREADD WT controls 
PV-Cre x hM3Dq-flox 
(Excitatory DREADD) 
Heterozygous PVCre/Gq-DREADD 
Wild type Non-DREADD WT controls 
Stargazer Homozygous stargazers (stg/stg) Epileptic stargazers (STG) 
Heterozygous (+/stg) and wild type (+/+) Non-epileptic controls (NE) 
 
2.2 Genotyping 
2.2.1 DNA extraction from the ear-notches 
Genotyping was performed to verify the mouse genotype. Ear notches were collected from the 
offspring of PVCre/Gi-DREADD mice, PVCre/Gq-DREADD mice and littermates from 
stargazer colony. Ear notches were mixed in 600µl of DNA lysis buffer (100mM Tris, 5mM 
EDTA, 0.2% SDS, 200mM NaCl, pH 8.5) and 5µl of proteinase K (Roche, Basel), and digested 
overnight at 55°C. Next day, microtubes were centrifuged at 13,000rpm for 10 min. 
Supernatant from microtubes were transferred into other microtubes containing 600µl of 
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isopropanol. Samples were again centrifuged at 13,000 rpm for 5 min. Supernatant from each 
tube was poured off carefully and remaining residual supernatant was pipetted out. The DNA 
pellet was then resuspended in 200µl of Tris-EDTA (TE) buffer (10mM Tris, 1mM EDTA, pH 
8.0) and vortexed for few seconds before allowing it to dissolve for 1 hour at 55°C.  
 
2.2.2 Polymerase chain reaction (PCR) 
DNA obtained after the abovementioned procedure was processed for amplification using 
PCR. For animals from DREADD colonies (either from PV-Cre x hM4Di-flox or PV-Cre x 
hM3Dq-flox colony), PCR was performed separately to confirm Cre knockin and hM4Di-flox 
or hM3Dq-flox using primers listed in the Table below (Table 2.1). In case of littermates from 
stargazer colony common forward, wild type reverse and mutant reverse primers were used 
(Table 2.2). The information about the primers was obtained from The Jackson Laboratory 
website (Jax protocol-026219, 026220, 001756, 013148) and primers were purchased from 
Integrated DNA Technologies (IDT). According to the written instructions in the data sheets, 
primers were reconstituted in TE buffer (pH 8.0) and were stored at -20°C upon arrival.  
 
Table 2.1 Primers used for genotyping of PVCre/Gi-DREADD and PVCre/Gq-DREADD mice.  
 
Primer type Sequence (5’à3’) 
hM4Di mutant forward CGA AGT TAT TAG GTC CCT CGA C 
hM4Di mutant reverse TCA TAG CGA TTG TGG GAT GA 
hM3Dq mutant forward CGC CAC CAT GTA CCC ATA C 
hM3Dq mutant reverse GTG GTA CCG TCT GGA GAG GA 
Wild type forward AAG GGA GCT GCA GTG GAG TA 
Wild type reverse CCG AAA ATC TGT GGG AAG TC 
Cre forward CCT GGA AAA TGC TTC TGT CCG 
Cre reverse CAG GGT GTT ATA AGC AAT CCC 
 
Table 2.2 Primers used for genotyping of stargazer mice.  
Primer type Sequence (5’à3’) 
Common forward TAC TTC ATC CGC CAT CCT TC 
Wild type reverse TGG CTT TCA CTG TCT GTT GC 




PCR mastermix was prepared as illustrated in table 2.3, 2.4, and 2.5.  
Table 2.3 PCR mastermix preparation for animals of PVCre/Gi-DREADD colony. 
For PV-Cre knockin For hM4Di-flox 
PCR master mix components Volume (µl) 
(each animal) 
PCR master mix components Volume (µl) 
(each animal) 
Platinum PCR Supermix 
(Invitrogen, CA, USA) 
12.5 Platinum PCR Supermix 
(Invitrogen, CA, USA) 
12.5 
Nuclease Free Water 
(Invitrogen, CA, USA) 
8.5 Nuclease Free Water (Invitrogen, 
CA, USA) 
8.5 
Cre forward primer 0.5 hM4Di mutant forward primer 0.5 
Cre reverse primer 0.5 hM4Di mutant reverse primer 0.5 
Wild type forward primer 0.5 Wild type forward primer 0.5 
Wild type reverse primer 0.5 Wild type reverse primer 0.5 
 
Table 2.4 PCR mastermix preparation for animals of PVCre/Gq-DREADD colony. 
For PV-Cre knockin For hM3Dq-flox 




PCR master mix components Volume (µl) 
(each animal) 
Platinum PCR Supermix 
(Invitrogen, CA, USA) 
12.5 Platinum PCR Supermix 
(Invitrogen, CA, USA) 
12.5 
Nuclease Free Water 
(Invitrogen, CA, USA) 
8.5 Nuclease Free Water (Invitrogen, 
CA, USA) 
8.5 
Cre forward primer 0.5 hM3Dq mutant forward primer 0.5 
Cre reverse primer 0.5 hM3Dq mutant reverse primer 0.5 
Wild type forward primer 0.5 Wild type forward primer 0.5 
Wild type reverse primer 0.5 Wild type reverse primer 0.5 
 
Table 2.5 PCR mastermix preparation for animals of stargazer colony. 
 
For animals from PV-Cre x hM4Di-flox or PV-Cre x hM3Dq-flox colony, 2µl of genomic 
DNA was added to 23µl of PCR mastermix as shown in Table 2.3 and 2.4. In case of animalsof 
PCR master mix components Volume (µl) 
(each animal) 
Platinum PCR Supermix (Invitrogen, CA, USA) 22.5 
Common forward primer 0.25 
Wild type reverse primer 0.3 
Mutant reverse primer 0.2 
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stargazer colony, 1.75µl of genomic DNA was mixed with 23.25µl of PCR mastermix as shown 
in Table 2.5. 25µl of the solution was homogenously mixed. The mixture was then processed 
for run in PCR machine (Supercycler SC-200, Kyratech, QLD, Australia) following the 
optimized PCR cycle steps (Table 2.6). 
 
Table 2.6 PCR cycle steps 
Step Temperature (°C) Time Note 
1 94 3 min  
2 94 30 seconds  
Repeated 35 times 3 62 30 seconds 
4 72 30 seconds 
5 72 2 min  
6 10  Hold 
  
2.2.3 Agarose Gel Electrophoresis 
Agarose gel (2%) was prepared by mixing 1.6gm of agarose in 80ml of Tris-Borate-EDTA 
(TBE) buffer (90mM Tris, 90mM Boric acid, 3.18mM EDTA, pH 8.3). 10µl of the PCR 
product was loaded into each well of agarose gel. 5 µl of DNA ladder (TrackIt, Invitrogen, CA, 
USA) was added to one well as a reference ladder. The gel was allowed to run at 85V for 90 
min and stained with SybrSafe (Life Technologies, CA, USA). The gel was then placed on a 
UV light source to view and photograph bands. Figure 2.3A, B and C are the representative 
images of genotype bands on an agarose gel for animals of PV-Cre x hM4Di-flox, PV-Cre x 

















































Fig. 2.3 Representative image of genotype bands on agarose gel. Images showing the (A) homozygous (Homo) 
PV-Cre knockin (350bp and 300bp) and the hM4Di-flox (B) homozygous (Homo) PV-Cre knockin (350bp and 
300bp) and the hM3Dq-flox for three mice to verify PV-Cre knockin and hM4Di-flox or hM3Dq-flox. [for 
hM4Di-flox and hM3Dq-flox:  heterozygous (het) 300 bp and 204 bp; homozygous (Homo) 204 bp; wild-type 
(WT) 300 bp]  (C) Image showing the bands for wild-type (+/+) mice at 360 bp, heterozygous (+/stg) mice with 
two bands at 360 bp and 155 bp, and epileptic stargazers (stg/stg) with a band at 155 bp.  
 
2.3 Immunofluorescence Confocal Microscopy 
2.3.1 Animal perfusion and fixation 
Adult mice from PV-Cre x hM4Di-flox, PV-Cre x hM3Dq-flox and stargazer colonies were 
deeply anesthetized with an intraperitoneal (i.p.) injection of 60mg/kg of sodium pentobarbital. 
Supplemental doses of pentobarbital were injected if required to achieve deep level of 
anaesthesia. Toe-pinch response method was used to determine the depth of anaesthesia using 
blunt forceps. Transcardial perfusion was performed with 5% heparin in 0.1M phosphate 
buffered saline (PBS) for first 30 seconds followed by 4% paraformaldehyde (PFA) in 0.1M 
Sorensen’s phosphate buffer (PB) for next 10 min. Tremor was seen in the tail and toe of 
animals confirming the circulation of PFA (fixative) around the whole body. Heparin was used 
as an anticoagulant agent and PFA was used to preserve the histological integrity of the tissue. 





2.3.2 Tissue processing and immunolabelling  
After post-fixation, brains were washed three times in 0.1M PB. This was followed by 
cryoprotection of the brains in increasing concentration of sucrose prepared in PBS i.e. 10% 
for 30 min, 20% for 30 min, and 30% at 4°C until the brains sunk to the bottom of the glass 
container. Sinking of the brains indicated the complete infiltration of sucrose into the brain. 
For sectioning, the cerebellum was dissected from the rest of the brain. Brains were sectioned 
into 30µm coronal sections. Cerebellum was also sectioned into 30µm thin sagittal sections. 
Sectioning was performed on a freezing cryostat (Leica CM1950, Wetzlar, Germany). 
Temperature inside the cryostat chamber was maintained to -20°C. Sections were collected 
into 12-well plates containing PBS.  
Slices were then transferred into blocking buffer [4% Normal Goat Serum (NGS), 0.1% Bovine 
Serum Albumin (BSA), 0.1% Triton X-100 in PBS] for 2 h at room temperature. All sections 
were incubated in a mixture of primary antibodies for 48 h at 4°C. Primary antibody solution 
was prepared in PBS with 0.1% BSA and 0.3% Triton X-100. After incubation, tissue sections 
were washed in PBS for 45 min (15 min, 3 times each). Sections were then labelled with 
secondary antibodies for 12 h at 4°C. Secondary antibody solution was prepared in PBS. After 
labelling the tissues with secondary antibodies, they were washed in PBS for 30 min (10 min, 
3 times each). Primary and secondary antibodies used for immunofluorescence confocal 
microscopy in this project are listed in Table 2.7 and Table 2.8, respectively. Sections were 
then mounted on polysine-coated glass slides and cover-slipped with mounting medium (1,4 
diazabicyclo (2.2.2) octane DABCO-glycerol). Slides were left for air-drying in the dark at 
room temperature.   
 
Table 2.7 Primary antibodies used in this project for immunofluorescence confocal microscopy 
Target Protein Type Source/ Catalogue No.  Dilution  
Parvalbumin Mouse monoclonal Swant/235 1:2000 
Parvalbumin Rabbit polyclonal Swant/PV27 1:2000 
HA-tag Rabbit polyclonal Cell Signalling/3724S 1:500 
GAT-1 Rabbit polyclonal Abcam/ab426 1:500 
GAT-3 Rabbit polyclonal Alomone Labs/AGT-003 1:200 
GAD 65 Mouse monoclonal Abcam/ab26113 1:500 




Table 2.8 Secondary antibodies used in this project for immunofluorescence confocal 
microscopy 
Product Secondary conjugate Source/ Catalogue No.  Dilution  
Goat anti-rabbit Alexa Fluor 488 Life Technologies/11008 1:1000 
Goat anti-mouse Alexa Fluor 568 Life Technologies/11031 1:1000 
 
2.3.3 Confocal imaging and analysis 
Images were acquired using Nikon A1+ Inverted Confocal Laser Scanning Microscope with 
following channel configurations; green channel at 488nm laser excitation and red channel at 
568nm laser excitation. During confocal imaging, detector offset for each channel were kept 
zero. Detector gain and laser power were optimized accordingly. Scan speed and image pixel 
size were also set accordingly. Confocal images were taken at 10X, 20X and 40X 
magnification. Cell counting and staining intensity analysis was performed with ImageJ 
software (version 1.51, NIH, USA) using the same settings for all animals and their respective 
control counterparts.  
 
2.4 Electroencephalography (EEG) recordings 
2.4.1 Surgical implantation of prefabricated headmounts and microcannulas 
For survival surgeries performed in this project, twelve-weeks old PVCre/Gi-DREADD or 
PVCre/Gq-DREADD mice were ordered at least two days before scheduled surgery date. 
Animals were handled once daily for 2 days. During surgery, animals were fully anesthetized 
with a continuous flow of isoflurane and subcutaneously injected with 5mg/kg of Carprofen 
(for pain control) and 2mg/kg of Marcaine (for local anaesthesia). Animals were provided with 
supplemental heat during surgery by placing them on a small heat pad. Once animals were fully 
anesthetized, the head was fixed with a stereotaxic frame (David Kopf Instruments, Tujunga, 
CA, USA) and the scalp was shaved to expose the skin. A sagittal incision was made to expose 
the skull. Two pairs of holes were carefully drilled in the skull, each pair being 1.5 mm lateral 
on either side of the longitudinal fissure. The first pair was located 1 mm anterior to bregma 



















Fig. 2.4 Image showing the headmounts, position of EEG electrodes and cannula placement, and 
preamplifier used in this study. (A) Schematic showing the channels of prefabricated headmount used in this 
study. (B) Wiring and connection information of the prefabricated headmount. (C) Diagram showing the position 
of EEG electrodes and cannula placement. (D) Preamplifier used to amplify the EEG waveforms. (E) Photograph 
of an animal during EEG recording with preamplifier connected to the headmount.  
 
 
(Pinnacle Technologies, Austin, TX, USA) were inserted through these burr holes. 
Prefabricated headmount (Pinnacle Technologies, Austin, TX, USA) was then placed over the 
head and lead wires were soldered to their respective channels of headmount (as illustrated in 
figure 2.4). The headmount with soldered regions was further secured using dental acrylic 
cement (Vertex Dental, Netherlands) and the loose skin around the incision site was then 
sutured (Sofsilk Sutures, Covidien, Ireland).  
 
For focal CNO injections, one extra burr hole was drilled into the skull, based on the stereotaxic 
coordinates for either the SScortex (AP: -1.22 to -2.06 mm, ML: 2.8 mm, DV: -1.5 mm) or 
RTN thalamus (AP: -1.34 to -1.94 mm, ML: 2.1-2.3 mm, DV: -3.2 to -3.5 mm)  (Mouse Brain 
Atlas, Paxinos and Franklin, 3rd Edition) for insertion of a guide cannula. A dummy cannula 
was inserted inside the guide cannula to prevent blood or any other fluid clogging it. Dummy 
and guide cannula for focal injections were obtained from Plastics One Inc., VA, USA. Dental 
acrylic cement was applied around the base of cannula to secure its position.  
 
2.4.2 Post-operative care 
Mice were placed inside individual cages as soon as they showed the signs of consciousness 
and activity after the surgical procedure. For four days post-surgery, animals were monitored 
twice daily. The food intake was monitored via body weight measurement and water intake 
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was measured by weighing the water bottle. Activity of animal during that period was also 
carefully monitored. Post-operative checks were restricted to once daily after fourth day, 
provided that animals showed sufficient recovery.  
 
2.4.3 EEG recording procedure 
After the full recovery of animals from surgical manipulation (at least seven days after surgery), 
EEG signals were recorded from the subdural space over the cerebral cortex using the Pinnacle 
mouse tethered system (Pinnacle Technologies, Austin, TX, USA) with simultaneous video 
recording. The prefabricated mouse headmount was attached to a preamplifier to amplify and 
filter the EEG waveforms. EEG signals were filtered at 0.5 Hz high pass and 50 Hz low pass. 
Before each recording, animals were acclimatized in testing environment and equipment for 1 
hour. Sirenia® software was used for acquisition of EEG traces.  
 
2.4.4 Analysis of EEG traces 
Video/EEG analysis was performed offline manually by an investigator, blind to the genotype, 
scrolling through EEG traces using Seizure Pro® software. Bursts of paroxysmal oscillatory 
activity in EEG traces were defined as absence-like SWDs if they conformed to criteria 
published for the morphological characteristics of SWDs in mice and if they were associated 
with behavioural arrest (Table 2.9). Artefacts due to muscle activity (extremely fast spikes of 
20–60ms of duration, not followed by slow waves, and mostly non-rhythmic), walking or 
scratching and grooming (rhythmic and high amplitude discharges) were readily recognised as 
such and on video were not associated with behavioural arrest hence they were not considered 
as epileptiform activity.  
 
2.4.5 Use of ethosuximide (ETX) to confirm absence-like nature of discharges 
In this study, to verify the absence-like nature of the epileptic discharges occurring in PVCre/Gi-
DREADD animals, ETX was used. This drug is specific for absence seizures; therefore, it can 
be used to differentiate absence seizures from other EEG changes. Separate cohort of PVCre/Gi-
DREADD animals were assigned to both the SScortex and the RTN thalamus group. Animals 
were injected with 10mg/kg CNO focally on day 1 to confirm that CNO injection generates 
absence-like SWDs. After 24 h, on day 2, same animals were injected with ETX (200mg/kg, 
i.p.) and CNO (10 mg/kg, focal). Dose of ETX injection was based on previous published 




2.5 Drug/chemical preparation and delivery 
All drugs used in this study were prepared immediately before use. During experiments they 
were stored in refrigerator (4 degrees C). 
 
2.5.1 Clozapine-N-oxide (CNO) 
CNO or vehicle were injected intraperitoneally on the basis of the calculated dose for the body 
weight of the animal. For focal injection, 0.3μl of CNO was infused into the specific brain 
region at a rate of 0.1μl /min. During preparation, 1.5 mg of CNO (Advanced Molecular 
Technologies, Australia) was dissolved in 75μl of dimethyl sulfoxide (DMSO). The volume 
was then adjusted to 15 ml by addition of 0.9% sterile saline to prepare CNO of 0.1 mg/ml 
concentration (for 1 mg/kg dosage group). For 5 and 10 mg/kg dosage groups, CNO of 0.5 
mg/ml and 1 mg/ml was prepared, respectively. Vehicle was prepared by mixing DMSO with 
0.9% sterile saline.  It was delivered via a Hamilton microinjection syringe attached to 
polythene tubing (Microtube Extrusions, Australia) and a 33-gauge internal cannula (Plastics 
One Inc., VA, USA) inserted into the previously implanted guide cannula. To verify the 
cannula tip localization and CNO diffusion to the specified focal regions, methylene blue dye 
was injected at the same volume and rate as CNO and histology was performed.  
 
2.5.2 Ethosuximide (ETX) 
ETX (Sigma Aldrich, USA) was first dissolved in 500μl DMSO. The volume was then adjusted 
to 10ml by addition of 0.9% sterile saline to prepare ETX of 20mg/ml concentration. ETX was 
injected intraperitoneally (200mg/kg) on the basis of calculated dose for the body weight of 
the animal. 
 
2.5.3 Pentylenetetrazole (PTZ) 
PTZ (Sigma Aldrich, USA) of 3mg/ml, 2mg/ml and 1mg/ml concentration was prepared in 
0.9% sterile saline for 30mg/kg, 20 mg/kg and 10 mg/kg dosage groups, respectively. It was 
injected intraperitoneally on the basis of calculated dose for the body weight of the animal. 
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                           Table 2.9 List of published studies on mice defining the morphology and characteristics of absence-like SWDs. 
Published article 
(Animals used) 
Criteria to fit as SWDs (quoted directly from the respective published articles) Morphology of SWDs 
Chung et al., 2009 
(HCN2 knockout 
apathetic mice) 
...repetitive rhythmic (2–8 Hz), high amplitude (>2 fold above background) sharp 
wave activity lasting longer than 1 second… 
 
Arain et al., 2012 
(GABAA receptor α1 
subunit knockout mice) 
... SWDs were defined as trains (>1 sec) of rhythmic biphasic spikes, with a voltage 
at least twofold higher than baseline and that were associated with after going slow 
waves… 
 
Frankel et al., 2014 
(C3H/He mice) 
... at least 2 connected spike-wave complexes (typically spanning at least 0.5 seconds) 
with amplitudes at least two-fold higher than background... 
 
Kim et al., 2015 
(Tottering-6j mice) 
...A SWD lasting for >1 s was considered an absence-like seizure. When the time 
interval between two SWDs was <1 s, the discharges were regarded as a single 
seizure... 
             
Heuermann et al., 2016 
(TRIP8b knockout mice) 
...SWDs were scored for each animal only if the EEG demonstrated a distinct 3–8 Hz 
spike–wave morphology, with amplitudes at least 2 times higher than baseline... 
 
 
Maheshwari et al., 2016 
(Stargazer and tottering 
mice) 
...Seizure activity was defined by bilateral spike and wave discharges with amplitude 




Meyer et al., 2018 
(Stargazer mice) 
...regular spike-wave burst structure, spike amplitude 1.5× baseline, spike frequency 
of 5–9 Hz, and a minimum duration of 0.5 second... 
           
This study Bursts of oscillations were defined as SWD if they had a spike-wave structure  
(spike, positive transient, and slow wave pattern) with a frequency of 3–8 Hz, an  





2.6 Behavioural tests 
All animals were trained in moving rotarod for two consecutive days before the test day to 
make them accustomed in testing instrument and environment. On test day, mice were allowed 
to perform in open field and moving rotarod. Open field test was performed always before 
rotarod test. Both tests were conducted before and after CNO injection.  
 
2.6.1 Open-field test 
Animals were acclimatized to the testing room for 1 hour before starting the test. They were 
placed in opaque open field area (40x40x20cm). They were allowed to move freely in open 
field for 10 min and their movements were tracked with an overhead video camera linked with 
Top Scan software (Clever Sys Inc., USA). 
 
2.6.2 Rotarod test 
Rotarod test was conducted for 5 min in moving rotarod from 4-20 rpm (Rotamex 5.0, 
Columbus Instruments, USA). Three trials were performed for each mouse with 2 min gap 
between each trial. Latency of fall was recorded for each trial.  
 
2.7 Western blotting 
2.7.1 Tissue collection and processing 
Animals were sacrificed by cervical dislocation. Brains were immediately extracted, snap-
frozen on dry ice and stored at -80°C. The cerebellum was dissected from the rest of the brain. 
The forebrain was mounted in the cryostat chuck using embedding media (Leica Microsystems, 
USA). The temperature inside the cryostat chamber was always maintained at -10°C. 300 µm 
thick coronal sections were cut and thaw-mounted on glass slides. Slides were temporarily 
stored in polystyrene box containing dry ice to prevent the degradation of the tissues. The 
primary SScortex and corresponding VP thalamus (Fig. 2.5) was punched out from the sections 
using 1.0 mm biopsy punches (Integra Miltex, 33-31AA) under dissecting microscope. Mouse 
brain atlas (Mouse Brain Atlas, Paxinos and Franklin, 3rd Edition) was used to identify primary 
SScortex and VP thalamus in the coronal sections. Mircopunched tissues were collected into 
microtubes containing homogenization buffer (0.5M Tris, 100mM EDTA, 3% SDS, pH 6.8), 
1% phenylmethylsulfonyl fluoride (PMSF) and 1% protease inhibitor (P8340, Sigma). 
Samples were sonicated for 5 min, heated for 2 min in hot bath at 100°C and then centrifuged 
at 13,000 rpm for 5 min at 4°C. Supernatant from each microtube was transferred into new 


































Fig. 2.5 Microdissection of tissue from the brain. Representative coronal sections of the mouse brain showing 
the SScortex (coloured portion). SScortex and corresponding VP thalamus regions were punched out from both 
hemispheres of coronal sections i.e. plates 25-46 in the mouse brain atlas (Franklin and Paxinos, 2008).  
 
 
2.7.2 Protein quantification 
Detergent compatible protein assay was used to determine the protein content in the brain 
samples. This assay was conducted according to the manufacturer’s directions (DC protein 
assay, 500-0116, Bio-Rad). According to the protocol, BSA standards were first prepared 
(Table 2.10) in the same homogenization buffer as the brain samples. Same buffer was used to 





blank (diluent only) were pipetted into a 96 well plate. 25μl of working reagent ‘A’ and 200μl 
of reagent ‘B’ was also added into each well. The plate was covered with aluminium foil and 
incubated at room temperature for 20 min. Absorbance was measured at 630 nm on plate 
reader. Protein concentration of brain samples was calculated after generating standard curve 
from BSA standards.  
 
Table 2.10 Preparation of BSA standards 
Standard concentration 
(μg/ml) 
Diluent (μl) 1500 μg/ml 
standard 
200 μg/ml standard 
500 200 100 - 
400 110 40 - 
300 160 40 - 
200 312 48 - 
100 100 - 100 
50 150 - 50 
25 140 - 20 
 
2.7.3 Gel electrophoresis and blot transfer 
8.5% resolving gel and 4% stacking gel was prepared to run sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) and to separate protein samples for 
immunodetection. Reagents for resolving gel were mixed in a falcon tube i.e. 6.81ml MQ H2O 
(Milli-Q Integral, Millipore, Germany), 3.75ml Tris-HCl (1.5M, pH 8.8), 4.20ml of 30% 
acrylamide, 150μl of 10% SDS, 75μl of 10% APS and 7.5μl TEMED (for 2 gels). The mixture 
was poured into a plastic cassette and was left to set for 30 min. A layer of MQ H2O was added 
on the top of resolving gel to prevent the gel from drying. Stacking gel was prepared in another 
falcon tube by mixing 3.01ml MQ H2O, 1.25ml Tris HCl (0.5M, pH 6.8), 0.66ml of 30% 
acrylamide, 50μl of 10% SDS, 25μl of 10% APS and 5μl TEMED (for 2 gels). The layer of 
MQ H2O added on the top of resolving gel was removed before pouring the stacking gel into 
the plastic cassette. An electrophoresis comb was inserted, and gel was allowed to set for half 
an hour. Brain samples containing 25μg protein were mixed with 4x loading buffer and MQ 
H2O. The mixture was vortexed and heated for 10 min at 70°C. Samples were loaded into the 
gel after removing the comb. A reference protein ladder (Novex Sharp Pre-stained Protein 
Standard, LC 5800, CA, USA) was included in each gel to verify the molecular weight. SDS-





half-filled with running buffer (Tris-Glycine, 0.1% SDS) at 100V to 130V for about 90 min. 
Proteins were then transferred onto nitrocellulose membrane (RPN303D, GE Healthcare Life 
Sciences, Germany) in chilled transfer buffer (Tris-Glycine, 10% methanol, 0.025% SDS) at 
100V for up to 80 min. 
 
2.7.4 Immunoblotting and analysis 
Following transfer of protein from gel onto nitrocellulose membrane, the membrane was 
washed in Tris buffered saline (TBS; 50mM Tris, 0.87% NaCl, pH 7.6) for 3-5 min. 
Membranes were blocked with Odyssey blocking buffer (Li-COR Biosciences) for 45 min at 
room temperature. Blocking was followed by 24 h incubation of membranes at 4°C with 
primary antibody solution. Primary antibody solution was prepared by mixing TBS-Tween 
(TBST i.e. TBS mixed with 0.1% Tween), blocking buffer and primary antibody. After 
incubation, the membranes were washed with TBS-Tween (3 times, 5 min each) and incubated 
with secondary antibodies diluted in TBS-Tween for 1 hour in the dark at room temperature. 
Primary and secondary antibodies used for western blotting experiments in this project are 
listed in Table 2.11 and Table 2.12, respectively. Membranes were washed with TBS-Tween 
(3 times, 5 min each) and TBS (2 times, 5 min each). After drying the membranes, they were 
scanned with the Odyssey Infrared Imaging System (Li-COR Biosciences). Protein bands were 
photographed and analyzed using Odyssey Image Studio Lite v3.1. The intensity of loading 
control (b-actin or a-tubulin) band was used to normalize other protein of interest.  
 
Table 2.11 Primary antibodies used in this project for western blotting.  
Target Protein Type Source/ Catalogue No.  Dilution  
b-actin  Mouse monoclonal Abcam/ab8226 1:1000 
b-actin Rabbit monoclonal Cell Signalling/13E5 1:1000 
a-tubulin Rabbit polyclonal Abcam/ab4074 1:5000 




GAT-3 Rabbit polyclonal Alomone Labs/AGT-003 1:200 
GAD65 Mouse monoclonal Abcam/ab26113 1:750 







Table 2.12 Secondary antibodies used in this project for western blotting.  
Product Secondary conjugate Source/ Catalogue No.  Dilution  
Goat anti-rabbit IRDye 680 Li-Cor Biosciences/926-32221 1:10000 
Goat anti-rabbit IRDye 800 CW Li-Cor Biosciences /926-32211 1:10000 
Goat anti-mouse IRDye 800 CW Li-Cor Biosciences /926-32210 1:10000 
 
2.8 Data analysis 
Statistical analyses of significant differences between mice groups i.e. DREADD animals and 
control animals (non-DREADD or vehicle treated DREADD) or epileptic stargazers and non-
epileptic control littermates were calculated using appropriate statistical tests. The normality 
of the data was checked by using D’Agostino-Pearson normality test. In DREADD related 
experiments, comparison of values between before and after injection in same treatment group 
was performed using Wilcoxon matched-pairs signed-rank test. Tukey’s post hoc multiple 
comparison test was performed to compare values from two independent treatment groups and 
Dunnett’s post hoc multiple comparison test was used to compare treatment groups with single 
control. Statistical differences in staining intensity and expression levels of protein between 
epileptic stargazers and non-epileptic control littermates were tested using Mann-Whitney 
unpaired rank test. Data were presented as mean ± standard error of the mean (SEM). All 


















CHAPTER 3. Impact of Silencing Feed-forward Inhibitory PV+ Interneurons on 
Absence Seizure Generation and Behaviour  
 
3.1 Introduction 
Absence epilepsy is due to the disruption of normal functioning of the CTC circuitry. 
Pathological SWDs seen in this form of epilepsy is believed to be mediated by multifactorial 
molecular and cellular mechanisms. Previous work conducted in Leitch laboratory in well-
established stargazer mouse model of absence epilepsy has shown significant loss of AMPA 
receptors in PV+ interneurons potentially leading to the loss of FFI within the CTC network 
thus contributing to the generation of SWDs. However, it is not yet established whether the 
functional impairment of PV+ interneurons is directly involved in absence seizure generation.   
PV+ interneurons are the most common subset of GABAergic neurons within the brain 
(Kelsom and Lu, 2013; Hu et al., 2014; Tremblay et al., 2016). These interneurons regulate 
hyperexcitability of the entire brain and maintain a balance between excitation and inhibition 
(Paz and Huguenard, 2015; Jiang et al., 2016). They play critical roles in various brain 
functions such as behaviour (Ferguson and Gao, 2018), cognition (Bender et al., 2012; Murray 
et al., 2015), learning (Wolff et al., 2014; Lee et al., 2017), memory (Murray et al., 2011; Kim 
et al., 2016), generation of physiological oscillations (Sohal et al., 2009) etc. Impairment in the 
functioning of these interneurons contribute to different neurological and psychiatric disorders, 
including epilepsy (Jiang et al., 2016; Marafiga et al., 2020), Alzheimer’s disease (Sanchez‐
Mejias et al., 2020), schizophrenia (Lewis et al., 2012; Nguyen et al., 2014) and autism (Wöhr 
et al., 2015).  
PV+ interneurons are predominantly expressed in both components of the CTC network i.e. 
SScortex and RTN thalamus (Adams et al., 1997; Jones, 2002). In the CTC network, these 
interneurons provide strong FFI to the principal excitatory cortical neurons and to excitatory 
relay neurons in the VP thalamus. This inhibition prevents runaway excitation (Cammarota et 
al., 2013; Paz and Huguenard, 2015; Jinag et al., 2016). Moreover, these interneurons also 
mediate neuronal inhibition via feed-forward and/or feed-back mechanisms in other brain 
networks involving cortex and thalamus (Delevich et al., 2015; Nassar at al., 2018), and other 
brain regions such as hippocampus (Kullman et al., 2011; Hu et al., 2014), striatum 
(Szydlowski et al., 2013) and amygdala (Lucas et al., 2016).  
In the stargazer mouse model of absence epilepsy, the mutation underlying the epileptic 
phenotype is a defect in the calcium voltage-gated channel auxiliary subunit gamma 2 i.e. 





Letts et al., 1998). Stargazin is a transmembrane AMPAR regulatory protein (TARP) critical 
for synaptic targeting and membrane trafficking of AMPARs at excitatory glutamatergic 
synapses (Chen et al., 2000). Previous work from Leitch laboratory using this animal model 
reported that there is a loss of AMPA-type receptors at the excitatory synapses in feed-forward 
inhibitory PV+ interneurons of the CTC network. (Adotevi and Leitch, 2016; 2017; 2019; 
Barad et al., 2012; 2017). Other studies have also shown impaired AMPA receptor expression 
in these inhibitory interneurons in the SScortex (Maheshwari et al., 2013) and the thalamus 
(Menuz and Nicoll, 2008) of the stargazers. Thus, loss of excitatory drive to these feed-forward 
inhibitory PV+ interneurons might potentially cause the loss of FFI and impaired FFI is likely 
to contribute to absence seizures in stargazer mice. GluA4 containing AMPA receptors are 
exclusively found at synapses on PV+ inhibitory interneurons (Kondo et al., 1997, Mineff and 
Weinberg, 2000) and knocking out GluA4 subunit of AMPA receptors (i.e. Gria4 −/− mouse) 
also resulted in absence seizures (Paz et al., 2011). Studies conducted in normal non-epileptic 
mice indicated that functionally silencing hippocampal PV+ interneurons generates epileptic 
seizures (such as temporal lobe seizures) (Drexel et al., 2017; 2019) and activation of these 
interneurons has anti-epileptic effects against PTZ-induced seizures (Clemente-Perez et al., 
2017; Johnson et al., 2018), kainic acid (KA)-induced seizures (Wang et al., 2018), 4-
aminopyridine (4-AP) induced seizures (Assaf and Schiller, 2016; Cǎlin et al., 2018). However, 
the functional role of these interneurons within the CTC network on absence seizure has not 
yet been established.    
Hence, the aim of this part of study was to investigate impact of functionally silencing feed-
forward inhibitory PV+ interneurons of either the SScortex or the RTN thalamus, in terms of 
absence seizure generation and behavioural parameters in non-epileptic (PVCre/Gi-DREADD) 
mice. DREADDs technology was used to silence PV+ interneurons in the SScortex or the RTN 
thalamus. To selectively target these interneurons, mice expressing Cre recombinase in PV+ 
interneurons (PV-Cre) were bred with mice expressing inhibitory Gi-DREADD receptors i.e. 
hM4Di-flox mice. Expression of inhibitory Gi-DREADD receptors in PV+ interneurons was 
first confirmed via confocal fluorescence microscopy. Simultaneous video/EEG recordings 
were made after global (via i.p. CNO injection) and focal (via regional injection of CNO into 
either the SScortex or the RTN thalamus) silencing of PV+ interneurons. Behavioural tests 









3.2.1 Immunofluorescence confocal microscopy, image acquisition and analysis 
Immunofluorescence confocal microscopy was performed to confirm the expression of 
inhibitory Gi-DREADD receptors in PV+ interneurons. Antibodies against HA-tag (Cell 
Signaling, C29F4) and parvalbumin (Swant Inc., PV-235) were used to label DREADD 
receptors and PV+ interneurons, respectively. Immunolabelling was performed in brain 
sections from PVCre/Gi-DREADD mice (n=13) and non-DREADD WT control animals 
(n=16). Immunolabelling, confocal imaging, quantification of immunolabelled cells and 
analysis were performed as described previously in chapter 2 subsection 2.3. Images were 
taken in the brain regions with known PV+ interneurons distributions i.e. SScortex, RTN 
thalamus and cerebellum. Immunolabelled cells in the SScortex were counted using 10X 
magnified confocal images (total 2469 HA-tagged cells and 2423 PV cells counted). In the 
cerebellum 20X magnified confocal images were used (total 2258 HA-tagged cells and 2164 
PV cells counted) whereas in the RTN thalamus cells were counted using 40X images (total 
340 HA-tagged cells and 439 PV cells counted). Cell counting was based on 67 confocal 
images from PVCre/Gi-DREADD mice. 
 
3.2.2 Surgical implantation of prefabricated headmounts and microcannulas for EEG 
recordings 
To test the effect of global (i.p.) and focal (SScortex or RTN thalamus) silencing of feed-
forward inhibitory PV+ interneurons on absence seizure generation, EEG recordings were 
performed in PVCre/Gi-DREADD and non-DREADD WT control animals. Surgical 
manipulations for the implantation of prefabricated headmounts (Pinnacle Technologies, 
Austin, TX, USA) and microcannulas (Plastics One Inc., VA, USA) were performed as 
previously described in the chapter 2 subsection 2.4. Simultaneous video/EEG recordings were 
performed on animals 10 min before and for 1 hour after i.p. or focal injection of CNO/vehicle. 
Total number of animals used in these experiments are shown in the Tables below (Table 3.1 











Table 3.1 Number of animals used in EEG recordings for i.p. injection group. 
CNO/vehicle PVCre/Gi-DREADD mice 
(DREADD) 
Wild type control mice 
(Non-DREADD) 
1 mg/kg 8 4 
5 mg/kg 9 6 
10 mg/kg 8 6 
Vehicle 8 6 
 
 
Table 3.2 Number of animals used in EEG recordings for focal (SScortex and RTN thalamus) 
injection group. 
 
CNO/vehicle SScortex group RTN thalamus group 




1 mg/kg 10 7 10 8 
2.5 mg/kg 10 9 9 10 
5 mg/kg 13 11 10 10 
10 mg/kg 10 8 9 8 
Vehicle 10 7 9 4 
 
3.2.3 Preparation and delivery of clozapine-N-oxide (CNO) and ethosuximide (ETX) 
CNO was freshly prepared before every scheduled experiment as previously described in 
chapter 2 subsection 2.5. CNO was injected intraperitoneally or focally (into the SScortex or 
the RTN thalamus) after 10 min of baseline EEG recordings. It was injected intraperitoneally 
on the basis of the calculated dose for the body weight of the animal. For focal injections, 0.3 
μl of CNO was infused into the specific brain region (either the SScortex or the RTN thalamus) 
at a rate of 0.1 μl /min. It was delivered via a Hamilton microinjection syringe. At the end of 
focal EEG experiments, methylene blue dye was injected at the same volume and rate as CNO 
into the focal regions of the brain under investigation. Histology was performed to verify the 
localization of cannula tip and estimate the diffusion of CNO (see supplementary figure 1). 
The stereotaxic coordinates of the CNO and dye injections in the SScortex were 1.22 to 2.06 
mm posterior to bregma, 2.8 mm lateral to the midline and 1.5 mm below the cortical surface. 
The coordinates for RTN thalamus injections were 1.34 to 1.94 mm posterior to bregma, 2.1-
2.3 mm lateral to the midline and 3.2-3.5 mm ventral to the cortical surface (Mouse Brain Atlas, 





(spike and wave-like discharges) occurring after focal injection of CNO at doses 5-10mg/kg, 
impact of anti-absence epileptic drug ETX on seizure generation was tested. ETX was prepared 
as previously described in chapter 2. ETX was injected intraperitoneally (200mg/kg) on the 
basis of calculated dose for the body weight of the animal. 
 
3.2.4 Behavioural tests 
Two behavioural tests were employed to test the effect of global and focal silencing of PV+ 
interneurons in animal behaviour. Rotarod and open-field tests were used to examine the motor 
function of animals. Before the test day, animals were pretrained on a moving rotarod for two 
consecutive days to accustom them to the testing instrument and environment. On the test day, 
animals were acclimatized to the testing room for 1 hour before the experiment. Before CNO 
injection, mice were allowed to move freely in the open-field arena (40×40×20cm) for 10 min 
and their movements tracked with an overhead video camera linked to Top Scan software 
(Clever Sys Inc., USA). Open-field testing was followed by an interval of 3 min before three 
rotarod trials of 5 min each with 2 min gaps between successive trials. Rotarod testing was 
performed on a moving rotarod 4–20 RPM (Rotamex 5.0, Columbus Instruments, USA). 
Latency of fall was recorded for each trial. Both behavioural tests were performed after CNO 
injections according to the abovementioned protocol. Total number of animals used in these 
experiments are shown in Tables below (Table 3.3 and Table 3.4). 
Table 3.3 Number of animals used in behavioural tests for i.p. injection group. 
CNO/vehicle PVCre/Gi-DREADD mice 
(DREADD) 
Wild type control mice 
(Non-DREADD) 
1 mg/kg 20 10 
5 mg/kg 20 9 
10 mg/kg 20 10 















Table 3.4 Number of animals used in behavioural tests for focal (SScortex and RTN thalamus) 
injection group. 
 
CNO/vehicle SScortex group RTN thalamus group 




1 mg/kg 9 7 10 8 
2.5 mg/kg 9 10 11 10 
5 mg/kg 10 9 13 8 
10 mg/kg 11 7 10 8 
Vehicle 11 7 10 8 
 
3.3 Results 
3.3.1 Inhibitory Gi-DREADD receptors are expressed in feed-forward inhibitory PV+ 
interneurons 
Double-labelled immunohistochemistry with antibodies against HA-tag and PV was performed 
to confirm the expression of inhibitory DREADD receptors in PV+ interneurons of PVCre/Gi-
DREADD mice (Fig.3.1). HA-tag for DREADD (identified by pseudocolour green) was only 
expressed in tissue sections from PVCre/Gi-DREADD mice but not in non-DREADD WT 
controls. PV+ interneurons were highly expressed throughout all SScortical layers (except 
layer 1), RTN thalamus and the cerebellar cortex of cerebellum in all genotypes. Co-
localization of HA-tag in PV+ interneurons was found throughout the SScortex (Fig. 3.1A,B), 
the RTN thalamus (3.1C,D) and the cerebellar cortex of cerebellum (Fig. 3.1E,F). In the 
SScortex of PVCre/Gi-DREADD mice, almost all PV+ interneurons expressed HA-tag (Fig. 
3.1A white arrows). The percentage of co-localization of HA-tag in PV+ interneurons in the 
SScortex was above 90% in PVCre/Gi-DREADD mice (Fig. 3.1B). Similarly, in the RTN 
thalamus, PV+ interneurons strongly expressed HA-tag (Fig. 3.1C white arrows). The 
percentage of co-localization of HA-tag in PV+ interneurons in the RTN thalamus was also 
above 90% in PVCre/Gi-DREADD mice (Fig. 3.1D). In both regions, very few cells appeared 
to be labelled for HA that were not also labelled for PV (red arrow). In the cerebellum, HA-tag 
was intensely expressed in PV+ Purkinje cell soma in PVCre/Gi-DREADD mice (Fig. 3.1E 
white arrows). The percentage of co-localization of HA-tag in PV+ inhibitory Purkinje cell 
soma was above 90%. (Fig. 3.1F). Co-labelling with HA-tag and PV antibody was seen 
throughout the molecular layer of cerebellar cortex of PVCre/Gi-DREADD mice, as dendritic 













































Fig. 3.1 Expression of Gi-DREADD receptors in PV+ interneurons. (A, C, E) Confocal images showing the 
expression of HA-tag in PV+ interneurons in the SScortex, the RTN thalamus and the cerebellar cortex of 
PVCre/Gi-DREADD animals, respectively. White arrows in merged images represent colocalized cells. Red arrows 
indicate the HA-positive neurons that are immunonegative for PV and blue arrows indicate PV+ neurons which 
are immunonegative for HA. (B, D, F) Percentage of co-localization of HA and PV in neurons in the SScortex, 
the RTN thalamus, and the cerebellum, respectively. Immunolabelled cells in the SScortex and the cerebellum 
were counted at 10X magnified confocal images whereas those in the RTN thalamus were counted using 40X 
images. (Het = PVCre/Gi-DREADD offspring from homozygous PV-Cre female and heterozygous hM4Di-flox 
male; Homo = PVCre/Gi-DREADD offspring from homozygous PV-Cre female and homozygous hM4Di-flox 





was no HA-tag labelling in the non-DREADD WT controls (Fig. 3.1A,C,E, bottom panel). 
 
3.3.2 Silencing feed-forward inhibitory PV+ interneurons via i.p. and focal CNO 
injections generated absence-like seizure  
Firstly, as a proof of concept, the impact of globally silencing PV+ interneurons on seizure 
generation was tested via i.p. CNO injection. Simultaneous video/EEG recordings were 
performed on animals 10 min before and for 1 hour after i.p. CNO injection at doses of either 
1 mg/kg (DREADD animals: n = 8; non-DREADD WT controls: n= 4), 5 mg/kg (DREADD 
animals: n = 9; non-DREADD WT controls: n= 6), 10 mg/kg (DREADD animals: n= 8; non-
DREADD WT controls: n = 6), and vehicle-treated (DREADD animals: n = 8; non-DREADD 
WT controls: n = 6). Bursts of paroxysmal oscillatory activity (indicated by asterisks) was seen 
in both hemispheres of the brain which were associated with behavioural arrest (Fig. 3.2). 
Seizure activity was seen after 5 mg/kg and 10 mg/kg of i.p. CNO injection in PVCre/Gi-
DREADD animals but not in the 1 mg/kg dose group, vehicle treated animals or non-DREADD 
WT control animals (Fig. 3.2). The bursts of paroxysmal oscillatory activity had a characteristic 
spike and wave-like morphological profile with a spike frequency between 3 and 7 Hz. In 
DREADD animals, the mean onset of seizure was 31.27 ± 5.46 min in the 5 mg/kg dose group 
(n = 9) and 28.91±4.92 min in the 10 mg/kg group (n= 8). The mean number of bursts during 
1 hour of EEG recording period was 4 ± 1.01 bursts in the 5 mg/kg dose group and 5.5 ±1.37 
in the 10 mg/kg group and was independent over increasing dose of CNO. Increasing dose of 
CNO also did not affect other EEG parameters such as mean spike frequency, mean duration 
of each burst and last incident of seizure during 1 hour of recording. The mean frequency of 
such discharges was 5.34 ± 0.76 spikes/sec and 5.18± 0.44 spikes/sec for 5 mg/kg and 10 mg/kg 
dose group of CNO, respectively. The mean duration of each burst was 3.16 ± 0.57 seconds 
and 4.01 ± 0.57 seconds for 5 mg/kg and 10 mg/kg dose group of CNO, respectively. During 1 
hour of EEG recording, last incident of seizure was 43.54±4.77 min and 34.17±5.97 min after 
CNO injection for 5mg/kg and 10mg/kg dose group, respectively.  
 
One PVCre/Gi-DREADD animal injected with 5mg/kg CNO displayed tonic-clonic convulsive 
type seizures after 22.58 min of CNO injection (Fig. 3.3). In this case the convulsive seizures 
were characterized by extremely high-amplitude spikes on the EEG and accompanied by severe 























Fig. 3.2 Representative EEG traces of PVCre/Gi-DREADD (DREADD) animals and non-DREADD WT 
controls after i.p. injection of CNO/vehicle. Bursts of paroxysmal oscillatory activity (asterisks) with the 
characteristics of SWDs and associated behavioural arrest were seen only in DREADD animals injected with 5–
10 mg/kg i.p. CNO. No SWDs were evident in 1 mg/kg or vehicle treated groups or non-DREADD WT control 
animals. All representative EEG traces were obtained from different animals. Each trace represents 3–6 min of 


















Fig. 3.3 Tonic-clonic convulsive seizures with very high amplitude in EEG were evident in one PVCre/Gi-
DREADD animal after i.p. 5 mg/kg CNO injection. Hash signs (#) on the trace represent tonic-clonic seizures. 










The characteristics and morphology of such discharges were very different to the rhythmic 
spike and wave oscillations seen in the other PVCre/Gi-DREADD animals in the 5 mg/kg and 
10 mg/kg dose groups hence this animal was excluded from the analysis. 
 
After confirming that global silencing of feed-forward inhibitory PV+ interneurons via i.p. 
CNO injection generates paroxysmal oscillatory discharges having similar morphological 
profiles of absence-like SWDs, CNO injections were targeted focally into either the SScortex 
(Fig. 3.4) or the RTN thalamus (Fig. 3.6). Feed-forward inhibitory PV+ interneurons were 
directly silenced in either of these brain regions to test that loss of FFI within CTC network is 
one mechanism by which the normal physiological oscillations switch to pathological SWDs 
like oscillations as seen in absence seizures. Similar to the i.p. injection groups, EEG traces 
were recorded for 10 min before and for 1 hour after focal CNO/vehicle injection at doses of 
either 1, 2.5, 5 and 10 mg/kg. Different cohorts of animals were used in this experiment and 
each animal had only a cortical or thalamic canula inserted for injection of CNO. Injection of 
CNO into both focal regions (2.5, 5 and 10 mg/kg) in PVCre/Gi-DREADD animals generated 
bursts of paroxysmal oscillatory activity (indicated by asterisks on EEG traces) in both brain 
hemispheres and those bursts were associated with behavioural arrest (Fig 3.4 and 3.6). The 
morphology and character of such bursts were similar to absence-like SWDs. However, 
1mg/kg CNO or vehicle treated DREADD animals and CNO treated non-DREADD animals 
showed no signs of seizures (Fig 3.4 and 3.6).  
One PVCre/Gi-DREADD animal, when focally injected with 5 mg/kg CNO into the SScortex 
showed a single tonic-clonic convulsive event with jerky body movements which lasted for 
















































Fig. 3.4 Representative EEG traces of PVCre/Gi-DREADD (DREADD) animals and non-DREADD WT 
controls after focal injection of CNO/vehicle into the SScortex. Bursts of paroxysmal oscillatory activity 
(asterisks) with the characteristics of SWDs and associated behavioural arrest were seen after CNO injection (2.5–
10mg/kg) only in DREADD animals but not in 1mg/kg or vehicle treated groups or non-DREADD WT control 










Fig. 3.5 Tonic-clonic convulsive seizure in EEG was evident in one PVCre/Gi-DREADD animal with 5 mg/kg 
CNO injected into the SScortex. Hash sign (#) on the trace represents tonic-clonic seizure. Trace represents 










































Fig. 3.6 Representative EEG traces of PVCre/Gi-DREADD (DREADD) animals and non-DREADD WT 
controls after focal injection of CNO/vehicle into the RTN thalamus. Bursts of paroxysmal oscillatory activity 
(asterisks) with the characteristics of SWDs and associated behavioural arrest were seen after CNO injection (2.5–
10mg/kg) only in DREADD animals but not in 1mg/kg or vehicle treated groups or non-DREADD WT control 




Analysis of the various EEG parameters in PVCre/Gi-DREADD mice injected with 2.5, 5 and 
10 mg/kg CNO (both in the SScortex and the RTN thalamus groups) showed that increasing 
dose of CNO has no significant difference in any parameters. Comparison is shown in the Table 






Table 3.5 Comparison of various EEG parameters after focal CNO injection into the SScortex 
or the RTN thalamus of PVCre/Gi-DREADD animals during 1 hour of EEG recording. 
 
 
3.3.3 Route of administration of CNO affected onset of bursts of oscillatory activity 
Impact of the route of CNO injection (i.p. or focal) on seizure generation was analysed which 
revealed that onset of seizures after focal injection was significantly faster than i.p. injection 
(Fig. 3.7A). The mean onset of seizures in the i.p. CNO injection group was at 31.27 ± 5.46 min 
(n = 9) for 5 mg/kg and 28.91± 4.92 min (n = 8) for the 10mg/kg dosage group. In the SS cortex 
group, mean onset of seizures was 13.89±2.93 min (n = 13) after 5 mg/kg CNO, and 
14.76±2.75 min (n = 10) after 10 mg/kg CNO (Fig. 3.7A). In the thalamus group, mean seizure 
onset was 15.25±3.96 min (n = 10) after 5 mg/kg CNO and 10.14±1.83 min (n = 9) after 
10 mg/kg CNO). Other parameters of EEG discharges such as burst rate, burst duration and 
spike frequency remained similar irrespective of the dose of CNO or the route of administration 
(Fig. 3.7B,C,D). No significant difference in mean rate of discharges/hour was seen after either 
i.p. [(4 ± 1.01 and 5.50 ±1.3 bursts/hour for 5 mg/kg (n =9) and 10 mg/kg (n=8) respectively) 
or focal administration of CNO: (SS cortex group: 6.46± 1.54 (n = 13) after 5 mg/kg CNO and 
6.7± 1.58 (n = 10) after 10 mg/kg CNO; thalamus group: 5.8± 1.95 (n = 10) after 5 mg/kg CNO 
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Fig. 3.7 Overall comparison of various EEG parameters after i.p. and focal (SScortex and RTN thalamus) 
injection of CNO during 1 hour of EEG recording. (A) First incident of seizure (B) Mean rate of discharges 
(C) Mean duration of seizure (D) Mean frequency of seizure (E) Last incident of seizure. All values represent 










Likewise, there was no significant difference in the mean duration of each seizure burst for any 
of the CNO levels tested via i.p. or focal routes i.e. i.p. group: 3.16 ± 0.57 seconds (n = 9) after 
5 mg/kg CNO and 4.01 ± 0.57 seconds (n = 8) after 10 mg/kg CNO, SS cortex group: 
3.48 ± 0.51 seconds (n = 13) after 5 mg/kg CNO and 3.91 ± 0.67 seconds (n = 9) after 10 mg/kg 
CNO, thalamus group: 3.49 ± 0.38 seconds (n = 10) after 5 mg/kg CNO and 4.60± 0.79 seconds 
(n = 9) after 10 mg/kg CNO (Fig. 3.7C). Similarly, no significant differences were seen in mean 
frequency of seizure (spikes/sec) i.e. i.p. group: 5.34 ± 0.76 (n = 9) after 5 mg/kg CNO and 
5.18± 0.44 (n = 8) after 10 mg/kg CNO; SS cortex group: 5.27 ± 0.49  (n = 13) after 5 mg/kg 
CNO and 5.03 ± 0.61  (n = 10) after 10 mg/kg CNO; thalamus group: 4.87± 0.43 min (n = 10) 
after 5 mg/kg CNO and 5.09 ± 0.57 min (n = 9) after 10 mg/kg CNO (Fig. 3.7D). Likewise, no 
significant changes were seen also in the last incident of seizure across route of administration 
or dose level of CNO (Fig. 3.7E).  
 
3.3.4 ETX suppressed absence-like seizures generated by focal CNO injections 
 
Next, the impact of anti-absence epileptic drug ETX on seizure generation was investigated. 
ETX is widely used to prevent absence seizures in both human patients and genetic animal 
models of absence epilepsy. The rationale behind the use of ETX in this study was to confirm 
that the bursts of oscillatory absence-like SWDs occurring after focal injection of CNO at doses 
of 2.5–10 mg/kg are definite absence seizures and are not any other forms of EEG changes. 
CNO (10 mg/kg) was injected focally into a cohort of PVCre/Gi-DREADD mice (SScortex 
group: n = 3, (Fig. 3.8A); RTN thalamus group: n = 4, (Fig. 3.8B) and video/EEG recordings 
were made for 10 min before and for 1 hour post CNO injection. CNO induced bursts of 
oscillatory spikes and wave-like discharges in all mice tested. Next day, the same cohort of 
animals was treated with 200 mg/kg of ETX before 10 mg/kg CNO injection. EEG recordings 
were performed at least 1-hour post CNO injection. Administration of ETX completely 
prevented spikes and wave-like discharges in all tested PVCre/Gi-DREADD animals. This 
provided a strong evidence that the nature of epileptiform activity seen in EEG recordings after 















































Fig. 3.8 ETX test conducted in PVCre/Gi-DREADD animals. (A) Representative EEG traces from PVCre/Gi-
DREADD animal injected with 10mg/kg of CNO into the SScortex on day 1 showing bursts of discharges 
(asterisks). After 24 h, the same animal was treated with ETX (200mg/kg) prior to injection of 10mg/kg of CNO 
into the SScortex, which prevented SWDs. (B) Representative EEG traces from a PVCre/Gi-DREADD animal 
injected with 10mg/kg of CNO into the RTN thalamus on day 1 showing bursts of discharges (asterisks). After 
24 h, the same animal was injected focally with 10mg/kg of CNO into the RTN (thalamus) and ETX (200mg/kg) 





















3.3.5 Silencing feed-forward inhibitory PV+ interneurons via i.p. and focal CNO 
injections increased immobility 
Silencing PV+ interneurons via i.p. and focal (SScortex or RTN thalamus) routes generated 
absence-like seizures which were evident during 1 hour of EEG recording. It was also revealed 
that silencing PV+ interneurons led to increased immobility in dose-dependent manner only in 
DREADD animals. Analysis of the data indicated that DREADD animals spent significantly 
more time immobile after i.p. CNO doses of 5 and 10mg/kg i.e. 45.89 ±3.44 min (n = 9) and 
52.61 ±1.21 min (n = 8), respectively in comparison to vehicle-treated and 1mg/kg CNO 
injected animals, which were immobile for 29.27 ± 5.53 min (n = 8) and 34.20 ± 1.73 min 
(n = 8), respectively (Fig. 3.9A). Injection of CNO into non-DREADD WT control animals at 
doses 5 and 10mg/kg did not significantly change the mobility in animals i.e. 5mg/kg CNO 
group: 31.30±1.55 min (n = 6), 10mg/kg CNO group: 34.11±2.04 min (n = 6). Similarly, 
vehicle treated and 1 mg/kg CNO treated non-DREADD animals spent 26.63±4.27 min (n = 6), 
28.28±4.59 min (n = 4) immobile, respectively (Fig. 3.9A).  
 
In the SScortex group, DREADD mice injected with CNO doses of 2.5, 5 and 10 mg/kg spent 
significantly more time immobile after CNO treatment. The mean time spent immobile during 
the 1 hour recording period post CNO injection was: 39.09 ± 3.51 min (n = 10) after 2.5mg/kg; 
49.76 ± 1.83 min (n = 13) after 5mg/kg and 45.64± 3.32 min (n = 10) after 10mg/kg compared 
to vehicle-treated 24.97±3.74 min (n = 10) or 1mg/kg CNO injected 29.71±4.05 min (n = 10) 
animals (Fig. 3.9B). Administration of CNO into non-DREADD WT control animals did not 
significantly change mobility compared to vehicle treated animals (2.5mg/kg CNO 
33.54± 3.69 min (n =9); 5mg/kg CNO 28.56 ±2.12 min (n = 11); 10mg/kg CNO 34.20±2.93 
min (n = 8); vehicle 21.86±2.69 min (n = 7); 1mg/kg CNO 30.72±3.50 min (n = 7) (Fig. 3.9B).  
 
Analysis of the data following focal injection of CNO into the RTN thalamus of DREADD 
mice also revealed animals spent more time immobile after higher 5-10 mg/kg doses, although 
this trend did not reach to significance (Fig. 3.9C). DREADD mice treated with vehicle, 1, 2.5, 
5, and 10mg/kg CNO spent 37.43±4.49 min (n =9), 38.35±4.0 min (n =10), 34.10±3.78 min (n 
























































Fig. 3.9 Immobility in animals after CNO injection during 1 hour of EEG recording. Comparison of mean 
time spent immobile by PVCre/Gi-DREADD (DREADD) and non-DREADD animals during 1 hour of EEG 
recording after (A) I.P. CNO injection and focal CNO injection into the (B) SScortex and (C) the RTN thalamus. 
All values represent mean ± SEM. Comparison between treatment groups were performed using Tukey’s post hoc 






Injection of CNO into non-DREADD WT control animals of RTN thalamus group also did not 
significantly change mobility compared to vehicle treated animals and any of the dose   levels 
tested (vehicle 28.53±2.44  min (n = 4); 1mg/kg CNO 29.08±3.69  min (n = 8); 2.5mg/kg CNO 
30.30±4.10 min (n =10); 5mg/kg CNO 27.31±3.15 min (n = 10); 10mg/kg CNO 38.63±2.83 
min (n = 8) (Fig. 3.9C). 
 
3.3.6 Silencing feed-forward inhibitory PV+ interneurons via intraperitoneal (i.p.) CNO 
injection impaired motor function, decreased locomotion and increased anxiety 
Impact of globally silencing PV+ interneurons on animal behaviour was tested by i.p. CNO 
injection in PVCre/Gi-DREADD mice and non-DREADD WT control mice. As rodent models 
of absence epilepsy exhibit absence seizures associated with behavioural arrest, impaired motor 
co-ordination and ataxia (Jarre et al., 2017), motor function in open-field and moving rotarod 
was tested in this study. Open-field test was conducted to examine the total distance travelled 
and the relative time spent in central and peripheral zones (CZ and PZ) in the open-field arena. 
Total ambulatory distance is correlated with the locomotory behaviour of the animal, whereas 
relative time spent in the CZ and PZ of the open field is an indicator of anxiety levels. Rotarod 
test was performed to evaluate motor coordination of animals.  
 
Analysis of the open-field data revealed that there was a significant difference in all tested 
parameters in PVCre/Gi-DREADD mice treated with 5 mg/kg and 10 mg/kg of i.p. CNO 
compared to control non-DREADD WT littermates, or vehicle treated PVCre/Gi-DREADD 
mice. However, drug doses of 1 mg/kg i.p. CNO had no effect on PVCre/Gi-DREADD mice or 
controls. Movement track-paths recorded in the open-field arena revealed decreased 
locomotion and an increased tendency to stay in the PZ, after administration of higher (5-
10 mg/kg) i.p. doses of CNO to DREADD mice (Fig. 3.10A). In the 5 mg/kg dose group, total 
ambulatory distance and total time spent in the PZ before CNO injection was 1562 ±133.6 cm 
and 532.1 ± 7.62 seconds, respectively, which changed significantly after CNO injection to 
553.3±95.35 cm and 587.1 ± 3.88 seconds respectively (n = 20) (Fig.3.10B,C). Similarly, in 
10 mg/kg dose group, total ambulatory distance and total time spent in the PZ changed 
significantly from 1769±95.87 cm and 543.8±6.38 seconds before CNO injection to 
360.3±88.62 cm and 591.9±2.48 seconds respectively after CNO injection (n = 20) 



















































Fig. 3.10 Comparison of parameters of open-field test in animals after injection of different i.p. doses of 
CNO. (A) Representative images of movement track paths from open-field test for CNO treated PVCre/Gi-
DREADD (DREADD) animals and non-DREADD WT control animals. Graph showing (B) total distance 
travelled (C) total time spent in PZ (D) % of time spent in CZ by DREADD and non-DREADD WT control mice 
after i.p. injection of CNO or vehicle. All values represent mean ± SEM. Comparisons between treatment groups 
were performed using Tukey's post hoc multiple comparison test. (Individual data points for B, C, D are shown 






after drug doses of 5-10 mg/kg (before 5 mg/kg CNO: 11.33± 1.29%, after 5 mg/kg CNO: 
2.01± 0.62%; before 10 mg/kg CNO: 9.36 ±1.06%, after 10 mg/kg CNO: 1.18± 0.31%; n = 20)  
(Fig. 3.10D). By contrast mice treated with 1 mg/kg CNO showed no significant changes in 
any of the parameters tested in open field. None of the control groups (vehicle treated or non-
DREADD WT groups) also showed any changes in locomotion or relative time spent in the 
CZ or PZ (Fig. 3.10B,C,D). Thus, silencing feed-forward inhibitory PV+ interneurons via i.p. 
CNO injection at dose levels 5–10 mg/kg decreased locomotion and increased anxiety levels 
only in PVCre/Gi-DREADD animals. 
 
To test the impact of silencing feed-forward inhibitory PV+ interneurons on motor co-
ordination, the same cohort of animals was tested on a moving rotarod. Rotarod test is widely 
used to examine motor coordination in rodents. Rotarod data revealed that there was a 
significant difference in the mean latency of fall in PVCre/Gi-DREADD mice before and after 
i.p. CNO injection only in 5 mg/kg and 10 mg/kg dose group but not in 1 mg/kg dose group 
and vehicle treated group. In 5 mg/kg dose group, the mean latency of fall before CNO injection 
was 295.1 ± 1.23 seconds which decreased significantly after CNO injection i.e. 
173.8 ± 6.21 seconds; n = 20 mice (Fig. 3.11A). Similarly, in 10 mg/kg dose group, the mean 
latency of fall reduced significantly from 294± 1.16 seconds before injection to 
86.40± 4.30 seconds (n = 20) after CNO injection (Fig. 3.11A). However, mice treated with 
1 mg/kg CNO showed no motor impairment on the rotarod (latency of fall before CNO 
injection = 296.30 ±0.96 seconds; after CNO injection 286.7 ± 3.45 s; n = 20). Also, vehicle 
treated PVCre/Gi-DREADD mice showed no changes in motor co-ordination before and after 
CNO injection (latency of fall before CNO injection =293.4±2.45 seconds; after CNO injection 
291.7 ± 2.17 s; n = 20). No significant differences were seen in vehicle and CNO treated non-
DREADD WT control groups (Fig. 3.11B). Wilcoxon matched-pairs signed rank test was 
performed to compare mean latency between before and after injection in same treatment group 
(Fig. 3.9A,B) whereas Tukey’s post hoc multiple comparison test was performed to compare 
treatment groups of DREADD and non-DREADD animals (Fig. 3.11C).  
 
3.3.7 Silencing feed-forward inhibitory PV+ interneurons via focal CNO injection 
decreased locomotion but did not impair motor function  
Impact of focally silencing feed-forward inhibitory PV+ interneurons on behavioural 
parameters was tested by CNO injection into either the SScortex or the RTN thalamus of 


















































Fig. 3.11 Latency of fall in rotarod test in animals after different doses of i.p. CNO injection. (A) (B) 
Comparisons between before and after injection in same treatment group were performed using Wilcoxon 
matched-pairs signed-rank test. (C) Tukey's post hoc multiple comparison test to compare independent treatment 





were assigned for both treatment groups. Locomotory behaviour in PVCre/Gi-DREADD mice 
was significantly changed in a dose dependent manner after focal injection of CNO.  
CNO doses of 2.5–10 mg/kg injected into the SScortex or the RTN thalamus significantly 
reduced the total ambulatory distance travelled by DREADD animals compared to before 
treatment, whereas CNO had no effect on non-DREADD WT controls. Dunnett's post hoc 
multiple comparison test showed statistically significant differences in the mean distance 
travelled after CNO doses of 2.5 mg/kg (820.9±202.1 cm; n = 9), 5 mg/kg 
(793.3±207.1 cm; n= 10), 10 mg/kg CNO (358.2 ±91.86 cm, n = 11) compared to before 
CNO/vehicle treatment (1950±109.6 cm, n = 9–11) in the SScortex group (Fig. 3.12A). No 
significant changes were seen in non-DREADD WT control animals i.e. mean distance 
travelled after CNO doses of 2.5 mg/kg (1308±126.4 cm; n = 10), 5 mg/kg 
(1243±101.4 cm; n = 9), 10 mg/kg CNO (1233±132 cm, n= 7) compared to before 
CNO/vehicle treatment (1714±149.9 cm, n =7-10) (Fig. 3.12C). Tukey's post hoc multiple 
comparison test also showed significant difference between DREADD and non-DREADD WT 
animals of 10mg/kg CNO treated group (Fig. 3.12E). Similarly, CNO injection into the RTN 
thalamus significantly reduced locomotion in DREADD animals of 2.5–10 mg/kg dose groups 
but not in non-DREADD WT controls. During the 10 min testing period before thalamic CNO 
injection, DREADD animals travelled 1786±124.32 cm (n =10-13) in open-field arena; this 
decreased significantly after 2.5, 5 and 10 mg/kg of CNO injection to 265.1±88.69 cm (n= 11), 
458.8±115.9 cm (n = 13), and 295.6 ±134.5 cm (n = 10), respectively via Dunnett's post hoc 
multiple comparison test (Fig.  3.12B). However, there was no change in the total ambulatory 
distance in non-DREADD  WT controls i.e. mean distance travelled after CNO doses of 
2.5 mg/kg (1063±189.5 cm; n = 10), 5 mg/kg (1184±213.5 cm; n =8), 10 mg/kg 
(1236±147.6 cm, n= 8) compared to before CNO/vehicle treatment (1630±151.6 cm, n =8-10) 
(Fig. 3.12D). Tukey's post hoc multiple comparison test also showed significant difference 
between DREADD and non-DREADD WT animals of 2.5 and 10mg/kg CNO treated group 
(Fig. 3.12F).  
 
Impact of focally silencing PV+ interneurons on anxiety levels was also analysed. Higher doses 
of CNO injected into the SScortex or the RTN thalamus significantly increased the time spent 
in the PZ by DREADD animals compared to before treatment, whereas CNO had no effect on 
non-DREADD WT controls. Dunnett's post hoc multiple comparison test showed statistically 
significant differences in the mean time spent in PZ after CNO doses of 2.5 mg/kg 





(593.9±2.20 sec, n = 11) compared to before CNO/vehicle treatment (554.3±6.125 sec, n = 9–
11) in the SScortex group (supplementary figure 5, page 241). Similarly, in the RTN thalamus 
group, Dunnett's post hoc multiple comparison test showed statistically significant differences 
in the mean time spent in the PZ after CNO doses 5 mg/kg (583.8±5.09 sec; n= 13), 10 mg/kg 
CNO (592.3±3.75 sec, n = 10) compared to before CNO/vehicle treatment 
(551.1±6.65 sec, n = 10–13) (supplementary figure 5, page 241). No significant changes were 
seen in non-DREADD WT control animals (supplementary figure 5, page 241). 
 
Silencing feed-forward inhibitory PV+ interneurons via focal CNO injections into either the 
SScortex or the RTN thalamus did not cause impairment of motor control when tested on the 
moving rotarod. There was no significant difference in the mean latency of fall in PVCre/Gi-
DREADD animals before and after focal CNO/vehicle injection at any dose. Likewise, there 
was no significant differences in the mean latency of fall in non-DREADD animals before and 
after focal CNO/vehicle injection at any dose. Comparison of the mean latency of fall between 
treatment groups and genotypes (DREADD and non-DREADD animals) before and after 






































Fig. 3.12 Total distance travelled in open-field arena by animals after focal CNO/vehicle injection. Graphs (A) (C) (E) and (B) (D) (F) represent animals of the SScortex 
group and the RTN thalamus group, respectively. Comparisons between treatment groups in graphs A-D were performed using Dunnett's post hoc multiple comparison test 
keeping ‘before CNO/vehicle treatment’ as a single control. Tukey's post hoc multiple comparison test was performed to compare independent treatment groups of DREADD 










































Fig. 3.13 Latency of fall in rotarod test in animals after injection of different focal doses of CNO. Graphs 
comparing mean latency of fall in rotarod test by PVCre/Gi-DREADD (DREADD) animals and non-DREADD 
WT controls after focal CNO/vehicle injection into the (A) (B) SScortex and (C) (D) RTN thalamus. All values 
represent mean ± SEM. Comparisons between before and after injection in same treatment group were performed 














Table 3.6 Comparison of mean latency of fall of PVCre/Gi-DREADD and non-DREADD 
animals after CNO/vehicle injection into SScortex and RTN thalamus on rotarod test. 
 
3.4 Discussion 
The work reported in this chapter demonstrated that global and focal silencing of PV+ 
interneurons within CTC network generates paroxysmal oscillatory activity similar to SWDs 
on EEG with associated behavioural arrest. Global silencing of PV+ interneurons impaired 
motor coordination, decreased locomotion, increased anxiety and immobility in PVCre/Gi-
DREADD animals. Focal silencing also reduced locomotory behaviour and increased 
immobility, but motor function was not altered. In contrast, no significant changes were 
observed in non-DREADD WT controls or vehicle treated PVCre/Gi-DREADD mice. 
Administration of the anti-absence epileptic drug ethosuximide prevented the focally induced 
absence-like seizures in PVCre/Gi-DREADD mice. The data presented in this chapter have been 
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Vehicle 288.8±5.56 289.5±3.72 11 296.2±1.75 294.3±2.2 7 
1mg/kg CNO 290.4±5.03 296±1.38 9 292.7±2.17 290.4±2.83 7 
2.5mg/kg CNO 295.1±1.76 286.7±5.53 9 290.4±2.83 296.4±1.36 10 
5mg/kg CNO 298.1±0.93 292.8±3.41 10 298.9±0.59 299±0.57 9 






Vehicle 292.7±3.90 291.6±3.73 10 286.9±3.90 292.2±2.47 8 
1mg/kg CNO 286.6±6.22 294.6±1.64 10 289±4.79 296.1±1.63 8 
2.5mg/kg CNO 284.9±5.03 284±5.22 11 292.7±3.86 295.9±1.14 10 
5mg/kg CNO 293±2.97 292.8±3.43 13 293.8±3.28 293.4±4.37 8 





3.4.1 HA-tagged DREADD receptors are highly expressed in feed-forward inhibitory 
PV+ interneurons 
Inhibitory Gi-DREADD receptors were highly expressed in PV+ interneurons of PVCre/Gi-
DREADD mice. This was confirmed by the colocalization of DREADD HA-tag and PV in 
cells known to express the calcium binding protein PV. However, this co-labelling for HA-tag 
and PV was not seen in non-DREADD WT control animals. Analysis of the confocal images 
showed that PV+ interneurons were highly expressed in layers 2-6 of the SScortex (except 
layer 1) in both PVCre/Gi-DREADD and non-DREADD WT control mice. This result is 
consistent to the labelling of PV cells in the SScortex of epileptic stargazers and non-epileptic 
littermates in previously published study from our research group (Adotevi and Leitch, 2016) 
and other published rodent studies (Celio, 1986; Dávid et al., 2007; Tanahira et al., 2009; Xu 
et al., 2010). Labelling of PV+ interneurons in the RTN thalamus and Purkinje cells of the 
cerebellum was also in agreement with other published studies (De Talamoni et al., 1993; Arai 
et al., 1994; Schwaller et al., 2002; Csillik et al., 2005). Quantification data showed that 
colocalization of HA-tag in PV+ interneurons was above 90% in the SScortex, the RTN 
thalamus, and the cerebellum whereas none of the PV+ interneurons in non-DREADD WT 
control mice showed labelling for HA-tag. These levels of co-expression in PVCre/Gi-
DREADD mice are consistent with the Jackson Lab datasheet (008069) for PV-Cre mice which 
states that the recombination in PV-Cre knockin allele is around 90%.  
 
There have been relatively few studies using DREADD technology to modulate PV+ 
interneurons. One recent report utilized transgenic mice approach i.e. PV-Cre x LSL-hM3Dq 
mice and reported exclusive colocalization of DREADD receptors in the PV expressing cells 
of the motor cortex and cerebellum. However, they did not quantify the colocalization (Johnson 
et al., 2018). Apart from that, most of the other studies have utilized DREADD-based 
recombinant lentiviral vector (LV) or adeno-associated viral vector (AAV) to express 
DREADD receptors into the specific regions of brain of PV-Cre transgenic mice. Some 











Table 3.7 Comparison of the percentage of infection efficiency and specificity of labelling 
across the various regions of brain in studies utilizing PV-Cre mice and viral (AAV) method 
of DREADD delivery.  
Study Region of the brain Infection efficiency Specificity 
Yi et al., 2014 Hippocampus ~80% ~94% 
Zou et al., 2016 Hippocampus ~71% ~96% 
Xia et al., 2017 Medial prefrontal cortex ~85% ~93% 
Chen et al., 2018 Barrel cortex - ~95% 
Hijazi et al., 2019 Hippocampus 83% 87% 
Page et al., 2019 Prefrontal cortex ~92% ~96% 
Bicks et al., 2020 Prefrontal cortex - ~82% 
 
Abovementioned studies have shown that the infection efficiency and specificity of labelling 
generally vary in viral mediated DREADD delivery, whereas in this current study percentage 
of DREADD receptors (HA-tagged cells) colabelled for PV and percentage of PV cells 
colabelled for DREADD receptors was above 90% in all tested regions (SScortex, RTN 
thalamus, and Purkinje cells of cerebellum).  
 
3.4.2 Global and focal silencing of PV+ interneurons generated absence-like SWDs 
associated with behavioural arrest 
DREADD receptors can be activated either via intraperitoneal (i.p.) or focal CNO injection 
into a specific brain region (Armbruster et al., 2007; Rogan and Roth, 2011). Studies have 
shown that CNO can be injected from 0.3-20mg/kg intraperitoneally to activate PV cells of the 
specific brain regions where viral DREADD construct have been injected to infect PV cells 
(Mahler et al., 2014; Zou et al., 2016; Chen et al., 2018; Ng et al., 2018; Page et al., 2019; 
Bicks et al., 2020). Studies have also shown that CNO can be injected focally for DREADD 
mediated activation of site-specific neurons (Mahler et al., 2014; Ge et al., 2017; Lichtenberg 
et al., 2017; McGlinchey and Aston-Jones, 2017). In this current study, firstly, as a proof of 
concept, PVCre/Gi-DREADD animals were intraperitoneally injected with CNO to investigate 
the impact of globally silencing feed-forward inhibitory PV+ interneurons on seizure 
generation. Secondly, PV+ interneurons of the CTC microcircuit (either the SScortex or the 
RTN thalamus) were targeted via focal CNO injection. Both global (i.p., 5mg/kg and 10mg/kg) 
and focal (2.5, 5 and 10mg/kg) silencing of PV+ interneurons generated paroxysmal oscillatory 
bursts. These bursts were identified as absence-like seizures based on their EEG signature 





positive transient and slow wave with amplitude minimum two-times higher than baseline (see 
listed references in chapter 2, Table 2.9). Irrespective of the dose of CNO (2.5-10mg/kg) and 
route of administration (i.p. or focal), the mean duration and rhythmicity (spike frequency) of 
such bursts were 3-5 seconds and 3-7 Hz, respectively. Morphological profile, duration of 
seizure and frequency was consistent with the characteristics of SWDs seen in various rodent 
models of absence epilepsy (see review Jarre et al., 2017). However, mean onset of paroxysmal 
oscillatory bursts was significantly faster in focal group (~15 min) than i.p. group (~30 min). 
Peripheral administration of CNO requires additional time to cross the blood brain barrier first 
and into the brain. This finding was also similar to other published studies where they have 
shown that plasma level of CNO peaks within 30 min and sharply decline over next 2 h after 
systemic injection of CNO (MacLaren et al., 2016; Roth, 2016; Manvich et al., 2018; Jendryka 
et al., 2019). And, behavioural effects of CNO is seen up to 6 h of injection (Alexander et al., 
2009). One recent study has shown that focal injection of CNO can robustly activate targeted 
neuronal population and time scale of this effect is from min to h (Stachniak et al., 2014) which 
is also similar to this study where mean onset of paroxysmal oscillatory bursts is ~15 min 
(SScortex and RTN thalamus group).  
 
Studies have shown that permanent silencing of hippocampal PV+ interneurons generates 
clusters of epileptic discharges which progresses to spontaneous recurrent seizures (Drexel et 
al., 2017; 2019). These published results alongside the outcomes of this current study support 
the idea that functional silencing might restrict the GABA release from PV+ interneurons and 
disrupt the powerful inhibitory effect of these interneurons onto local excitatory neurons. This 
disruption can impair inhibition resulting the shift of excitation/inhibition balance more 
towards excitation causing the generation of epileptic discharges. Intrestingly, voltage clamp 
recordings from principal excitatory cells after optogenetic suppression of the activity of PV+ 
(Moore et. al., 2018) and SOM+ (Kato et al., 2017) interneurons in layer 4 of auditory cortex 
increased both excitation and inhibition to principal neurons. These studies concluded that the 
net effect of suppressing these interneurons results in a coordinated increase in both excitation 
and inhibition to principal neurons. Thus, it is important to note that altered activity of 
inhibitory interneurons in the inhibitory microcircuits affects not only inhibitory but also 
excitatory inputs to principal excitatory cells.   
 
Recently published studies have raised questions over the use of CNO as the ‘designer drug’ 





clozapine after systemic CNO injection and reverse-metabolized clozapine may act as 
DREADD activator in brain tissue. They further stated that clozapine is an atypical 
antipsychotic having affinities towards various receptor targets which is capable of producing 
different behavioural and physiological effects. They reported decreased locomotion in non-
DREADD WT controls after systemic injection of 1 mg/kg of CNO and 1 mg/kg of clozapine. 
Whereas, low subthreshold 0.1 mg/kg dose of clozapine significantly decreased locomotor 
activity in hM4Di expressing rats but not in controls. They suggested the use of low doses of 
clozapine (0.1mg/kg) instead of CNO (Gomez et al., 2017) as a DREADD activator. However, 
the dose of clozapine recommended by Gomez and colleagues (0.1mg/kg) has previously been 
found to increase anxiety in mice (Manzaneque et al., 2002). In addition to the psychiatric 
effects, clozapine was linked to agranulocytosis and found to have pro-epileptic effects 
(Ruffman et al., 2006). Other studies involving the use of CNO have failed to find DREADD-
independent behavioural or off-target effects at doses up to 10 mg/kg, at least within a 30–
150 min timeframe after i.p. injection (Mahler et al., 2014; Ge et al., 2017; Lichtenberg et al., 
2017; McGlinchey and Aston-Jones, 2017). A recent study has demonstrated that, after the 
systemic administration of CNO, the concentration of reverse-metabolized clozapine in 
plasma, cerebrospinal fluid and brain tissue is very low compared to CNO and the brain 
availability of both compounds varies with species (Jendryka et al., 2019). It is now suggested 
and highly recommended to design experiments with non-DREADD expressing animals to 
control potential off-target effects of CNO/clozapine. In this current study, non-DREADD 
expressing WT controls were assigned for all doses of CNO (i.p. and focal). Vehicle-treated 
controls were also included in both treatment groups (i.p. and focal) and genotypes (DREADD 
and non-DREADD animals). Simultaneous video/EEG recording were conducted up to 1 hour 
of CNO injection. Importantly, non-DREADD wild-type controls and vehicle-treated controls 
showed no signs of epileptiform activity, at any of the CNO doses tested.  
 
3.4.3 Global and focal silencing of feed-forward inhibitory PV+ interneurons affected 
locomotory behaviours and mobility  
To understand the impact of silencing PV+ interneurons on behavioural terms, two behavioural 
tests were employed, as animal models of absence epilepsy show defective motor function 
including ataxia, head tossing, dyskinesia, and tremor as other behavioural features (Jarre et 






In this study, global silencing of PV+ interneurons via i.p. CNO injection significantly impaired 
motor coordination on the rotarod test in a dose dependent manner. However, focal silencing 
of PV+ interneurons via CNO injection into the SScortex and RTN thalamus did not change 
the motor performance in PVCre/Gi-DREADD mice. This is likely due to the fact that global 
silencing of PV+ interneurons via i.p. CNO injection silenced all PV+ interneurons including 
PV expressing Purkinje cells in the cerebellum. The cerebellum plays important role in motor 
control, precision, and accurate timing of the movement. However, focal silencing had no 
effect on motor performance as SScortex and RTN thalamus are not the brain regions directly 
involved in motor co-ordination. Knockout mice (such as TARP γ-2 Purkinje cells knockout; 
γ-7 knock out) which lack excitatory input to Purkinje cells, show wide range of motor deficits 
including ataxic gait, severely reduced ambulation and rearing in the open-field, impaired 
performance in the wire hang test, and reduced forelimb and hindlimb grip strength on the 
rotarod (Yamazaki et al., 2015). One optogenetic study also found that activation of Gi/o 
pathway in Purkinje cells reduces motor coordination and control on the rotarod (Gutierrez et 
al., 2011). Other studies conducted on conditional Purkinje cell knockout animals also showed 
significantly impaired motor performance (Todorov et al., 2012; Tsai et al., 2012). Studies 
utilizing DREADD technology and viral methods to selectively silence or excite PV+ 
interneurons in brain regions, other than the cerebellum, have had no effect on motor 
performance in rotarod test. For example, DREADD mediated silencing of hippocampal PV 
neurons didn’t change motor skills in PV-Cre mice (Hijazi et al., 2019). Chemogenetic 
excitation of PV+ interneurons in the dorsal horn in PV-Cre mice also had no significant effect 
in motor impairment (Petitjean et al., 2015). Likewise, Liu and colleagues also reported 
unaltered ability of motor coordination on rotarod tests after CNO mediated activation of PV+ 
interneurons in rostro-dorsal RTN in PV-Cre mice (Liu et al., 2017). Also, chemogenetic 
inactivation of hippocampal glutamatergic neurons in CaMKIIα-hM4Di double transgenic 
mice had no effect on motor performance (Zhu et al., 2014). Thus, it can be concluded that 
decreased latency of fall or impaired motor skill in rotarod test of PVCre/Gi-DREADD animals 
in this study only after global silencing of PV+ interneurons are due to the silencing of feed-
forward inhibitory PV+ interneurons of cerebellum.   
 
In the open-field test, global silencing of PV+ interneurons significantly reduced locomotion 
in PVCre/Gi-DREADD animals after treatment with i.p.  doses of CNO (i.e. 5 and 10mg/kg). 
These animals relatively spent more time in the peripheral zone and corners of the open-field 





treated PVCre/Gi-DREADD mice or CNO/vehicle treated non-DREADD WT control animals. 
Staying closely in proximity to the walls or decreased latency to enter the central part of the 
arena indicates anxiety-related behaviour in rodents (Prut and Belzung, 2003; Lipkind et al., 
2004; Seibenhener and Wooten, 2015). In this particular experiment, the amount of time spent 
by non-DREADD animals in central zone before and after CNO treatment was around 5-8% 
which is in agreement with other published studies for WT control animals (Moy et al., 2007; 
Bailey and Crawley, 2009; de Oliveira et al., 2015) which also indicated that non-DREADD 
control and vehicle treated mice do not display anxiety-like behaviour. Thus, global silencing 
of PV+ interneurons was found to be linked with decreased locomotion and increased levels of 
anxiety. 
 
In this study, focal silencing of PV+ interneurons of either the SScortex or the RTN thalamus 
significantly reduced total ambulatory distance. Open-field test performed in PV knockout 
mice showed decreased locomotory behaviour and exploration (Farré-Castany et al., 2007). 
Similarly, in another study, PV knockout mice displayed less structured bouts of locomotion, 
less rearing activity (Wöhr et al., 2015) compared to that of WT animals. Other conditional PV 
knockout animals lacking TrKB (Lucas et al., 2014; Xenos et al., 2018) and KCC3 (Ding and 
Delpire, 2014) in PV+ interneurons also showed decreased locomotion. But variable results 
were found in studies utilizing chemogenetic manipulation of PV+ interneurons have shown 
variable outcome. Page and colleagues found that chronic activation of PV+ interneurons in 
the prefrontal cortex significantly increases anxiety (but unchanged locomotory behaviour) in 
female PV-Cre mice compared to the male counterparts. No significant differences in those 
parameters were observed after acute activation of PV cells (Page et al., 2019). Another study 
revealed increased anxiety without locomotory changes after acute injection of CNO in PV-
Cre mice injected with excitatory (Gq) DREADD construct in the hippocampus (Zou et al., 
2016). In contrast, chronic silencing of hippocampal PV+ interneurons (supplying CNO in 
drinking water for 27 days) in PV-Cre mice expressing inhibitory Gi-DREADD receptors, 
resulted no changes in locomotor activity and anxiety levels (Xia et al., 2017). Similarly, 
Perova and colleagues found no difference in locomotion between CNO treated and saline 
treated groups of PV-Cre animals virally injected with inhibitory Gi-DREADD receptors in the 
prefrontal cortex (Perova et al., 2015). 
 
In this study it was also revealed that silencing PV+ interneurons via both global and focal 





dose of CNO treated DREADD animal group but not in vehicle-treated group and non-
DREADD WT control animals. Animal models of absence epilepsy show SWDs that are 
associated with behavioural arrest (Jarre et al., 2017). In this study, immobility/behavioural 
arrest was witnessed during seizure and between bursts of seizures. However, non-DREADD 
WT control animals showed no significant increment of immobility with the same doses of 
CNO. Thus, increased immobility after higher doses of CNO in this study might be linked to 
increased anxiety due to the silencing of PV+ interneurons (Tovote et al., 2015; Babaev et al., 
2018). Moreover, PV knockout animals (Farré-Castany et al., 2007; Wöhr et al., 2015) and 
conditional PV knockout animals (Ding and Delpire, 2014; Lucas et al., 2014; Xenos et al., 
2018) also displays decreased locomotion. It is important to note that increased immobility of 
DREADD animals after CNO injection in this study is not due to off-target activity of reverse 
metabolized clozapine because CNO treated non-DREADD animals and vehicle treated 




In summary, the results from this chapter demonstrated that selectively silencing PV+ 
interneurons of feed-forward microcircuits in CTC network generates paroxysmal oscillatory 
bursts having similar morphology and characteristics of SWDs seen in various rodent models 
of absence epilepsy. Absence-like bursts seen in this study were also associated with 
behavioural arrest. This also provided us an understanding that functional loss of PV+ 
interneurons can disrupt FFI and this may be one of the mechanisms through which SWDs are 
generated. To further characterize the functional roles of PV+ interneurons on seizure 
generation, it is necessary to test the impact of activating PV+ interneurons during absence 
seizures. This forms the basis of the next chapter where impact of activating PV+ interneurons 
in the excitatory Gq-DREADD animals will be tested during chemically induced absence 


















In the previous chapter, it was demonstrated that functionally silencing feed-forward inhibitory 
PV+ interneurons within the CTC network generates absence-like SWDs (Panthi and Leitch, 
2019). Thus, the next important question in this study was whether activating feed-forward 
inhibitory PV+ interneurons in the CTC network during absence seizures would prevent or 
reduce seizure activity.  
To do this, PTZ was used to induce seizures in excitatory Gq-DREADD (PVCre/Gq-DREADD) 
animals where the feed-forward inhibitory PV+ interneurons could be activated with CNO. 
PTZ is routinely used in epileptic studies to induce both absence and generalized tonic-clonic 
seizures (Snead, 1992; Velíšková et al., 2017) and also has been used for the screening of 
antiepileptic drugs since 1970s (see reviews by Krall et al., 1978 and Löscher, 2011). PTZ 
impairs GABA mediated inhibition by antagonizing GABAA receptors (Huang et al., 2001). 
The severity of PTZ induced seizure is dose dependent. Low dose PTZ (~20mg/kg) 
administration is an established experimental method to induce generalized absence seizures 
involving thalamocortical mechanisms whereas high doses (> 40mg/kg) induce spike trains 
with tonic-clonic seizures (Snead, 1992; Snead et al., 2000).  
As previously stated, PV+ interneurons are responsible for preventing runaway excitation 
within CTC network and dysfunction of these interneurons leads to the generation of seizures 
(see reviews by Liu et al., 2014 and Jiang et al., 2016). In a recent study, optogenetic activation 
of PV+ interneurons of RTN thalamus during PTZ-induced seizures provided antiepileptic 
effects (Clemente-Perez et al., 2017). Furthermore, a DREADD based study has indicated that 
activating PV+ interneurons increases the latency and decreases the susceptibility of PTZ-
induced tonic-clonic and myoclonic seizures (Johnson et al., 2018). Cortical activation of PV+ 
interneurons also terminated 4-AP induced spontaneous electrographic seizures (Assaf and 
Schiller, 2016). In other studies, activating hippocampal PV+ interneurons attenuated KA-
induced temporal lobe seizures (Krook-Magnuson et al., 2013; Wang et al., 2018). Moreover, 
parvalbumin knockout (PV-/-) mice have higher susceptibility to the chemically induced 
seizures and these animals experienced more severe seizures compared to WT controls 
(Schwaller et al., 2004). However, there have been no studies to date reporting the 





Hence, the aim of this chapter was to investigate the impact of activating feed-forward 
inhibitory PV+ interneurons within the cortex and thalamus in excitatory Gq-DREADD 
(PVCre/Gq-DREADD) animals during PTZ-induced absence seizures. First, 
immunohistochemistry was performed to confirm the expression of excitatory Gq-DREADD 
receptors in the PV+ interneurons within the CTC network. Secondly, simultaneous video/EEG 
based PTZ experiments were performed in two steps. On day 1, PTZ was administered to test 
absence seizure generation in the cohort of experimental animals. This was then followed on 
day 2 by the activation of PV+ interneurons via focal CNO injection during PTZ-induced 
seizures.  
4.2 Methods 
4.2.1 Immunofluorescence confocal microscopy, image acquisition and analysis 
To confirm the expression of excitatory Gq-DREADD receptors in feed-forward inhibitory 
PV+ interneurons of PVCre/Gq-DREADD mice, antibodies against HA-tag (Cell Signaling, 
C29F4) and parvalbumin (Swant Inc., PV-235) were used to label DREADD receptors and 
PV+ interneurons, respectively. Immunolabelling was performed on tissue sections from 
PVCre/Gq-DREADD mice and non-DREADD WT control animals. Immunolabelling, confocal 
imaging, quantification of immunolabelled cells and analysis were performed as described 
previously in chapter 2 subsection 2.3.   
 
4.2.2 Surgical implantation of prefabricated headmounts and microcannulas for EEG 
recordings 
To test the impact of activating feed-forward inhibitory PV+ interneurons during PTZ-induced 
absence seizures, EEG recordings were performed on PVCre/Gq-DREADD and non-DREADD 
WT control animals. Surgical manipulations for implantation of prefabricated headmounts 
(Pinnacle Technologies, Austin, TX, USA) and microcannulas (Plastics One Inc., VA, USA) 
were conducted according to procedures detailed in the chapter 2 subsection 2.4.  
Before performing the main experiments, a pilot study was conducted to determine the dose of 
PTZ necessary to induce absence seizures. Briefly, a cohort of animals (n=6) were injected 
intraperitoneally with three different doses of PTZ (10, 20, 30 mg/kg). Based on simultaneous 
video/EEG data, a dose of 20mg/kg was selected.  
 
For experimental tests, PVCre/Gq-DREADD (n=14) and non-DREADD WT control (n=10) 
animals were allocated to two different treatment groups: either SScortex implanted group 





n=7; controls n=5). Experiments were performed on two consecutive days according to the 
schematic outlined in the figure 4.1 (see supplementary figure 2 for more details). On day 1, 
seizures were induced in all animals (PVCre/Gq-DREADD mice and non-DREADD WT 
control mice) by i.p. injection of 20mg/kg PTZ. After 24 h, on day 2, the same cohort of animals 
were treated with the same dose of PTZ (i.p.) and 5mg/kg CNO (into either the SScortex or the 
RTN thalamus). The timing and dose of CNO was based on previous experiments in chapter 3 
where 5mg/kg CNO was lowest yet effective dose that activated inhibitory Gi-DREADD 




















Fig. 4.1 Schematic of the protocol for EEG recordings before and after focal CNO and i.p. PTZ injections. 
  
4.2.3 Preparation and delivery of CNO and PTZ 
CNO and PTZ were freshly prepared before every scheduled experiment as previously 
described in chapter 2 subsection 2.5. On both days, PTZ was injected intraperitoneally 
(20mg/kg) based on the calculated dose for the body weight of the animal. On day 2, CNO 
(5mg/kg) was injected focally (either into SScortex or RTN thalamus). After 10 min of baseline 
EEG recording, 0.3μl of CNO was infused into the regional areas at a rate of 0.1μl/min via 
Hamilton microinjection syringe. At the end of experiments, methylene blue dye was injected 
at the same volume and rate as CNO into the focal regions of the brain under investigation. 
Histology was performed to verify the localization of cannula tip and estimate the diffusion of 
CNO (see supplementary figure 2). The stereotaxic coordinates of the CNO and dye injections 





1.5 mm below the cortical surface. The coordinates for RTN thalamus injections were 1.34 to 
1.94 mm posterior to bregma, 2.1-2.3 mm lateral to the midline and 3.2-3.5 mm ventral to the 
cortical surface (Mouse Brain Atlas, Paxinos and Franklin, 3rd edition).    
 
4.2.4 EEG recording and analysis of EEG traces 
EEG recordings were performed according to procedures detailed in the chapter 2 subsection 
2.4. Based on the video/EEG data, bursts of oscillations were counted as absence-like SWDs 
if they had a spike-wave structure (spike, positive transient, and slow wave pattern) with a 
frequency of 3–8 Hz, an amplitude at least two times higher than baseline and lasted for >1 
second with behavioural arrest or motionless staring as behavioural features (based on the 
references listed in chapter 2, Table 2.9). Tonic-clonic seizures were characterized by high 
amplitude polyspikes. Behavioural expressions for tonic-clonic seizures ranged from clonic 
jerking with or without loss of balance (lying on belly or on cage walls) to wild jumping in 
some cases. Myoclonic seizures were characterized by brief (few seconds) jerks resulting sharp 
spikes in EEG (Lüttjohann et al., 2009; Van Erum et al., 2019). Bursts of absence-like seizures 
and myoclonic seizures spanning less than 1 second were also separately counted. 
 
4.2.5 Data analysis 
Statistical analysis of significant differences of the onset of seizures between PVCre/Gq-
DREADD and non-DREADD WT control animals were calculated using Mantel-Cox log-rank 
test. Comparison within the same treatment group was performed using Wilcoxon matched-
pairs signed-rank test. Comparison between treatment groups was performed using Mann 
Whitney unpaired rank test. Data were presented as mean ± standard error of the mean (SEM). 




4.3.1 Excitatory Gq-DREADD receptors are expressed in feed-forward inhibitory PV+ 
interneurons 
Double-labelled immunohistochemistry with antibodies against HA-tag and PV was performed 
to confirm the expression of excitatory Gq-DREADD receptors in PV+ interneurons of 
PVCre/Gq-DREADD mice (Fig. 4.2). HA-tag for DREADD (identified by pseudocolour green, 
panel 1) was only expressed in the brain sections from PVCre/Gq-DREADD mice but not in 





SScortical layers (except layer I), within the RTN thalamus and the cerebellar cortex in all 
genotypes (identified by pseudocolour red, panel 2). Co-localization of HA-tag in PV+ 
interneurons was found throughout the SScortex (Fig. 4.2A,B), the RTN thalamus (Fig. 
4.2C,D) and the cerebellar cortex (Fig. 4.2E,F). In the SScortex of PVCre/Gq-DREADD mice, 
PV+ interneurons highly expressed HA-tag (Fig. 4.2A white arrows); co-localization of HA-
tag in PV+ interneurons was above 90% (Fig. 4.2B). Similarly, in the RTN thalamus, PV+ 
interneurons strongly expressed HA-tag (Fig. 4.2C white arrows); the percentage of co-
localization of HA-tag in PV+ interneurons of RTN thalamus was also above 90% in PVCre/Gq-
DREADD mice (Fig. 4.2D). In the cerebellum, HA-tag was highly expressed in PV+ Purkinje 
cell soma (Fig. 4.2E white arrows). The percentage of co-localization of HA-tag in PV+ 
inhibitory Purkinje cell soma was also above 90% (Fig. 4.2F). The pattern of staining and levels 
of colocalization between HA-tag and PV in all three brain regions of PVCre/Gq-DREADD 
animals were very similar to the results obtained in PVCre/Gi-DREADD animals as previously 
described in chapter 3 (figure 3.1).  
 
4.3.2 20mg/kg IP PTZ is required to induce absence-SWDs  
A pilot study was first conducted on a cohort of animals (n=6) to establish the dose of PTZ 
required to induce absence seizures (Fig. 4.3A). According to the literature, absence-SWDs 
can be induced in different mice and rat models using i.p. injections of PTZ at doses between 
10 and 40 mg/kg (Marescaux et al., 1984; Snead et al., 2000; Girard et al., 2019; Van Erum et 
al., 2019).  In this study, simultaneous video/EEG data showed that 10 mg/kg of PTZ did not 
induce seizures in any of the mice tested (Fig. 4.3B), whereas animals injected with 30mg/kg 
PTZ induced severe tonic-clonic seizures (Fig. 4.3D). In contrast, a dose of 20mg/kg 
consistently produced absence-SWDs. However, they were mixed with tonic-clonic and 






























































Fig. 4.2 Expression of Gq-DREADD receptors in PV+ interneurons. (A, C, E) Confocal images showing the 
expression of HA-tag in PV+ interneurons in the SScortex, the RTN thalamus and the cerebellum of PVCre/Gq-
DREADD animals, respectively. White arrows in merged images represent colocalized cells. Blue arrows indicate 
PV positive neurons which are immunonegative for HA. (B, D, F) Percentage of co-localization of HA-tag and 
PV in neurons in the SS cortex, the RTN thalamus, and the cerebellum, respectively. Immunolabelled cells in the 
SScortex and the cerebellum were counted at 10x magnified confocal images whereas in the RTN thalamus cells 
were counted using 40x images. (Het = PVCre/Gq-DREADD offspring from homozygous PV-Cre female and 































Fig. 4.3 Protocol of the pilot PTZ experiment and representative EEG traces. (A) Schematic protocol for 
EEG recordings before and after IP PTZ injection in the pilot study. Representative EEG traces from animals after 
(B) 10mg/kg (C) 20mg/kg (D) 30mg/kg of PTZ injection. Asterisks (*), hash signs (#) and M represent absence-
like seizures, tonic-clonic seizures and myoclonic jerks, respectively. Each trace represents 5 min of EEG 









Hence, 20mg/kg PTZ was selected as the dose required to elicit absence seizures in mice 
surgically implanted with either cortical or thalamic cannulae for subsequent experiments to 
test the impact of activating FFI during seizures. 
 
4.3.3 Activating feed-forward inhibitory PV+ interneurons via focal CNO injection 
suppressed PTZ-induced absence seizures 
 
Day 1: PTZ injection (20mg/kg, i.p.) only 
On day 1, i.p. administration of PTZ (20mg/kg) induced seizures in all animals. However, 
various types of seizures were seen i.e. absence-like seizures, tonic-clonic seizures and 
myoclonic seizures. In the SScortex treatment group, 20mg/kg PTZ administration induced 
absence seizures in 5 out of 7 PVCre/Gq-DREADD and 3 out of 5 non-DREADD WT controls. 
Six out of 7 PVCre/Gq-DREADD animals experienced tonic-clonic seizures whereas all non-
DREADD WT controls had tonic-clonic seizures after systemic PTZ injection of 20mg/kg. 
Similarly, PTZ induced myoclonic seizures in only 3 animals of both PVCre/Gq-DREADD and 
non-DREADD WT control groups. In the RTN thalamus treatment group, absence seizures 
were observed in all DREADD mice (n=7) and in 3 out of the 5 non-DREADD WT controls. 
PTZ injection induced tonic-clonic seizures in only 3 out of 7 PVCre/Gq-DREADD animals 
whereas all non-DREADD WT animals of this treatment group experienced tonic-clonic 
seizures. Myoclonic seizures were seen in 5 out of 7 PVCre/Gq-DREADD and 3 out of 5 non-
DREADD WT controls. 
EEG data showed that the first incident of seizure (of any type) was very consistent. In the 
SScortex group (Fig. 4.4A), mean onset of seizures was 3.65±0.63 min in PVCre/Gq-DREADD 
(n=7) and 3.59±0.62 min in the non-DREADD WT control animals (n=5), respectively. 
Similarly, in the RTN thalamus group (Fig. 4.4A), seizures were induced 3.82±0.74 min and 
3.87±1.03 min after PTZ injection in PVCre/Gq-DREADD (n=7) and non-DREADD WT 
control animals (n=5), respectively. The last incident of seizure was also similar between the 
treatment groups. The last seizure burst was recorded 20.50±7.87 min and 14.41±6.03 min after 
PTZ injection in the PVCre/Gq-DREADD (n=7) and non-DREADD WT control animals (n=5) 
SScortex groups, respectively (Fig. 4.4B). Similarly, in the RTN thalamus group, last epileptic 
burst was seen 13.07±2.83 min and 14.27±5.00 min after PTZ injection in PVCre/Gq-DREADD 





So, in summary, there was no significant difference in the latency to first seizure and the last 
incident of seizure between treatment groups and genotypes (Fig. 4.4A,B) after a single 



























Fig. 4.4 First and last incident of seizure in animals after PTZ treatment on day 1. Comparison of (A) onset 
of seizure and (B) last incident of seizure during 1 hour of EEG recording in PVCre/Gq-DREADD (DREADD) 
(n=7) and non-DREADD (n=5) WT control animals of the SScortex group and the RTN thalamus group after 
PTZ treatment on day 1. All values in graphs represent mean ± SEM. Comparison between treatment groups was 
performed using Mann Whitney unpaired rank test.  
 
The percentage of time spent in each of the three different seizure types during 1 hour of EEG 
recording on day 1 after a single injection of PTZ is shown in figure 4.5A,C. PTZ treated 
PVCre/Gq-DREADD animals of the SScortex group spent 36.13% of the total seizure period in 
absence-like seizures and 52.70% in tonic-clonic seizures (Fig. 4.5C). Likewise, non-
DREADD WT control animals spent 48.10% of total seizure period in absence-like seizures 
and 42.71% of total seizure period in tonic-clonic seizure (Fig. 4.5C). In the RTN thalamus 
group, PVCre/Gq-DREADD animals spent 51.05% of total seizure period having absence-like 
seizures and 12.56% having tonic-clonic seizure (Fig. 4.5C). Non-DREADD WT animals of 
this group spent 30.92% of total seizure period in absence-like seizure and 49.23% of total 



































Fig. 4.5 Comparison of the % of time spent in seizures by animals on day 1 and day 2. Schematic of protocol for EEG recordings before and after (A) PTZ injection on 
day 1 and (B) PTZ and CNO injection on day 2. Comparison of the percentage of different types of seizures in PVCre/Gq-DREADD (DREADD) (n=7) and non-DREADD WT 





Day 2: CNO (5mg/kg, focal) and PTZ (20mg/kg, i.p.)  
Having established that the seizure onset for PVCre/Gq-DREADD and non-DREADD WT 
animals is ~ 5 min post PTZ injection (on day 1), CNO (5mg/kg, focally; either into the 
SScortex or the RTN thalamus) was injected 10 min prior PTZ (20mg/kg, i.p.) injection, on 
day 2 to test the impact of activating feed-forward inhibitory PV+ interneurons during PTZ-
induced seizures. The timing and dose of CNO were chosen based on data from the previous 
experiments from chapter 3. 5mg/kg CNO was chosen because this is lowest yet effective dose 
that consistently generated absence-like seizures in PVCre/Gi-DREADD mice in experiments 
from chapter 3. Simultaneous video/EEG recordings were made according to the protocol 
outlined in schematic figure 4.5B. The percentage of time spent in each of the different seizure 
types during 1 hour of EEG recording on day 2 after CNO and PTZ administration is shown in 
figure 4.5D. On day 2, the relative time spent having seizures was substantially reduced in 
PVCre/Gq-DREADD animals of both treatment groups (cortical or thalamic) compared to day 
1, whereas in non-DREADD WT controls there was no evidence of a reduction in seizures on 
day 2 (Fig. 4.5D).  
 
4.3.3.1 Activating PV+ interneurons either prevented or increased the onset of seizures 
in DREADD mice 
Activating PV+ interneurons prevented seizures in two out of 7 tested PVCre/Gq-DREADD 
animals of the SScortex group i.e. 28% did not experience any types of seizure during 1 hour 
of EEG recording on day 2 (Fig 4.6). Likewise, in the RTN thalamus group, 3 out of 7 (42%) 
PVCre/Gq-DREADD animals were entirely seizure free on day 2 (Fig 4.6). Seizure activity on 
both days was further evaluated by analyzing the various parameters of EEG recording i.e. 
latency to first seizure, mean duration spent in seizures, total discharges/hr and mean length of 
bursts.   
Activating PV+ interneurons increased the latency to first seizure (of any type) 
A log-rank test was performed to compare the latency to the first seizure between treatment 
groups (Fig. 4.6). This test indicated that the latency to first seizure was significantly prolonged 
in PVCre/Gq-DREADD animals of both SScortex and RTN thalamus groups on day 2 compared 
to that of day 1 (Fig 4.6).  
On day 2, activating feed-forward inhibitory PV+ interneurons prevented PTZ-induced 
seizures in some mice as stated above.  In the remaining PVCre/Gq-DREADD animals of both 



























Fig. 4.6 Graphs showing the latency to first seizure in animals. Comparison of the latency to first seizure (any of the three seizure type) in DREADD and non-DREADD 
WT controls of the SScortex group and the RTN thalamus group between day 1 (PTZ only treated) and day 2 (CNO and PTZ treated). Comparisons between the treatment 





In the SScortex group, latency to first seizure was 4.32±0.55 min (n=5) on day 1 which 
increased to 8.43±31 min (n=5) on day 2. Likewise, in the RTN thalamus group, on day 1, 
mean onset of seizure was 3.24±0.34 min (n=4), which increased to 10.08±3.19 min (n=4) on 
day 2. In contrast, activation of PV+ interneurons did not prolong the latency to first seizure in 
non-DREADD WT control animals [SScortex group, day 1: 3.59±0.62 min (n=5), day 2: 
4.03±1.56 min (n=5); RTN thalamus, day1; 3.87±1.03 min (n=5), day 2: 3.51±1.09 min (n=5)]. 
 
Activating PV+ interneurons also prolonged the latency to first absence, tonic-clonic and 
myoclonic seizure 
Next, the individual seizure types were analyzed in relation to the latency to first seizure. 
Latency to first absence or tonic-clonic or myoclonic seizures in PTZ injected PVCre/Gq-
DREADD animals pre-treated with CNO (in either of the brain regions of CTC network) on 
day 2 was delayed compared to that of day 1(Fig. 4.7-4.9).  
 
Absence seizures 
In the SScortex group, on day 1, PTZ induced absence seizures in 5 PVCre/Gq-DREADD 
animals. All 5 animals were completely absence seizure free on day 2 when CNO and PTZ 
were co-administered (Fig. 4.7). In PVCre/Gq-DREADD animals of RTN thalamus group, 4 
out of 7 (57%) animals did not experience absence seizure on day 2 (Fig. 4.7). In the remaining 
3 animals, latency to first absence burst on day 2 was also prolonged compared to that of day 
1 i.e. day 1: 3.71±0.73 min; day 2: 13.55±4.54 min. 
 
Tonic-clonic seizures 
PTZ treatment induced tonic-clonic seizures in 6 PVCre/Gq-DREADD animals of the SScortex 
group on day 1. On day 2, activation of feed-forward inhibitory PV+ interneurons 4 out of 6 
(67%) PVCre/Gq-DREADD animals were completely free from tonic-clonic seizures (Fig. 4.8). 
The remaining animals showed increased onset of tonic clonic-seizures compared to that of 
day 1 i.e. day 1: 3.69±1.19 min; day 2: 9.56±5.64 min. Similarly, in the RTN thalamus group, 
PTZ treatment produced tonic clonic-seizures in 3 PVCre/Gq-DREADD animals on day 1. Upon 
co-administration of CNO and PTZ, on day 2, 67% animals did not experience any tonic-clonic 





























Fig. 4.7 Graphical display showing the latency to first absence seizure in animals. (A) Comparison of the latency to first absence seizure in all tested DREADD and non-
DREADD WT controls of the SScortex group and the RTN thalamus group between day 1 (PTZ only treated) and day 2 (CNO and PTZ treated). (B) Comparison of the latency 































Fig. 4.8 Graphical display showing the latency to first tonic-clonic seizure in animals. (A) Comparison of the latency to first tonic-clonic seizure in all tested DREADD 
and non-DREADD WT controls of the SScortex group and the RTN thalamus group between day 1 (PTZ only treated) and day 2 (CNO and PTZ treated). (B) Comparison of 
the latency to first tonic-clonic seizure in animals which experienced tonic-clonic seizures on day 1 (PTZ only treated). Comparisons between the treatment groups were made 




































Fig. 4.9 Graphical display showing the latency to first myoclonic seizure in animals. (A) Comparison of the latency to first myoclonic seizure in all tested DREADD and 
non-DREADD WT controls of the SScortex group and the RTN thalamus group between day 1 (PTZ only treated) and day 2 (CNO and PTZ treated). (B) Comparison of the 







Similarly, 67% (2 out of 3) and 60% (3 out of 5) PVCre/Gq-DREADD animals of the SScortex 
group and RTN thalamus group were completely free from myoclonic seizures on day 2 
compared to day 1 (Fig. 4.9). Remaining animals of the RTN thalamus group also showed  
prolonged latency to first myoclonic seizures i.e. day 1: 4.24±0.10 min; day 2: 15.90±2.90 min. 
 In comparison, on day 2, non-DREADD WT animals of either treatment group, did not show 
significant changes in the latency to first seizure compared to that of day 1 (Fig. 4.7-4.9).   
 
4.3.3.2 Activating PV+ interneurons reduced the mean duration spent in seizures  
On day 2, PVCre/Gq-DREADD animals in both the SScortex and RTN thalamus groups, spent 
less time in PTZ-induced seizures compared to day 1. Mean duration spent in different type of 
seizures during 1 hour of EEG recording on both days is shown in figure 4.10. On day 1, 
PVCre/Gq-DREADD animals of the SScortex group (n=7) spent 17.85±9.32 and 26.04±11.15 
seconds in absence-like seizures and tonic-clonic seizures, respectively after PTZ 
administration which was reduced by 89.49% (to 1.876±1.87 seconds) and 88.91% (to 
2.88±2.0 seconds) on day 2 after CNO and PTZ co-administration (Fig. 4.10). Similarly, 
PVCre/Gq-DREADD animals of the RTN thalamus group (n=7) also spent less time in absence 
like seizures on day 2 compared to that of day 1 (Fig. 4.10). During 1 hour of EEG recording, 
those animals spent 31.11±13.64 seconds in absence seizures on day 1 after PTZ administration 
which was reduced by 82.35% to 5.49±3.41 seconds on day 2 after co-administration of CNO 
and PTZ (Fig. 4.10). Interestingly, there was only 30% reduction in tonic-clonic seizures in 
this treatment group (day 1: 7.65±2.96 seconds, day 2: 5.37±3.53 seconds). In the SScortex 
group, the duration spent in other types of seizures (myoclonic seizures, myoclonic jerks and 
absence-like seizures spanning <1 seconds) almost remained unchanged on both days, whereas 
duration spent in other types of seizures substantially decreased on day 2 in RTN thalamus 
group (Fig. 4.10). In contrast, non-DREADD WT animals did not experience a reduction in 
the time spent in seizures after CNO activation of FFI on day 2 compared to only PTZ treatment 
























































Fig. 4.10 Mean duration spent in seizure by animals during 1 hour of EEG recording. Graphs showing the 
total time spent in various types of seizures by PV
Cre
/Gq-DREADD (DREADD) (n=7) and non-DREADD WT 
(n=5) animals of the SScortex and the RTN thalamus group on day 1 and day 2. All values represent mean ± SEM. 














4.3.3.3 Activating PV+ interneurons reduced total number of discharges and mean length 
of epileptic bursts 
Analysis of the EEG data showed that total number of discharges (absence or tonic-clonic or 
myoclonic bursts) in PVCre/Gq-DREADD mice of both SScortex group and the RTN thalamus 
group was reduced on day 2 compared to that of day 1 (Fig. 4.11). PVCre/Gq-DREADD animals 
of SScortex group (n=7) treated with PTZ exhibited 4.57±2.24 absence discharges which was 
reduced to 0.85±0.85 discharges on day 2 (Fig. 4.11A). Similarly, these animals experienced 
2.71±1.28 tonic-clonic discharges and 2.14±1.81 myoclonic jerks on day 1 which was reduced 
to 0.42±0.205 tonic-clonic discharges and 0.71±0.42 myoclonic jerks on day 2, respectively 
(Fig. 4.11A). 
 
Similar effects were seen in RTN thalamus group. PVCre/Gq-DREADD animals of this group 
(n=7) treated with PTZ displayed 7.42±2.58 absence-like discharges on day 1 which was 
reduced to 2.42±1.41 discharges on day 2 (Fig. 4.11B). Those animals also displayed 0.57±0.20 
tonic-clonic discharges and 2.71±1.26 myoclonic seizures on day 1 which were reduced to 
0.28±0.18 tonic-clonic discharges and 0.42±0.29 myoclonic seizures on day 2 (Fig. 4.11B). 
Contrastingly, such type of reduction was not evident in non-DREADD WT animals (Fig. 
4.11A,B). 
 
Analysis of the EEG data also showed that, there was a reduction in mean duration of each 
epileptic burst in PVCre/Gq-DREADD animals on day 2 compared to that of day 1 (Fig. 
4.11A,B). In the SScortex group, the mean length of absence and tonic-clonic seizures was 
3.21±1.15 and 11.18±3.40 seconds, respectively which decreased to 0.66±0.43 and 
3.60±2.71seconds on day 2 (Fig. 4.11A). Similar reductions were also seen in the PVCre/Gq-
DREADD animals of RTN thalamus group. PVCre/Gq-DREADD animals of the RTN thalamus 
group on day 1 displayed absence and tonic-clonic seizures spanning 3.42±0.86 and 7.65±2.96 
seconds, which was reduced to 0.90±0.43 and 5.37±3.53 seconds on day 2 (Fig. 4.11B). 
Overall, PVCre/Gq-DREADD animals of both treatment groups experienced a reduction in the 
number of epileptic discharges and mean length of such discharges on day 2, whereas non-
DREADD WT control animals of both treatment groups did not show reductions in either 
number or duration of epileptic bursts (Fig. 4.11A,B). Representative EEG traces of 10 min 
after PTZ injection on day 1, and CNO & PTZ injection on day 2 in PVCre/Gq-DREADD 

















































Fig. 4.11 Total epileptic bursts and length of bursts in animals during 1 hour of EEG recording. Comparison 
of mean number of epileptic bursts (discharges/hr) and mean length of bursts between PV
Cre
/Gq-DREADD 
(DREADD) (n=7) and non-DREADD WT (n=5) animals of (A) the SScortex and (B) the RTN thalamus group 
after PTZ treatment on day 1 and CNO & PTZ treatment on day 2. All values represent mean ± SEM. Comparisons 



















Fig. 4.12 Representative EEG traces from a PVCre/Gq-DREADD animal after i.p. PTZ injection on day 1 and focal (SScortex) CNO and i.p. PTZ injection on day 2. 








DAY 1: PTZ (i.p.) 20mg/kg  




















Fig. 4.13 Representative EEG traces from a PVCre/Gq-DREADD animal after i.p. PTZ injection on day 1 and focal (RTN thalamus) CNO and i.p. PTZ injection on 
day 2. Asterisks (*), hash signs (#) and M represent absence-like, tonic-clonic and myoclonic seizures, respectively. Each trace represents 10 min of EEG recording.  
DAY 1: PTZ (i.p.) 20mg/kg  






The study undertaken in this chapter demonstrated that activating feed-forward inhibitory PV+ 
interneurons in the CTC network possesses antiepileptic effects during chemically (PTZ) 
induced seizures. Analysis of the individual seizure types revealed that activation of PV+ 
interneurons was effective against PTZ-induced absence seizures including other forms of 
seizures induced by PTZ. Such activation either prevented or delayed the latency to first 
seizure, reduced the mean duration spent in seizures, decreased total discharges/hr and mean 
length of epileptic bursts. In contrast, such effects were not evident in non-DREADD WT 
control animals. These results demonstrate a potential for using PV+ interneurons as a 
therapeutic target to control absence seizures in some cases of absence epilepsy.  
 
4.4.1 Excitatory Gq-DREADD receptors are highly expressed in feed-forward inhibitory 
PV+ interneurons   
Confocal immunofluorescence microscopy confirmed the expression of excitatory (Gq) 
DREADD receptors in PV+ interneurons in PV
Cre
/Gq-DREADD animals. DREADD HA-tag 
and PV were highly co-expressed in cells known to express calcium binding protein PV. None 
of the non-DREADD WT control animals showed colocalization between PV cells and HA-
tag. The labelling of PV+ cells in this study was consistent with that of other published studies 
(del Río and DeFelipe, 1994; Tamamaki et al., 2003; Dávid et al., 2007; Fishell, 2007; Xu et 
al., 2010). PV
Cre
/Gq-DREADD animals showed high colocalization (>90%) of PV cells and 
HA-tag in the SScortex, the RTN thalamus and the Purkinje cells of cerebellum. This double 
transgenic approach of expressing DREADD receptors in feed-forward inhibitory PV+ 
interneurons was highly consistent compared to efficiency and specificity of viral mediated 
DREADD labelling in PV-Cre animals. Studies have shown that the infection efficiency and 
specificity of labelling vary between 70 and 95% in viral mediated delivery of DREADD 
constructs into brain regions (Zou et al., 2016; Xia et al., 2017; Hijazi et al., 2019; Bicks et al., 
2020). In this current study, percentage of DREADD receptors (HA-tagged cells) colabelled 
for PV and percentage of PV cells colabelled for DREADD receptors (HA-tag) was always 
above 90% in all tested regions. This result is similar to the results obtained in chapter 3 (Panthi 








4.4.2 Activation of feed-forward inhibitory PV+ interneurons suppressed PTZ induced 
absence seizures 
PTZ is one of the chemicals that is widely used to induce generalized absence seizures in 
animals. Other chemicals such as γ-hydroxybutyrate (GHB), bicuculline, picrotoxin, penicillin 
are also routinely used to induce absence seizures (Snead et al., 1992; Kostopoulos et al., 2017), 
but PTZ has been preferentially used for testing new drugs against absence seizures for more 
than seventy years (Krall et al., 1978; Löscher, 2011). Moreover, use of low dose of PTZ is an 
established method to induce seizures within the thalamocortical circuit (Snead, 1992; Coulter 
and Lee, 1993).  
 
In the pilot study, a single 20mg/kg (i.p.) dose of PTZ was sufficient to induce absence seizures 
in animals. However, a dose of 20mg/kg also induced absence seizures including tonic-clonic 
seizures and myoclonic seizures. Seizures were categorized on the basis of the morphology of 
EEG waveforms and behavioural features in the video. One recent study reported that 
administration of 20mg/kg (i.p.) dose of PTZ induced whisker trembling and SWDs with 
behavioural arrest in Tau58/4 transgenic mice (Van Erum et al., 2019). In another study Van 
Erum and colleagues also reported that the latency, severity and behavioural features of PTZ 
induced seizures vary with the concentration of PTZ, genotype and the age of the animal (Van 
Erum et al., 2020). These types of variability were also reported in rats (Klioueva et al., 2001; 
Lüttjohann et al., 2009). Importantly, in our current study, the proportion of absence and tonic-
clonic seizures after PTZ treatment (on day1) in PV
Cre
/Gq-DREADD and non-DREADD WT 
control animals was not significantly different. Thus, it can be concluded that various types of 
seizures seen even after injection of low dose (20mg/kg) of PTZ in this study might be due to 
strain related differences or transgene effect.  
 
In the study reported in this thesis, the latency to first seizure after PTZ treatment (on day 1) 
was ~5 min which is consistent with other published studies in mice (Keskil et al., 2001; 
Medina et al., 2001; Ilhan et al., 2006; Erbayat-Altay et al., 2008; Nassiri-Asl et al., 2009; 
Koutroumanidou et al., 2013; Faghihi et al., 2017; de Freitas et al., 2018). These other studies 
have shown that irrespective of dose of PTZ (ranging from 20-80mg/kg, i.p.), the latency of 
seizure onset is around 5 min. One study, however, has reported that increasing the 
concentration of PTZ from 50-70mg/kg, decreases the time of onset of seizure from 300 
seconds to 90 seconds (Schwaller et al., 2004). In another study conducted in mice, latency to 





mg/kg dose of PTZ (Girard et al., 2019). Additionally, Van Erum and colleagues recently 
reported genotype and age-related differences in susceptibility and onset of PTZ-induced 
seizures (Van Erum et al., 2020). However, in the current study, regardless of genotype, first 
and last incident of seizure after PTZ administration on day 1, was very consistent in all animals 
of both treatment groups. 
 
On day 2, PTZ (20mg/kg, i.p.) was tested after pre-treatment with CNO (5mg/kg, into either 
the SScortex or the RTN thalamus). Such regional activation of PV+ interneurons significantly 
delayed the latency to first absence seizure (including other seizure types) compared to that of 
day 1 in PV
Cre
/Gq-DREADD animals. Furthermore, there was a reduction in the total time 
spent in seizure, in the number of total discharges and mean duration of each bursts of 
discharges on day 2. However, non-DREADD WT control animals of both treatment groups 
(SScortex and RTN thalamus) did not experience such protection or decreased seizure 
susceptibility on day 2. 
 
Similar to these results, DREADD mediated activation of PV+ interneurons reduced the seizure 
susceptibility and severity of PTZ treated (50mg/kg) transgenic (PV-Cre x LSL-hM3Dq) 
animals (Johnson et al., 2018). In addition, Johnson and colleagues also performed 
complementary experiments where they injected AAV with excitatory DREADD (hM3Dq) 
constructs into the cortex of the PV-Cre mice. Similar antiepileptic effects were observed in 
animals when CNO and PTZ were co-administered using viral vector method (Johnson et al., 
2018). Likewise, Clemente-Perez and colleagues used optogenetics to activate PV+ 
interneurons of the RTN thalamus which suppressed seizures induced by PTZ administration 
(35-60mg/kg) (Clemente-Perez et al., 2017). The protective role of these interneurons was also 
assessed in another study where authors found that the severity of PTZ induced seizure is 
significantly higher in parvalbumin-deficient mice (PV
-/-
) compared to that of WT (PV
+/+
) 
genotype (Schwaller et al., 2004).  
 
Studies have shown that activation of PV+ interneurons of other regions of the brain also offers 
protective role against other chemically induced seizures. Chemogenetic activation of 
hippocampal PV+ interneurons suppressed 4-AP induced epileptiform activity in PV-Cre mice 
(Cǎlin et al., 2018). Another study has also shown that stimulation of PV+ interneurons has 
similar protective effect against 4-AP induced spontaneous electrographic seizures (Assaf and 





effects against KA-induced temporal lobe seizures (Krook-Magnuson et al., 2013; Wang et al., 
2018). Altogether, these findings indicate that PV+ interneurons might serve as a novel 
therapeutic target to control seizures. 
 
4.4.3 PV+ interneurons- a potential target for antiepileptic therapy?  
In the previous chapter, using inhibitory DREADD (PV
Cre
/Gi-DREADD) animals, selective 
unilateral (one hemisphere) silencing of feed-forward inhibitory PV+ interneurons via regional 
injection of CNO either into the SScortex or the RTN thalamus generated absence-like SWDs 
(Panthi and Leitch, 2019). Conversely, in this chapter, selectively activating these interneurons 
either prevented PTZ-induced absence seizures or suppressed the severity of absence seizures. 
Furthermore, PTZ induced tonic-clonic and myoclonic seizures were also reduced in severity 
by regional activation of feed-forward inhibitory PV+ interneurons.  
 
As PV+ interneurons synapse on to soma/proximal dendrites/axon initial segment of excitatory 
pyramidal cells (Inan and Anderson, 2014; Tremblay et al., 2016) and axonal branches of a PV 
cell has contacts over thousands of pyramidal cells (Freund and Buzsaki, 1996; Packer and 
Yuste, 2011), activating them may have generated widespread post-synaptic inhibitory currents 
onto pyramidal neurons, thereby attenuating PTZ-induced seizures.  
 
One study reported that targeting single type of interneuron may not always be sufficient to 
control seizures. Ledri and colleagues found that optogenetic activation of several 
subpopulation of interneurons of hippocampus [PV, SOM, Cholecystokinin (CCK), 
Neuropeptide Y (NPY)-expressing] more effectively inhibits 4-AP induced epileptiform 
activity in the brain slices compared to individual set of interneurons alone (Ledri et al., 2014). 
As several subclass of interneurons have different functional connectivity to the principal 
neurons, this approach might have powerfully inhibited various compartments of principal cells 
and efficiently suppressed epileptiform activity. Clearly, in this current study activating just 
PV+ interneurons had profound effect on suppressing seizures.  
 
Similarly, other optogenetic studies revealed that activating hippocampal PV+ interneurons 
attenuate KA-induced temporal lobe seizures (Krook-Magnuson et al., 2013) and pilocarpine 
induced mesial temporal lobe seizures (Lévesque et al., 2019). Wang and colleagues used 
chemogenetics and reported the prominent role of hippocampal PV+ interneurons in blocking 





studies activation of PV+ interneurons did not stop or shorten seizures as expected. Instead, 
such optogenetic activation triggered preictal and interictal spikes leading to seizure-like 
discharges in medial entorhinal slices perfused with the proconvulsive compound 4-AP 
(Yekhlef et al., 2015). In another optogenetic kindling epilepsy model, activation of these 
interneurons failed to attenuate seizures rather inhibition was effective in reducing the duration 
of seizures (Khoshkhoo et al., 2017), in direct contrast to previous optogenetic studies (Krook-
Magnuson et al., 2013; Ledri et al., 2014). Thus, it is possible that impact of interneurons 
depends on their functional features based on their anatomical location and patterns of 
excitability of the regions under study.  
 
Different outcomes in response after activating PV+ interneurons may also depend on the 
implemented experimental approach. Optogenetic activation of these interneurons in medial 
entorhinal cortex produced anti-epileptic effects when they were activated in the pre-ictal stage 
but ineffective when activated during an epileptic event (Yekhlef et al., 2015). Likewise, Assaf 
and Schiller revealed that optogenetic activation of cortical PV+ interneurons effectively 
suppresses 4-AP induced seizures when stimulated a few seconds before the onset of seizures, 
but it worsened the seizure control when activated between seizures i.e. interictal phase. In both 
studies, activation of PV+ interneurons did not block ongoing seizures. In this current study, 
to test the impact of activating feed-forward inhibitory PV+ interneurons during PTZ-induced 
absence seizure, animals were focally treated with CNO, 10 min prior i.p. PTZ injection. This 
was based on the result from the previous chapter where inhibitory Gi-DREADD receptor were 
activated ~15 min of focal CNO injection and result from the experiments conducted on day 1 
in this chapter showed that PTZ induces seizures ~5 min post injection.   
 
It is also important to mention that selective silencing of excitatory pyramidal neurons may 
have protective role against absence seizures. This approach is relatively unexplored. Few 
recent studies have shown that susceptibility of seizure activity reduces when excitatory 
neurons are targeted with chemogenetics (Kätzel et al., 2014; Avaliani et al., 2016; Chen et al., 
2020) or optogenetics (Tønnesen et al., 2009; Krook-Magnuson et al., 2013). Studies have 
shown that chemogenetic silencing of CAMkinase expressing pyramidal cells in motor cortex 
(Katzel et al., 2014) and hippocampus (Chen et al., 2020) has antiepileptic effect against 
pilocarpine induced and kindling induced epileptic seizures, respectively. Optogenetics 









Altogether, DREADD mediated activation of feed-forward inhibitory PV+ interneurons in 
either the SScortex or the RTN thalamus of the CTC network yielded antiepileptic effects 
against absence seizures. Thus, these interneurons could serve as ‘choke points’ for anti-seizure 
therapy and the findings from this study could be highly significant in developing new targeted 
approach for the treatment of absence epilepsy. Data from this and the previous chapter have 
provided us an understanding that dysfunctional FFI is likely to be involved in the generation 
of absence seizures. It is possible that dysfunctional FFI may alter the synthesis and transport 
of inhibitory neurotransmitter (GABA) compromising GABAergic signalling. This forms the 
basis of next chapter where changes in the GABA levels in terms of GABA synthesizing 


























Chapter 5. Impact of Dysfunctional FFI on GAD Isoforms and GABA Transporters—
Evidence from Epileptic Stargazers and CNO Treated DREADD Animals 
 
5.1 Introduction 
In the previous two chapters, it was established that functionally silencing feed-forward 
inhibitory PV+ interneurons in the CTC network is sufficient to generate absence-like SWDs 
associated with behavioural arrest (Panthi and Leitch, 2019). Furthermore, activating FFI 
during PTZ-induced seizures abolishes absence seizures in the majority of animals and reduced 
the severity of seizures. In the stargazer mouse model of absence epilepsy, in which FFI is 
impaired, GABA levels are altered in CTC neurons. Hence, the aim of this chapter was to 
investigate whether impaired FFI impacts GABA expression by affecting its synthesizing 
enzymes (GAD65 and GAD67) or transporter proteins (GAT-1 and GAT-3). 
 
Stargazer mice have a deficit in a protein called stargazin. Stargazin is a transmembrane AMPA 
receptor regulatory protein (TARP) which is responsible for trafficking AMPA receptors into 
the synapse and regulating their functions (Chen et al., 2000, Tomita et al., 2005). Our 
laboratory has previously reported that a deficit in stargazin in the stargazer model of absence 
epilepsy leads to the reduced expression of GluA4-AMPARs at excitatory synapses in feed-
forward inhibitory (PV+) interneurons of the CTC network i.e. SScortex (Adotevi and Leitch, 
2016; 2017; 2019) and RTN thalamus (Barad et al., 2012; 2017). This impairment is likely to 
reduce FFI within the cortical and thalamic microcircuits of the CTC network. Additionally, it 
has been shown that both GABA receptors and GABA neurotransmitter are altered within the 
CTC network of epileptic stargazers. Phasic and tonic GABAAR are specifically increased in 
the VP thalamus region (at synaptic and extrasynaptic sites on relay neurons) but not in the 
RTN thalamus (Seo and Leitch, 2014; 2015). Changes in GABAAR expression in the stargazer 
VP thalamus only occur after seizure onset at PN16-18 (Seo and Leitch, 2017) suggesting a 
compensatory post-seizure effect that most likely contributes to seizure maintenance rather 
than generation. Likewise, GABA neurotransmitters levels have been found to be increased in 
the SScortex (Hassan et al., 2018), but reduced in the VP thalamus of epileptic stargazers. No 
significant difference in the GABA levels expression were evident in the RTN thalamus of 
stargazers compared to non-epileptic controls (Leitch laboratory, pers. comm).  
 
GABA levels are controlled by the enzymes responsible for their production (GAD65 and 





mediate their reuptake (GAT-1 and GAT-3). GAD65 is mostly distributed in the axon terminals 
where it catalyzes GABA synthesis on demand, which is crucial for phasic inhibition (Tian et 
al., 1999). GAD67 is distributed throughout the neurons. It is responsible for synthesizing the 
majority of GABA and is important in mediating tonic inhibition (Asada et al., 1997; 
Schousboe and Waagepetersen, 2009). GAT-1 and GAT-3 are responsible for the recycling or 
removal of GABA from the synapse after its release from presynaptic terminals. GAT-1 is 
mainly expressed throughout neurons and in some astrocytic processes and is responsible for 
regulating GABA levels during sustained neuronal activity whereas GAT-3 is distributed 
primarily in astrocytes and regulates GABA levels in extrasynaptic areas (see reviews by 
Scimemi, 2014 and Melone et al., 2015).  
 
Expression levels of GAD65 and GAD67 were reduced in human temporal lobe epilepsy 
patients (Wang et al., 2016). GAD65 knockout animals are highly vulnerable to seizures 
(Asada et al., 1996; Kash et al., 1997; Stork et al., 2000; Qi et al., 2018), whereas GAD67 
knockout animals do not survive post-birth (Asada et al., 1997; Condie et al., 1997). It is 
important to mention that mice with a disrupted GAD67 allele, the GAD67 GFP knock-in mice 
(Gad67-GFP+/−), display abnormal locomotor behaviour or altered anxiety behaviour (Smith 
et al., 2018). Another study found that insertion of Cre into the VGAT gene (VGAT-Cre mice) 
disrupts expression at both mRNA and protein level and reduced GABAergic synaptic 
transmission (Straub et al., 2020).  
 
In the GAERS, rat model of absence epilepsy, absence seizures are due to enhanced tonic 
inhibition within the VP thalamus as a result of failure in reuptake of extracellular GABA by 
GAT-1. Increased tonic GABAergic inhibition is evident in the VP thalamus of GAERS after 
postnatal day 17 and is sustained up to PN30 when SWDs first appear (Cope et al., 2009). 
These workers also reported increased tonic GABAergic inhibition in VP thalamus of 
stargazers; however, this was not evident until PN19-21, which is after seizures occur and thus 
unlikely to be causative of seizure generation in this model. In a recent study, GABA uptake 
assays were performed in primary cultures of astrocytes obtained from the thalamus and cortex 
of GAERS. Uptake activity of each transporter was determined by selectively blocking each 
transporter with specific drugs.  GAT-1 and GAT-3 mediated uptake was decreased in thalamic 
astrocytes; and the GAT-3 mediated uptake was reduced in cortical astrocytes (Pina et al., 
2019). These findings were also accompanied by increased levels of expression of GAT-1 and 





was decreased in astrocytes derived from epileptic animals (Pina et al., 2019). Moreover, GAT-
1 knockout mouse shows spontaneous ETX-sensitive SWDs (Cope et al., 2009), physical and 
behavioural abnormalities (Jensen et al., 2003; Chiu et al., 2005). GAT-1 is functionally 
deficient in ventro basal astrocytes in GAERS (Pirttimaki et al., 2013).  
 
Clearly, there are various mechanisms which can impair the normal GABAergic inhibition 
within the CTC network. Abnormalities in the expression of GADs and GATs may have a role 
in altered GABAergic inhibition leading to absence seizures within the CTC network. 
Expression level and localization profile of these protein targets are not yet studied using 
absence seizure model.   
 
Hence, the aim of this chapter was to investigate whether altered GABA levels in the stargazer 
mouse model of absence epilepsy which has dysfunctional FFI are the result of altered 
expression of GADs and/or GATs. The first objective of this study was to examine the 
expression levels of GADs and GATs in the stargazer mouse model of absence epilepsy where 
seizure onset occurs early in postnatal development (PN17-18 days) (Qiao and Noebels, 1993), 
equivalent to age of onset in humans, and are chronic continuing throughout adulthood. This 
second objective was to examine whether acute functional silencing of FFI in DREADD mice 
is sufficient to alter the level of GADs and/or GATs and thus impacts GABA levels on 
presynaptic terminals.  
 
5.2 Methods 
Details of the confocal microscopy, western blotting procedures and analysis used in this study 
are fully described in chapter 2. Procedures that are specifically related to the experiments 
performed in this chapter are described below.  
 
5.2.1 Immunofluorescence Confocal Microscopy and analysis 
Immunofluorescence confocal microscopy was performed to investigate the expression pattern 
and staining intensity of GADs (65 and 67) and GATs (1 and 3) in the SScortex and the 
thalamus (RTN and VP) of epileptic stargazers (n=4) and non-epileptic controls (n=3). 
Antibodies against GAD65, GAD67, GAT-1 and GAT-3 were used. Antibodies dilutions used 
in this experiment are listed in Table 2.7 and 2.8 (chapter 2). Confocal imaging was performed 
as described previously in chapter 2. Sections from the brain slices as shown on the schematic 



































Fig. 5.1 Schematic of the tissue sections chosen for confocal analyses. (A) Scheme illustrating the mouse brain 
and approximate region of the primary SScortex (yellow shaded portion) (adapted from Greifzu et al., 2011) with 
(B) relative bregma readings and (C) the regions in the coronal plane from where tissue sections were chosen for 
confocal analyses. Black dotted boxes, yellow and red shaded regions in the figure B represent approximate 
SScortex, RTN and VP regions, respectively. (B and C were adapted from Allen Brain Atlas, online version, 




















































Fig. 5.2 Method of visual identification of cortical layers and analyses of confocal images. Representative 
confocal images showing the method of identification of cortical layers to measure the confocal fluorescence 
intensity for each layer and targeted proteins. (A) Layer 2&3 and 5&6 were separated from layer 4 by visual 
identification of the strong aggregation of PV+ cells in PV panel. (B) White dots were used to separate cortical 
layers in PV panel and same white dots were replicated in GADs or GATs panel. Rectangular region of interest 
(ROI) was randomly created for cortical layers (yellow box), external capsule (blue box) and the glass slide 
without tissue specimen (red box). Similar method was followed to measure staining intensity in the thalamus 
region.   
 
the SScortex and the thalamus was calculated using ImageJ software (NIH, USA). Layers of 
the SScortex (2&3, 4 and 5&6) in the tissue sections were identified visually based on intensely 
labelled PV+ cells in layer 4 (Czeiger and White, 1997; Staiger et al., 1997; Dávid et al., 2007; 






Mean intensity of staining of targeted proteins in each cortical layer i.e. 2&3, 4 and 5&6 was 
calculated by measuring the intensity within layer specific rectangular region of interest (ROI) 
(e.g. yellow ROI’s) (Fig. 5.2). ROI’s were randomly created and kept same for relevant 
confocal images. The background intensity for each image was the mean intensity of external 
capsule (blue ROI’s) plus the intensity of regions of the glass slide without tissue specimen 
(red ROI) (Fig. 5.2). Layer specific staining intensity of each protein target (GADs, GATs and 
PV) was finally determined by calculating the ratio of mean intensity of staining to its 
background staining. Intensity calculation were based on 10-15 confocal images for each 
genotype and every abovementioned protein target.  
 
5.2.2 Western blotting 
To demonstrate the expression level of GADs and GATs, brain tissue from the SScortex and 
the VP thalamus regions was extracted. 27 epileptic stargazers and 31 non-epileptic control 
animals from 20 different litters were included in the stargazer-based experiments.   
In the DREADD-based experiments, brain tissue from the SScortex of CNO treated PV
Cre
/Gi-
DREADD mice and control counterparts (vehicle treated PV
Cre
/Gi-DREADD mice and CNO 
treated non-DREADD WT controls) was also extracted. 12 CNO treated DREADD animals, 8 
vehicle treated DREADD animals and 8 CNO treated non-DREADD WT controls were used 
in the experiments. CNO/vehicle administrated to different cohort of animals. In the first group, 
animals were intraperitoneally injected with single dose (10mg/kg) of CNO/vehicle and were 
sacrificed 30 min after injection. In second group, animals were treated with single but 
increasing dose of CNO/vehicle (i.e. 2.5, 5, 10mg/kg) focally into the SScortex for 3 
consecutive days. On the third day, 15 min after CNO/vehicle treatment, animals were 
sacrificed, and the brain was extracted. The timing of sacrifice was based on the result from 
the chapter 3 where silencing PV+ interneurons generated absence-like seizures ~30 and ~15 
min after i.p. and focal CNO injection, respectively.   
 
Tissue lysates were analysed with western blotting using appropriate antibodies to each protein 
targets (GADs and GATs). Primary and secondary antibodies used for this experiment are 
listed in Tables 2.11 and 2.12, respectively (chapter 2). Scanning and the analysis of the blots 








5.2.3 Data analysis 
Comparison of intensity of staining between the cortical layers (2&3 vs 4 vs 5&6) and the 
thalamic regions (RTN vs VP) in both mice groups were performed using Wilcoxon matched-
pairs signed-rank test and comparison of relevant layers/regions between mice groups were 
performed using Mann-Whitney unpaired rank test. Statistical differences in the expression 
levels of protein between epileptic stargazers and non-epileptic control littermates were tested 
using Mann-Whitney unpaired rank test. Data were presented as mean ± standard error of the 
mean (SEM). All statistical analyses were performed in GraphPad Prism 8.0 with statistical 
significance set at p<0.05.  
 
5.3 Results  
5.3.1 Expression pattern of GADs and GATs in the SScortex and the thalamus of 
stargazers and non-epileptic controls 
The expression pattern of GADs and GATs in the PV+ interneurons in the SScortex (Fig. 5.3 
and 5.4) and the thalamus (Fig. 5.5 and 5.6) was examined using confocal immunofluorescence 
microscopy. Tissue sections from epileptic stargazers and non-epileptic controls were double 
labelled with GADs or GATs and PV antibodies. 
 
Expression pattern GADs in the SScortex 
PV cells soma were brightly stained throughout all cortical layers (2-6) (Fig. 5.3 and 5.4). PV 
cells were most prominent in layer 4 of the SScortex which was visualized in the form of 
intense band in the SScortex (Fig. 5.3 and Fig. 5.4).  
 
GAD65 expression was uniform throughout the cortical layers and the expression was 
restricted to the axon terminals. GAD65 staining did not colocalize to the cell bodies of PV+ 
interneurons (Fig. 5.3A). Magnified merged images (green boxes) showed the evidence of co-
labelling of GAD65 positive puncta-like structures with PV+ interneurons (Fig. 5.3A). 
GAD67 was strongly expressed in the cell bodies of the neurons. Cell bodies of PV+ 
interneurons were intensely colocalized with GAD67 (Fig. 5.3B). Colocalization was seen in 
both epileptic stargazers and non-epileptic littermates (Fig. 5.3B).  
 
Overall, the staining pattern of GADs in the SScortex was similar for both epileptic stargazer 








































Fig. 5.3 Expression of GAD65 and GAD67 in cortical PV+ interneurons. Representative confocal images 
showing the expression of (A) GAD65 (B) GAD67 and PV+ interneurons in the SScortex of epileptic stargazers 
(STG) and non-epileptic littermates (NE). Merged images at low magnification (10X) and medium magnification 
(40X) are shown. White dotted boxes indicate regions of magnified image in the SScortex. Green boxes in the 
40X merged images were magnified in the bottom panels of figures A and B to show puncta-like structures (white 






















































Fig. 5.4 Expression of GAT-1 and GAT-3 in cortical PV+ interneurons. Representative confocal images 
showing the expression of (A) GAT-1 (B) GAT-3 and PV+ interneurons in the SScortex of epileptic stargazers 
(STG) and non-epileptic littermates (NE). Merged images at low magnification (10X) and medium magnification 
(40X) are shown. White dotted boxes indicate regions of magnified image in the SScortex. Green boxes in the 











Expression of GATs in the SScortex 
Expression pattern of GAT-1 and GAT-3 across the SScortex was uniform (Fig. 5.4A,B). 
Colocalization between PV soma and GATs was not seen. However, both GATs were labelled 
in the punctuate-like structures around PV labelled cells in the SScortex (Fig. 5.4A,B; green 
box in 40X merged images). Visually, the staining pattern of GAT-1 and GAT-3 in the 
SScortex was not significantly different between epileptic stargazers and non-epileptic controls 
(Fig. 5.4A,B). 
 
Expression of GADs in the thalamus 
In the RTN thalamus, GAD65 expression was restricted to the axon terminals. GAD65 staining 
did not colocalize to the cell bodies of PV+ interneurons but magnified merged images (green 
boxes) showed GAD65 positive puncta-like structures surrounding PV cells (Fig. 5.5A). 
However, GAD67 was strongly expressed in the cell bodies of the neurons. Cell bodies of PV+ 
interneurons were intensely colocalized with GAD67 in the RTN thalamus (Fig. 5.5B). 
Colocalization was seen in both epileptic stargazers and non-epileptic littermates (Fig. 5.5B). 
Expression of both GADs in the VP thalamus was uniform (Fig. 5.5A,B) as VP contains the 
neuronal processes projecting from RTN. Overall, the staining pattern of GADs in thalamus 
(RTN and VP) was similar for both epileptic stargazer and non-epileptic controls (Fig. 5.5A,B).  
     
Expression of GATs in the thalamus 
Expression pattern of GAT-1 and GAT-3 was uniform in the RTN and VP thalamus (Fig. 
5.6A,B). Colocalization between PV soma and GATs was not seen across the RTN thalamus. 
However, both GATs showed punctuate staining around PV labelled cells in the RTN thalamus 
(Fig. 5.6A,B, green box in 40X merged images). Overall, the staining pattern of GAT-1 and 
GAT-3 in the thalamus was not significantly different between epileptic stargazers and non-
epileptic controls (Fig. 5.6A,B). 
 
Altogether, it can be concluded that the visual expression pattern of GADs and GATs in the 
SScortex and the thalamus are not significantly different between epileptic stargazers and their 






















































Fig. 5.5 Expression of GAD65 and GAD67 in thalamic PV+ interneurons. Representative confocal images 
showing the expression of (A) GAD65 (B) GAD67 and PV+ interneurons in the thalamus of epileptic stargazers 
(STG) and non-epileptic littermates (NE). Merged images at low magnification (10X) and medium magnification 
(40X) are shown. White and blue dotted boxes indicate regions of magnified image in the thalamus (fourth panel: 
RTN thalamus and fifth panel: VP thalamus). Green boxes in the 40X merged images of RTN thalamus were 





















































Fig. 5.6 Expression of GAT-1 and GAT-3 in thalamic PV+ interneurons. Representative confocal images 
showing the expression of (A) GAT-1 (B) GAT-3 and PV+ interneurons in the thalamus of epileptic stargazers 
(STG) and non-epileptic littermates (NE). Merged images at low magnification (10X) and medium magnification 
(40X) are shown. White and blue dotted boxes indicate regions of magnified image in the thalamus (fourth panel: 
RTN thalamus and fifth panel: VP thalamus). Green boxes in the 40X merged images of RTN thalamus were 
































Fig. 5.7 Omission controls were employed to test the specificities of the antibodies used. Representative 
confocal images showing the specificity of secondary antibody binding after omission of primary antibodies in 
tissue sections from the (A) SScortex and (B) thalamus of epileptic stargazers (STG) and non-epileptic littermates 
(NE). Merged images at low magnification (10X) are also shown. 
 
Omission of primary antibodies eliminated neuronal cell specific immunolabeling in tissue 
sections (Fig. 5.7A,B) which indicates the specificity of the antibodies used in this study. 
 
5.3.2 Quantification of staining intensity of GADs, GATs and PV labelling in the SScortex 
and the thalamus of stargazers and non-epileptic controls 
Confocal images were used to quantify staining pattern of GADs, GATs and PV in the 
SScortex, RTN and VP thalamus of epileptic stargazers and non-epileptic controls.  
 
Data indicated that intensity of staining of PV significantly higher in layer 4 and 5&6 compared 
to layer 2&3 in both epileptic stargazers and non-epileptic controls (Fig. 5.8A). However, there 
was no significant difference in the staining intensity between the relevant cortical layers when 
compared between the genotypes (Fig. 5.8A). This finding is an agreement with the previous 














































Fig. 5.8 Confocal fluorescence intensity of PV labelling. Graphs showing the comparison of confocal 
fluorescence intensity of PV labelling across (A) the cortical layers and (B) the thalamus in epileptic stargazers 
and non-epileptic littermates. All values represent mean ± SEM. Comparisons between the cortical layers (2&3 
vs 4 vs 5&6) and the thalamic regions (RTN vs VP) in both mice groups were performed using Wilcoxon matched-
pairs signed-rank test and comparison of relevant layers/regions between mice groups were performed using 










layers between epileptic stargazers and non-epileptic controls (Adotevi and Leitch, 2016). 
Intensity of PV labelling in the RTN was significantly higher compared to the VP, in both 
genotypes (Fig. 5.8B). However, no significant differences were seen in either the RTN or the 
VP region, when staining intensity of PV labelling was compared between mice groups (Fig. 
5.8B).  
 
Analysis of the confocal images showed that intensity of GAD65 (Fig. 5.9A) and GAD67 (Fig. 
5.9C) labelling was significantly higher in layer 4 compared to other cortical layers in both 
epileptic stargazer and their non-epileptic littermates. The overall trend of cortical GADs 
staining in both genotypes was similar (Fig. 5.9A,C). There was no significant difference in 
the staining intensity between the relevant cortical layers of the genotypes (Fig. 5.9A,C). In the 
thalamus of both epileptic stargazers and non-epileptic controls, staining intensity of GAD65 
was not significantly different between the RTN and the VP regions (Fig. 5.9B). However, 
intensity of GAD67 labelling in the RTN was significantly higher than the VP regions in both 
mice groups. However, between genotypes no significant differences in the staining intensity 
were seen in both thalamic regions (Fig. 5.9D).  
 
The trend of GAT-1 labelling across the cortical layers of both epileptic stargazers and non-
epileptic controls was similar (Fig. 5.10A). In both genotypes, staining intensity was higher in 
layer 2&3 and layer 4 compared to that of layer 5&6 (Fig. 5.10A). However, there was no 
significant difference in the staining intensity between the cortical layers when compared 
between the relevant cortical layers of mice groups (Fig. 5.10A). Intensity of GAT-3 labelling 
was higher in layer 4 and layer 5&6 compared to layer 2&3 in epileptic stargazers (Fig. 5.10C). 
Some variability in layer-wise expression in non-epileptic stargazer was seen (Fig. 5.10C). 
Thalamic staining intensity of GATs labelling was similar for both genotypes (Fig. 5.10B,D). 
Overall, there was no significant difference in the staining intensity between the relevant 
cortical layers (Fig. 5.10A,C) and thalamic regions (Fig. 5.10B,D) between mice groups. 
 
Altogether, it can be concluded that staining intensities of GADs and GATs in the SScortex 
and the thalamus are not significantly different between epileptic stargazers and their non-


















































Fig. 5.9 Confocal fluorescence intensity of GAD65 and GAD67 labelling. Graphs showing the comparison of 
confocal fluorescence intensity of GAD65 and GAD67 labelling across (A,C) the cortical layers and (B,D) the 
thalamus in epileptic stargazers and non-epileptic littermates. All values represent mean ± SEM. Comparisons 
between the cortical layers (2&3 vs 4 vs 5&6) and the thalamic regions (RTN vs VP) in both mice groups were 
performed using Wilcoxon matched-pairs signed-rank test and comparison of relevant layers/regions between 











































Fig. 5.10 Confocal fluorescence intensity of GAT-1 and GAT-3 labelling. Graphs showing the comparison of 
confocal fluorescence intensity of GAT-1 and GAT-3 labelling across (A,C) the cortical layers and (B,D) the 
thalamus in epileptic stargazers and non-epileptic littermates. All values represent mean ± SEM. Comparisons 
between the cortical layers (2&3 vs 4 vs 5&6) and the thalamic regions (RTN vs VP) in both mice groups were 
performed using Wilcoxon matched-pairs signed-rank test and comparison of relevant layers/regions between 





5.3.3 Relative expression of GADs and GATs in the tissue lysates of the SScortex and the 
VP thalamus of stargazers via western blotting analysis 
Next, western blotting analysis was performed to analyse the relative levels of GADs and 
GATs in the whole-tissue lysate of the SScortex and the VP thalamus of epileptic stargazers 
and non-epileptic littermates. Data showed the protein level of GAD65 was significantly 
increased in SScortex of epileptic stargazers above their non-epileptic littermates. In stargazers, 
there was a 24% increase in GAD65 expression (NE 1.00±0.03, n=18; STG 1.24±0.11, n=15; 
p=0.024, Fig. 5.11A,B). However, the expression of GAD67 and GAT-3 was not significantly 
different between genotypes (Fig. 5.13C-F). GAD67 expression trended towards higher levels 
in epileptic stargazers but didn’t reach to significance i.e. NE 1.00±0.07, n=16; STG 
1.217±0.11, n=13, Fig. 5.11C,D. There was no change in GAT-3 expression in epileptic 


























Fig. 5.11 Western blot analysis of GAD65, GAD67 and GAT-3 in the SScortex of stargazers (stg) and non-
epileptic littermates (NE). (A,C,E) Representative immunoblots showing expression of GAD65, GAD67 and 
GAT-3 with a-tubulin/b-actin, respectively. (B,D,F) Relative expression of GAD65, GAD67 and GAT-3 in the 
SScortex presented as bar graphs, respectively. All values represent mean ± SEM. Comparisons were performed 





Data also showed that protein levels of GAD65, GAD67 and GAT-3 in the VP thalamus of 
epileptic stargazers and non-epileptic controls were unaltered. There were no statistically 
significant differences in the expression of GAD65, GAD67 and GAT-3 between the genotypes 
(Fig. 5.12A-F) i.e. GAD65 (NE 1.00±0.03, n=9; STG 1.38±0.30, n=5), GAD67 (NE 1.00±0.07, 


































Fig. 5.12 Western blot analysis of GAD65, GAD67 and GAT-3 in the VP thalamus of stargazers (stg) and 
non-epileptic littermates (NE). (A,C,E) Representative immunoblots showing expression of GAD65, GAD67 
and GAT-3 with b-actin, respectively. (B,D,F) Relative expression of GAD65, GAD67 and GAT-3 in the VP 
thalamus presented as bar graphs, respectively. All values represent mean ± SEM. Comparisons were performed 
using Mann-Whitney unpaired rank test.  
 
Overall, western blotting analysis has shown that GAD65 levels are significantly increased in 
the SScortex of stargazer epileptic mice. A trend towards heightened levels of GAD67 in the 
SScortex of epileptic animals and unaltered cortical levels of GAT3 have also been 
demonstrated. Neither of these protein targets showed significant difference in VP thalamus 






5.3.4 Expression of GADs and GATs was unchanged in DREADD animals 
To investigate whether acute functionally silencing FFI in DREADD animals is enough to 
cause alteration of GADs and GATs, western blotting was performed in whole-tissue lysate of 
the SScortex of CNO treated DREADD animals and control counterparts (vehicle treated 
DREADD animals and CNO treated non-DREADD WT animals).  
Expression level of GAD65, GAD67 and GAT-3 was not significantly different between 
CNO/vehicle treated (single i.p. dose of 10mg/kg) animal groups in the SScortex (Fig. 5.13A-
F) i.e. [GAD65: CNO treated DREADD animals (0.86±0.03, n=6); vehicle treated DREADD 






























Fig. 5.13 Western blot analysis of GAD65, GAD67 and GAT-3 in the SScortex of CNO treated (single dose) 
DREADD animals and their control counterparts. (A,C,E) Representative immunoblots showing expression 
of GAD65, GAD67 and GAT-3 with b-actin, respectively. (B,D,F) Relative expression of GAD65, GAD67 and 
GAT-3 in the SScortex presented as bar graphs, respectively. All values represent mean ± SEM. Comparisons 







CNO treated DREADD animals (1.151±0.12, n=6); vehicle treated DREADD (1.025±0.13, 
n=4); CNO treated non-DREADD WT control animals (1.00±0.15, n=4)]; [GAT-3: CNO 
treated DREADD animals (0.62±0.08, n=6) and vehicle treated DREADD (0.79±0.06, n=4) 

























Fig. 5.14 Western blot analysis of GAD65, GAD67 and GAT-3 in the SScortex of CNO treated (focal, three 
doses) DREADD animals and their control counterparts. (A,C,E) Representative immunoblots showing 
expression of GAD65, GAD67 and GAT-3 with b-actin, respectively. (B,D,F) Relative expression of GAD65, 
GAD67 and GAT-3 in the SScortex presented as bar graphs, respectively. All values represent mean ± SEM. 
Comparisons were performed using Mann-Whitney unpaired rank test.  
 
Similarly, in the other group CNO/vehicle was injected focally where animals were treated 
with single but increasing dose of CNO/vehicle (i.e. 2.5, 5, 10mg/kg) focally into the SScortex 
for 3 consecutive days. Relative expression of protein levels of GAD65, GAD67 and GAT-3 
in the SScortex was not significantly different (Fig. 5.14A-F) i.e. [(GAD65: CNO treated 
DREADD animals (0.58±0.11, n=6); vehicle treated DREADD (0.65±0.02, n=4); CNO treated 





animals (0.58±0.13, n=6); vehicle treated DREADD (0.82±0.21, n=4); CNO treated non-
DREADD WT control animals (1.00±0.31, n=4)]; [(GAT-3: CNO treated DREADD animals 
(1.027 ±0.14, n=6); vehicle treated DREADD (0.79±0.14, n=4); CNO treated non-DREADD WT 
control animals (1.00±0.18, n=4)]. 
Unfortunately, GAT-1 was unable to be detected by antibodies from two different suppliers, 
despite using the highest recommended concentration.  
 
5.4 Discussion 
In this chapter the impact of loss of FFI on GABA synthesizing and transporting proteins were 
investigated. GAD65 levels were significantly increased in the SScortex of epileptic stargazer mice 
compared to non-epileptic littermates, whereas levels of GAD67 and GAT-3 were unaltered. In 
contrast, none of these were altered in VP thalamus of epileptic stargazers. Acute administration 
of CNO into inhibitory Gi-DREADD animals, which is sufficient to generate absence-like seizure, 
did not change the expression level of these proteins.   
 
5.4.1 Histochemical localization profile and staining intensity of GADs and GATs in the 
stargazer SScortex and thalamus 
 
5.4.1.1 GADs (65 and 67) 
The PV stanning pattern in all confocal images was similar to previous studies (Staiger et al., 1997; 
Dávid et al., 2007; Xu et al., 2009; Adotevi and Leitch, 2016). This pattern was visually 
indistinguishable, and the intensity of PV labelling was not statistically significant between 
epileptic stargazers and their non-epileptic control littermates. Omission control showed a very 
low level of background fluorescence.  
 
GAD65 expression was uniform throughout the cortical layers and thalamus. GAD65 showed 
punctate staining due to its expression in axon terminals and no colocalization with PV+ soma 
occurred. This is in agreement with previous studies where GAD65 labelling was seen in the axon 
terminals scattered in the neuropil as well as the puncta outlining the cell bodies (Esclapez et al., 
1993; Kiser et al., 1998; Tian et al., 1999). Some studies also found the expression pattern of 





and extensive not only in puncta and neuropil but also in the soma of PV labelled cells in the 
SScortex which is in agreement with published rodent studies (Turner et al., 2010; Bean et al., 
2014; Fujihara et al., 2015; Lazarus et al., 2015). GAD67 labelling was brighter in layer 4 
compared to other cortical layers which is similar to previous published result (Cybulska-
Klosowicz et al., 2013) (Fig. 5.3B). GAD67 staining was strong in the cell bodies of RTN thalamus 
similar to previous published reports (Esclapez et al., 1993; Delfs et al., 1996; Menuz and Nicoll, 
2008; Seo and Leitch, 2014). Expression pattern GADs in the VP thalamus was uniform which 
may be due to the fact that VP contains the neuronal processes projecting from RTN.  
Expression pattern of GADs in the SScortex and thalamus was not visually different between 
epileptic stargazers and non-epileptic controls. Layer specific staining pattern of GADs in the 
SScortex showed that even though there were differences in staining between layers in both 
epileptic and non-epileptic littermates but overall layer-specific staining intensity trend for each 
genotype was similar.  
 
To date, there have been relatively few studies, focusing the expression and staining pattern of 
GADs in animal models of epilepsy. Few studies found that mRNA level of GADs decreases in 
the cerebral cortex and hippocampus in pilocarpine-treated rats, but such changes were not 
observed in the RTN thalamus (Esclapez and Houser, 1999; Kang et al., 2001). Another study has 
shown altered mRNA levels and density of GAD labelled neurons in piriform cortex after kainate 
and pilocarpine induced seizures (Freichel et al., 2006). Authors found loss of substantial number 
of GABAergic neurons followed by increased histochemical labelling of GAD isoforms in 
remaining neuronal population (Freichel et al., 2006). GAD expressing GABAergic neurons are 
bigger part of a network which are functionally connected to the excitatory neurons. One of the 
possible reasons of increased level of GADs in the abovementioned study could be the fact that 
GABAergic neurons may maintain high levels of activity by increasing GABA synthesis to control 
the increased excitability after pilocarpine or kainate injection. Such increase in GAD levels may 
help in regulating the inhibitory strength when the excitation is too high during seizures. 
Surprisingly, in this current study, expression pattern of GADs in epileptic stargazers which show 
spontaneous absence seizures was not changed in comparison to their non-epileptic counterparts.  
Importantly, GAD65 knockout animals were found to be more susceptible to seizures (Kash et al., 





et al., 1997). One study showed that GAD67 deficient mice has significantly reduced GAD65 
puncta density in the cortex without ring-shaped structure (Chattopadhyaya et al., 2007). GAD65 
knockout mice, however, did not show altered cortical morphology and expression level of GAD67 
(Hensch et al., 1998). It is widely established that GAD65 and GAD67 synthesize GABA for 
different functional purpose and different developmental time period (Pinal and Tobin, 1998; 
Soghomonian and Martin, 1998). GABA synthesis from GAD65 is ‘on demand’ i.e. for vesicular 
release regulating phasic inhibition (Tian et al., 1999) whereas GAD67 is involved in the synthesis 
of majority of GABA for cytoplasmic store and regulation of tonic inhibition (Asada et al., 1997; 
Schousboe and Waagepetersen, 2009). Thus, it can be concluded that functional differences 
between GAD isoforms also reflect the difference of localization and expression pattern. 
 
5.4.1.2 GATs (1 and 3) 
GAT-1 and GAT-3 staining was uniform throughout the SScortex and the thalamus and no 
differences in staining patterns were observed between epileptic stargazers and non-epileptic 
controls. Expression of GATs was primarily in the neuropil without co-labelling with soma of PV 
labelled cells. Puncta of both GATs were dispersed around the soma of PV cells. This is similar to 
a recent work in the rat cerebral cortex where authors found GAT-1 and GAT-3 immunopositive 
puncta and neuropil (Melone et al., 2015). In this study cortical intensity of GAT-1 staining was 
highest in the layer 2&3 and layer 4, regardless of genotype. This concurs with the previous work 
conducted in SD rats where authors found that GAT-1 mRNA hybridization signal is intense in 
layer 2-4 (Minelli et al., 1995). The same research group also revealed that the intensity of GAT-
3 expression is mostly in the layer 4 (Minelli et al., 1996). Conversely, this current study found 
that GAT-3 immunoreactivity is in increasing order from cortical layer 2 to 6 in epileptic stargazers 
and some variations were observed in non-epileptic controls. This current study also found that 
immunoreactivity of GAT-3 across all cortical layers is relatively less intense compared to that of 
GAT-1 which again is in agreement to the studies published in rats (Minelli et al., 1995; 1996).  
Previous studies conducted in rat, monkey and humans revealed the expression of GAT-1 in 
neurons and astrocytes (see review Conti et al., 2004), whereas localization profile of GAT-3 was 
always been a matter of uncertainty as some studies showed the neuronal expression of GAT-3 
(Clark et al., 1992; Durkin et al., 1995) and others highlighted exclusive astrocytic expression 





revealed that GAT-1 immunoreactivity is 54% and 42% in neuronal and glial profiles whereas 
GAT-3 labelling was significantly higher in glial processes (72%) (Melone et al., 2015). Moreover, 
expression of GAT-1 in oligodendrocytes and microglia was also reported (Fattorini et al., 2017; 
2020).  
 
It is important to note that both GAT-1 and GAT-3 achieve adult-like pattern of expression by the 
second PN week in the thalamus and third PN week in the cortex (Vitellaro-Zuccarello et al., 2003) 
and this timing coincides with the developmental increase of tonic GABAA current seen in GAERS 
(Cope et al., 2009). Cope and colleagues also found that blockade of thalamic GAT-1 induces 
ETX-sensitive SWDs in normal Wistar rats and GAT-1 knockout mice also show similar ETX-
sensitive spontaneous SWDs (Cope et al., 2009). In another study, GAT-1 knockout mouse was 
found to have normal life span but had reduced body weight, tremor, gait abnormality and anxiety 
as physical and behavioural disorders (Jensen et al., 2003; Chiu et al., 2005). It is possible that 
these abnormalities seen in abovementioned rodent studies are due to compromised GABA uptake 
and dysfunctional GABA clearance from synaptic cleft due to dysfunctional GABA transporters 
(GATs).  
 
In this study, proximal neurite processes of PV+ interneurons in layer 4 are from other neurons. 
Soma of PV+ interneurons labelled in the layer 4 have their axon terminals in other layers such as 
V and VI. This issue can be clarified by using cortical layer marker for layer V and VI i.e. Anti-
BCL11B antibody (CTIP2). Another option would be using optical Z stacks images and 3D third 
party software to count puncta surrounding the soma and processes of PV+ cells. GAD65+ve-
PV+ve terminals that are less then 1um off the surface of pyramidal neurons of adjacent layers can 
also be counted and these may be the part of future study. As previously mentioned, GATs are 
expressed in astrocytes, with GAT-3 being exclusively astrocytic, use of suitable astrocytic makers 
such as N-Myc downstream-regulated gene 2 (NDRG2) or S100β or glial fibrillary acidic protein 









5.4.2 Increased expression of GAD65 in the stargazer somatosensory cortex 
Western blotting result has shown that GAD65 levels are significantly increased in the SScortex 
of epileptic stargazer mice. This result indicates that increased level of GABA seen in the SScortex 
of epileptic stargazer (Hassan et al., 2018) is due to the increased level of its synthesis enzyme 
GAD65. However, it cannot be concluded that increased level of GAD65 which primarily involved 
in phasic inhibition in epileptic stargazer is a consequence of seizures or this has specific 
contribution in seizure generation. Thus, this upregulation alone might not necessarily trigger 
functional changes in epileptic stargazers. This also supports the evidence that dysfunction of 
GAT-1 leading to excess tonic inhibition might be a mechanism in stargazers which is previously 
reported in GAERS (Cope et al., 2009). However, due to issues in antibodies, this study was unable 
to quantify changes in GAT-1 levels via western blotting. As studies have shown the involvement 
of GAT-1 in absence seizures (Cope et al., 2009; Pirttimaki et al., 2013), it would have been 
interesting to see the expression level of GAT-1 in the SScortex and VP thalamus of stargazers in 
this study. No changes in the expression levels of GAT-3 in the SScortex and the VP thalamus of 
stargazers were observed in this study which is consistent with published data of normal functional 
activity in the thalamus of GAERS (Pirttimaki et al., 2013). Recent work in Leitch laboratory 
found that GABA levels in stargazers are reduced in VP thalamus (per. comm.). It is also important 
to mention that expression level of GADs was unaltered in RTN thalamus in GAERS and non-
epileptic rats (Danober et al., 1998) and no significant difference was seen in the GABA levels in 
the RTN thalamus of stargazers and their non-epileptic controls (Leitch lab, pers. comm.). 
On the other hand, no significant differences in the expression levels of GADs and GAT-3 were 
observed in the SScortex of PV
Cre
/Gi-DREADD animals and their control counterparts treated 
with CNO. One recent study also failed to detect any significant differences in the expression 
levels of GAD65/67 in the prefrontal cortex and hippocampus when PV was selectively knocked 
down in those regions (Perez et al., 2019). Alteration of GABAergic transmission via selective 
silencing of PV+ interneurons in this study generated absence-like seizures but changes were not 
seen in the GADs and GATs that are responsible in synthesis and reuptake of GABA. In other 
words, functional changes were not evident in protein level. It is possible that physiological factors 
that regulate the GABA level by adjusting GADs and GATs are not dependent over the subtle 
functional changes caused by silencing of PV+ interneurons in a specific microcircuitry.  Thus, it 





CNO injection might not have distinct role in changing or maintaining GABA level within the 
circuit even though same dose of CNO is sufficient to generate absence-like seizures. Additional 
experiments using electrophysiological or pharmacological tools are, however, necessary to revisit 
and validate these findings in the cellular level.     
 
Of note, GAT inhibitors might also have therapeutic potential against absence seizures. It is 
believed that GAT inhibitors increase GABA levels in the synapse, facilitate inhibitory 
neurotransmission, inhibit neuronal excitability thereby mediate seizure protection (Madsen et al., 
2010). GAT inhibitors such as tiagabine, EF1502 and SNAP-5114 has shown anti-convulsant 
activity against established model of epilepsy (Nielsen et al., 1991; Dalby, 2000; White et al., 
2005). However, increasing the amount of extracellular GABA by using GAT inhibitors might not 
always alleviate all seizure types as tiagabine aggravate absence seizures in human patients and 
are contraindicated (Perucca et al., 1998; Ettinger et al., 1999; Panayiotopoulos, 1999). 
Nevertheless, inhibition of GABA uptake may be an interesting approach and also can be utilized 
in the proof-of-concept studies in various rodent models of absence epilepsy. 
Altogether, it can be concluded that deregulation of GADs and GATs function may compromise 
GABAergic signalling and absence seizures. Additionally, astrocytes might be a crucial factor in 
the etiopathology of absence seizures. Importantly, study of these protein targets during 
developmental time points would specifically clarify their roles in absence seizure genesis.  
 
5.5 Conclusion 
Thus, it can be concluded that upregulation of GAD65 in the SScortex of epileptic stargazers may 
be a consequence of absence seizures or this may have specific contribution in absence seizure 
generation. Experiments should be conducted over developmental time points (different juvenile 
ages and adulthood) which would clarify if seizure causes upregulation of GAD65, or if the 
dysfunctional FFI due to reduced PV+ interneuron activation even before seizure onset alters 
GAD65 levels. Additionally, optogenetic, chemogenetic or pharmacological manipulations should 








Chapter 6. General Discussion 
 
This final chapter is a critical review of the findings of this PhD project. Firstly, a brief overview 
of the findings from the three experimental chapter is presented. This is followed by in-depth 
analysis of the data obtained from the experiments. This includes critical evaluation of the findings 
in relation to current published literature. Following this is a discussion of significance of findings 
and their feasibility in clinical terms and future therapeutic use. Experimental methods employed 
in this study are also critically assessed in this chapter. Also, direction for future experimental 
approach and studies are discussed.       
 
6.1 Overview of findings 
The experiments in chapter 3 were conducted to examine the impact of functionally silencing feed-
forward inhibitory PV+ interneurons within the CTC network on seizure generation and behavior. 
Using confocal microscopy, the expression of the DREADD receptors in feed-forward inhibitory 
PV+ interneurons within the CTC network in PV
Cre
/Gi-DREADD mice was first confirmed. 
Analysis of EEG traces revealed that focal silencing (regional injection of the designer drug CNO 
into the SScortex or the RTN thalamus) of feed-forward inhibitory PV+ interneurons generates 
paroxysmal oscillatory activity similar to SWDs on EEG with associated behavioral arrest. Focal 
silencing also impaired locomotory behavior in PV
Cre
/Gi-DREADD animals. Administration of 
the anti-absence drug (ETX) prevented the focally induced SWDs. Global silencing of all PV+ 
interneurons (via i.p. CNO injection) induced epileptiform activity with the characteristics of 
SWDs and decreased locomotion. Additionally, global silencing impaired motor control on the 
moving rotarod and increased anxiety in open-field test. In contrast, such effects were not evident 




Based on the findings from chapter 3 where silencing PV+ interneurons was linked to absence-
like seizures, it was crucial to test the impact of activating these interneurons during absence 
seizures. Thus, in chapter 4, excitatory DREADD (PV
Cre
/Gq-DREADD mice) approach was 
employed. Simultaneous video/EEG data revealed that selectively activating feed-forward 
inhibitory PV+ interneurons via focal CNO injection into either region of CTC network prevents 





clonic and myoclonic seizures were also reduced in severity by activation of feed-forward 
inhibitory PV+ interneurons. Activating these interneurons delayed the latency to first seizure, 
decreased mean duration spent in seizure, reduced total number of discharges and shortened the 
length of PTZ-induced seizures.  
 
Chapter 5 aimed to investigate whether dysfunctional FFI impacts the inhibitory neurotransmitter 
GABA by altering expression of GADs and GATs. To do this, stargazer mouse model of absence 
epilepsy and CNO treated PV
Cre
/Gq-DREADD animals were used. Analysis of the relative 
expression of GADs and GATs using western blotting showed that the protein level of GAD65 in 
whole SScortex tissue was significantly increased in epileptic stargazers compared to their non-
epileptic littermates. Levels of GAD67 and GAT-3 in the SScortex of epileptic stargazers were 
unaltered. In the VP thalamus, the expression levels of these protein targets were unchanged in 
both mice groups. The expression levels of these proteins were also unchanged in PV
Cre
/Gq-
DREADD animals treated with CNO which is sufficient to generate absence-like seizures. 
Confocal microscopy revealed that there is no significant difference in the visual expression 
pattern and intensity of staining of GADs and GATs in the SScortex and the thalamus between 
epileptic stargazers and their non-epileptic controls.  
 
Overall, the results from this study using both inhibitory (Gi) and excitatory (Gq) DREADD 
approaches have enhanced our understanding that dysfunctional FFI in CTC microcircuits is likely 
to contribute in absence seizure generation and GAD65 upregulation may be a contributing or 
compensating mechanism for reduced FFI.  
 
6.2 Discussion of KEY Findings 
6.2.1 Use of Cre-dependent DREADD to manipulate PV+ interneurons 
In this study, mice expressing inhibitory Gi-DREADDs (hM4Di-flox) or excitatory Gq-
DREADDs (hM3Dq-flox) were bred with PV-Cre mice expressing Cre recombinase in PV+ 
interneurons. hM4Di-flox and hM3Dq-flox mice have a loxP-flanked STOP cassette designed to 
prevent transcription of the downstream HA-hM4Di-pta-mCitrine and HA-hM3Dq-pta-mCitrine 
coding region, respectively. Mating these strains via Cre-loxP recombination technology removes 





generates littermates where HA-tagged DREADD receptors are specifically expressed in PV+ 
interneurons. The success of mating was first verified by testing the genetic make-up of animals 
via genotyping. Cellular expression and localization of HA-tagged DREADD receptors in PV+ 
cells were confirmed via confocal immunofluorescence microscopy.  
 
In this study, labelling of PV was found in the SScortex, RTN thalamus and the Purkinje cells of 
cerebellum of animals. This was consistent with other published studies describing distribution of 
PV+ neurons in the brain (del Río and DeFelipe, 1994; Tamamaki et al., 2003; Fishell, 2007; Xu 
et al., 2010). Expression pattern of PV in those brain regions was not visually distinguishable 
between genotypes (DREADD vs non-DREADD WT controls). The PV-Cre mouse used in this 
study was from Jackson laboratories (JAX stock #008069) which states when PV-Cre knockin 
allele is bred with a strain containing loxP site flanked sequence of interest, recombination occurs 
in more than 90% of neurons that express parvalbumin. In agreement to that statement, in this 
study, colocalization of HA-tagged DREADD receptor in PV+ interneurons were above 90% in 
the SScortex, the RTN thalamus, and Purkinje cells of cerebellum, whereas none of the PV+ 
interneurons in non-DREADD WT control animals showed labelling for HA-tag.  
 
The use of double transgenic mice approach used in this study is not the only way to establish the 
expression of DREADD receptors within PV cells. Cre-dependent/independent viral approach 
(Zhu and Roth, 2015) and Tet-dependent transgenic mice approach (Tet-off system) (Alexander 
et al., 2009; Zhu et al., 2014) are other ways of manipulating PV+ interneurons with DREADDs. 
Cre-dependent viral method is the most commonly used approach. According to this approach, 
virus (AAV or LV) particles containing DREADD construct are delivered into the targeted area in 
the brain of PV-Cre mice. This approach requires complicated stereotactic techniques and wait of 
2-3 weeks time period for expression. Also, single injection can only deliver viral construct in one-
specific region. Studies have shown that the infection efficiency and specificity of labelling vary 
between 70 and 90% (Yi et al., 2014; Zou et al., 2016; Chen et al., 2017; Xia et al., 2017; Hijazi 
et al., 2019; Page et al., 2019; Bicks et al., 2020). Another method is Tet-dependent transgenic 
mice approach where littermates from TRE (Tetracycline-responsive promoter element)-
DREADD are crossed with mice having the tetracycline-controlled transactivator protein (tTA) 





tTA binds to the TRE and activates transcription of the DREADD in the targeted brain regions. 
This is reversible approach as administration of tetracycline or doxycycline eliminates DREADD 
expression. This approach is relatively less popular and few published research articles are 
available (Alexander et al., 2009; Garner et al., 2012; Zhu et al., 2014).  
 
One of the most important aspects of using double transgenic approach (PV
Cre
/DREADD-floxed 
mice) utilized in this study is that DREADD receptors can be expressed in almost all PV+ 
interneurons (>90%) in different brain regions and PV+ interneurons can be activated via regional 
CNO injection into desired regions of the brain. Alternatively, DREADD expressing PV+ 
interneurons can be globally activated by systemic administration of CNO.   
 
6.2.2 Functionally silencing feed-forward PV+ interneurons generated absence-like SWDs, 
whereas activation prevented/suppressed PTZ-induced seizures  
This current study specifically targeted the most common type of GABAergic neurons (PV+ 
interneurons) of the CTC network. These interneurons primarily regulate the FFI within the 
network. As previously described, studies conducted in well-established stargazer model of 
absence epilepsy have shown abnormal expression of AMPA receptors particularly at input 
synapses of PV+ neurons can possibly impair FFI and contribute to the generation of absence-
SWDs (Barad et al., 2012; Maheshwari et al., 2013; Adotevi and Leitch, 2016; 2017; 2019). 
However, the extent to which the deficits in AMPAR expression leads to dysfunctional FFI has 
not been examined through any functional studies. Functional recordings from PV+ interneurons 
of stargazer animals would be highly beneficial to determine the degree to which the impaired 
AMPA receptor might have been involved in the alteration of activity of PV+ interneurons. But, 
the distance between the stargazin locus to parvalbumin locus in chromosome 15 is very close and 
if stargazers are bred with promoter-driven animals, double crossover is very unlikely and 
identification of these cells during physiological study would be technically challenging 





/Gq-DREADD were used. PV+ interneurons of the CTC 
network (SScortex and RTN thalamus) were functionally targeted (silenced or excited) by regional 
injection of CNO. Acute unilateral silencing of these interneurons in either regions of the CTC 





induced absence seizures. Thus, it is likely that PV+ interneurons within feed-forward inhibitory 
CTC microcircuit regulate the neuronal oscillations and prevent runaway excitation, and 
dysfunctional FFI within the microcircuit is likely to contribute in absence seizure generation.  
PV+ interneurons in CTC network are connected to the cell bodies, proximal dendrites and axonal 
initial segments of excitatory neurons. Upon receiving excitatory input, it is possible that these 
interneurons fire and release inhibitory GABA onto the excitatory neurons which enables their 
powerful FFI and limit over excitation. Functional silencing of these interneurons via CNO 
application (into either the SScortex or the RTN thalamus) in this study might have prevented the 
role of PV+ interneurons in maintaining the FFI leading to the generation of absence-like SWDs. 
This is particularly interesting because functional activation of PV+ interneurons in both 
abovementioned regions suppressed chemically induced absence seizures. Additionally, functional 
activation also suppressed chemically induced tonic-clonic seizures and myoclonic jerks. These 
results support the idea that PV+ interneurons might serve as the ‘choke point’ for seizure control 
and this chemogenetic intervention of parvalbumin interneuron inhibitory reserve might capitalize 
as a personalized treatment approach in some cases of absence epilepsy.  
 
 Results from this thesis in light of recent developments and existing theories 
There is a long-standing debate regarding the specific role of CTC components in the 
pathophysiology of absence seizures. Based on the results from animal models and human studies, 
various concepts and theories have been postulated since 1950s (see review Meeren et al., 2005). 
Cutting-edge techniques have been implemented to gain the mechanistic insights of this disease, 
but it is likely that we still have crucial gaps in the knowledge about the cellular, synaptic and 
network mechanisms involving the initiation and/or maintenance of absence seizures.    
Studies conducted in animal models of absence epilepsy have provided evidence of the onset of 
seizure activity in the cortex specifically SScortex. Human studies also showed widespread cortical 
ictal and post-ictal changes in haemodynamic measurements (cerebral blood flow/volume and 
fMRI) before the involvement of other regions of the brain (see review Crunelli et al., 2020). On 
the other hand, since 1950s, many experimental studies have revealed that thalamic regions are 
also responsible in generating absence-SWDs. Recently, Sorokin and colleagues emphasized that 
thalamic components themselves can recruit epileptic cortical network for absence seizure 





originator of absence-SWDs, it is incapable of maintaining discharges on its own, nor is the 
thalamus. In this current study, it has been shown that selective inhibition of either cortical or 
thalamic PV+ interneurons elicits absence-like seizures in normal non-epileptic mice and 
activation of these interneurons terminates chemically induced absence seizures. Altogether, this 
study has shown that a subtle functional change in neuronal excitability even restricted to any of 
the components of CTC microcircuit can generate generalized absence-SWDs throughout the CTC 
network and activation significantly can prevent seizure activity. Similar localized changes by 
knocking out a single gene (Cacna1a, coding for P/Q-type Ca2 + channels) in layer 6 
corticothalamic neurons generated absence seizures in non-epileptic mice (Bomben et al., 2016). 
Conditional knock out of CaV2.1 channel function from PV+ interneurons compromised GABA 
release from cortical PV+ neurons and generated various types of generalized seizures including 
absence seizures (Rossignol et al., 2013). One recent work has shown that, protein level of 
parvalbumin is lower in the SScortex of WAG/Rij compared to wistar rats. Authors concluded that 
such reduction might be a contributing factor of SWDs in WAG/Rij rats (Arkan et al., 2019). Also, 
parvalbumin deficient mice has shown to have higher susceptibility and severity to chemically 
induced seizures (Schwaller et al., 2004).  
 
Previously it was thought that a key aspect of absence network is a synchronized action potential 
firing of cortex, thalamus and SWDs seen in EEG. This was supported by in vivo studies conducted 
in feline model (reviewed in Gloor et al., 1990) and WAG/Rij model of absence epilepsy (Inoue 
et al., 1993), where action potential firing of cortical and thalamic neurons concurred with the 
spike component of the cortical SWDs. Previous in vitro studies suggested that seizure-related 
coordinated firing in the thalamocortical system is through bursts of action potential mediated by 
T-type calcium channel of thalamocortical relay neurons and reticular thalamic nuclei. It was 
thought that these neurons elicit burst of action potentials at each cycle of paroxysmal activity 
forming a rhythm. As thalamocortical cells are reciprocally connected with corresponding cortical 
regions, the cortical structure then thought to coordinate and/or fall into the rhythm generated by 
thalamic network (von Krosigk et al., 1993; McCormick and Contreras, 2001; also reviewed in 
Huguenard, 2019).  
However, recent few studies have established that cortical, thalamocortical and RTN neurons are 





cycle and SWDs (McCafferty et al., 2018b; Meyer et al., 2018). These studies also showed that 
synchronized firing of these neurons during SWDs might be lower than previously thought. It is 
possible that widespread synchronous neural activity may not be a key feature of absence seizures 
and reductions in synchronized firing would not be a desired therapeutic goal. Altogether, use of 
modern techniques has provided new insights in understanding the ictogenesis of absence seizures. 
These studies have revealed the pre-ictal and ictal single cell temporal firing dynamics within the 
CTC network which was not established via previous in vivo and in vitro studies. However, it will 
always be a challenge to specifically isolate the exact roles of the cortical and thalamic components 
within CTC network in generation and/or maintenance of absence seizures.    
 
Of note, the involvement of basal ganglia networks in absence seizures may also be important in 
understanding the pathophysiology of absence seizures. Ictal changes in fMRI-BOLD signals in 
the basal ganglia was seen in children with absence seizures. The ictogenic firing of cortico-striatal 
neurons and cortico-subthalamic neurons during SWDs in animal models also indicates the 
possibility of involvement of basal ganglia in absence seizure generation (see review Crunelli et 
al., 2020). Furthermore, striatal application of 1-naphthyl acetyl spermine (NASPM) which 
selectively blocks calcium-permeable AMPA receptors, and are highly expressed in striatal fast-
spiking interneurons (PV+), induces absence seizures in wild-type mice and DREADD mediated 
activation of these interneurons remarkably reduces absence seizures in Stxbp+/− mice (Miyamoto 
et al., 2019). There are few other technical aspects which should be taken into account such as 
brain slice studies vs intact brain, genetic epileptic animal model vs non-epileptic animals, invasive 
imaging vs non-invasive imaging and human data vs animal studies. Mechanistic limitation of 
brain functioning in animal models also should be considered.  
 
6.2.3 Functional silencing of feed-forward PV+ interneurons altered animal behavior 
Global and focal silencing of feed-forward inhibitory PV+ interneurons significantly reduced 
locomotory behavior in open-field test in inhibitory DREADD (PV
Cre
/Gi-DREADD) animals. 
During 1-hour EEG recording, DREADD animals were also significantly immobile compared to 
their control counterparts. Interestingly, in previous studies, animals lacking parvalbumin (either 
PV knockout or conditional PV knockout) also showed decreased locomotory behavior (Farré-





2018). DREADD based studies utilizing PV-Cre animals have shown no changes in locomotion 
as those studies manipulated PV+ interneurons in other regions such as prefrontal cortex and 
hippocampus (Perova et al., 2015; Zou et al., 2016; Xia et al., 2017; Page et al., 2019). Global 
silencing also caused the animals to spend more time in the peripheral zone and corners of the 
open-field arena and less time in the central zone which indicated the increased anxiety in 
DREADD animals compared to their wild-type counterparts. Staying in the close proximity to the 
wall of the arena indicates anxiety-related behavior in rodents (Prut and Belzung, 2003; Lipkind 
et al., 2004; Seibenhener and Wooten, 2015). The anxiety level of non-DREADD WT control 
animals of open field was similar to other published studies for WT control animals (Moy et al., 
2007; Bailey and Crawley, 2009; de Oliveira et al., 2015).   
 
Global silencing of feed-forward inhibitory PV+ interneurons significantly impaired motor 
performance in moving rotarod test but focal silencing (into either the SScortex or the RTN 
thalamus) did not alter the motor performance. This is likely due to the fact that global silencing 
of PV+ interneurons via i.p. CNO injection silenced all PV+ interneurons including PV expressing 
Purkinje cells in the cerebellum. Similar to the findings of this study, conditional Purkinje cell 
knockout animals also showed significantly impaired motor performance (Todorov et al., 2012; 
Tsai et al., 2012; Yamazaki et al., 2015). Moreover, DREADD based study using viral expression 
methods to selectively silence or excite PV+ interneurons in brain regions, other than the 
cerebellum, have had no effect on motor performance in rotarod test (Zhu et al., 2014; Petitjean et 
al., 2015; Liu et al., 2017; Hijazi et al., 2019). One optogenetic study found that activation of Gi/o 
pathway in Purkinje cells significantly reduces motor coordination and control on the rotarod 
(Gutierrez et al., 2011).  
 
Thus, it can be concluded that functional silencing of feed-forward inhibitory PV+ interneurons in 
the SScortex or the RTN thalamus has impact on behavioral parameters such as locomotion, 
anxiety, motor performance. Studies have shown the involvement of these interneurons in 
cognition and learning (Verret et al., 2012; Donato et al., 2013; Cisneros-Franco et al., 2020; Lee 
et al., 2017; Parker, 2020). However, changes in locomotory behavior in relation to CTC 
feedforward microcircuits has not been directly established. Animals lacking N-methyl-D-





SScortex is shown to have reduced (but statistically non-significant) locomotion (Carlen et al., 
2012). Increased immobility and anxiety in CNO-treated DREADD animals might be due to the 
influence of the amygdala anxiety circuitry as basolateral amygdala receive inhibitory input from 
cortex and thalamus (Tovote et al., 2015; Babaev et al., 2018).  
 
The PV+ interneurons provide powerful inhibitory effects to the huge network of glutamatergic 
excitatory neurons. The functional loss of PV+ interneurons in CTC feed-forward microcircuits 
via DREADD approach employed in this study, may have affected pyramidal neurons within the 
SScortex or the RTN thalamus and disrupted coordinated firing between the groups of pyramidal 
cells leading to the reduction in coordinated activity of other networks and circuits of the brain. 
This also might be one of the answers to the impaired animal behavior in this study. 
 
6.2.4 Impact of dysfunctional FFI on GABA synthesizing enzymes (GADs) and transport 
proteins (GATs) 
Expression level of GAD65 was upregulated in the SScortex of stargazers while other protein 
targets (GAD67 and GAT-3) were unaltered. Visual staining pattern and staining intensities of 
GADs and GATs in the SScortex and thalamic regions (RTN and VP) were similar and unaltered 
between epileptic stargazers and non-epileptic controls. Expression level of all protein targets 
(GADs and GAT-3) in the PV
Cre
/Gi-DREADD animals treated with CNO was also unchanged.  
Upregulation of GAD65 in the SScortex of stargazer was in agreement with the result of another 
study where GABA level was found to be increased in the SScortex of epileptic stargazers (Hassan 
et al., 2018). Stargazers show spontaneous seizures which may have long-term changes in the CTC 
circuit leading to the continuous increased activity of excitatory neurons. To overcome this 
situation, GABA synthesis should be increased at the synaptic sites to regulate such excitatory 
activity. Thus, upregulation of GAD65 might be a part of adaptive response or compensatory 
changes in epileptic stargazers.   
 
In addition, this upregulation of GAD65 [which primarily acts in phasic inhibition (Erlander et al., 
1991)], in epileptic stargazers (Hassan et al., 2018) supports the GAT-1 dysfunction seen in 
GAERS (Cope et al., 2009). Cope and colleagues found that excess extrasynaptic GABAA 





GAERS and stargazers. In relation to human patients, SL6A1 mutation leading to GAT-1 loss of 
function (Mattison et al., 2018) is the most common epileptic phenotype in children (Dikow et al., 
2014; Johannesen et al., 2018). One human study revealed higher GABA levels in the ipsilateral 
thalamus of a child with SWDs (Leal et al., 2016).  
 
It is important to note that, crossbreeding GABAAR δ subunit knockout mice with stargazer mice 
removes the absence seizure phenotype (McCafferty et al., 2018a). Thus, GAT-1 agonists and δ-
containing GABAA receptors may be new targets for the treatment of absence seizures. Studies 
have shown that GAT inhibitors such as tiagabine has anti-convulsant activity against established 
model of epilepsy (Nielsen et al., 1991; Dalby, 2000; White et al., 2005) but aggravates absence 
seizures in human patients and are contraindicated (Perucca et al., 1998; Ettinger et al., 1999; 
Panayiotopoulos, 1999). Expression level of the GAT-3 was unchanged in this study which is 
consistent with reports of normal functional activity in the thalamus of GAERS (Pirttimaki et al., 
2013). A recent study conducted GABA uptake assays and examined the protein expression levels 
of GATs using primary culture of cortical and thalamic astrocytes from GAERS which suggested 
that dysfunction GAT transporters may contribute in absence seizures and astrocytes may be an 
important factor in understanding the pathophysiology of this disorder (Pina et al., 2019).   
Thus, this study alone cannot conclude that increased level of GAD65 in epileptic stargazer is 
either a consequence of seizures or this has specific contribution in seizure generation. Western 
blotting alongside with electrophysiological experiments should be performed during 
developmental time point which can clarify the specific roles of GADs and GATs. 
 
6.3 Clinical Implications 
Absence seizures associated with generalized synchronous 3-4 Hz SWDs are characterized by 
brief, frequent and sudden alteration of awareness during childhood, referred as childhood absence 
epilepsy. This disorder is also associated with cognitive weakness, impaired learning, psychosocial 
problems as well as physical safety. Anti-seizure medications such as ethosuximide, valproic acid, 
lamotrigine etc. are commonly used first-line agents to control the seizures but clinical trials have 
found that freedom from treatment failure of these medications is considerably lower and not 
promising (Glauser et al., 2010; 2013; Cnaan et al., 2017). The remission rate is only 58% (Kim 





clinical trials conducted in absence epileptic patients, which directly affects in evidence-based 
decision-making during treatment. Clinical use of other broad-spectrum anti-seizure medications 
as anti-absence drug is also not encouraging (Nolan et al., 2019). The poor efficacy and serious 
side effects of these first-line prescribed medications may be due to their broad mechanism 
involving reduction of excitation. ‘One for all’ concept of prescribing first-line medications to 
every cases of CAE is also a major reason behind decreased efficacy of these drugs. As 
neurophysiology of the neuronal networks contributing in seizure generation might vary from 
patient to patient, there is always a need of patient-specific treatment approach. This requires a 
deep understanding of cellular and molecular mechanism of normal functioning of brain 
microcircuits and gene targets which might be responsible in the genesis of absence seizures.  
 
The work conducted in this thesis highlighted the functional role of most prominent GABAergic 
interneurons (parvalbumin expressing) of the brain which regulates inhibition within the 
microcircuit involving cortex and thalamus i.e. CTC network. The results from this thesis indicated 
that impaired FFI due to dysfunctional PV+ interneurons within CTC network might be one of the 
potential mechanisms of absence seizure generation and altered behavioral pattern. These findings 
are based on both inhibitory and excitatory approach. Thus, novel therapeutic compounds should 
be employed to target these interneurons in the specific-brain regions for the treatment of some 
cases of childhood absence epilepsy.     
 
6.4 Evaluation of Methods 
6.4.1 DREADD approach  
Techniques like chemogenetics and optogenetics have revolutionized neuroscience by providing 
new tools to selectively manipulate the activity of specific neuronal population. DREADDs 
technique employed in this thesis provides slow but extended modulation of system. Optogenetics 
allow fast neuronal modulation with high temporal resolution. However, for lengthy experiments 
DREADDs are always ahead and effective as thermal properties of light system in optogenetics 
have shown to produce nonspecific effects (Owen et al., 2019).  
 
There are few limitations associated with DREADD (chemogenetics) technology. For example, 





pharmacology of CNO. The mode of neuronal activation is acute and it does not permanently 
silence or activates neurons. In this study, CNO was used as the ‘designer drug’ to silence or 
activate feed-forward inhibitory PV+ interneurons. The use of CNO as the ‘designer drug’ has 
recently been called into question, especially DREADD specific actions of CNO delivered 
intraperitoneally was a subject to criticism (Gomez et al., 2017). Gomez and colleagues showed 
the possibility of off target/sedative effect in animals due to the reverse metabolization of CNO to 
clozapine after systemic injection.  This work included in this thesis was particularly aware of this 
and behavioral experiments were planned to avoid or overcome the possibility of such 
consequences. To minimize such potential off-target effects, non-DREADD WT animals and 
vehicle-treated controls were included in all CNO doses of every behavioral and EEG experiments 
performed. Alternative chemical approach such as the use of olanzapine, compound 21, JHU37152 
and JHU37160 to activate DREADD have recently been proposed but these compounds are not 
yet fully characterized (Thompson et al., 2018; Bonaventura et al., 2019; Jendryka et al., 2019; 
Weston et al., 2019). The use two different ligands to confirm DREADD mediated behavioural 
results is also recently suggested (Goutaudier et al., 2019) which can be implemented in the future 
studies.  
 
6.4.2 Immunofluorescence Confocal Microscopy 
Confocal microscopy was performed to confirm the selective expression of inhibitory (Gi) and 
excitatory (Gq) DREADD receptors in PV+ interneurons and to investigate the layer specific 
expression pattern of GADs and GATs. Confocal microscopy is an excellent technique to examine 
the cellular expression and co-localization of two or more molecules at the same physical position 
in a given biological sample. However, there is always a compromise between magnification, 
resolution and scan time during confocal imaging. The higher the magnification and resolution, 
the more time is required for the scan which frequently causes the photobleaching of the specimen. 
In this study, anti-fade DABCO-glycerol solution was used as mounting medium to minimize the 
photobleaching (Longin et al., 1993; Ono et al., 2001). Slides were foiled and stored in dark to 
preserve fluorescent dyes. Background signal was subtracted from the measurements to accurately 
measure the intensity of signal of interest (Waters, 2009). Confocal imaging, quantitative 
measurements and analysis of the data from the tissue sections of relevant genotypes were 






6.4.3 Surgical manipulation and EEG recording 
In this study, surgical manipulations were performed on animals to implant electrodes, 
prefabricated headmounts and microcannulas for EEG recordings. In the beginning of this study, 
very few animals experienced excessive operative bleeding during surgical procedures. However, 
no major surgical complications in animals were seen during this entire study. Animals were 
injected with drugs for pain control and local anesthesia prior surgical procedures. Surgeries were 
performed in continuous flow of isoflurane gas (inhalation anesthetic) and supplemental heat (by 
using heat pad). Animals were rested at least seven days to allow full recovery from surgical 
manipulation. Animals were monitored and handled every day after their arrival to the animal 
facility and were also acclimatized to testing environment and equipment before every EEG 
recording. 
In this study, EEG signals were recorded using the Pinnacle mouse tethered system (Pinnacle 
Technologies, Austin, TX, USA). Recently, Bluetooth wireless amplifier EEG system is 
introduced which is claimed to produce artifact-free data with simple implant procedure. It seems 
to be more portable and cost-effective (Ref: Pinnacle website). However, battery life of the 
bluetooth device might be an issue for lengthy experimental procedures. In this study, video/EEG 
analysis was performed offline by manually scrolling through EEG traces and absence-like SWDs 
were confirmed electro-clinically i.e. visual inspection of the morphology/characteristics of EEG 
profile and animal behavior in the video. However, software platforms such as MATLAB and 
Python offer various graphic user interfaces like EEGLab, Brainstorm, FieldTrip, PyEEG etc. for 
easy and precise quantification of EEG parameters, power spectral analysis, statistical analysis and 
for the removal of artifacts (Maheshwari et al., 2020). Multiple screws for the acquisition of 
electrocorticogram traces along with local field potential from the targeted sites (SScortex and 
RTN thalamus) can be very useful to correlate the EEG activity with site specific firing of PV+ 
neurons (Clemente-Perez et al., 2017). These approaches can be utilized in future experiments. 
6.4.4 Behavioral tests 
In this study, two motor function tests were employed to investigate the impact of silencing (global 
and focal) feed-forward inhibitory PV+ interneurons on animal behavior. Open-field and rotarod 
tests were included to determine behavioral parameters such as locomotion and motor co-





tests have yielded significant conclusive findings. Additionally, other behavioral tests can be 
implemented in future studies to establish behavioral-EEG phenotyping and to quantify various 
other behavioral parameters.  
 
6.4.5 Antibodies 
The antibodies used in this study are commercially available, well characterized and widely used 
in many published studies. Dilution level of antibodies for use in the different experiments were 
optimized based on manufacturers protocol and guidelines. Appropriate loading controls (b-actin 
or a-tubulin) were used in western blotting experiments. Single band of loading control and protein 
target was confirmed by comparing them with reference protein ladder corresponding to the 
molecular weights specified by manufacturer. The incubation time in primary and secondary 
antibody solution for both western blotting and confocal IHC techniques was optimized. 
 
6.4.6 Western blotting 
Western blotting is extensively used analytical technique to separate and identify proteins. This 
technique is used to measure the amount of protein expressed in a sampled tissue. In this study, 
western blotting was employed to compare the changes in expression of protein targets (GADs 
and GATs) between epileptic stargazers and non-epileptic controls, and CNO-treated DREADD 
animals, CNO-treated non-DREADD animals and vehicle-treated DREADD animals. Sample 
preparation is a major step in western blotting. To avoid protease degradation of proteins, collected 
brain tissue from the animals was quickly snap-frozen and lysed. Buffers used during sample 
preparation and electrophoresis were always freshly prepared. 
 
There are different ways of detecting protein of interest from the blot, namely colorimetric, 
chemiluminescent and infrared methods. In this study, infrared fluorescent detection method was 
employed. In this method, secondary antibody is conjugated to NIR (near-infrared) fluorescent 
dye. Blots were documented in NIR imaging system i.e. Odyssey Imaging system. This is a 
quantitative two-color detection method which has several advantages over conventional detection 
methods. This imaging system provides low background autofluorescence and high sensitivity. 
Fluorescent signal is directly proportional to the target protein content and unaffected by exposure 





IR dye having different emission spectra. Normalization against loading control is also very easy 
and more accurate. In this study, inspite of using antibodies from two different suppliers and even 
after using highest recommended concentration, GAT-1 was not detected in the same tissue 
samples that were used to detect other protein targets. One of the reasons might be the miss-folding 
of proteins which can obstruct the binding of the epitope to the recognition site of antibody.  
 
It is true that western blotting is used as a first pass test. The expectation is that antibodies that 
stain a single band corresponding the mass of the intended target are more likely to be specific in 
IHC analysis. The expression level of protein targets (GADs and GATs) (via WB) and their 
localization profile (via IHC) is not yet reported in stargazers mouse model of absence epilepsy. 
This is the first study to do so. Thus, in this study, WB and IHC were performed at the same time.  
 In this study, GAD65 expression was significantly increased in stargazers compared to non-
epileptic control in western blotting but this was not replicated in IHC and GAT-1 labelling was 
observed in IHC but was unable to be detected in western blotting. Epitope, a part of antigen which 
is recognized by the primary antibody may not be identically available in WB and IHC 
assays. Tissue samples are treated differently in WB and IHC and this influences the epitopes 
exposed on the target protein which might have profound consequences for the ability of a given 
antibody to bind specifically to its target.  
 
6.4.7 Uses and limitations of absence seizure rodent models  
Pharmacological models of absence epilepsy deal with the mechanisms of ictogenesis. In addition 
to absence seizures, all pharmacological animal models present dose, age, time dependent tonic-
clonic and myoclonic generalized seizures and sedation and anesthesia (with GABAA receptor 
antagonists and GABA agonists) (Kostopoulos, 2017). To study epileptogenesis, the process by 
which normal brain develops epilepsy, genetic animal models are the best. However, these are also 
associated with limitations. In addition to SWDs, genetic models such as stargazers display ataxia 
and movement disorders, which are not features of CAE (Panayiotopoulos, 1999). In this respect, 
rat models (GAERS and WAG/Rij), have a certain advantage, only SWDs are observed with 
behavioural arrest and no other behavioural abnormalities (Jarre et al., 2017). One drawback of 
mouse model is that they offer monogenic mutations, whereas CAE in human patients is 





absence epilepsy are known to better simulate CAE. All animal models display 5-9 Hz SWDs 
instead of the 2.5-4 Hz frequency observed in patients with CAE. The most important limitation 
of genetic rodent models is the persistence of SWDs in adulthood. On the contrary, absence 
seizures progressively disappears at adulthood in human patients (Jarre et al., 2017). However, 
rodent models of absence epilepsy have greatly contributed on the genetics of absence epilepsy 
and strongly improved our understanding of the pathophysiology of this disease.  
 
6.5 Future experimental directions 
Chronic activation of PV cells in absence seizure models and functional tests in stargazers 
In this study, acute activation of PV+ interneurons during chemically induced seizures was found 
to have anti-epileptic effect in non-epileptic mice. Thus, the next key challenge would be 
chronically activating PV+ neurons in rodent models of absence epilepsy to see if that can ‘reset’ 
epileptogenic circuits. GABA current in stargazer cortical and thalamic neurons could be measured 
using the optogenetics approach. Similarly, AMPA currents in PV+ interneurons could be 
measured to confirm whether reduction in AMPA receptor expression result in decreased AMPA 
excitatory post synaptic potential. Experiments can be conducted to restore stargazin mutation in 
stargazer CTC network using AAV vectors in order to establish the impact of loss of AMPAR 
expression in PV+ interneurons to the stargazer epileptic phenotype. 
 
Identification and characterization of specific subtypes of PV cell responsible for the effect 
In this study, PV+ interneurons as a group were manipulated using Cre-loxP recombination 
approach. While effective, it could not distinguish the differences among the subtypes of PV+ 
interneurons. Thus, this study was unable to specify the subtypes of PV+ interneurons responsible 
for the effects. In fact, until now, techniques which specifically target subtypes of PV+ 
interneurons are not established. However, given that basket cells are the most common type of 
PV+ interneurons within the CTC network, it is likely that outcomes from this study can be mostly 
attributed to basket cells. With the advancements in genetic manipulations, it can be predicted that 








Local field potential (LFP) measurements alongside electrocorticography 
This current study recorded EEG from cranial surface of animals. One unfortunate aspect of EEG 
is that local neuronal activity has to pass through brain, cerebrospinal fluid, meninges and skull 
before reaching to the electrodes. EEG signals also often get mixed up with disturbances from the 
other body activities in the form of artefacts. Seizure activity seen in the scalp EEG is from the 
coordination of firing of neural population and/or synaptic responses. Thus, EEG is not sufficient 
to measure specific changes in the local field activity arising from the shift in action potential of 
PV+ interneurons of either the SScortex or the RTN thalamus. To isolate the specific roles of PV+ 
interneurons of specific brain regions on absence seizure genesis, maintenance or generalization, 
LFP measurement is imperative. In relation to this current study, LFP measurements will enable 
us to determine the latency of activation (silencing or excitation) of DREADD expressing PV+ 
interneurons after regional CNO injection. This will also allow us to correlate simultaneous LFP 
changes at the targeted site with changes in SWDs in EEG. This is important because firing of 
cortical, thalamocortical and RTN neurons in epileptic animals (GAERS) was found to be 
decreased 2-3 seconds before SWDs were detected in EEG (McCafferty et al. 2018b). LFP 
measurements will also allow us to investigate the impact of ipsilateral manipulation to the 
contralateral CTC circuit. Bilateral silencing and activation of these interneurons are other options 
for future studies. Ex vivo whole cell patch-clamp experiments in brain slices can also be included 
in future studies. Focal inhibition of PV+ interneurons of RTN would be expected to not only 
reduce FFI to the thalamocortical relay neurons but also intra RTN inhibition. Also, this could 
have an effect on the other RTN and its microcircuitry. Thus, the effect of RTN mediated FFI 
and intra-RTN inhibition could be part of a potential future study using LFP measurements. This 
is particularly important because different studies have shown conflicting functional consequences 
of altered inhibition within RTN. 
 
Possibilities of multiplexing with chemo- and/or opto-genetics 
Optogenetic and chemogenetics have their own pros and cons. Optogenetics is ahead of 
chemogenetics in real-time neuromodulation and increased temporal resolution. However, it 
should be noted that utilizing these two approaches have produced similar outcomes (Zhu et al., 
2016). In relation to this current study, use of both approaches in a same animal to silence and/or 





many critical questions. This might be possible because optogenetics requires light to regulate the 
excitability and chemogenetics requires a designer drug. Thus, in vivo multiplexing using these 
two different approaches may be a part of future studies. Multiplexing within chemogenetics is 
also possible as Vardy and colleagues have successfully combined inhibitory KORD and 
excitatory hM3Dq (DREADD) in same animal to study behaviour (Vardy et al., 2015). 
 
Use of alternative DREADD agonists 
Recently, the use of designer drug CNO to activate DREADDs has become controversial (Gomez 
et al., 2017) and many reports published since then suggested alternative approaches, the need of 
optimization of CNO dose, and the use of standard controls in DREADD based experiments. 
Alternative DREADD activators such as compound 21, olanzapine, perlapine etc. can be used for 
future in vivo studies. Thus, the strength of genetics by paying attention to the shortcomings of 
pharmacology is required to maximize the potential of the chemogenetic approach.  
 
Study of GADs and GATs over multiple developmental time points 
This study concluded that the upregulation of GAD65 in the SScortex of adult epileptic stargazers 
might be a compensatory or contributory mechanism for reduced FFI. However, future 
experiments should cover multiple developmental time points such as before after seizure onset. 
This is particularly important because formation and maturation of CTC network, expression of 
stargazin and AMPA receptors, and other phenotypic changes in stargazers are developmentally 
regulated i.e., at PN7–10: thalamocortical and corticothalamic connections are complete, feed-
forward inhibition starts, at PN13-15: the first observable phenotypic features (ataxic gait) appear, 
at PN17–18: absence seizures are observed. Moreover, studies have shown that developing brain 
are more vulnerable to seizures (Ben-Ari, 2006; Jacobs et al., 2009). Seizure onset in stargazer 
mutant mouse is around PN17-18 (Qiao and Noebels, 1993) and childhood absence epilepsy also 
develops early on in childhood (Tenney and Glauser, 2013). Thus, study of the developmental 
changes of GADs and GATs in animal models of absence epilepsy could be a part of future studies. 
Additionally, optogenetic, chemogenetic or pharmacological manipulations should be performed 
to target GAD65 and to explore its role in absence seizure generation. For example: Stargazers 





hM3Dq-flox animals to manipulate (silence or activate) GAD expressing neurons within CTC 
network. 
 
PV/DREADD approach feasible as a future treatment option?  
Findings of the scientific observations always should direct towards their possibility of translation 
into clinical research i.e. the bench to bedside process. Many bench-side successes often get lost 
in translation. Several research groups have begun exploring the less invasive DREADD based 
methods. Some of them succeeded in extending this approach from rodents to non-human primates 
(Grayson et al., 2016; Upright et al., 2018; Bonaventura et al., 2019; Deffains et al., 2020). This 
should be considered as a milestone as it opens the doors towards human studies. In relation to 
PV/DREADD approach for anti-epileptic therapy, the safety and efficacy viral vector should be 
first considered before any clinical trials. However, interneuron-specific promoter small enough 
for virus (AAV)-based gene therapy is yet to be identified.  Altogether, even if DREADD approach 
fails to deliver on the future therapeutic use, undoubtedly this technique will continue to help 
decipher the underlying mechanisms of seizure genesis helping us to understand the etiology of 
the disease and to develop more effective drugs.   
 
6.6 Conclusion 
Childhood absence epilepsy is most common form of pediatric epilepsy which is characterized by 
SWDs associated with impaired awareness. Imbalanced excitation/inhibition in the CTC network 
is regarded as the cause but precise mechanisms are still unclear and likely to be multifactorial. 
Pharmacological treatment methods are possible but are ineffective for one third of patients. 
Hence, patient specific treatment approaches are imperative to improve the quality of life of 
patients. However, designing novel and effective epilepsy treatments is always a challenge. This 
requires a deep understanding and identification of different cellular and molecular mechanisms 
underlying absence seizures. Analysis of patient-specific genetic mutations is also crucial to 
develop personalized treatments.  
The work included in this thesis shed new light on the impact of functionally manipulating the 
most common GABAergic interneurons within the CTC network on absence seizure generation. 
This study also examined the expression level of enzyme synthesizing GABA (GADs) and proteins 





shown that functional disruption of FFI within the CTC microcircuit is one of the causative 
mechanisms for the generation absence seizures. Additionally, upregulation of one of the isoforms 
of GABA synthesizing enzyme i.e. GAD65 might be a compensatory or contributory mechanism 
for reduced FFI. These data could contribute towards an understanding of the underlying cellular 
and molecular mechanisms causing pathological CTC oscillations that could be targeted in the 
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Preparation of reagents and solutions 
0.1M Sorensen’s phosphate buffer (PB) 
• Solution A: 28.39 gm of Na2HPO4 in 1L MQ H2O 
• Solution B: 27.59 gm NaH2PO4 x H2O in 1L MQ H2O 
• 4 parts of solution A and 1 part of solution B was mixed.  
 
10x PBS 
• 5.675 gm Na2HPO4 
• 1.361 gm KH2PO4 
• 43.8 gm NaCl 
• 0.5 L MQ H2O 
 
8% PFA (always made fresh on the day of perfusion) 
• 20 gm PFA mixed with 200 ml MQ H2O 
• Solution was heated up to 60 °C with continuous stirring  
• Few drops of 0.1 M NaOH was added 
• Solution was filtered  
• Volume was adjusted to 250 ml with MQ H2O 
 
4% PFA 
• 250 ml of 8% PFA mixed with 250 ml of 0.2 M PB 
 
5% Heparin 
• 5 ml of Heparin mixed with 10 ml of 10X PBS and 85 ml of MQ H2O 
 
Sucrose solution (cryopraotectant) 
• 30% sucrose: 30 gm sucrose in 100 ml PBS 
• 20% sucrose: 20 ml of 30% sucrose solution mixed with 10 ml PBS 





IHC Blocking buffer 
• 4% Normal Goat Serum (NGS) 
• 0.1% Bovine Serum Albumin (BSA) 
• 0.1% Triton X-100 in PBS 
 
IHC Primary antibody solution  
• 0.1% BSA 
• 0.3% Triton X-100 in PBS 
 
IHC Secondary antibody solution 
• 0.3% Triton X-100 in PBS 
•  
DABCO-glycerol 
• 15 ml Glycerol-gelatin 
• 37.5 mg DABCO 
 
WB Homogenization buffer  
• 0.5 M Tris (pH6.8) 
• 100 mM EDTA 
• 3% SDS, pH 6.8 
 
10x Tris-Glycine buffer 
• 144 gm Glycine 
• 30.3 gm Tris-base 
• 1 L MQ H2O 
 
WB Running buffer 
• 100 ml 10x Tris-Glycine buffer 
• 10 ml 10% SDS 





WB Transfer buffer 
• 100 ml 10x Tris-Glycine buffer 
• 100 ml methanol 
• 2.5 ml 10% SDS 
• 1 L MQ H2O 
 
5x Tris buffered saline (TBS) 
• 30 gm Tris 
• 43.5 gm NaCl 
• 1 L MQ H2O 
 
TBS-Tween 
• 200 ml 5x TBS 
• 1 ml Tween-20 
• 1 L MQ H2O 
 
DNA lysis buffer (pH 8.5) 
• 12.11 gm Tris-base 
• 1.80 gm EDTA 
• gm SDS 
• 11.68 gm NaCl 
• 1 L MQ H2O 
 
TE buffer (pH 8.0) 
• 1.211 gm Tris base 
• 0.372 gm EDTA 
• 1 L MQ H2O 
10x TBE buffer 
• 108 gm Tris base, 55 gm Boric acid 





Supplementary Fig. 1 Image showing the localization and diffusion of methylene blue dye in PVCre/Gi-
DREADD animal. Representative coronal slices of mouse brain showing histological localization of methylene blue 
dye injected via a cannula located in either (A) SS cortex or (B) thalamus, verifying CNO site of diffusion within 



















































Supplementary Fig. 2 (A) CNO acts presynaptically facilitating GABA release and PTZ acts on GABAA receptors 
of postsynaptic neurons to induce seizures. (B) CNO was injected 10 min before PTZ injection on day 2. This was 
based on the results from chapter 3 where CNO activated PV+ neurons within 15 min and in chapter 4 (day 1) PTZ 
















































Supplementary Fig. 3 Image showing the localization and diffusion of methylene blue dye in PVCre/Gq-
DREADD animal. Representative coronal slices of mouse brain showing histological localization of methylene blue 
dye injected via a cannula located in either (A) SScortex and (B) thalamus, verifying CNO site of diffusion within 






Supplementary Fig. 4 Non-cropped full western blots for antibodies used in this study.  








Supplementary Fig. 5 Total time spent in the peripheral zone (PZ) of open-field arena by animals after focal 
CNO/vehicle injection. Graphs represent animals of the SScortex group and the RTN thalamus group. Comparisons 
between treatment groups were performed using Dunnett's post hoc multiple comparison test keeping ‘before 






Supplementary Fig. 6 Individual data points corresponding to the figure 3.9. 






















































Supplementary Fig. 6 Individual data points corresponding to the figure 3.10. 
(Comparison of parameters of open-field test in animals after injection of different i.p. doses of CNO.) 
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A B S T R A C T
Feed-forward inhibition (FFI) is an essential mechanism within the brain, to regulate neuronal firing and prevent
runaway excitation. In the cortico-thalamocortical (CTC) network, fast spiking parvalbumin-expressing (PV+)
inhibitory interneurons regulate the firing of pyramidal cells in the cortex and relay neurons in the thalamus. PV
+ interneuron dysfunction has been implicated in several neurological disorders, including epilepsy. Previously,
we demonstrated that loss of excitatory AMPA-receptors, specifically at synapses on PV+ interneurons in CTC
feedforward microcircuits, occurs in the stargazer mouse model of absence epilepsy. These mice present with
absence seizures characterized by spike and wave discharges (SWDs) on electroencephalogram (EEG) and
concomitant behavioural arrest, similar to childhood absence epilepsy. The aim of the current study was to
investigate the impact of loss of FFI within the CTC on absence seizure generation and behaviour using new
Designer Receptor Exclusively Activated by Designer Drug (DREADD) technology. We crossed PV-Cre mice with
Cre-dependent hM4Di DREADD strains of mice, which allowed Cre-recombinase-mediated restricted expression
of inhibitory Gi-DREADDs in PV+ interneurons. We then tested the impact of global and focal (within the CTC
network) silencing of PV+ interneurons. CNO mediated silencing of all PV+ interneurons by intraperitoneal
injection caused the impairment of motor control, decreased locomotion and increased anxiety in a dose-de-
pendent manner. Such silencing generated pathological oscillations similar to absence-like seizures. Focal si-
lencing of PV+ interneurons within cortical or thalamic feedforward microcircuits, induced SWD-like oscilla-
tions and associated behavioural arrest. Epileptiform activity on EEG appeared significantly sooner after focal
injection compared to peripheral injection of CNO. However, the mean duration of each oscillatory burst and
spike frequency was similar, irrespective of mode of CNO delivery. No significant changes were observed in
vehicle-treated or non-DREADD wild-type control animals. These data suggest that dysfunctional feed-forward
inhibition in CTC microcircuits may be an important target for future therapy strategies for some patients with
absence seizures. Additionally, silencing of PV+ interneurons in other brain regions may contribute to anxiety
related neurological and psychiatric disorders.
1. Introduction
Parvalbumin-expressing (PV+) inhibitory interneurons are the
most common type of GABAergic neurons within the brain (Kelsom and
Lu, 2013; Hu et al., 2014; Pelkey et al., 2017). They mediate fast feed-
forward inhibition (FFI) and prevent runaway excitation (Cammarota
et al., 2013; Paz and Huguenard, 2015; Jiang et al., 2016) in neural
networks. They also contribute to feed-back inhibition and are critically
involved in the generation of physiological oscillations within brain
networks (Sohal et al., 2009; Armstrong and Soltesz, 2012).
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Additionally, they play roles in brain plasticity, cognition and learning
(Milenkovic et al., 2013). PV+ interneuron dysfunction has been im-
plicated in several neurological and psychiatric disorders, including
epilepsy, autism, depression, schizophrenia and Alzheimer's disease
(Lewis et al., 2012; Marín, 2012; Holland et al., 2014; Nguyen et al.,
2014; Dodell-Feder et al., 2015; Evans et al., 2015).
In the cortico-thalamocortical (CTC) network PV+ interneurons are
strategically positioned to provide strong feed-forward inhibition to the
principal excitatory cortical neurons (pyramidal cells) and also to ex-
citatory relay (thalamocortical TC) neurons in the ventroposterior (VP)
thalamus. Sensory information is relayed through the thalamus to the
somatosensory (SS) cortex via thalamocortical (TC) projections from
the VP relay neurons to cortical layer IV; the cortex is reciprocally
connected back to the thalamus via corticothalamic (CT) projections
from pyramidal cells to the thalamic VP neurons. Surrounding the VP
thalamus is the reticular thalamic nucleus (RTN) comprising a shell of
PV+ inhibitory interneurons. The RTN inhibitory interneurons receive
strong excitation via collaterals from CT projections and provide FFI to
the VP relay neurons. Oscillations within the CTC network are directly
related to the stronger synaptic excitation in the CT-RTN pathway than
the CT-VP route, favouring activation of the RTN PV+ inhibitory in-
terneurons (Warren et al., 1994; Paz et al., 2011). CTC network oscil-
lations are initiated when FFI is followed by T-current dependent post-
inhibitory rebound bursts of action potentials in VP relay neurons. The
VP relay neurons in turn re-excite PV+ inhibitory interneurons in RTN
via TC projection collaterals thereby activating feedback inhibition and
oscillatory neural activity within the CTC network (Williams and Stuart,
2000; Beenhakker and Huguenard, 2009; Avoli, 2012). CTC oscilla-
tions, thus involve the finely tuned synchronous firing of thalamic and
cortical neurons at specific frequencies. Disruption in the balance be-
tween excitation and inhibition within these CTC microcircuits can
swing the network into hyperexcitability and hypersynchronous, pa-
thological oscillations (McCormick and Diego, 2001; Crunelli and
Nathalie, 2002), which are manifest as absence seizures and spike-wave
discharges (SWDs) on electroencephalogram (EEG) (Panayiotopoulos,
2001).
We previously reported that absence seizures in the stargazer mouse
model of absence epilepsy are associated with a loss of glutamatergic α-
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors
(AMPA-type receptors), specifically at excitatory synapses in PV+ in-
terneurons in the RTN thalamus and SS cortex (Barad et al., 2012;
Adotevi and Leitch, 2016, 2017, 2019) due to a deficit in the trans-
membrane AMPA receptor regulatory protein (TARP gamma-2) also
called stargazin. Loss of excitatory drive to PV+ inhibitory inter-
neurons would potentially lead to impaired FFI and disinhibition within
these CTC microcircuits. The PV+ interneurons in the RTN thalamus
and SS cortex express predominantly GluA4-AMPA receptors and
knockout of this type of AMPA receptor subunit in the Gria4 −/− mouse
also results in absence seizures (Paz et al., 2011). Further evidence that
activation of PV+ interneurons and FFI are important in seizure pre-
vention, comes from in vivo optogenetic activation of these inter-
neurons, which has been shown to interrupt spontaneous ongoing sei-
zures (e.g. in temporal lobe epilepsy Krook-Magnuson et al., 2013; and
stroke-induced thalamocortical epilepsy Paz et al., 2013). However,
other in vitro studies on brain slices suggest that optogenetic activation
of GABAergic interneurons can enhance epileptiform activity (Yekhlef
et al., 2014; Shiri et al., 2015). In the Genetic Absence Epilepsy Rat
from Strasbourg (GAERS) enhancement of tonic inhibition in the VP
thalamus is associated with absence seizures (Cope et al., 2009; Crunelli
et al., 2012). So, while there is evidence that activation of PV+ ex-
pressing interneurons and FFI prevents seizure spread in both experi-
mental models (Trevelyan et al., 2007; Cammarota et al., 2013) and
patients (Schevon et al., 2012) there is also conflicting evidence from in
vitro studies that increased GABAergic inhibition may, under certain
conditions and dependent upon the brain region tested, initiate seizures
(Sessolo et al., 2015).
To investigate whether loss of excitation to PV+ interneurons and
FFI within the CTC network can lead to the generation of pathological
SWDs and absence seizures in vivo, we used Designer Receptors
Exclusively Activated by Designer Drugs (DREADDs) technology to se-
lectively silence PV+ interneurons in the cortex and thalamus.
DREADDs are mutationally modified muscarinic receptors (Armbruster
et al., 2007; Rogan and Roth, 2011). Based on the G-protein coupled
receptor (GPCR) signalling cascade modified, DREADDs can be of var-
ious types (Armbruster et al., 2007), However, Gi-DREADD (hM4Di for
neuronal silencing) and Gq-DREADD (hM3Dq for neuronal firing) are
the most common available DREADDs. These engineered GPCRs are
only activated by the designer drug clozapine-N-Oxide (CNO).
DREADDs can be expressed in specific cell types using viral delivery
methods (Agulhon et al., 2013; Fortress et al., 2015; Pina et al., 2015;
Falkner et al., 2016; Lopez et al., 2016; Fernandez et al., 2017) or
double-transgenic mice approaches (Sciolino et al., 2016; Zhu et al.,
2016).
To date, there have been only a few studies using DREADD tech-
nology to modulate PV+ interneurons; these have used PV-Cre mice
injected with DREADD-based recombinant lentiviral vector (LV) or
adeno-associated viral (AAV) vector for region and cell specific
DREADD receptor expression (Kaplan et al., 2016; Zou et al., 2016;
Drexel et al., 2017; Xia et al., 2017). In our study, we use recently
developed Cre-dependent DREADD mice (Zhu et al., 2016) crossed with
PV-Cre mice to express Gi-DREADDs in PV+ interneurons in the brain.
We report the physiological and behavioural impact of silencing these
interneurons both globally and focally in the CTC network, in terms of
seizure generation and motor function using simultaneous EEG/video
recording and behavioural tests.
2. Materials & methods
2.1. Animals and breeding paradigm
Experiments were performed on adult male and female transgenic
mice expressing inhibitory DREADD receptors in PV+ interneurons.
PV-Cre mice and Cre-recombinase conditional DREADD lines (Zhu
et al., 2016) were obtained from Jackson Laboratories, USA. To avoid
unwanted germline recombination, only female PV-Cre were crossed
with male hM4Di-floxed mice (JAX stock #008069). Homozygous fe-
male PV-Cre mice were crossed with homozygous hM4Di-floxed males
to generate litters of PV-Cre/Gi-DREADD mice, or crossed with het-
erozygous hM4Di-floxed males to generate litters with PV-Cre/Gi-
DREADD and non-DREADD expressing wild-type (WT) control litter-
mates, as illustrated in Fig. 1A. Mating these strains (PV-Cre and
hM4Di-floxed) removes the loxP site-flanked STOP signal only in the
cell type specified by the Cre driver used. A hemagglutinin (HA)-tag is
present alongside the DREADD sequence in the targeting vector used to
generate the DREADD transgenic mice. Antibodies directed against the
HA-tag can be used to detect the location of the DREADD receptor in
the cell after Cre-mediated removal of the STOP cassette under the
strong control of the CAG promoter (Zhu et al., 2016). Mice were bred
and housed at the University of Otago Animal Facility. All mice were
housed at controlled room temperature (22–24 °C). Mice had ad libitum
access to food and water. All animal procedures were approved by the
University of Otago Animal Welfare Office and Ethics Committee (D94/
16).
2.2. Genotyping
Genotyping was performed on ear-punches from offspring of PV-
Cre/Gi-DREADD crossed mice. Briefly, ear-punches were digested in
lysis buffer and proteinase K at 55 °C overnight. Next day, after several
centrifugation procedures, DNA was obtained and processed for PCR.
Genotyping was done to confirm PV-Cre and hM4Di expression sepa-
rately using the following Cre, hM4Di mutant and wild-type primers
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(Integrated DNA Technologies, USA): CCT GGA AAA TGC TTC TGT
CCG Cre-forward; CAG GGT GTT ATA AGC AAT CCC reverse for Cre
allele; CGA AGT TAT TAG GTC CCT CGA C hM4Di-flox forward; TCA
TAG CGA TTG TGG GAT GA reverse for hM4Di-flox allele; AAG GGG
CTG CAG TGG AGT A wild-type forward; CCG AAA ATC TGT GGG AAG
TC reverse for wild-type allele. Agarose gel (2%) electrophoresis was
performed and the PCR product allowed to run at 70–80 V for ~2 h.
Finally, the gel was placed on a UV light source to view and photograph
bands. Fig. 1B is a representative image for the PV-Cre knockin and
hM4Di-flox for three separate mice. Bands at 350 bp and 300 bp indicate
the PV-Cre knockin. For hM4Di-flox, bands at 300 bp and 204 bp in-
dicate the heterozygous hM4Di-flox, a band at 204 bp represents the
homozygous hM4Di-flox, and a band at 300 bp confirmed wild-type
mice.
2.3. Immunofluorescence confocal microscopy and image acquisition
Pentobarbital (60mg/kg) was injected intraperitoneally to deeply
anesthetize the mice. Transcardial perfusion was performed with 5%
heparin in phosphate buffered saline (PBS) and 4% paraformaldehyde
(PFA) in 0.1M Sorensen's phosphate buffer. Brains were extracted and
post-fixed in 4% PFA overnight at 4 °C. Post- fixation was followed by
cryoprotection in increasing concentrations of sucrose in PBS (10%,
20%, and 30%). The cerebellum was dissected from the rest of the brain
and sliced into 30-μm sagittal sections on a cryostat (Leica CM1950,
Wetzlar, Germany) and collected in PBS, the rest of the brain was
sectioned into 30-μm coronal sections. Slices were then transferred into
blocking buffer (4% Normal Goat Serum (NGS), 0.1% Bovine Serum
Albumin (BSA), 0.1% Triton X-100) for 2 h at room temperature. All
sections were incubated in a cocktail of primary antibodies, rabbit anti-
HA-tag, Cell Signalling (1:500) and mouse anti-parvalbumin (PV),
Swant Inc. (1:2000), for 48 h at 4 °C. After incubation, tissue sections
were washed in PBS for 45min (15min, 3 times each). Sections were
then labelled with secondary antibodies, rabbit IgG, Alexa Fluor 488,
Life Tech/A-11008 (1:1000); mouse IgG, Alexa Fluor 568, Life Tech/A-
11031 (1:1000) for 12 h at 4 °C followed by PBS washing. Sections were
then mounted on polysine-coated glass slides and cover-slipped with
mounting medium (1,4 diazabicyclo (2.2.2) octane DABCO-glycerol).
Images were acquired using Nikon A1+ Inverted Confocal Laser
Scanning Microscope with channel configuration; HA-tag (green
channel, 488 nm laser excitation) and PV (red channel, 568 nm laser
excitation). All immunolabelled cells in the SS cortex and cerebellum
sections were counted at 10× in confocal images whereas those in RTN
thalamus were counted using 40× confocal images. Cell counting was
performed with ImageJ software (NIH, USA).
2.4. Surgical implantation of prefabricated headmounts and micro cannulas
Twelve-week old animals were single caged and handled for 2 days
before surgery. Prefabricated mouse headmounts (Pinnacle
Technologies, Austin, TX, USA) were surgically implanted at least one
week before scheduled EEG test recording. Briefly, animals were an-
esthetized with a continuous flow of isoflurane and subcutaneously
injected with 5mg/kg of Carprofen and 2mg/kg of Marcaine. Once the
animal was fully anesthetized, the head was fixed with a stereotaxic
frame (David Kopf Instruments, Tujunga, CA, USA) and the scalp
shaved to expose the skin. A sagittal incision was made to expose the
skull. Two pairs of holes were carefully drilled in the skull, each pair
being 1.5 mm lateral on either side of the longitudinal fissure. The first
pair were located 1mm anterior to bregma and other two 3.5mm
anterior to bregma. Four stainless screws with lead wires attached
(Pinnacle Technologies, Austin, TX, USA) were inserted through these
burr holes. Screws were soldered to their respective channels of head-
mount. The headmount with soldered regions was further secured using
dental acrylic cement (Vertex Dental, Netherlands); the loose skin
around the incision site was then sutured.
For focal CNO injections, one extra burr hole was drilled into the
skull, based on the stereotaxic coordinates for either the SS cortex or
thalamus (Mouse Brain Atlas, Paxinos and Franklin, 3rd Edition) for
insertion of a guide cannula (the location of the cannula tip was vali-
dated by histology post-mortem in all mice, see Supplementary Fig. 1).
A dummy cannula was inserted inside the guide cannula to prevent
blood or any other fluid clogging it. Dental acrylic cement was applied
around the base of cannula to secure its position. Mice were allowed to
recover for at least one week and monitored carefully for 24 h im-
mediately after surgery, then twice daily. Carprofen (5mg/kg, SC), was
administered if any signs of discomfort were seen. After full recovery,
EEG recordings and behavioural testing were performed according to
the protocols outlined below. The experimenter was blind to the gen-
otype.
2.5. Drug preparation and delivery
CNO was freshly prepared at the required dose concentration, prior
to each experiment. Briefly, 1.5mg of CNO (Advanced Molecular
Technologies, Australia) was dissolved in 75 μl of dimethyl sulfoxide
(DMSO). The volume was then adjusted to 15ml by addition of 0.9%
sterile saline to prepare CNO of 0.1 mg/ml concentration (for 1mg/kg
dosage group). For 5 and 10mg/kg dosage groups, CNO of 0.5mg/ml
and 1mg/ml was prepared. Vehicle was prepared by mixing DMSO
with 0.9% sterile saline. CNO or vehicle were injected intraperitoneally
on the basis of the calculated dose for the body weight of the animal.
For focal injection, 0.3 μl of CNO was infused into the specific brain
region at a rate of 0.1 μl /min. It was delivered via a Hamilton micro-
injection syringe attached to polythene tubing (Microtube Extrusions,
Australia) and a 33-gauge internal cannula (Plastics One Inc., VA, USA)
inserted into the previously implanted guide cannula. At termination of
CNO focal experiments, methylene blue dye was injected at the same
volume and rate as CNO into the focal region of the brain under in-
vestigation (either SS cortex and RTN thalamus) and histology per-
formed to verify correct cannula tip localization and estimate drug
diffusion from the injection site (see Supplementary Fig. 1).
Fig. 1. (A) Schematic showing breeding to generate PV-Cre/Gi-DREADD off-
spring and WT (non-DREADD) control mice by crossing a female homozygous
PV-Cre mouse with either a homozygous or heterozygous Gi-DREADD male
mouse. (B) Representative gel electrophoresis blot showing the homozygous
(Homo) PV-Cre knockin (350 bp and 300 bp) and the hM4Di-flox [heterozygous
(Het) 300 bp and 204 bp; homozygous (Homo) 204 bp; wild-type (WT) 300 bp]
for three mice to verify PV-Cre knockin and hM4Di-flox. Genotyping was per-
formed separately for PV-Cre knockin and hM4Di-flox in the same mouse.
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The impact of the absence seizure specific anti-epileptic drug
ethosuximide (ETX) (Sigma-Aldrich, USA) was tested at 200mg/kg
body weight. ETX was first dissolved in 500 μl DMSO; the volume was
then adjusted to 10ml by addition of 0.9% sterile saline to prepare ETX
of 20mg/ml concentration. ETX was injected intraperitoneally
(200mg/kg) on the basis of calculated dose for the body weight of the
animal.
2.6. Behavioural tests
For behavioural testing of motor function, all animals were first pre-
trained on a moving rotarod for two consecutive days before the test
day, adopting the same protocol as the test regime, to accustom them to
the testing instrument and environment. On the test day, animals were
acclimatized to the testing room for 1 h prior to CNO injection and
testing in an opaque open-field area (40×40×20cm). Mice were al-
lowed to move freely in the open-field for 10min, and their movements
tracked with an overhead video camera linked to Top Scan software
(Clever Sys Inc., USA). Open-field testing was followed by a interval of
3min before three rotarod trials of 5min each with 2min gaps between
successive trials. Rotarod testing was performed on a moving rotarod
4–20 RPM (Rotamex 5.0, Columbus Instruments, USA). Latency of fall
was recorded for each trial.
The same protocol was followed for behavioural testing before and
after CNO injection at drug doses ranging from 1 to 10mg/kg and also
before and after vehicle treatment. CNO was injected intraperitoneally
(IP) at doses of 1mg/kg (DREADD animals: n=19, non-DREADD
controls: n=9), 5mg/kg (DREADD animals: n=18, non-DREADD
controls: n=8), 10mg/kg (DREADD animals: n=18, non-DREADD
controls: n=9), or vehicle (DREADD animals: n=15, non-DREADD
controls: n=8). CNO was injected focally at 1, 2.5, 5, 10mg/kg into
either the SS cortex [(1mg/kg DREADD animals: n=5, non-DREADD
controls: n=4); (2.5 mg/kg DREADD animals: n=6, non-DREADD
controls: n=7); (5 mg/kg DREADD animals: n= 7, non-DREADD
controls: n= 6); (10mg/kg DREADD animals: n=9, non-DREADD
controls: n=4); (vehicle-treated DREADD animals: n=6, non-
DREADD controls: n=4)] or RTN thalamus [(1 mg/kg DREADD ani-
mals: n=7, non-DREADD controls: n=4); (2.5 mg/kg DREADD ani-
mals: n=7, non-DREADD controls: n= 6); (5 mg/kg DREADD ani-
mals: n=10, non-DREADD controls: n=4); (10mg/kg DREADD
animals: n=7, non-DREADD controls: n=4); (vehicle-treated
DREADD animals: n=6, non-DREADD controls: n=4)].
2.7. EEG recording and analysis of EEG traces
EEG signals were recorded from the subdural space over the cere-
bral cortex in freely moving mice using the Pinnacle mouse tethered
system (Pinnacle Technologies, Austin, TX, USA) with simultaneous
video recording. The prefabricated mouse headmount was attached to a
preamplifier to amplify and filter the EEG waveforms. EEG signals were
filtered at 0.5 Hz high pass and 50 Hz low pass. Sirenia® software was
used for acquisition of EEG traces. EEG/video analysis was performed
offline manually by an investigator, blind to the genotype, scrolling
through EEG traces using Seizure Pro® software. Bursts of paroxysmal
oscillatory activity in EEG traces were defined as absence-like SWD
seizures if they conformed to criteria published for the morphological
characteristics of SWDs in mice and if they were associated with be-
havioural arrest. Briefly, bursts of oscillations were counted as SWD if
they had a spike-wave structure (spike, positive transient, and slow
wave pattern) with a frequency of 3–8 Hz, an amplitude at least two-
times higher than baseline, and lasted for> 1 s (Chung et al., 2009;
Arain et al., 2012; Frankel et al., 2014; Kim et al., 2015; Heuermann
et al., 2016; Maheshwari et al., 2016; Meyer et al., 2018). Artefacts due
to muscle activity (extremely fast spikes of 20–60ms of duration, not
followed by slow waves, and mostly non-rhythmic), walking or
scratching and grooming (rhythmic and high amplitude discharges)
were readily recognised as such and on video were not associated with
behavioural arrest hence they were not considered as epileptiform ac-
tivity.
2.8. Data analysis
Statistical analyses of significant differences between DREADD an-
imals and non-DREADD WT controls or vehicle-treated animals were
calculated using two-way ANOVA for testing between groups (DREADD
animals versus non-DREADD animals) and CNO/vehicle as factors.
Comparison between two independent treatment groups was performed
using Tukey's post hoc multiple comparison test. Dunnett's post hoc
multiple comparison test was used to compare treatment groups with a
single control. Comparison between before and after injection in same
treatment group was performed using Wilcoxon matched-pairs signed-
rank test. Data were presented as mean ± standard error of the mean
(SEM). All statistical analysis was performed in GraphPad Prism 8.0
with statistical significance set at p < .05.
3. Results
3.1. DREADD receptors are expressed in PV+ interneurons
To confirm that DREADD receptors were selectively expressed in PV
+ interneurons, we first performed double-labelled im-
munohistochemistry with antibodies against HA-tag and PV, on brain
sections with known PV+ GABAergic interneurons distributions
(Fig. 2). Co-localization of HA-tag in PV+ interneurons was found
throughout the SS cortex (Fig. 2A,B), RTN thalamus (Fig. 2C,D), and the
cerebellar cortex of cerebellum (Fig. 2E,F). HA-tag for Gi-DREADD
(identified by pseudocolour green) was only expressed in brain sections
from PV-Cre/Gi-DREADD mice but not in non-DREADD WT controls.
PV+ interneurons were highly expressed throughout all SS cortical
layers except layer I in all genotypes (PV-Cre/Gi-DREADD and non-
DREADD WT controls) in agreement with published descriptions for PV
immunoreactivity in cortical layers in rodents (del Río and DeFelipe,
1994; Tamamaki et al., 2003; Fishell, 2007; Xu et al., 2010). Most PV-
expressing neurons in the SS cortex are basket cells (Meyer et al., 2002)
and chandelier cells (Inda et al., 2009). In the SS cortex of PV-Cre/Gi-
DREADD mice, almost all PV+ interneurons expressed HA-tag (Fig. 2A
white arrows). The percentage of co-localization of HA-tag in PV+
interneurons in the SS cortex was above 90% in PV-Cre/Gi-DREADD
mice (Fig. 2B). Similarly, the RTN thalamus, which comprises pre-
dominantly GABAergic, PV+ interneurons strongly expressed HA-tag
(Fig. 2C white arrows). The RTN represents a shell of inhibitory feed-
forward interneurons which project onto the relay neurons of the
ventroposterior (VP) region of the thalamus. The percentage of co-lo-
calization of HA-tag in PV+ interneurons of RTN thalamus was also
above 90% in PV-Cre/Gi-DREADD mice (Fig. 2D). In the CTC network,
very few cells appeared to be labelled for HA that were not also labelled
for PV (red arrow). In the cerebellum, HA-tag was intensely expressed
in PV+ Purkinje cell soma in PV-Cre /Gi-DREADD mice (Fig. 2E white
arrows). The percentage of co-localization of HA-tag in PV+ inhibitory
Purkinje cell (PC) soma was above 90%. (Fig. 2F). Co-labelling with
HA-tag and PV antibody was seen throughout the molecular layer of
cerebellar cortex of PV-Cre/Gi-DREADD mice, as dendritic projections
from the Purkinje cells extend throughout the molecular layer. In
contrast, there was no HA-tag in the non-DREADDWT controls (Fig. 2A,
C, E, bottom panel).
3.2. Silencing PV+ interneurons via intraperitoneal (IP) CNO injection
impaired motor function and increased anxiety
Next we tested the behavioural impact of globally silencing PV+
interneurons expressing Gi-DREADD receptors, by IP injection of CNO
(Fig. 3). In particular we focussed on motor function in open-field
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(Fig. 3B–D, Supplementary Fig. 2) and rotarod tests (Fig. 3E), as rodent
models of absence epilepsy exhibit absence seizures associated with
behavioural arrest, loss of motor co-ordination, and ataxia (Jarre et al.,
2017). Open-field testing was performed according to the protocol
outlined in schematic Fig. 3A, to determine the total distance travelled
in the open-field and the relative time spent in central and peripheral
zones (CZ and PZ). Total ambulatory distance is correlated with the
locomotory behaviour of the animal, whereas relative time spent in the
CZ and PZ of the open-field is an indicator of anxiety levels. There was a
significant difference in all tested parameters in PV-Cre/Gi-DREADD
mice treated with 5mg/kg and 10mg/kg of IP CNO compared to con-
trol non-DREADD WT littermates, or vehicle treated PV-Cre/Gi-
DREADD mice. However, drug doses of 1mg/kg IP CNO had no effect
on PV-Cre/Gi-DREADD mice or controls.
Movement track-paths recorded in the open-field arena revealed
decreased locomotion and an increased tendency to stay in the PZ, after
administration of higher (5-10mg/kg) IP doses of CNO to DREADD
mice (Fig. 3B). In the 5mg/kg dose group, total ambulatory distance
and total time spent in the PZ before CNO injection was
1513.07 ± 143.54 cm and 534.57 ± 7.24 s, respectively, which
changed significantly after CNO injection to 487.40 ± 93.32 cm and
589.20 ± 4.0 s respectively (n=18) (Supplementary Fig. 2A,E). Si-
milarly, in 10mg/kg dose group, total ambulatory distance and total
time spent in the PZ changed significantly from 1709.58 ± 96.5 cm
and 550.21 ± 4.74 s before CNO injection to 303.38 ± 84.90 cm and
594.75 ± 1.44 s respectively after CNO injection (n=18) (Supple-
mentary Fig. 2A,E). The percentage of time DREADD mice spent in CZ
(Fig. 3D; Supplementary Fig. 2C) was significantly reduced after drug
doses of 5-10mg/kg (before 5mg/kg CNO: 10.90 ± 1.21, after 5mg/
kg CNO:1.80 ± 0.67; before 10mg/kg CNO:8.30 ± 0.79, after 10 mg/
kg CNO:0.87 ± 0.24; n= 18). In contrast mice treated with 1mg/kg
CNO showed no significant changes in any of the parameters tested in
open field. None of the control groups (vehicle treated or non-DREADD
WT groups) showed any changes in locomotion or relative time spent in
the CZ or PZ (Fig. 3C,D; Supplementary Fig. 2B,D,F). The non-DREADD
WT mice spent a similar amount of time in the CZ as the vehicle group
before and after CNO administration (6–8%) which was consistent with
published data for WT control mice in other studies investigating an-
xiety-related behaviours in mice (Bailey and Crawley, 2009) indicating
that non-DREADD control and vehicle treated mice do not display an-
xiety-like behaviour. Thus, silencing PV+ interneurons via IP CNO
injection at dose levels 5–10mg/kg decreased locomotion and in-
creased anxiety levels only in PV-Cre/Gi-DREADD animals.
To test the impact of silencing feed-forward PV+ interneurons on
motor co-ordination, the same cohort of animals was tested on a
moving rotarod, which is widely used to evaluate motor coordination in
rodents, and is especially sensitive in detecting cerebellar dysfunction.
Each mouse was tested on the moving rotarod for three successive trials
of 5 mins before and after IP CNO injection at doses of either 1, 5, and
10mg/kg (Fig. 3A, E & Supplementary Fig. 3A,B). There was a sig-
nificant difference in the mean latency of fall in PV-Cre/Gi-DREADD
mice before and after peripheral (IP) CNO injection of 5mg/kg and
10mg/kg but not after 1mg/kg (Fig. 3E & Supplementary Fig. 3A). In
5mg/kg dose group, the mean latency of fall before CNO injection was
294.57 ± 1.35 s which decreased significantly after CNO injection
(175.39 ± 6.64 s; n=18 mice). Similarly, in 10mg/kg dose group, the
mean latency of fall reduced significantly from 293.39 ± 1.27 s before
injection to 89.09 ± 4.38 s (n=18) after CNO injection. However,
mice treated with 1mg/kg CNO showed no motor impairment on the
rotarod (latency of fall before CNO injection=296.10 ± 1.01 s; after
CNO injection 288 ± 3.33 s; n=19) (Fig. 3E & Supplementary
Fig. 3A). Control vehicle treated PV-Cre/Gi-DREADD mice showed no
changes in motor co-ordination before and after CNO injection (latency
of fall before CNO injection=294.58 ± 1.96 s; after CNO injection
289.55 ± 2.57 s; n=15). Likewise, Tukey's post hoc multiple com-
parison test and Wilcoxon matched-pairs signed-rank test showed no
significant difference between vehicle and CNO treated non-DREADD
WT control groups (Fig. 3E; Supplementary Fig. 3B).
3.3. Silencing PV+ interneurons via intraperitoneal (IP) CNO injection
increased immobility and generated absence-like seizures
To test the effect of silencing feed-forward PV+ interneurons on
seizure generation, EEG recordings were first performed on a cohort of
PV-Cre/Gi-DREADD and non-DREADD WT control animals surgically
implanted with surface EEG electrodes and injected with IP CNO. The
EEG testing protocol and electrode placement are illustrated in Fig. 4A
& B, respectively. Simultaneous EEG/video recording was performed on
animals 10min before and for 1 h after IP CNO injection at doses of
either 1mg/kg (DREADD animals: n=8; non-DREADD WT controls:
n=4), 5mg/kg (DREADD animals: n=9; non-DREADD WT controls:
n=6), 10mg/kg (DREADD animals: n=5; non-DREADD WT controls:
n= 6), and vehicle-treated (DREADD animals: n=8; non-DREADD WT
controls: n=6). Bursts of paroxysmal oscillatory activity (indicated by
asterisks) associated with behavioural arrest were seen after IP CNO
injection of 5mg/kg and 10mg/kg in PV-Cre/Gi-DREADD animals but
not in the 1mg/kg dose group, vehicle treated animals or non-DREADD
WT control animals (Fig. 4D). IP CNO injection also led to increased
immobility in PV-Cre/Gi-DREADD animals in a dose-dependent
manner. Analysis of the mean time spent immobile during EEG re-
cording indicated that animals spent significantly more time immobile
after CNO doses of 5 and 10mg/kg of IP CNO 47.28 ± 3.23min
(n= 9) and 50.83 ± 2.74min (n=5) respectively, compared to ve-
hicle-treated and 1mg/kg CNO injected animals, which were immobile
for 29.70 ± 5.70min (n=8) and 34.19 ± 1.73min (n=8) respec-
tively. Injection of CNO into non-DREADD WT control animals at doses
5 and 10mg/kg did not significantly change mobility compared to
vehicle treated animals (5 mg/kg CNO 34.01 ± 2.93min (n=6),
10mg/kg CNO 35.28 ± 2.86min (n=6) or vehicle 31.62 ± 3.17min
(n=6), (Fig. 4C).
Analysis of the bursts of paroxysmal oscillatory activity (with as-
sociated behavioural arrest) in PV-Cre/Gi-DREADD mice injected with
5 and 10mg/kg IP CNO, indicated mean seizure onset at
31.26 ± 5.46min in the 5mg/kg dose group (n=9) and
36.21 ± 5.58 in 10mg/kg group (n=5) (Fig. 4E). However, the first
seizure detected in an IP cohort mouse was 10.14min. The mean
number of bursts during the 1 h EEG recording period, was 4 ± 1.01
bursts in the 5mg/kg dose group and 5.8 ± 2.27 in the 10mg/kg
group (Fig. 4E). EEG trace parameters such as mean spike frequency,
mean duration of each burst, and time of last seizure were not sig-
nificantly different. The bursts of paroxysmal oscillatory activity had a
characteristic spike and wave-like morphological profile with a spike
Fig. 2. (A, C, E) Confocal images showing the expression of HA-tag in PV-interneurons in SS cortex, RTN thalamus, and cerebellum respectively (HA panel 1, PV
panel 2, merged images panel 3, enlarged 40× merged images panel 4). Neurons with co-localized markers are identified by pseudo-colour yellow in 40× merged
images (white arrows). Red arrows indicate the HA-positive neurons that are immunonegative for PV and blue arrows indicate PV positive neurons which are
immunonegative for HA. (B, D, F) Percentage of co-localization of HA and PV in neurons in the SS cortex, RTN thalamus, and cerebellum, respectively. All
immunolabelled cells in SS cortex and cerebellum sections were counted at 10× in confocal images whereas those in RTN thalamus were counted using 40× images.
(Het= PV-Cre/Gi-DREADD offspring from homozygous PV-Cre female and heterozygous Cre-dependent hM4Di male; Homo=PV-Cre/Gi-DREADD offspring from
homozygous PV-Cre female and homozygous Cre-dependent hM4Di male\; WT=Non-DREADD WT control animals). (For interpretation of the references to colour
in this figure legend, the reader is referred to the web version of this article.)
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frequency between 3 and 6 Hz. The frequency (spikes/s), was calculated
based on number of spikes with an amplitude minimum two-times
higher than baseline, followed by positive transient, and slow wave
pattern. The mean frequency of such discharges was 5.35 ± 0.76
spikes/s and 4.76 ± 0.64 spikes/s for 5mg/kg and 10mg/kg dose
group of CNO, respectively (Fig. 4E). The mean duration of each burst
was 3.16 ± 0.58 s and 4.77 ± 0.63 s for 5mg/kg and 10mg/kg dose
group of CNO, respectively (Fig. 4E). In all cases, behavioural arrest
was associated with these bursts of oscillatory activity. Only one PV-
Cre/Gi-DREADD animal, injected with 5mg/kg IP CNO, displayed
(caption on next page)
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tonic-clonic convulsive type seizures after 22.58min of CNO injection
(see Supplementary Fig. 4A). In this case the convulsive seizures were
characterized by extremely high-amplitude (up to 3990μv) spikes on
the EEG and accompanied by severe jerking movements. The char-
acteristics and morphology of such discharges were very different to the
rhythmic spike and wave oscillations seen in the other PV-Cre/Gi-
DREADD animals in the 5mg/kg and 10mg/kg dose groups hence this
animal was excluded from the analysis.
3.4. Silencing PV+ interneurons via focal CNO injection into the SS cortex
or RTN (thalamus) generated absence-like seizures associated with
behavioural arrest
Having confirmed that global silencing of PV+ interneurons via IP
CNO injection causes bursts of paroxysmal oscillatory discharges com-
prising spikes and wave-like discharges, we next performed targeted
CNO injections focally into either the SS cortex (Fig. 5) or the RTN
thalamus (Fig. 6). The aim was to directly silence PV+ feed-forward
interneurons in either of these brain regions to test our hypothesis that
loss of feed-forward inhibition specifically within CTC network micro-
circuits, is one mechanism by which the CTC can switch into hyper-
excitable pathological oscillations evident as SWDs in absence seizures.
Evidence in the literature suggests that the cortex is the site of seizure
initiation while the thalamus is primarily involved in seizure main-
tenance (Meeren et al., 2002; Polack et al., 2007).
Simultaneous EEG/video recordings were made of PV-Cre/Gi-
DREADD and non-DREADD WT control animals based on the experi-
mental procedure illustrated in Figs. 5A and 6A. EEG traces were re-
corded for 10min before and 1 h after either vehicle or focal CNO in-
jection at doses of either 1, 2.5, 5 and 10mg/kg. Different cohorts of
animals were used for testing the impact of silencing PV+ interneurons
in the SS cortex (Fig. 5) and RTN thalamus (Fig. 6) i.e. each animal had
only a cortical or thalamic canula inserted surgically, not both. Analysis
of EEG traces following focal injection of CNO revealed bursts of par-
oxysmal oscillatory activity (indicated by asterisks on EEG traces) in
both brain hemispheres and concomitant behavioural arrest after focal
CNO injection of 2.5, 5 and 10mg/kg in PV-Cre/Gi-DREADD animals
into either cortical or thalamic regions (Fig. 5E, 6E; Supplementary
Figs. 5–7) but not 1mg/kg.
The bursts of oscillatory activity recorded after CNO focal injections
into the SS cortex (Fig. 5E) were characterized as bilateral SWDs based
on spike amplitude (minimum two-times higher than baseline), positive
transient, and slow wave pattern. There was no significant difference in
mean duration of seizure (s), mean frequency (spikes/s), and mean rate
(discharges/h) across all 3 doses of CNO (Fig. 5F). The mean frequency/
rhythmicity (Hz) of epileptiform activity was consistent with the
characteristics of SWDs associated with absence seizures in other mouse
models of absence epilepsy (Jarre et al., 2017). All PV-Cre/Gi-DREADD
animals tested with CNO drug doses of 2.5, 5 and 10mg/kg focally
injected into the SS cortex displayed these characteristic SWDs (n=26)
with the exception of one animal. This PV-Cre/Gi-DREADD animal,
when focally injected with 5mg/kg CNO (SS cortex) showed a single
tonic-clonic convulsive event with jerky body movements which lasted
for just 3.61 s (see Supplementary Fig. 4B). This animal was not in-
cluded in the analyses of absence-like seizures. None of the non-
DREADD WT control animals exhibited signs of paroxysmal oscillatory
activity at any of the drug doses tested (Fig. 5E). No bursts of oscillatory
activity were seen in any of the 1mg/kg dose groups or in vehicle
treated PV-Cre/Gi-DREADD animals. The DREADD mice injected with
CNO doses of 2.5, 5 and 10mg/kg spent significantly more time im-
mobile after treatment. The mean time spent immobile during the 1 h
recording period post CNO injection was: 39.91 ± 3.41min (n=6)
after 2.5 mg/kg; 47.80 ± 2.20min (n=11) after 5mg/kg; and
47.32 ± 3.65min (n=9) after 10mg/kg compared to vehicle-treated
19.64 ± 6.56min (n=4) or 1mg/kg CNO injected 25.30 ± 6.05min
(n=7) animals. Injection of CNO into non-DREADD WT control ani-
mals did not significantly change mobility compared to vehicle treated
animals (2.5 mg/kg CNO 36.20 ± 3.21min (n=6); 5mg/kg CNO
32 ± 0.923min (n=8); 10mg/kg CNO 30.44 ± 3.48min (n=4);
vehicle 25.97 ± 1.97min (n=4); (Fig. 5D).
Analysis of video/EEG data following focal injection of CNO into the
RTN thalamus of PV-Cre/Gi-DREADD mice also revealed animals spent
more time immobile after higher 5-10mg/kg doses, although this trend
did not reach significance (Fig. 6D). Injection of CNO into non-DREADD
WT control animals did not significantly change mobility compared to
vehicle treated animals (Fig. 6D) at any of the dose levels tested. The
oscillatory discharges recorded after CNO injection into the RTN tha-
lamus demonstrated a complex spike-wave structure. These discharges,
when analysed on an expanded time scale, comprised repetitive spikes,
positive transients with multiple waves (Fig. 6E) similar to the absence-
like seizures seen in GABAA receptor alpha-1 subunit KO mice (Arain
et al., 2012). However, like the SS cortex group, there was no sig-
nificant difference in mean spike frequency (spikes/s), mean duration
of each oscillatory burst, or burst rate (number of oscillatory bursts/h)
across all 3 doses of CNO (Fig. 6F). They were clearly not polyspike-
and-wave discharges (PSD) associated with myoclonic seizures, which
consist of very brief (< 0.5 s), high frequency (approximately 50ms
interspike interval) complexes (García-Cabrero et al., 2012; Arain et al.,
2015). SWDs can be differentiated from PSDs based on two morpho-
logical features: SWDs have a lower spike frequency (interspike interval
125–166ms), and a higher rhythmicity than the PSDs. In our study, the
mean interspike interval for all three (IP, SS cortex, thalamus) modes of
CNO injection was 209.02 ± 24.74ms (total 263 epileptiform dis-
charges counted). The complex SWD-like oscillations evident after focal
CNO injections, were also associated with behavioural arrest. None of
the non-DREADDWT control animals exhibited any signs of paroxysmal
oscillatory activity at any of the CNO drug doses tested by focal injec-
tion into the thalamus (Fig. 6E).
3.5. Treatment with ETX suppressed absence-like seizures generated by
focal CNO injections
To further characterise the bursts of oscillatory spikes and wave-like
discharges occurring after focal injection of CNO at doses of 5–10mg/
Fig. 3. (A) Schematic of protocol for behavioural testing before and after IP CNO/vehicle injection. (B) Open-field test: representative images of movement track
paths showing decreased locomotion and increased tendency to stay in peripheral zone (PZ) by CNO treated DREADD animals but not non-DREADD WT control
animals. (C) Open-field test: graph of total distance travelled by DREADD and non-DREADD WT control mice after IP injection of CNO or vehicle. Total ambulatory
distance was significantly reduced in open-field testing of DREADD animals after CNO doses of 5mg/kg (n=18) and 10mg/kg (n=18) but not 1mg/kg (n=19) or
vehicle (n=15). There were no changes in non-DREADD WT control animals [1 mg/kg (n=9), 5mg/kg (n=8), 10mg/kg (n=9), vehicle treated (n=8)]. (D)
Open-field test: graph showing % of time spent in central zone by DREADD and non-DREADD WT control animals after IP CNO or vehicle injection. DREADD mice
treated with 5-10mg/kg CNO (n=18 for both doses) spent significantly less time in the central zone compared to 1mg/kg (n=19) or vehicle (n=15) treated
animals or non-DREADD WT controls. There were no significant differences between non-DREADD WT controls or vehicle treated mice [1mg/kg dosage group
(n=9), 5mg/kg dosage group (n=8), 10mg/kg dosage group (n=9), vehicle treated (n=8)]. (E) Rotarod test: graph showing the comparison of latency of fall
between DREADD and non-DREADD control animals after different doses of IP CNO injection. Motor co-ordination was significantly reduced in DREADD animals
after 5 mg/kg (n=18) and 10mg/kg (n=18) doses but not 1 mg/kg (n=19) or in the vehicle treated (n=15) group. There was no change in the latency of fall in
non-DREADD control animals [1 mg/kg (n=9), 5mg/kg (n=8), 10mg/kg (n=9), vehicle treated (n=8)]. All values represent mean ± SEM. Comparisons
between treatment groups were performed using Tukey's post hoc multiple comparison test.
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kg, we investigated the impact of the anti-epileptic drug ethosuximide
(ETX) on seizure generation (Supplementary Fig. 8). ETX is specific for
absence seizures; therefore it can be used to differentiate absence sei-
zures from other EEG changes. CNO (10mg/kg) was injected focally
into a cohort of PV-Cre/Gi-DREADD mice (SS cortex group: n=3,
Supplementary Fig. 8A; RTN thalamus group: n=4, Supplementary
Fig. 8B) and video/EEG recordings made for 10min before and 60min
post CNO injection. CNO induced bursts of oscillatory spikes and wave-
like discharges in all mice tested. To test if the anti-absence drug ETX
was able to block seizure activity, the same cohort of animals was
(caption on next page)
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subsequently injected with 200mg/kg of ETX prior to injection of
10mg/kg CNO and recorded continuously for at least 1 h post CNO
injection. Administration of ETX prevented spikes and wave-like dis-
charges in all tested PV-Cre/Gi-DREADD animals, which provides
strong supporting evidence for the absence-like nature of these dis-
charges.
3.6. Route of administration affects onset of bursts of oscillatory activity
Analysis of the impact of the route of CNO injection (IP or focal) on
seizure generation revealed an earlier onset of seizures after focal in-
jection than IP injection (Fig. 7A). The mean onset of seizures in the IP
CNO injection group was at 31.27 ± 5.46min (n=9) for 5mg/kg and
36.22 ± 5.58min (n=5) for the10mg/kg dosage group. In the SS
cortex group, mean onset of seizures was 14.94 ± 3.35min (n=11)
after 5mg/kg CNO, and 14.71 ± 3.08min (n=9) after 10mg/kg CNO
(Fig. 7A). In the thalamus group, mean seizure onset was
18.58 ± 6.14min (n=6) after 5mg/kg CNO, and 9.60 ± 3.42min
(n=5) after 10mg/kg CNO). However, irrespective of route of ad-
ministration, seizures were first evident in some animals within each
dosage group by 15mins post CNO injection (first seizure detected in an
IP cohort mouse was 10.14min, in focal SS cortex cohort mouse was
6.09min and in focal thalamus cohort mouse was 6.79min); seizures
had terminated in all animals by 60min post CNO injection (Fig. 7B).
Other morphological features of the discharges (spike frequency,
burst duration and burst rate) remained consistent irrespective of CNO
drug dose level or route of administration. No significant differences
were seen in the mean duration of each seizure burst for any of the drug
levels tested via IP or focal routes i.e. IP group: 3.16 ± 0.58 s (n=9)
after 5mg/kg CNO, and 4.78 ± 0.63 s (n=5) after 10mg/kg CNO, SS
cortex group: 3.02 ± 0.48 s (n=11) after 5mg/kg CNO, and
3.29 ± 0.30 s (n=9) after 10mg/kg CNO, thalamus group:
3.14 ± 0.33 s (n=6) after 5mg/kg CNO, and 3.54 ± 0.91 s (n=5)
after 10mg/kg CNO (Fig. 7C). Similarly, no significant differences were
seen in mean frequency of seizure (spikes/s) i.e. IP group:
5.35 ± 0.76min (n=9) after 5mg/kg CNO, and 4.76 ± 0.64min
(n=5) after 10mg/kg CNO; SS cortex group: 5.57 ± 0.53min
(n=11) after 5mg/kg CNO, and 5.26 ± 0.64min (n= 9) after
10mg/kg CNO; thalamus group: 5.14 ± 0.65min (n=6) after 5mg/
kg CNO, and 5.56 ± 0.94min (n=5) after 10mg/kg CNO (Fig. 7D).
Likewise, there was no significant difference in mean rate of dis-
charges/h after either IP (4 ± 1.01 and 5.80 ± 2.27 bursts/h for
5mg/kg and 10mg/kg respectively) or focal administration of CNO (SS
cortex group: 4.91 ± 1.07 (n=11) after 5mg/kg CNO, and
7.11 ± 1.71 (n=9) after 10mg/kg CNO; thalamus group:
3.67 ± 1.38 (n=6) after 5mg/kg CNO, and 5.20 ± 1.46 (n=5)
after 10mg/kg CNO) (Fig. 7E).
3.7. Focal silencing of PV+ interneurons in CTC network had no effect on
motor co-ordination on the rotarod but significantly altered locomotory
behaviour in the open-field
Silencing PV+ interneurons via focal CNO injection into either the
cortex or thalamus did not cause impairment of motor control tested on
the rotarod. There were no significant differences in the latency of fall
in PV-Cre/Gi-DREADD animals at any dose of CNO tested compared to
non-DREADD WT controls and vehicle treated groups (Supplementary
Fig. 3 C–F).
However, when tested in the open-field, locomotory behaviour in
PV-Cre/Gi-DREADD was altered after focal injection of CNO in a dose
dependent manner (Fig. 8; Supplementary Fig. 9). CNO doses
2.5–10mg/kg of CNO injected into the SS cortex (Supplementary
Fig. 9A,B) or thalamus (Supplementary Fig. 9C,D) significantly reduced
the total ambulatory distance travelled by DREADD animals compared
to before treatment, whereas CNO had no effect on non-DREADD WT
controls. Dunnett's post hoc multiple comparison test showed statisti-
cally significant differences in the mean distance travelled after CNO
doses of 2.5mg/kg (1097.97 ± 214.38 cm; n=6), 5mg/kg
(692.99 ± 213.07 cm; n=7), 10mg/kg CNO (451.43 ± 120.19 cm,
n=9) compared to before CNO/vehicle treatment
(1857.95 ± 139.31 cm, n=6–9) in the SS cortex group (Fig. 8A). No
significant changes were seen in non-DREADD WT control animals
(n=4–7 per treatment group) (Fig. 8B, Supplementary Fig. 9B). Si-
milarly, CNO injection into the thalamus significantly reduced loco-
motion in the DREADD 2.5–10mg/kg dose groups but not non-
DREADD controls (Supplementary Fig. 9 C,D). During the 10min
testing period prior to CNO thalamic injection, DREADD animals tra-
velled 1747.48 ± 164.42 cm (n=7–10) in open-field arena; this de-
creased significantly after 2.5, 5 and 10mg/kg of CNO injection to
338.14 ± 123.72 cm (n=7), 463.85 ± 144.72 cm (n=10), and
244.14 ± 110.33 cm (n=7) respectively (Fig. 8C). Again, there was
no change in the total ambulatory distance in non-DREADD WT con-
trols (n=4–6 per treatment group) (Fig. 8D, Supplementary Fig. 9D)
after CNO injection into the thalamus compared to before CNO/vehicle
injections.
4. Discussion
The current study has shown that silencing PV+ interneurons in the
CTC network, by focal injection of CNO into either the SS Cortex or RTN
thalamus, of mice expressing Gi-DREADD receptors in PV+ inhibitory
neurons leads to the generation of bursts of paroxysmal oscillatory
activity with characteristic SWD-like morphology on EEG, similar to
absence seizures in genetic mouse models of absence epilepsy. Seizures
were associated with behavioural arrest but the periods of immobility
were not restricted to just the duration of the oscillatory burst. The
arrested behaviour continued for extended periods throughout a series
of oscillatory bursts and was associated with reduced locomotion in
open-field testing. Global silencing of all PV+ interneurons with a
single dose of CNO, in addition to causing epileptiform oscillations on
EEG and impaired locomotor function in open-field testing, resulted in
increased time spent in peripheral zones (indicative of increased an-
xiety) and loss of motor co-ordination on rotarod tests. The latter be-
havioural effect may reflect silencing of PV+ interneurons in brain
regions other than the CTC network, as this effect was not evident on
focal silencing of CTC PV+ interneurons.
Fig. 4. (A) Schematic of protocol for EEG recordings before and after IP CNO/vehicle injection. (B) Diagram showing the position of EEG electrodes; recordings were
made from EEG1 and EEG2 channels. (C) Graph showing time spent immobile by DREADD and non-DREADD animals during 1 h of EEG recording period after IP
CNO injection. Immobility in DREADD animals was dose dependent and statistically significant at 5-10mg/kg compared to vehicle treated mice (DREADD animals:
vehicle treated n=8; CNO treated 1mg/kg n=8; 5mg/kg n=9; 10mg/kg; n=5). CNO did not affect mobility in non-DREADD WT control mice compared to
vehicle treated mice (non-DREADD control animals: vehicle treated n=6; CNO 1mg/kg n=4; 5mg/kg n=6; 10mg/kg n=6). (D) Representative EEG traces of
DREADD animals and non-DREADD controls after IP injection of CNO or vehicle. Bursts of paroxysmal oscillatory activity (asterisks) with the characteristics of SWDs
and associated behavioural arrest were seen only in DREADD animals injected with 5–10mg/kg IP CNO. SWDs were characterized by spike, positive transient and
slow-wave pattern with spike amplitude 2× baseline, spike frequency of> 2Hz and a minimum duration of 1 s. No SWDs were evident in 1 mg/kg or vehicle treated
groups or non-DREADD WT control animals. All representative EEG traces were obtained from different animals. Each trace represents 3–6min of EEG recording. (E)
Comparison of different parameters of EEG recording after IP CNO injection in DREADD animals No significant changes were seen in any of the parameters. All values
represent mean ± SEM. Comparisons between treatment groups were performed using Tukey's post hoc multiple comparison test.
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4.1. HA-tagged DREADD receptor is highly expressed in PV+ interneurons
Validation of the selective expression of inhibitory hM4Di-DREADD
receptor in PV+ interneurons in PV-Cre/Gi-DREADD mice was pro-
vided by the high co-expression of labelling for the DREADD HA-tag
and PV in cells known to express the calcium-binding protein PV (e.g.
thalamic RTN soma and cerebellar Purkinje cells) but absence of
staining for HA-tag in PV+ interneurons in non-DREADD WT littermate
controls. The labelling of PV+ cells in our study was consistent with
that of other published studies describing distribution of PV+ neurons
in the brain (del Río and DeFelipe, 1994; Tamamaki et al., 2003;
Fishell, 2007; Xu et al., 2010). PV+ interneurons were highly expressed
in SS cortical layers II-VI but not in layer I, in all PV-Cre/Gi-DREADD
mice and non-DREADD WT controls, which is similar to our previously
published studies on PV-immunoreactivity in the cortex of stargazer
model of absence epilepsy and non-epileptic littermates (Adotevi and
Leitch, 2016) and other rodent studies (Celio, 1986; Tanahira et al.,
2009; Xu et al., 2010). PV-Cre/Gi-DREADD mice showed extremely
high co-localization (> 90%) of HA-tag in PV+ interneurons in SS
cortex, RTN thalamus and Purkinje cells of cerebellum, whereas none of
the PV+ interneurons in non-DREADD WT control animals showed
labelling for HA-tag. These levels of co-expression in PV-Cre/Gi-
DREADD mice are consistent with the Jackson Lab datasheet (008069)
for PV-Cre mice which states that the recombination in PV-Cre knockin
allele is around 90%.
To date, there have been relatively few studies, which have used
DREADD technology to modulate PV+ interneurons. Reports in the
literature on the expression levels of DREADD receptor in PV+ inter-
neurons, are limited to those that have used viral vectors to deliver the
DREADD receptor into PV-Cre transgenic mice; either DREADD-based
recombinant lentiviral vector (LV) or adeno-associated viral vector
(AAV). Specific PV+ cells have been targeted by viral vector injections
into different regions of the brain including the hippocampus (Yi et al.,
2014; Zou et al., 2016; Drexel et al., 2017; Xia et al., 2017; Calin et al.,
2018); medial prefontal cortex (mPFC) (Perova et al., 2015); primary
visual cortex (Kaplan et al., 2016); and frontal cortex (Ng et al., 2018).
These studies reported percentage co-localization of DREADD receptor
with PV+ interneurons between 70 and 85% in the targeted brain re-
gions. Hence, viral infection efficiency using LV and AAV mediated
DREADD expression, is below the 90% achieved in our study.
4.2. Global silencing of PV+ interneurons affects motor function and
anxiety levels
We employed two motor function tests to investigate the impact of
globally silencing PV+ inhibitory interneurons on locomotor beha-
viour, as rodent models of absence epilepsy display altered motor
function including ataxia and impairment of motor co-ordination (Jarre
et al., 2017). The stargazer model of absence epilepsy, which has re-
duced excitatory input to PV+ inhibitory interneurons in the CTC
network, and in the cerebellum (due to reduced synaptic AMPA re-
ceptors), presents with several phenotypic features including absence
seizures, head tossing and cerebellar ataxia (Noebels et al., 1990; Letts,
2005; Menuz and Nicoll, 2008; Yamazaki et al., 2015).
In the present study, motor performance on the rotarod test was
significantly impaired in a dose dependent manner only after global
silencing of PV+ interneurons via IP CNO injection, but not after focal
injection of CNO into the SS cortex or RTN thalamus in PV-Cre/Gi-
DREADD mice. This is likely due to the silencing of PV+ Purkinje cells
in the cerebellar cortex, as knockout mice (TARP γ-2 PC KO; γ-7 KO),
which lack excitatory input to Purkinje cells, display wide-ranging
motor deficits including ataxic gait, severely reduced ambulation and
rearing in the open-field, impaired performance in the wire hang test,
and reduced forelimb and hindlimb grip strength on the rotarod
(Yamazaki et al., 2015). The cerebellum plays a vital role in the motor
control, precision and accurate timing of movement. IP injection of
CNO into PV-Cre/Gi-DREADD mice would cause the global silencing of
PV+ interneurons including the cerebellar Purkinje cells. In contrast,
focal CNO injection into the SS cortex and thalamus had no effect on
rotarod performance. The SS cortex and RTN thalamus are not the brain
regions directly involved in regulation of motor co-ordination hence
silencing of PV+ interneurons in CTC network would not be expected
to be associated with loss of motor co-ordination on the rotarod. Si-
milarly, other studies using DREADD technology and viral expression
methods to selective silence or excite PV+ interneurons in specific
brain regions, other than the cerebellum, have had no effect on motor
coordination in rotarod tests. For example, Liu et al. (2017) reported no
motor impairment on rotarod tests following CNO activation of PV+
interneurons in the rostro-dorsal RTN, using viral-mediated focal ex-
pression of hM3Dq-DREADD in PV-Cre mice. Likewise, specifically ex-
citing PV+ interneurons in the dorsal horn produced no significant
motor impairment via rotarod testing (Petitjean et al., 2015). Chemo-
genetic inactivation of the target neurons of PV+ interneurons e.g.
hippocampal glutamatergic neurons in CaMKIIα-hM4Di mice, also has
no effect on motor control (Zhu et al., 2014). From these collective
studies and given that the rotarod test is especially sensitive in de-
tecting cerebellar dysfunction, we conclude that impairment in rotarod
performance in our PV-Cre/Gi-DREADD transgenic mice only after
global silencing of PV+ interneurons, is a consequence of silencing
cerebellar PV+ neurons.
Assessment of locomotor activity in open-field tests following global
silencing of PV+ interneurons also revealed a significant reduction in
the total ambulatory distance travelled in PV-Cre/Gi-DREADD before
and after treatment with IP CNO doses of 5–10mg/kg. Furthermore, we
found that this group of mice spent relatively more time in the per-
ipheral zones and corners of the maze and less time in the central zone
compared to the other treatment groups (vehicle treated Gi-DREADD or
CNO/vehicle treated non-DREADD WT controls). Staying in close
proximity to the walls of the maze, is indicative of an anxiety-related
behaviour (Seibenhener and Michael, 2015). Increased anxiety is also
associated with reduced locomotion (Ennaceur, 2014). Hence, global
silencing of PV+ inhibitory interneurons appears to be associated with
increased levels of anxiety, coupled with reduced locomotion. Inter-
estingly, PV knock-out mice also display decreased locomotion (Farré-
Castany et al., 2007), less structured bouts of locomotion, less rearing
activity, but not increased anxiety (Wöhr et al., 2015) compared to that
Fig. 5. (A) Schematic of protocol for EEG recordings/behavioural testing before and after focal CNO/vehicle injection into SS cortex. (B) Diagram showing the
position of EEG electrodes; recordings were made from EEG1 and EEG2 channels. The headmount was rotated by 90° from the previous setup (as explained in
Fig. 4B). Changes were made to record EEG traces from both hemispheres of the brain. (C) Schematic representation of CNO delivery in SS cortex (modified from
Allen Mouse Brain Atlas) (D) Graph showing time spent immobile by DREADD and non-DREADD animals after focal CNO injection into the SS cortex. Immobility in
DREADD animals was dose dependent and statistically significant at 2.5-10mg/kg compared to vehicle treated mice (DREADD animals: vehicle treated n=4; CNO
treated 1mg/kg n=7; 2.5mg/kg n= 6; 5mg/kg n=11; 10mg/kg n=9. CNO did not affect mobility in non-DREADD WT control mice compared to vehicle treated
mice (non-DREADD control animals: vehicle treated n=4; CNO 1mg/kg n=4; 2.5 mg/kg n=6; 5mg/kg n=8; 10mg/kg n=4). (E) Representative EEG traces of
DREADD animals and non-DREADD controls after focal injection of CNO/vehicle into SS cortex. Bursts of paroxysmal oscillatory activity (indicated by asterisks)
associated with behavioural arrest were seen after CNO injection (2.5–10mg/kg) only in DREADD animals but not in 1mg/kg or vehicle treated groups or non-
DREADD WT control animals. SWDs were characterized as explained in Fig. 4D. All representative EEG traces are from different animals. Each traces represent
3–6min of EEG recording. (F) Comparison of different parameters of EEG recording after focal CNO injection into the SS cortex of DREADD animals. All values
represent mean ± SEM. Comparisons between treatment groups were performed using Tukey's post hoc multiple comparison test.
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Fig. 6. (A) Schematic of protocol for EEG recordings/behavioural tests before and after focal CNO/vehicle injection into RTN (thalamus). (B) Diagram showing the
position of EEG electrodes; recordings were made from EEG1 and EEG2 channels from both hemispheres of the brain (as explained in Fig. 5B). (C) Schematic
representation of CNO delivery in RTN (modified from Allen Mouse Brain Atlas) (D) Graph showing time spent immobile by DREADD and non-DREADD animals after
focal CNO injection into the RTN thalamus. Immobility increased in DREADD animals as CNO dose was increased but did not reach statistical significance (DREADD
animals: vehicle treated n=5; CNO 1mg/kg n=5; 2.5 mg/kg n=6; 5mg/kg n=6; 10mg/kg n=5). No differences were seen in non-DREADD control animals
(non-DREADD control animals: vehicle treated n=4; CNO 1mg/kg n=4; 2.5 mg/kg n=6; 5mg/kg n=6; 10mg/kg n=4. (E) Representative EEG traces of
DREADD animals and non-DREADD controls after focal injection of CNO/vehicle into RTN. Bursts of paroxysmal oscillatory activity (indicated by asterisks) asso-
ciated with behavioural arrest were seen after CNO injection (2.5–10mg/kg) only in DREADD animals but not in 1mg/kg or vehicle treated groups or non-DREADD
WT control animals. SWDs were characterized as explained in Fig. 4D. All representative EEG traces are from different animals. Each traces represent 2–3min of EEG
recording. (F) Comparison of different parameters of EEG recording after focal CNO injection in RTN (thalamus) of PV-Cre/Gi-DREADD animals. All values represent
mean ± SEM. Comparisons between treatment groups were performed using Tukey's post hoc multiple comparison test.
Fig. 7. Overall comparison of various EEG parameters after IP and focal (SScortex and RTN thalamus) injection during 1 h of EEG recording. (A) First incident of
seizure (B) Last incident of seizure (C) Mean duration of seizure (D) Mean frequency of seizure (E) Mean rate of discharges (IP: 5mg/kg n=9; 10mg/kg n=5; SS
cortex: 5mg/kg n=11; 10mg/kg n=9; RTN thalamus: 5 mg/kg n=6; 10mg/kg, n=5). All values represent mean ± SEM. Comparisons between treatment
groups were performed using Tukey's post hoc multiple comparison test.
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of WT animals. Other conditional PV knock-out animals (lacking TrKB
and KCC3 in PV+ interneurons, respectively) also displayed decreased
locomotion compared to their WT counterparts (Ding and Delpire,
2014; Lucas et al., 2014). Studies on PV−/− mice indicate that ab-
sence of PV results in an activity-dependent increase in inhibition thus
shifting the E/I balance towards increased inhibition not a loss of feed-
forward inhibition. Decreased PV expression, which occurs in the PV
knock-out mouse (Wöhr et al., 2015) would likely result in enhanced
inhibition due to increased presynaptic GABA release and postsynaptic
GABA-mediated currents (Vreugdenhil et al., 2003). Conversely, loss of
PV interneurons would reduce inhibitory input to principal excitatory
neurons (Marín, 2012). In our PV-Cre/Gi-DREADD mice, the PV inter-
neurons are silenced leading to reduced feed-forward inhibition, not
loss of PV protein.
Other studies have shown differential effects of acute and chronic
activation or silencing of PV+ interneurons. Zou et al. (2016) de-
monstrated that selective activation of PV+ interneurons in the hip-
pocampal dentate gyrus (using a single CNO injection in PV-Cre
transgenic mice with virally expressed excitatory Gq-DREADD), induced
an anxiolytic effect without affecting locomotor activity or depression-
related behaviour. In contrast, chronic silencing of hippocampal PV+
interneurons, by supplying CNO in drinking water for 27 days to PV-Cre
transgenic mice expressing Gi-DREADD receptors in this brain region,
resulted in no changes in locomotor activity and anxiety levels (Xia
et al., 2017). Similarly, Perova et al. (2015) found no difference in lo-
comotion between CNO treated and saline treated groups of PV-Cre
animals virally injected with Gi-DREADDs in the prefrontal cortex.
4.3. Silencing PV+ interneurons via focal CNO injection into the SS cortex
or RTN (thalamus) generated absence-like seizures associated with
behavioural arrest
To investigate the impact of silencing PV+ interneurons within the
CTC network on seizure generation, and test our hypothesis that loss of
feed-forward inhibition can underlie pathological SWDs in some genetic
models of absence epilepsy, we first checked global silencing of PV+
Fig. 8. Graphs comparing total distance travelled in open-field by DREADD mice and non-DREADD controls after focal CNO injection (A) CNO injection into SS
cortex significantly reduced total ambulatory distance at higher doses (2.5–10mg/kg) in DREADD mice but not vehicle treated or 1mg/kg CNO treated animals
(vehicle treated n=6; CNO 1mg/kg n=5; 2.5 mg/kg n= 6; 5mg/kg n=7; 10mg/kg n=9). (B) No significant differences in ambulatory distance were seen in
CNO or vehicle treated non-DREADD controls (vehicle treated group, n=4; CNO 1mg/kg n=4; 2.5 mg/kg n=7; 5mg/kg n=6; 10mg/kg n=4. (C) CNO
injection into RTN thalamus also significantly reduced total ambulatory distance at higher dose (2.5-10mg/kg) in DREADD mice but not vehicle treated or 1 mg/kg
CNO treated animals (vehicle treated group, n= 6; CNO 1mg/kg n= 7; 2.5 mg/kg n=7; 5mg/kg n=10; 10mg/kg n=7. (D) No significant differences in
ambulatory distance were seen in CNO or vehicle treated non-DREADD controls (vehicle treated group, n=4; CNO 1mg/kg n=4; 2.5 mg/kg n=6; 5mg/kg n= 4;
10mg/kg n=4). All values represent mean ± SEM. Comparisons between treatment groups were performed using Dunnett's post hoc multiple comparison test
keeping ‘before CNO/vehicle treatment’ as a single control.
S. Panthi and B. Leitch Neurobiology of Disease 132 (2019) 104610
15
interneurons via IP CNO injection as proof of concept. The DREADD
receptor can be specifically activated via either peripheral (IP) or focal
injection of CNO into a specific brain region (Armbruster et al., 2007;
Dong et al., 2010; Rogan and Roth, 2011). Both global and focal si-
lencing of PV+ interneurons within CTC microcircuits, resulted in ar-
rested behaviour and bursts of paroxysmal oscillations with a spike
frequency of 3–7 Hz. These oscillatory bursts were identified as SWD-
like based on their EEG signature conforming to previous published
criteria for SWD, i.e. trains (> 1 s) of rhythmic biphasic spikes with
spike amplitude minimum two-times higher than baseline, positive
transient, and slow- afterwave pattern (Arain et al., 2012, 2015). Their
mean frequency/rhythmicity (Hz) was consistent with the character-
istics of SWDs associated with absence seizures in various rodent
models of absence epilepsy (Jarre et al., 2017). Each burst of oscillatory
activity, had a conserved morphological profile with respect to burst
duration and spike frequency, irrespective of drug dose (2.5–10mg/kg)
or route of administration. The mean duration of each burst was 3–5 s
and mean spike frequency was between 3 and 7 Hz after both IP and
focal (cortical or thalamic) CNO injections. However, mean onset of
epileptiform oscillatory activity was faster (~15min) after focal ad-
ministration of CNO directly into the brain than IP peripheral injection
(~30min), as would be expected since CNO delivered peripherally
requires additional time to be transported from site of injection across
the blood brain barrier and into the brain. Following peripheral ad-
ministration of CNO, plasma levels of the drug peak within 30min and
then sharply decline over the subsequent 2 h period (Guettier et al.,
2009; MacLaren et al., 2016; Roth, 2016; Manvich et al., 2018;
Jendryka et al., 2019). Although plasma levels of CNO decline quickly,
behavioural effects of the drug may be evident for up to 6 h (Alexander
et al., 2009).
Recently published studies have questioned the DREADD specific
actions of CNO delivered peripherally. It has been shown that CNO is
reverse-metabolized to clozapine after intraperitoneal CNO injection
via cytochrome P450 enzymes within 1 h in liver (Gomez et al., 2017;
Manvich et al., 2018; Jendryka et al., 2019), leading to the possibility
that behavioural changes witnessed in animals after IP CNO injection
might be off-target/sedative effects of clozapine (reverse-metabolized
CNO) at endogenous sites rather than specifically DREADD-dependent
effects of CNO (MacLaren et al., 2016; Ilg et al., 2018). As cytochrome
P450 enzymes are also present at low levels in the brain (Mahler and
Aston-Jones, 2018), it is also possible that CNO may be directly meta-
bolized to clozapine in the brain upon focal injections. Converted clo-
zapine reaches maximal cerebrospinal fluid concentrations at 2 to 3 h
after IP CNO injection in non-human primates (Raper et al., 2017). In
support of this, Gomez et al. (2017) reported decreased locomotion at
this time point in non-DREADD WT controls after systemic injection of
1mg/kg of CNO and 1mg/kg of clozapine. Whereas, low subthreshold
0.1 mg/kg dose of clozapine significantly decreased locomotor activity
in hM4Di expressing rats but not in controls, suggesting that systemic
subthreshold clozapine injections induce preferential DREADD-medi-
ated behaviours. However, other studies have failed to find DREADD-
independent behavioural sedative or off-target effects (Mahler and
Aston-Jones, 2018). Mahler and Aston-Jones reported no significant
effects on various motivated behaviours in non-DREADD-expressing
animals, injected with CNO at doses up to 10mg/kg, at least within a
30–150min timeframe after IP injection (Mahler and Aston-Jones,
2018). This underscores the fact that if converted clozapine levels re-
main within the range of specificity for DREADDs during a given time
period, but below that for altering signalling at endogenous receptors
during the allotted testing period, CNO can be a suitable agonist for use
in such experiments. These authors concluded that the major claim in
the Gomez et al., (2017) study that CNO should be abandoned as a
DREADD agonist is premature and that the researchers should use the
relatively well-characterized CNO until a more selective agonist is fully
characterized. Moreover, an even more recent study by Jendryka et al.
(2019) demonstrated that the concentration of reverse-metabolized
clozapine in plasma, cerebrospinal fluid and brain tissue is very low
compared to CNO and that the brain availability of both compounds
varies with species. It is now accepted that most potential off-target
effects of CNO/clozapine are well controlled by administration of CNO
to non-DREADD-expressing animals. In our study we tested all CNO
doses (administered IP and focally directly into the brain), in both Gi-
DREADD mice and their non-DREADD WT control littermates. We also
conducted vehicle controls. All EEG/video recording was conducted in
the first 60min post CNO injection; all EEG/behavioural testing was
completed within 100min post CNO injection. None of the non-
DREADD WT control littermates showed any bursts of epileptiform
activity or SWDs, at any of the drug doses tested 1–10mg/kg).
Interestingly we did observe increased immobility during the 1 h
EEG recording period after IP CNO injections of 5 and 10mg/kg in our
Gi-DREADD mice compared to vehicle or 1mg/kg treated mice and
CNO treated non-DREADD WT controls. In animal models of absence
epilepsy, SWDs are accompanied by behavioural arrest/freezing during
the seizure episode (Noebels et al., 1990). In our study, we witnessed
behavioural arrest/immobility during seizure activity and also between
bursts of seizures. In contrast, non-DREADD WT controls injected with
the same doses of CNO showed no significant increased immobility
compared to before CNO or vehicle treatment. Hence we conclude that
increased immobility after 5 and 10mg/kg IP CNO injection into Gi-
DREADD mice is not an off-target/sedative effect of clozapine conver-
sion but may be linked to increased anxiety (Tovote et al., 2015; Babaev
et al., 2018) as a result of DREADD-mediated silencing of PV+ inter-
neurons, as PV knock-out mice also display decreased locomotion
(Farré-Castany et al., 2007; Wöhr et al., 2015). Likewise, higher drug
doses of CNO administered focally directly into the brain of Gi-DREADD
mice resulted in less distance travelled in the open-field, these animals
spent more time stationary. However, again there were no significant
effects observed in non-DREADD WT controls.
The differential effects of acute and chronic silencing of specific PV
+ interneurons within CTC network microcircuits and the functional
implications on network oscillations will require further investigation.
Focal inhibition of RTN PV+ interneurons would be expected to not
only reduce feed-forward inhibition to the TC relay neurons but also
intra RTN inhibition. Previous studies, have suggested that the RTN is
critical to SWD generation, but different studies have produced see-
mingly conflicting functional consequences of altered inhibition within
RTN. For example, lesioning rostral RTN eliminates SWDs; whereas
blocking GABAA receptors in RTN increases SWDs (Vergnes and
Marescaux, 1992; Feeney et al., 1977; Meeren et al., 2009; Zhou et al.,
2015). Altering inhibition within one feed-forward inhibitory circuit
could also induce compensatory changes in another CTC component via
changes in phasic or tonic inhibition or both. The functional impact of
altering intra-RTN inhibition and RTN-mediated feed-forward inhibi-
tion of TC relay neurons in vivo will need to be determined chronically,
using multi-electrode array techniques.
5. Conclusions
Our data demonstrate for the first time that selectively silencing PV
+ interneurons in feed-forward inhibitory microcircuits in the CTC
network in vivo, by acute focal injection of CNO into the SS cortex or
thalamus of PV-Cre-dependent Gi-DREADD mice, can induce absence-
like seizures and bursts of pathological oscillations with characteristic
SWD-like morphology on EEG. This suggests that one underlying me-
chanism for the generation of absence seizures in some rodent models
of absence epilepsy (e.g. stargazer and Gria4−/−) and potentially
some human patients, is disinhibition within feed-forward CTC micro-
circuits. Hence, these inhibitory interneurons could be a target for fu-
ture improved treatment strategies for some cases of childhood absence
epilepsy. Furthermore, dysfunctional PV+ GABAergic interneurons in
other brain regions could be important in comorbid brain disorders
such as anxiety, autism and schizophrenia.
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